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SUMMARY 
The 10,000 ｾ＠ x 15 minute supernatant from homogenised 
whole fifth instar Schistocerca gregaria hoppers provided a 
binding reagent which could be used for the measurement of cyclic 
GMP without further purification. Preparation of the binding 
protein was simple and inexpensive, and the assay had a specificity 
equal to or greater than those reported in previously published 
protein binding procedures. Cyclic GMP concentrations, measured 
in urine without preliminary purification, agreed well with those 
determined by radioimmunoassay. 
Binding capacity and specificity of the locust reagent 
were strongly influenced by proteins, phosphodiesterase inhibitors 
and chelating agents, and by the developmental state of the insect . 
. Cyclic AMP increased the slope of the cyclic GMP standard curve in 
a dose-related manner over the range.S-100 pmol cyclic AM.P per tube. 
Anti-cyclic GMP antisera were raised against 2'-0-succinyl 
cyclic GMP conjugated to ovalbumin or keyhole ｬｩｮｾ･ｴ＠ haemocyanin. 
The high specificity of two rabbit antisera for cyclic GMP 
permitted the direct analysis of urine and plasma specimens. 
urinary calcium and cyclic nucleotide excretion after 
an oral calcium load was not helpful in distinguishing 'absorptive' 
.from 'renal' hypercalciuria in a study of 28 patients. Fasting 
cyclic AMP output in excess of 4.7 vmol/g creatinine was, however, 
I 
a useful indicator of inappropriate PTH secretion in hypercalcaemic 
patients. Cyclic GMP excretion was raised in both PTH-mediated 
and non-PTE-mediated hypercalcaemia. 
Eighteen patients with lung, bronchial or oesophageal 
cancer had no abnormality in pre- and post-operation 24 hour 
cyclic AMP or cyclic GMP excretion when compared with 11 control 
patients. Plasma cyclic GMP levels were increased in some 
patients with cancer of the bladder or the intestine, and in 
association with cachexia. 
Urinary cyclic GMP/cyclic AMP ratios fell in three 
subjects during recovery from asthma attacks, and were decreased 
in a group of 23 hypertensive patients. 
Five hyperthyroid women and one woman with a glucagonoma 
had raised plasma cyclic AMP a.nd normal plasma cyclic GMP 
concentrations. 
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1.1 Cyclic AMP and the Second Messenger System 
lel.l The Discovery of Cyclic AMP 
In 1956, Sutherland, Rall and coworkers, while 
investigating the glycogenolytic effects of glucagon and 
adrenaline on the liver, isolated a small heat stable compound 
which was capable of activating glycogen phosphorylase (Rall 
et ,a1, 1957). At this stage they could not have known that 
their researches would result in a major breakthrough in the 
understanding of the mechanism of hormone action at the 
cellular level. 
This heat stable compound was soon identified (Rall and 
Sutherland, 1958; Lipkin et al, 1959) as cyclic 3'5' adenosine 
monophosphate (•cyclic AMP'). Cyclic AMP consists of the 
purine adenine linked through nitrogen 9 to carbon 1' of the 
sugar D-ribose. A phosphate bridge spans carbons 3' and 5' 
o_n th.e ribose ring. Figure l.lA illustrates the two 
conformations ('syn' and 'anti') which have been found for 
cyclic AMP in the crystalline state (Watenpaugh et £..!, 1968). 
It was soon established that cyclic AMP acted as an 
intracellular mediator for adrenaline and glucagon stimulation 
of glycogenolysis in liver cells (Sutherland and Rall, 1960). 
Since then it has become clear that cyclic ｊＮｾｍｐ＠ functions as 
an intracellular messenger which communicates the stimuli of 
a great many hormones in mammalian and non-mammalian animal 
tissues (Robinson et al, 1971), is involved in plant metabolism 
(Newton, 1974), and controls several key cellular processes in 
micro-organisms (Perlman and Pastan, 1971). Cyclic AMP has 
2 
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FIG.l.lA. The two conformations of cyclic AMP in 
.. 
the crystalline state. (from Watenpaugh et al,l968') 
'syn' conformation. 
N7 
'anti' conformation. 
.... ｾ＠ ....... ..: .. .... __ ｾ＠ ﾷﾷＢＧ ﾷ ＭｾＺｾ＠ ... ...... . ｾ＠ .... ﾷＭＭｾＭＣ ］Ｍ ､ ＭＮｾＬ｟＠ ...... ｟Ｎﾷｾ ﾷ＠ ﾷ ｾ＠ ｾ＠ ... . _ .... 
been implicated in such diverse processes as steroidogenesis, 
release of thyroid and peptide hormones, cell permeability 
changes 1 flagella formation in Escherichia coli, and slime 
mould aggregation. 
1.1.2 The 'Second Messenger' Concept 
In an effort to explain the general process by which a 
hormone stimulus is transmitted within a target cell, 
Sutherland and colleagues put forward their 'second messenger' 
concept (Sutherland et al, 1968). This scheme was based on 
a knowledge of the activity and membrane localisation of 
adenylate cyclase, and on studies of the degrading enzyme, 
cyclic AMP phosphodiesterase. In their model a hormone, the 
'first messenger', binds to a receptor site on the target cell 
and stimulates adenylate cyclase, situated within the membrane, 
to convert 5' adenosine triphosphate (ATP) to cyclic AMP in 
the presence of magnesium ion. Cyclic AMP, the 'second 
messenger', may then promote further changes within the 
cell, or it may be degraded to 5'-adenosine monophosphate {5'-
AMP:} by the action of cyclic nucleotide phosphodiesterase 
(Fig .l· .. lB). 
This concept still holds true today, although many more 
details of the various stages in the process are now known. 
1.1.3 Newer Concepts of the Second Messenger System 
It seems probable that target cells all contain similar 
adenylate cyclase systems, and that the specificity . of response 
of these cells to hormone stimulation resides in the presence 
of distinct receptors for specific hormones. The components 
4 ' 
FIG.l.lB. Schematic representation of the second messenger concept. 
(from Robison ･ｴＮｾＮ＠ 1971) 
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of the second messenger system have been extensively investigated 
and some details are known of hormone recognition sites, the 
transfer of information to the adenylate cyclase complex, the 
nature of the protein kinases and phosphodiesterases involved, 
and of the large number of compounds which modulate the system 
at various stages. 
1.1.3a Receptor Sites 
Plasma membrane receptor sites have been described for 
a large number of peptide hormones, and for catecholamines, 
prostaglandins, and some drugs, and the nature of these binding 
sites has been reviewed by several authors (Birnbaumer, 1972; 
Rodbell, ＱＹＷＲｾ＠ Lefkowitz ·. and Haber, 1973: Roth, 1973; 
Cuatrecasas, 1974a and 1974b, Lefkowitz, 1974; Helmreich et al, 
1976). 
Insulin (Cuatrecasas, 1969), glucagon and noradrenaline 
(.J._o)1nson et al, 1972) when covalently linked to agarose beads, 
can .still stimulate their target cells. These hormones, since 
they cannot penetrate the cell plasma membrane, must interact 
with the exterior surface of the cell. 
It is now generally agreed that a hormone 'receptor' is 
a discreet macromolecular structure present in the plasma 
membrane of a hormone responsive cell, and that it may be 
defined as 'an element of a target cell which specifically 
recognises a hormone and is responsible for initiating a 
hormonal response' (Birnbaumer et al, 1974). This definition 
implies a dual function for receptors, and it follows that 
･ｶｩ､･ｮ｣ｾ＠ for specific membrane binding sites for a hormone 
does not., by itself, establish the presence of biologically 
6.: 
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active ｲ･｣･ｰｴｯｲｳｾ＠ confirmation of subsequent changes within 
the cell is also necessary. 
Different functional regions within the cell plasma 
membrane have been identified, and a new terminology has 
been suggested to describe these (Rodbell, 1972). Specific 
binding sites for hormones, which may not necessarily be linked 
to adenylate cyclase, have been termed 'discriminator' or 
'acceptor' units. Regions within the membrane which may play 
a part in transmission of information form a binding site to 
the adenylate cyclase system have been called 'transducer' or 
'coupler' regions, while the adenylate cyclase enzyme has been 
likened to an 'amplifier' system. 
Hormone binding sites are protein and phospholipid 
complexes with molecular weights ranging from 40,000 for 
adrenergic receptor sites (Lefkowitz ｾ＠ al, 1971) to 300,000 
f<?·r_ ｩｾｳｵｾｩｮ＠ sites (Cuatrecasas, 1972). Target cells usually 
hav:e. fewer than one million binding sites for each hormone, 
and equilibrium between free and membrane bound hormone is 
reached within minutes at 37°C (Roth, 1973). The binding 
of hormones, hormone analogues and fragments seems to be 
directly related to their biological potency ＨｾＮＬｲ･ｹ｣ｨ･ｴ＠ et al, 
1971; Roth, 1973). 
Data from target cell bindin-g studies for adrenocor·tico-
trophic hormone {ACTH) {Lefkowitz et al, 1970), insulin (Kahn 
ｾｾ＠ al, 1972), adrenaline and glucagon (Tomasi et al, 1970), 
and oxytocin {Bockaert et al, 1972) may be interpreted in terms 
of at ｬｾ｡ｳｴ＠ two populations of hormone receptors. In general 
the small number of high affinity sites become occupied at low 
- - ..... ﾷﾷﾷ ｾ Ｍ ＭＭＭＭＭﾷｾｾＺ ｟ Ｎ｟ＮＮＮＮ＠ ,._._ ..... ...... ｾｾ＠ ... ＡＮＮＮＮ｟ Ｎ ｾ＠ .... -- ＭｾＭ :_-_ -___ -:--:------=-----.--:.---.. ＮＮＮＮＬＮ ｾ ＮＺＮ ＭＺＢＢ ［Ｌ＠ .- .-.. ..... -... ＺｾＮ Ｍ ... -... -.. -. -.. ｾ＠.. .. -<. Ｍ Ｍ ｾＭ Ｎ＠ - . Ｍ ＢＧＡＢＢＧ ﾷｾＬ［＠ ..... .. ':""!' ....-__ .--:o" _ _ ...,,l 
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circulating hormone levels, while the large number of lower 
affinity sites become increasingly ·occupied as hormone levels 
increase over the physiologically active range. While bound 
to receptor sites, peptide hormones appear to be protected 
from degradation (Roth, 1973), although a separate population 
of glucagon-degrading sites has been described in rat liver 
cells (Pohl et al, 1972). 
The total number of cell binding sites for a hormone is 
often much greater than the number required for maximal 
adenylate cyclase stimulation: Birnbaumer and Pohl (1973) have 
estimated that 80-90% of liver plasma membrane glucagon-
specific binding sites may not be 'receptors'. The role of 
the remaining 'redundant' receptors is unclear, but they may 
be important for the stimulation of systems which do not 
function via adenylate cyclase, as storage sites to maintain 
high levels of hormone at the cell surface, as 'latent' 
receptor sites which have not yet become linked to adenylate 
cyclase, or as deactivation sites (Birnbaumer et ｾＱＬ＠ 1974). 
There is evidence that receptor sites for several 
different hormones may be linked to the same adenyiate cyclase 
unit (Rodbell, 1972). The response to the binding of one 
hormone may then be modulated by binding of a different 
hormone to another receptor site which is linked to the same 
· catalytic unit. Target cells for insulin, growth hormone 
(GH), thyrotrophin releasing hormone (TSH) and catecholamines 
can 'self-regulate' the numbers of membrane · receptors on the 
cell surface (Raff, 1976). Chronic exposure to high levels 
of circulatinJ hormone results in loss of ｲ･｣･ｰｴｯｲｳｾ＠ while 
hormone deficiency causes an increase in receptor numbers. 
Also, hormone receptors may dissociate bound hormone more 
rapidly with increasing saturation of binding sites. This 
'negative co-operativity' has been described for insulin 
receptors on liver cells and cultured lymphocytes (De Meyts 
et al, 1973). 
-- --
1.1.3b 'Transduction' 
Birnbaumer (1973) and Helmreich et a1 (1976) have 
reviewed · the factors which are known to regulate signal transfer 
from a hormone receptor to adenylate cyclase. 
Phospholipids are thought to play an important part in 
the 'transduction' process. Studies using phospholipase A 
and digitonin treatment of liver plasma membranes (Pohl et ｾＱＬ＠
1971) and Lubrol-PX solubilisation of cat heart . adenylate 
cyclase (Levey, 1971) have shown that the phospholipids . 
ｰｾｯｳｰｨ｡ｴｩ､ｹｬ＠ ethanolamine, phosphatidyl choline and phosphatidyl 
serine were capable of restoring the response to hormonal 
stimulation. 
Guanosine 5' triphosphate ('GTP'), it$ synthetic 
analogues guanylylimidodiphosphate. ('GMP-PNP') and guanylyl-
methylene diphosphonate ('GMP-PCP'), and in some systems, 
guanosine 5' diphosphate ('GDP') and inosine 5' triphosphate 
('ITP'), are strong potentiators of hormone stimulated adenylate 
cyclase activity (Clark et al, 1974; Helmreich et al, 1976). 
This effect is seen at GTP levels often 100 to 1000 times 
lower than· the level of ATP required to produce an equivalent 
activation (Birnbaumer, 1971). It is not clear at present 
whether GTP exerts control at a site adjacent to a hormone 
. Ｍ ｾ ＭＭＭＭ ｾ Ｍ ＭｾＭＭ ＭＭ ＭＭＭ Ｍ ＭＭＭ､ ｾ ｾ｣ｾ ｾ ｾＭ ｾ Ｍｾｾ ｾ Ｂ ｾｾ＠ .. ﾷ Ｚ Ｎｾｾ ｾ Ｎ ＺｾｾｾｾＭｾ Ｍ ｾ Ｍ ｾ ｾ Ｎ ｾ Ｍ ｊ ｾ Ｎ Ｍ ｾ Ｎ＠ Ｍ Ｎｾ Ｍｾ ］ Ｍｾ ﾷﾷ ］ Ｍﾷ ｾ ﾷＭ ］ ＭＭ ｾ Ｍ ｾ Ｍ ｾ Ｍ ｾ Ｍ ｾ ＭＭ ｾ Ｍ Ｍｾ Ｍ ］ Ｍｾ ｾ Ｍﾷ ｾ ｾ ］ ＭＭｾ Ｎ ｾ ｾ Ｍ Ｎ ｾ Ｍ ｾ Ｍ ｾ Ｍ ｾｾ Ｍ ｾ Ｍ ｾｾｾ ＭＭ Ｍ ｾ Ｎ＠ Ｍ ｾ Ｍ ｾ Ｍ Ｍ ｾ Ｍ Ｍ Ｍ ｾ Ｎ＠ l 
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receptor on the plasma membrane, at the •transduction• stage 
of the process, or at both locations Ｈｐ･ｲｫｾｮｳＬ＠ 1973; 
Helmreich et . al, 1976). 
1.1.3c ｾ､･ｮｹｬ｡ｴ･Ｇ｣ｹ｣ｬ｡ｳ･＠
The adenylate cyclase enzyme (ATP pyrophosphate lyase 
Ｈ｣ｹ｣ｬｩｺｾｮｧＩ＠ EC: 4.6.1.1) has been identified in all metazoan 
species which have been examined, and the characteristics of 
the mammalian enzyme systems have been described by Robison 
ｾｴ｡ｬ＠ {1971), Birnbaumer (1973'), Perkins {1973) and Helmreich 
et al (1976). 
Adenylate cyclase is a protein or lipoprotein complex 
which is located predominantly on the interior surface of 
mammalian cell plasma membranes, although i t .s presence in 
mitochondria (Severson et al, 1972) and cell nuclei (Soifer 
and Hechter, 1971) has also been reported. 
Divalent cations have a pronounced effect on enzyme 
activity. Magnesium-ATP is required as a substrate, but 
further increases in magnesium levels enhance catalytic 
activity (Birnbaumer et al, 1970). In many tissues manganese 
can replace magnesium in this role, while cobalt may also be 
partially active. Calcium zinc, and copper ions often 
inhibit adenylate cyclase, as does the monovalent cation, 
lithium (Birnbaumer, 1973; Perkins, 1973). 
Sodium fluoride has a marked stimul_atory action on 
adenylate cyclase in broken cell systems, even when their 
sensitivity to hormone influence has been lost. Fl.uoride 
ion is probably the active molecular species involved, and 
it is thought to act. at some s ·tage subsequent to hormone-
----------------------------------- ·- ---- . - -- · 
receptor interaction (Drummond et a1, 1971).' The mechanism 
of fluoride activation of the system is not understood, although 
the formation of MgF 2 or MgF 2Po4 complexes, inhibition of ATP-
ase activity, or activation of 'latent• adenylate cyclase 
activity by dephosphorylation of an inactive, phosphorylated 
form of the enzyme, have all been proposed as possible 
contributory factors (Perkins, ＱＹＷＳｾ＠ Helmreich et al, 1976). 
Cholera toxin also has this capacity for direct stimulation 
qf adenylate cyclase in gut mucosal cells (Sharp and Hynie, 1971}, 
although i.n this case there is a lag period of one hour or so. 
The resultant large rise in intracellular cyclic ｾｍｐ＠ levels ｴｨｾｮ＠
causes an increased outpouring of salt and water into the gut. 
l.lo3d protein Kinases 
Most of the actions of cyclic AMP in mammalian cells are 
mediated through activation of protein kinases (ATP:protein 
phosphotransferases Ec· 2.7.1.37) which phosphorylate protein 
substrates within the cell. A cyclic AMP dependent protein 
kinase, which brought about the phosphorylation of phosphorylase 
b kinase, was first identified in·rabbit skeletal muscle by 
Walsh et al (1968). Kuo and Greengard (1969) demonstrated 
the general distribution of protein kinases in animal tissues, 
and their properties have been discussed in some detail by 
r.Jangan (1973). 
Protein kinase activity is often high in the cytoplasm, 
and activity is also present in cellular membranes, ribosomes, 
nucleoplasm and in association with chromatin. A variety of 
protein kinase substrates have been identified; these include 
---- .. --... ｾＮＺＮＮＮＮＮＮＮＮＮＮ＠ .. ; __ . .;;. __ ｾＭＭＭＺＮＮ［Ｎ［ＺＮﾷｾＭ ＭＮ ＭＭｾ＠ •. -.-.:.;:.-;.·:.· .. ＺＭｾＺＺ ［ ［ＺＮｾＺＮＺＭＭＮ］ﾷ］ﾷｾ ﾷ ］ﾷﾷ ﾷ ﾷﾷ］ＭﾷＭ ..... ··-:-:-.. ---::-:-.. . ""7 •• ;-c;; .• ｾ ］ Ｍ ］ ＭＭ ＺＭＺＭ .. -;-, ..,-;: ...=----=-.. ·=-·=·--·.,.,.. .. ｾｾ］ ﾷ Ｍ .. =· ·= .. --= .... ........... """··-·"""·· ...... ·· - ···=---- -!'!"!! ...'!!!!'---·------- ----------"""! 
liver and muscle phosphorylase· ｫｩｮｾｳ･＠ and glycogen synthetase, 
casein in mammary tissue, liver cell protamine and histones, 
adipose tissue lipase, and ribosomal and membrane proteins 
(Langan, 1973). · There is considerable evidence from studies 
on a number of tissue protein kinases that the enzymes, in 
their simplest form, have molecular weights in the region of 
140-160,000 (Langan, 1973) and contain two different subunits, 
as proposed by Brostrum and coworkers (1970). Binding of 
cyclic-AMP -to a regulatory subunit (R) causes dissociation of 
the inactive holoenzyme {RC) to yield an active catalytic 
component (C) which then utilises Mg-ATP to pho.sphorylate 
substrate proteins:-
RC + cyclic AMP ｾ＠ R-cyclic AMP + C 
ｾ＠
Inactive 
protein kinase 
Active form of 
protein kinase 
Cyclic- AMP binding to the regulatory units is reversible, 
w1th binding constants of the order of 10-8 mol/1 ｻｗ｡ｬｾｨ＠ et ｾＱＬ＠
1971; Garren et al, 1971). Protein kinases from various tissues 
do not seem to differ greatly in their function, and may show 
cross-reactivity: for example, rabbit skeletal muscle protein 
kinase will activate hormone sensitive lipase in rat adipose 
tissue (Corbin et al, 1970). Tissues often contain multi-
molecular forms of protein kinase, and regulatory units from 
one kinase may interact with catalytic units from other 
kinases (Tao and Hackett, 1973). Some protein substrates, 
such as histones or protamine are themselves capable of 
activating the enzyme by dissociation of the R-C complex 
(Miyamato ･ｴ｡ｾＬ＠ 1973). Ashby and Walsh (1972) have 
characterised a heat stable protein kinase inhibitor which 
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prevents the expression of protein kinase activity by 
combination with free catalytic units and which may therefore 
serve as another regulator of protein kinase activity. A 
further complexity in the control of protein substrate activity 
involves the capability of some protein kinases to phosporylate 
substrate proteins at multiple sites with a resulting modification 
of the properties of the phosphorylated proteins (Cohen, 1976). 
Dephosphor.ylation of phosphorylated protein substrates 
also offers an alternative means of controlling the system, and 
there is evidence that several protein phosphatases are ei·ther 
inhibited or activated by cyclic AMP. Recent studies on 
glyc"ogen metabolism indicate that a single protein phosphatase 
enzyme may be -responsible for dephosphorylation of the three 
enzymes, glycogen synthetase, phosphorylase kinase, and 
phosphorylase. Hormonal control of protein phosphatase activity 
may depend on dissociation of a catalytic subunit-inhibitor 
subunit complex which is analogous to the process of protein 
kinase activation (Killilea et al, 1976). 
In the case of cyclic AMP regulated glycogen degradation 
and synthesis, the most thoroughly investigated pathway 
involving cyclic AMP mediation, it is clear that the overall 
effect of the adenylate cyclase and two successive kinase 
reactions is to provide a 'cascade' system by which the signal, 
initiated by the binding of a small number of adrenaline or 
glucagon molecules, may be amplified by several orders of 
magnitude, culminating in the production of glucose-1-phosphate 
from glycogen (Fig.l.lC). In this same system, the cyclic ·AMP 
mediated phosphorylation of glycogen synthetase-! to the 
i 
l 
' 
' I 
! 
HORMONE (glucagon,adrenalin) FIG. 1 .lC. Regulation of glycogen 
I 
! 
ADENYLATE CYCLASE 
ATP cyclic AMP + PP. I , 
v 
r - - - - - - - - - - - --PROTEIN KINASE 
PHOSPHORYLASE b PHOS'PHORYLASE b 
KINASE (inactive) . KINASE (active) 
+ATP +ADP ! ' I v 
ｾ＠ ｾ＠
GLYCOGEN SYNTHETASE -D GLYCOGEN SYNTHETASE -I PHOSPHORYLASE b 
(inactive) +ADP (active) +ATP (inactive) +ATP 
UDP-GLUCOSE GLYCOGEN + P; 
degradation and synthesis 
by cyclic AMP. 
PHOSPHORYLASE a 
(active) +ADP 
! 
GLUCOSE-1-PHOSPHATE 
r-: . 
ｾ ＭＮ＠
' • ••. - '· • • •d • ﾷＭＭｾＭｾＭＭＭＭＭＭＭＭＭﾷＭＢｾＭＭＭＭ ｾ ＭＭＭＭＭＭﾷＭＭＭＭＭ Ｍ Ｍｾ ｾﾷ＠ ＭｾＭｾ Ｍ ﾷ ＭＭ ＭｾＭｾｾ ＭｾＭ ＭｾＭｾＭｾｾｾｾｾ ｾｾｾｾｾｾｾｾｾｾｾｾｾｾ＠ lS i 
inactive form, glycogen synthetase-D, attenuates glycogen 
synthesis. Protein kinases thus exert a concerted action 
involving both activation and deactivation of enzymes in 
the pathway. 
1.1.3e Cyclic AMP Phosphodiesterase 
An enzyme capable of destroying the biological activity 
of cyclic-AMP was first found in extrac·ts of heart, brain, and 
liver (Sutherland and Rall, 1958). Cyclic AMP phospho-
diesterase (EC 3.1. 3c) is a magnesium-·dependent enzyme which 
catalyses the. hydrolysis of the ribose carbon 3'-phosphate 
bond of cyclic AMP with formation of 5'-AMP. Cyclic nucleo-
tide phosphodiesterase ('c PDE') activity has been found in 
many tissues (Butcher and Sutherland, 1962) and their 
properties have been reviewed by Robison et al (1971) and 
by Appleman et al (1973). Cheung (1970) listed the 
ｳ｟ｰ･ Ｎ ｣ｾｦｩ｣ｾ＠ ties reported for total phosphodiesterase activity 
ｦｲＹｾ＠ a number of tissues, and concluded that the activity 
is specific for the 3'5' cyclic purine nucleotides cyclic 
AMP, cyclic GMP, and cyclic IMP. 
Manganese, copper, and nickel ions can partially replace 
magnesium as cofactor for the enzyme (Cheung, 1967). In 
general two types of phosphodiesterase have been identified 
in mammalian tissues: a high affinity membrane bound enzyme 
with a molecular weight of approximately 200,000, and a lower 
affinity, cytosol enzyme with a molecular weight in the region 
of 400,000 (Thompson and Appleman, 1971). Multiple forms of 
the ｰｨｯｾｰｨｯ､ｩ･ｳｴ･ｲ｡ｳ･＠ enzyme, with different activities for 
each cyclic nucleotide. have been described (Appleman §t al, 
197 3) • 
ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭｾｾＭｾＭｾＭｾｾＭＭＭＭＭ ﾷ＠ ...... 
Cyclic nucleotide phosphodiesterases 'are inhibited by 
a large number of compounds, including the methyl xanthines 
theophylline and methyl isobutyl xanthine, ethylene diamine 
tetra-acetic acid (ED'J.1A) , ascorbic acid, triiodothyronine, 
and many drugs such as papaverine, puromycin, diazoxide, 
tolbutamide, phenothiazines, imipramine, amitriptyline and 
[}?tetrahydrocannabinol {Appleman et 9-l, 1963; Weinryb et al, 
197 2) • Beer and coworkers {1972) have suggested that the 
therapeutic effects of several antidepressant drugs may be 
due to their inhibition of brain cyclic AMP pb.osphodiesterase. 
Few activators of phosphodiesterase have been described. 
Imidazole (Butcher and Sutherland, 1972), nicotinic acid 
(Abdullah and Hamadah, 1970), imidazole acetic acid (Roberts 
and Simonsen, 1970), histamine (Goodman, 1968) and ammonium 
ions (Nair, 1966) can activate phosphodiesterase activity in 
some systems. 
Cyclic AMP and cyclic GMP also regulate phosphodiesterase 
activity (Beavo et al, 1970), and the modulation of phospho-
diesterase by these cyclic nucleotides will be discussed in 
section 1.2. 
Proof of a direct action of hormones on phosphodiesterase 
has been hard to find. It is possible that one of the effects 
of insulin is to increase the activity of membrane bound 
phosphodiesterase, but even this process may involve an 
intermediate messenger (Robison et al, 1971). 
Figure l.lD illustrates some of the concepts of hormone 
action which have been mentioned in the text. 
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1.1.4 Anomalies in the 'Second Messenger' Concept of 
Hormone Action 
Although a large number of hormones, such as adrenaline, 
glucagon, and most pituitary and hypothalamic peptide hormones 
lave been shown to act by increasing cyclic AMP levels in 
target cells, there remain several hormones (for example 6 
insulin, steroid and thyroid hormones) for which a cyclic AMP 
mediated stimulatory mechanism has not been established. 
Studies on this last group of hormones have revealed 
that a second cyclic nucleotide, cyclic GMP, is also important 
in cell regulatory pxocesses, and may have profound effects on 
cell metabolism which are quite distinct from the actions of 
cyclic AMP. 
1 .. 2 fYclic GMP as an Alternative 'Second ｍ･ｳｳ･ｮｧ･ｾＧ＠
1.2.1 Cyclic GMP and Guanylate Cyclase 
Cyclic-3'5'-guanosine monophosphate ('cyclic GMP') was 
first identified in urine by Ashman and colleagues (1963) 
following the administration of ｛ ＳＲ ｾＭｩｮｯｲｧ｡ｮｩ｣＠ phosphate to 
rats. 
The structures of cyclic GMP and the other members of 
the cyclic nucleotide family, cyclic AMP, cyclic-3'5'-inosine 
monophosphate ('cyclic IMP'), cyclic-3'5'-uridine monophosphate 
('cyclic UMP'), cyclic-3 '5 ., -deoxy thymidine monophosphate 
('cyclicdTMP'), and cycl.i..c-3'5'-cytidine mon.ophosphate ('cyclic 
CMP'), are illustrated in Fig.l.2Ao Cyclic GMP exists in 
the 'syn' conformation in the crystalline state . and in · solution 
(Druyen et al, 1976). 
FIG.l.2A. Structures of ｴｨｾ＠ cyclic nucleotides. 
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Unlike cyclic AMP, cyclic GMP was not 'identified as 
part of a hormone stimulated metabolic pathway, and when it 
was first discovered, nothing was known of its significance 
in cellular metabolism. Research by a number of laboratories 
has now demonstrated that cyclic GMP is widely distributed in 
nature, being present in mammalian tissues (Goldberg et al, 
1969; Ishikawa et a1, 1969; Kuo ｾ＠ al, 1972),,fish (Ishikawa 
ｾｾ＠ al, 1969; Gray 1970), arthropoda (Kuo et al, 1972), plants 
(Haddox et a1, 1974) and bacteria (Goldberg et al, 1973a). 
An enzyme capable of converting GTP to cyclic GMP was 
first described in 1969 by several research groups working 
independently (White and Aurbach, ＱＹＶＹｾ＠ Hardman and Sutherland, 
1969; Schultz eta!, 1969). Guanylate cyclase (EC 4.6.la2) 
has been detected in all mammalian tissues examined, and the 
conversion of GTP to cyclic GMP has also been observed in 
·bacteria (Clark and Bernlohr, 1972). The mammalian enzyme 
dif£ers from adenylate cyclase in its subcellular distribution, 
activity following treatment with detergents, cation requirements 
and mechanism of activation {Goldberg et al, 1973b). 
1.2.la Subcellular Distribution of Guanylate Cyclase and Cyclic GMP 
Guanylate cyclase activity is present in two main forms 
in mammalian tissues. In contrast to adenylate cyclase, which 
is localised exclusively in cell membranes, considerable 
guanylate cyclase ac·tivi ty is present in the 'soluble • fractions 
after homogenisation of many tissues (Hardman and Sutherland, 
1969; Ishikawa et al, 1969: White and Aurbach, 1969; · 
. --
Nakazawa and Sano, 1974). The ratio of soluble to particulate 
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activity varies with each tissue examined. For example, 
ＸＰＭＹｾｾ＠ of the activity from rat lung is soluble, whereas 90% 
of rat intestine, and 70% of rat heart activity is in the 
particulate fraction (Hardman and Sutherland, 1969; Ishikawa 
et al, 1969). Hardman and Sutherland (1969) also demonstrated 
marked species differences for tissue enzyme distribution; in 
contrast to their findings in rat lung, only 20-35% of 
guanylate cyclase activity from pig, dog and sheep lung 
h?mogenates was detected in the 105,000 ｾ＠ supernatant fractions. 
The use of non-ionic detergents such as Triton X-100 
has revealed that much of the 'particulate' enzyme activity 
in tissue fractions may be in a 'latent• form. Ishikawa et 
al (1969) first reported that Triton_X-100 could produce a 
2.5-fold increase in guanylate cyclase activity from a · 
particulate fraction of rat small intestine. Adenylate cyclase 
activity in the same ｴｾｳｳｵ･＠ fraction was markedly depressed by 
the same treatment. In general, incubation of tissue 
'particulate' fractions with Triton X-100 results in large 
increases in guanylate cyclase ｡｣ｴｾｶｩｴｹＮ＠ A sevent.een-fold 
increase has been reported for a microsomal fraction of rat 
heart (White, 1975), although three- to five-fold activation 
is more ｦｲｾｱｵ･ｮｴｬｹ＠ found (Kimura and Murad, 1975a). 'Soluble' 
guanylate cyclase activity is generally much less influenced 
by Triton X-100 treatment. 
Steiner and coworkers have recently used immunohisto-
chemical techniques to study the intracellular distribution 
of cyclic AMP and cyclic GMP (Steiner et al, 1975). In 
thyroid follicular cells cyclic AMP was present throughout the 
l 
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cytoplasm whereas cyclic GMP was localised close to the 
follicular membrane. Adrenal cells contained cyclic GMP 
in close association with the nucleolus, nuclear membranes 
and with chromatin as well as in cytoplasmic areas, while 
cyclic AMP was detected only in the cytoplasm. Increases 
in the membrane- and nucleus-associated cyclic GMP were 
observed as a long-term effect of hypophysectomy in rats. 
Since total adrenal cyclic GMP levels remained unchanged 
after hypophysectomy, Steiner and coworkers have suggested 
that cyclic GMP-mediated effects may be controlled by a 
redistribution of the nucleotide within the cell, rather 
than by a change in total cell levels. Studies on rat 
seminiferous tubule cells again showed that cyclic GMP was 
localised extensively on cell membranes. In this same 
tissue, observations that cyclic GMP was associated with the 
chromozomes of cells which were preparing to replicate 
indicates that cyclic GMP may be involved in the regulation 
of· RNA and DNA synthesis in the nucleus. 
1.2.lb Activation and Inhibition of Guanylate Cyclase 
Guanylate cyclase has a strong requirement for 
manganese ion, and is ten times more active in the presence 
of this cation than with equimolar concentrations of magnesium 
{White and Aurbach, 1969; Hardman and Sutherland, ·1969). The 
rate of the enzyme reaction is dependent upon an optimal ratio 
of GTP to Mn2+ (White and Aurbach, 1969; Hardman and 
Sutherland, 1969), a situation analogous to that encountered 
2+ 
with Mg and ATP for adenylate cyclase. 
ＲＲ ｾＡ＠
• I 
Calcium ion ca.n enhance guanylate cyclase activity in 
the presence of Mn2+ with a GTP concentration equal to or 
greater than that of manganese (Hardman et al, 1972). In rat 
ductus deferens, guanylate cyclase activity is dependent on 
the presence of calcium (Schultz and Hardman, ＱＹＷＵＩｾ＠ and 
increases in intracellular calcium levels are associated with 
increased guanylate cyclase activity in several tissues. The 
important role played by calcium in cellular central mechanisms 
will be discussed in section 1.2.6. 
In marked contrast to its stimulatory action on 
adenylate cyclase, fluoride ion has no effect on guanylate 
cyclase activity in broken cell preparations {Hardman and 
Sutherland, 1969). 
Recently, sodium azide, a nucleophilic reagent which 
has an inhibitory effect on many enzymes (Dixon and Webb, 1964) 
has been found to produce large elevations in guanylate cyclase 
activity. Sodium azide, in the concentration range 1-10 mmol/1, 
stimulates 'soluble' and 'particulate' guanylate cyclase 
enzymes in rat liver, kidney (Kimura et a1, 1975) and adipo-
cytes {r.evelliers et al, 1976), and 'particulate' activity 
from rat cerebral cortex and cerebellum (Kimura et a1, 1975). 
Both Kimura et a1 and Levelliers et a1 observed that 
activation by azide was concentration and time dependent; 
preincubation times of 5 minutes and 45 seconds were necessary 
for maximum stimulation by 1.0 mmol/1 and 10 mmol/1 sodium 
azide respectively. This long phase in activation . may 
indicate that azide acts by induction of a conformational 
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change in the enzyme protein rather than by direct stimulation 
of catalytic activity. Kimura and colleagues (1975) have 
also demonstrated stimulation of guanylate cyclase by 
hydroxylamine and phenylhydrazine. 
Inhibition of guanylate cyclase has been reported with 
physiological levels of ATP (Ishikawa et al, 1969) with the 
ｮｵｾｬ･ｯｴｩ､･ｳ＠ ADP, ITP, CTP, UTP and cyclic AMP (White and 
Aurbach, 1969) with oxaloacetate 1 phosphoenol pyruvate and the 
cationsmercury, cadmium and zinc (Hardman and Sutherland, 1969). 
1.2olc Possible Interconvertibility of Guanylate and 
Adenylate Cyclases 
In spite of differences in intracellular distribution 
and sensitivity to activation and inhibition of adenylate and 
guanylate cyclase systems, Hollenberg and Cuatrecasas (1975) 
have proposed that one possible explanation of the effects of 
in9ulin and anti-insulin agents on fat cells is that there is 
a single membrane bound nucleotide cyclase enzyme which is 
capable of utilising either ATP or GTP substrates. In the 
absence of agonists the enzyme would have low activity. 
Insulin or cholinergic stimulation would change t .he enzyme to . 
a 'GTP-preferring' form, while glucagon,adrenalin, or ACTH 
activation would convert the enzyme to an 'ATP-preferring' 
configuration. 
Amer and Byn1e (1975) observed that ｴｨ･ｾＭ｡､ｲ･ｮ･ｲｧｩ｣＠
receptors of rat heart atrium changed over to the production 
of cyclic GMP when the tissue was cooled to 25°C. Adenylate 
and guanylate cyclases may, therefore, be interchangeable in 
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this case; availability of metabolic energy may determine 
which cyclic nucleotide is synthesised. 
The observation by Simon (1976) that cyclic GMP could 
apparently be converted to cyclic_ AMP in frog myocardial 
tissue suggests that a change in the balance between ·the two 
nucleotides by direct converstion of one into the other may 
be possible. 
1.2.2 Cyclic GMP-activated Protein Kinases 
Early studies on mammalian tissue cyclic GMP-activated 
protein kinases showed only very low levels of activity (Kuo 
and Greengard, 1970) although Anthropoda were found to be a 
rich source of these enzymes. The cyclic GMP-activated kinases 
in lobster muscle and silkmoth pupae fat body are present in 
the cell cytoplasm and, in the case of silkmoth pupae, are more 
abundant than the cyclic AMP activated protein kinases (Kuo 
and Greengard, 1971). 
More recently, Kuo (1974) has been able to demonstrate 
cyclic GMP dependent protein kinase activity in rat and guinea 
pig lung, heart, aorta, brain, liver, ileum, ｾ､ｩｰｯｳ･＠ tissue 
and pancreatic islets, which was two or three orders of 
magnitude higher than the levels previously measured. Improve-
. ments in the assay technique were achieved by the use of 
arginine-rich histone substrate, and a heat stable protein 
'modulator', thoughtto be similar to the protein inhibitor 
of cyclic AMP-activated protein kinase described by Ashby 
and Walsh (1972).. This protein modulator, whether prepared 
from mammalian or arthropod tissue, could inhibit or stimulate 
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mammalian and arthropod protein kinase activity depending on 
the class of protein kinase employed, and the nature of the 
protein which was used as substrate (Kuo, 1975). 'Sephadex' 
G-200 fractionation of a crude extract of guinea pig lung, 
for example, has revealed three dis·tinct peaks of protein 
kinase activity .. Peaks 1 and 3 contained cyclic AMP stimulated 
kinase activity which could be inhibited by the protein 
modulator when arginine rich histone was used as substrate. 
Peak 2 protein kinase activity was largely cyclic GMP 
dependent, and was enhanced by the modulator using the same assay 
system. Different substrate proteins gave rise to altered 
patterns of inhibition and activation for the protein kinase 
fractions, and this may indicate that the modulator can alter 
the substrate specificity of the enzyme (Kuo, 1975). The 
observation by Kuo (1975) that the modulator protein from 
epididymal fat pads of alloxan-induced ､ｩ｡｢･ｾｩ｣＠ rats has.a 
re<;luced influence on protein kinase relative to the modulator 
protein from control animals, suggests that protein kinase 
modulator protein activity may be influenced by hormones. 
Although protein kinase studies have used substrates such as 
ar9inine or lysine rich histones and protamine, which act as 
s-ubstrates for both the cyclic AMP and cyclic GMP-activated 
·enzymes, there is little information concerning the identity 
of the true endogenous protein substrates for cyclic GMP-
activated protein kinases. 
Cyclic GMP effects may not always require mediation 
by protein.kinase activationo The ･ｮｺｾｮ･＠ which catalyses the 
last common step in the de novo biosynthet.ic pathways for purine 
26 
ﾷｾＭ ＭＭｾ ｵ Ｍ• • ＭＭ•ｷｵ ｯ＠____ ,, .,_. ___ , ... ＮＮＮＮＬＮＮＮＮＬＮＮＮＮＮＮＬｾｾ＠ ......... . ｾｔ ｾ ＢＺＺＢＺＮＺＧｴｯＭＮｾ＠ • • • ••-•••• ,.. , , , , , ,,. ｾ••• •＠ •• , . . . .. . . ｾＮＬ＠ . .. . Ｌｾ＠ ...... Ｍ ｾ ＧＢＢＧ• ＾ •• • ＢＢＧ Ｇ • •＠ .. ••••• ) ｦｾ• Ｇ ＧＢ＠ ｾ＠ ........ •- 1.,'• -" • ' . i 
and pyrimidine ribonucleotides·, phqspho-ribosyl pyrophosphate 
synthetase (PRPP synthetase), can be stimulated directly by 
cyclic GMP. . This process is inhibited by cyclic AMP (Green 
and Martin, 1974)'. 
ＱＮＲｾＳ＠ Cyclic GMP Phosphodiesterase Activity 
Russell and coworkers (1973) were the first to isolate 
a cyclic GMP phosphodiesterase enzyme, following chromatography 
of a rat liver extract. It is now evident that mammalian 
tissue cells containing multiple forms of cyclic nucleotide 
phosphodiesterase enzymes ('CPDE') which have different 
relative activities for hydrolysis of cyclic AMP and cyclic 
GMP. 
Appleman and Terasaki (1975) have reported that diethyl-
aminoethyl cellulose (DEAE-cellulose) chromatography of rat 
liver extracts separated three peaks of phosphodiesterase 
activity .with specificity for hydrolysis of cyclic GMP only 
Ｈｐｾ｡Ｎｫ＠ 1), cyclic AMP and cyclic GMP (Peak 2) and cyclic AMP 
only (Peak 3). Three major fractions of cPDE activity were 
also found in rat heart, kidney, mammary gland, ｬｵｾｧ＠ .. ｾＮｮ､＠
brain using the same chromatographic separation, although 
the relative amounts of enzyme activity in each fraction 
varied considerably from one tissue to another. 
Cyclic GMP-specific hydrolysis by phosphodiesterase is 
stimulated by calcium in the presence of magnesium, and by a 
heat stable 'protein activator factor' ('PAF') which has ｢･ｾｮ＠
isolated from rat brain, kidney, liver and heart (Kakiuchi 
e t a 1, 197 5) • Kakiuchi and colleagues have undertaken a 
detailed study of this activator factor, and have obtained 
evidence that the active phosphodiesterase enzyme is a complex 
of phosphodiesterase enzyme, protein activator and calcium:-
CPDE 
enzyme + 
Inactive 
PAF + Ca2+ CPDE-PAF-Ca
2+ 
enzyme 
Active 
Calcium and PAF do not stimulate the activity of 
phosphodiesterases which hydrolyse either cyclic AMP only, or 
both cyclic nucleotides (Appleman and Terasaki, 1970). 
Phosphodiesterases which act on both cyclic nucleotides 
appear to have only one catalytic site at which cyclic AMP or 
cyclic GMP hydrolysis occurso They do, however, possess a 
second binding site with high affinity for cyclic GMP, which 
exerts a.n allosteric influence on the activity of the catalytic 
site. Cyclic AMP hydrolysis by this class of phosphodiesterase 
can be regulated by cyclic GMP (Appleman and Terasaki, 1975). 
Cyclic AMP-specific phosphodiesterases seem to be 
uninfluenced by cyclic GMP. Their activity is determined by 
the cyclic AMP substrate concentration and shows a 'negative-
cooperativity' effect, in which increased substrate levels 
lead to a ､ｩｭｩｮｩｾｨ･､＠ affinity of the enzyme for cyclic AMP 
(Appleman and Terasaki, 1975). 
Cyclic AMP can inh.ibi t the hydrolysis of cyclic GMP in 
a rat liver cPDE preparation (Beavo et al, 1971). 
Weiss (1975) has used polyacrylamide-gel electrophoresis 
to separate cyclic nucleo·tide phosphodiesterase fractions from 
. I 
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different areas o ·f rat brain, and has demonstrated a wide 
variation in the number of phosphodiesterase fractions in rat 
cerebellum (6 peaks), cerebrum (4 peaks) and caudate nucleus 
{2 peaks) • These phosphodiesterase fractions do, however, 
fall into the three ma.in groups described by Appleman and 
Terasaki in terms of cyclic nucleotide specificity. 
The use of improved separation techniques provides an 
indication that each tissue may possess an individual 'pattern' 
o.f cPDE' s each with different specifi ties and different 
susceptibilities to inhibitors (Weiss, 1975). 
There is evidence that cPDE inhibitors may vary in 
their potency to inactivata cyclic AMP and cyclic GMP 
phosphodiesterases. Amer (1974} has investigated the 
selectivity of theophylline, papaverine hydrochloride and 
glycyrrhetinic acid towards cyclic AMP or cyclic GMP 
phosphodiesterases from dog, rat, and rabbit ·fundic mucosa. 
Glycyrretinic acid was twice as potentas an inhibitor of cyclic 
AMP phosphodiesterase than as an inhibitor of cyclic GMP 
phosphodiesterase. Papaverine affected both phosphodiesterases 
equally, while theophylline was twice as effe.ctive against the 
cyclic GMP phosphodiesterase. The ability of these inhibitors 
to stimulate acid secretion in rabbit fundic mucosa was 
directly related to their capacity to increase the tissue cyclic 
GMP/cyclic AMP ratio. Acid production was stimulated by thea-· 
phylline, unaffected by papaverine, and decreased by gly-
cyrretinic acid. 
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A selective cyclic AMP phosphodiesterase inhibitor, 
'R020-1724' has been described by Sheppard et al (1972) and 
isobutylmethylxanthene ('IBMX') has been shown to inhibit 
cyclic GMP phosphodiesterase to a greater extent than cyclic 
AMP phosphodiesterase (Schultz et al, l973b)o 
1.2.4 Hormones and Other Agents which Increase Tissue Cyclic 
GMP Levels 
Over the past six years an increasing number of hormones 
and other agents which cause increases in tissue cyclic GMP 
levels have been identified. A survey of the literature on 
this subject (summarised in Table 1.2) has revealed several 
interesting findings. 
The first direct proof of hormonally induced increases 
in cellular cyclic GMP levels was provided by George et al 
(1970), who perfused isolated rat hearts with acetylcholine 
and observed an elevation of myocardial cyclic GMP concentration 
wh:i,.c.h coincided with the first signs of cholinergically-
induced depression of cardiac function. Since then, stimulation 
of guanylate cyclase by acetyl choline and by the cholinergic 
agents carbamylcholine and methacholine has been shown to 
increase cellular cyclic GMP levels in many tissues, including 
those of the central nervous system .. 
rrhe actions of acetyl choline on the central nervous 
system, autonomic ganglia, and parasympathe·tic post-ganglionic 
fibres can be classified into two main types. The first type 
of stimulation increases progressively with dose, and is 
mimickeC;l by muscarine, an alkaloid extracted from the poisonous 
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TABLE 1. 2 
Hormones and Other Agents which Increase Tissue Cyclic GMP Levels 
Agent Tissue 
-, 
'-
:-;------
; . ACETYL CHOLINE Rat heart - perfused 
in vitro 
l 
'i;; 
o( -ADRENERGIC 
STIMUI,ATION 
(Noradrenalin 
or adrenalin 
& proprc;tnolol) 
Calf heart - slices 
in vitro 
Rabbit cerebellum -
slices in vitro 
Rabbit fundus mucosa -
strips in vitro 
Rat ductus deferens -
segments in vitro 
Rabbit gallbladder -
segments in vitro 
Human neutrophils -
in vitro 
Human umbilical artery -
strips in vitro 
Rat pancreas islets -
in vitro 
Human plasma 
Human urine 
Rat ductus deferens -
segments in vitro 
ANGIOTENSIN II Effect of infusion on 
human plasma nucleotide 
levels 
ASCORBIC ACID Human platelet 
aggregation in vitro 
AZIDE Rat liver, kidney, 
cerebral vortex, 
cerebellum in vitro 
Effect on 
cyclic AMP 
levels* & 
comments 
ｾ＠ or u 
u 
u 
u 
N.R. 
u 
u 
u 
u 
u 
small f 
ｳｬｩｧｨｴｾ＠
N.R. 
Reference 
George et a1 (1970) 
) Kuo et a1 (1972) 
) 
) 
) 
Amer & McKinney (1973) 
Schultz et al (1972) 
Amer (1974) 
Ignarro & George ＨｾＷＴｽ＠
Clyman et al (1975) 
Kuo ｾｾ＠ al (1975) 
Ball et al (1970,1972) 
Ball·et al (1972) 
Kaminsky et al (1970) 
Williams et al (1972) 
Schultz et al (1975) 
Rosman ｾ＠ al (1972) 
Goldberg et. al (1975 .) 
Kimura et al (1975) 
.. Rat adipocytes - iu vitro N .Ro Levelliers et al (1970) 
ｾ Ｍ ＭＭ Ｍ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠ｲ ｾ•＠
t 
Ｇ ｾ ＮＭ［Ｚ＠ . . ＭＮＮＮＮＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭ ＭｾｾＭ
.•: .. 
ｾ Ｍ［Ｌ＠ ' 
1:·:. 
ｾＮ＠ . 
ｾﾷ ﾷ＠
/-. 
., 
I · 
.·• 
:· ·f 
BRADYKININ 
CALCIUM 
CALCITONIN 
Human umbilical artery - U 
strips in vitro 
Infusion into human ' 
subjects - increase in 
urinary cyclic GMP 
Mouse splenic lymphocytes N.R. 
in vitro 
Mouse brain preparation 
in vitro 
----
Rat ductus deferens -
segments in vitro 
+ lonophore A23187 on 
rat parotid gland -
slices .ill vitro 
u 
u 
Cyclic 
AMP 
response 
I 
· Infusion into thyropara-
thyroidectomised rats -
increase in urinary 
cyclic GMP. •variable• 
ＭＭＭＭ ﾷ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭﾷＭＭＭＭＭＭＭＭＭＭ｟ＬﾷＭＭＭＭＭＭＭＭＭＭｾ＠
. .....  
,.,. 
l \., \ \ 
i 
ｾ＠
CARBAMYL-
CHOLINE 
Rat fat cells and liver 
slices in vitro 
---
Rat ductus deferens, 
intestinal smooth muscle, 
submaxiliary gland 
in yitro 
NoRa 
·u 
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Clyman et al (197 5} 
Kaminsky et al (1970) 
- -
Katigiru et al {197 6) 
Olson et al (1976) 
Schultz et al {1973a) 
Butcher (1975} 
Goldberg et al (197 3b) 
ＭＭｾ＠
Illiano et al (197 3) 
- -
Schultz et al (1972) 
ｲＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｲＭＭＭＭＭＭＭＭＭＭＭＭｲＭＭＭ ﾷ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＴ＠
t . 
.. 
CNS 
STIMUT..JATORY 
DRUGS 
CHOLECYSTO-
KININ/ 
PANCREOZYMIN 
Effects of picrotoxin, U 
pentetrazol, oxo-
· tremorine, harmaline, 
arecoline (and atropine) 
on mouse cerebellum and 
media 1 forebrain in vi '!P . 
Amphetamines on mouse N.R. 
brain in vivo 
---
Isoniazid on mouse NmR. 
cerebellum in vivo 
Rabbit gallbladder strips ｾ＠
in vitro 
Rabbit fundic mucosa * 
strips in vit£Q_ 
Guinea pig pancreas 
islets in vitro 
Guinea pig pancreas 
slices in vit£2_ 
t 
li 
Opmeer et. al {1976) 
Ferrendelli et al 
(1972) - --r 
Mao et al (1975) 
) Amer & McKinney 
) (1973) 
) 
) 
Howell & Montague 
(1974) 
Albano et al (1970) 
［ ｾ＠71"-------·--------A-----:------------------l---·----l----------·---·---
·' 
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COLLAGEN 
CONCANAVALIN 
A 
ERYTHRO-
ｐｏｅｾｔｉｎ＠
ｾＭａｍｉｎｏ＠
BUTYRIC ACID 
( 'GABA I) 
GASTRIN 
GLUCOSE 
GLUCAGON 
HISTAMINE 
INSULIN 
Platelet aggregation . N.R. 
in vitro 
Human peripheral U 
lymphocyte proliferation 
in vitro 
Rabbit bone marrow ｾ＠
culture 
Mouse cerebellum 
· slices in vitro 
Rabbit ｾｵｮ､ｩ｣＠ mucosa 
strips in vitro 
E. coli 
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Goldberg et al (1974) 
Hadden et al (1972) 
Rodgers et al (1976) 
Ferrendelli et al 
(1975) 
Amer & McKinney (1973) 
Goldberg et al (1973a) 
Human urine after i.vG 
injection 
Cyclic Williams et al (1972) 
Rabbit cerebral cortex 
and cerebellum slices 
in vitro 
Rabbit gallbladder and 
fundic mucosa slices 
in vitro 
Mouse lung 
Rat intestinal smooth 
muscle slices in vitro 
Human umbilical artery 
segments in vitro 
Rat fat cells and liver 
slices in v;b.tE.Q_ 
Cultured fibroblasts -
stimulation of 
proliferation 
AMPtt 
(plasma & 
urine) .. 
Cyclic 
GMP incr-
ease 
small, 
not seen 
in plasma 
? of 
renal 
origin 
t 
t 
N.R. 
u 
Kuo et al (197 2) 
Amer & McKinney (1973) 
Polson et al (1974) 
Schultz et al (1972) 
ｃｬｾｮ｡ｮ＠ et al {1975) 
Illiano et al (1973) 
Goldberg et al (1974) 
MAALOXONE 
(A centrally 
active acetyl 
choline 
Mouse cerebellum in vivo 
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N.R. Goldberg (1972) 
inhibitor) Ｚﾷｾ＠ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＫＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｲＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＱ＠
ﾷｾ＠ METHOCHOLINE Rat uter'us endometrial :··.-. 
,; 
;,:.-
'-
ｾＭＧＺＮ＠
•. ,.. 
OESTROGENS 
strips in vitro 
Dog urine 
Rabbit lung 
Oestrone and diethyl-
stilboestrol treated 
u Goldberg et al (1975) 
t Goldberg et a1 (1973b) 
u 
Kuehl et al (1974) 
ｾ Ｎ＠ ovariectomised rats -
l;,;·--o-x_y_r.r_o_c_I_N __ ＭｉｉＭＺＭＭＺＭＺＭｲＭＺＭＺＭＺＭｲＭＺＭＺＭ｣ＭＺ｟ｮ｟ｩ｟ＺＭｯＭＺＭｾＭｴＭｲＭｾＭＺＭＺＭ･ＭＭＭＭｬ｟ｳＭＫＭＭｵＭＭＭＭＭＭＭＭＭＭＭＭＭＫＭｇＭｯ｟ｬ｟､｟｢｟･｟ｲ｟ｧ＠ __ e_t_a_l __ (l_9_7_3b-)-4 
｛ ｾ＠ strips in vitro 
J> - PARATHYROID Effect of large 
l't HORMONE dose on:-t': 
i.v. 
''· ( '. PTH I ) ( human urine tt Kaminsky et al (1970) 
(_, ________ ＭｴＭＭＭＭＭｨ｟ｲ｟ｾＭｾＭ｡Ｍｾ｟ｲ｟ｬ｟ｾ｟Ｚ｟ｳ｟ｭ｟｡＠ ______ ·----+-t_t ＭＭＭＭＭＭＭｉＭｍ｟､｟ｾ｟ｉ｡｟｡｟ｾ｟･｟ｾ｟ Ｑ ｧ｟ Ｙ ｟ Ｗ＠ ａ｟Ｚ｟ｾ｟｡｟ｬ｟Ｈ｟ｬ｟Ｙ｟Ｗ｟Ｓ｟｢｟Ｉ＠ _ 
ｾ＠ ｜Ｂ ｾ＠
'·i . 
l ? i_ 
PHORBOL 
MYRISTATE 
ACETATE 
(PMA) (A 
tumour 
promoter) 
Mouse fibroblasts and 
epidermis in vitro 
u Estensen et al {1974) 
ﾷｾ ﾷ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＱＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭｾＭＭｾＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭｾ＠,( 
PHY'rOHAEMA-
GGLUTININ 
Human peripheral 
ｬｾｮｰｨｯ｣ｹｴ･ｳ＠ in vitro 
u Hadden et ｾ＠ (1972) 
ｩｾ ｴ＠ｾＭＭＭＭＭﾷＭＭＭＭｾＭＭＭＭＭＭＭＭｾﾷＭＭＭＭＭＭＭＭＭＭＮＮＮＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭﾷＭＴＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＮＭＮＮＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭｾ＠
1:\ 
t· 
:;··. 
ｩＭＮｾ＠
,f\-
f::. 
.. ﾷｾﾷ＠
·>• ［ﾷｾ ｾ ｾ＠
POTASSIUM Rat intestinal smooth 
muscle and submaxillary 
gland slices in vitro 
Human umbilical artery 
segments in ｾｩｴｲﾣ＠
Mouse cerebellum slices 
in vitro 
u Schultz et al (1972) 
u Clyman et al (1975) 
t Ferrendelli (1975) 
ｾ ＭＭｾＭＭＭＮＮＭＭＭＭＭＭＭＭＭＭＭｾｾＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭｾｾＭＭＭＭＭＭＭＭＭＭＭＭｾＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭｾｾＭＭＭＭＭｩ＠ｾ ［ｾＮＺ＠ PROSTA- Rat uterus endometrial u Goldberg et al (1973b) 
.. , GLAND IN F 2tX strips in vitro ｦ｜ｾ＠ Canine and bovine vein Cyclic AMP Dt1nham et al (1974) 
r···: segments in vi tJ;.Q. response 
i:'; 'variable' 
ｾＺ ｟ ﾷ＠ ＭＭｾＭＭＭＭＭＭＭＭＭｾ｟｟｟ＮｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾｾＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭｾｾＭＭＭＭＭＭＭＭＭＭＭｾｾＭﾷＭﾷＭｾＭＭＭＭＭＭＭＭＭｾ ｾ＠
; ｾ＠
' "' ｾ＠
.. . 
. . . . . . .. ..... .. Ｍ ＭＭＭＭＭＭＭＭＭＭＭＭ ＭＭＭＭｾ＠
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SECRETIN Guinea pig pancreatic t Howell & Montague I islets in vitro (1974) 
Rat liver homogenate t Thompson et al (197 3) 
I . 
Human umbilical artery u Clyman et al ( 197 5) 
strips in vitro 
-E·. {. SEROTININ 
Isolated·rat uteri u Goldberg et al (1973b) J . 
I 
Rat intestinal smooth u Schultz et al (1972) 
muscle slices in vitro 
, . 
ｾ ﾷ ｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｲＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠
ｉ ﾷｾＮ＠f: 
h· 
i> · ｾ ｾ＠
Jr : 
1J- ｾ＠
ｦｾ ｾ＠
ｾ ＺｩＮ ﾷ＠
,;,' 
SOMATOSTATIN 
(Growth 
hormone 
release 
inhibitory 
hormone, 
I GHRIH') 
TRIIODO-
THYRONINE (IT I) 
3 · 
Male rat intact anterior 
pituitary in vitro 
Effect of ｾＮｶ＠ •. T3 on dog liver J.n v1vo 
t 
t 
(plasma 
cyclic 
GMP-U, 
cyclic 
AMP t) 
Kaneko et al (1974) 
- -
Fernandez-Po! & 
Hays {1975) 
t· ｩｾ ｜ Ｎ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ ﾷＭ ﾷ ＭＭＭＭ ﾷ ＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠
} ｾ ﾷ ﾷ＠ MISCELLANEOUS STIMULI 
:j l 
ｩ ｾ＠ ,· 
ｩ ﾷ Ｎ ＢｩＮＮＭｾＮＺﾷ＠
r ..:. 
ANOXIA 
ELECTRO-
CONVULSIVE 
SHOCK 
LACTATION 
LIGHT 
STRESS 
Rabbit spleen in vivo ｾ＠
Mouse cerebellum and mid- t 
forebrain in vivo 
Rat mammary gland ? a 
prolactin 
effect 
cyclic 
ａｍｐｾ＠
Frog and calf intact NeR. 
retinae in vitro 
Mouse brain in ｾｾ＠ U 
Rodgers et al {1976} 
Lust et al {1976) 
Smith & Rillim.a (1975 
Goridis et al(( 1974} 
Dinnendahl {1975) 
ＮＮＬ｟ ｜ Ｚ ＮＮＺＺＮ｟ Ｈｽｾ ｟ ［ｾ＠ - • _______________ '______ _____ ___ ______________ _ 
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HORMONE REPLACEMENT.EXPERIMENTS 
ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｲＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＬＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠
HYPOTHALAMIC Rat anterior pituitary cyclic Peake et al (197 2) 
EXTRACT ｾＺ＠ • slices in vitro .. GMP t ｾＮ ＭｾﾷＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭｾｾＭＭＭＭＭＭｾｾｾｾ］］ｾＭＭＭＭＭＭＭＭｾｌＭｾ］ＭＭＭＭｾｾｾｾＭＭＭＭＭＭﾷＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠
［ ｾ＠ . 
. , .. 
ｃＺｾ＠
COMBINATION OF Hypophysectomised rats -
ACTH, LH, FSH, effects on urinary 
PRL, GH, TSH, cyclic GMP levels 
CORTISOL 
·* t = increase, H = large increase, U = 
NoR. = not reported. 
Urine 
cyclic 
GMPt back 
to normal 
unchanged , ｾ＠
Hardman et al 
{1969) 
= decrease, 
Symbols refer to cyclic AMP changes unless otherwise stated. 
______________________________ ...:_ __________ ---
fungus 1-\manita muscaria, and has, therefore·, been termed a 
'muscarinic' a·ction of acetyl choline. Those actions of 
acetyl choline which are not mimicked by muscarine show 
s·timulation at low dose levels and inhibition at higher dose 
levels, and can be reproduced by nicotine treatment. This 
second type of acetyl choline effect has, therefore, been 
described as 'nicotinic'. 
Most of the evidence to date points to the involvement 
of cyclic GMP in the mediation of 'muscarinic' cholingergic 
stimulation Ｈｾｯｬ､｢･ｲｧ＠ et al, 1973b). The observation by 
Goldberg et al (1973a) that stimulation of rat sciatic nerve, 
---
which is linked only to 'nicotinic' type acetyl choline 
· receptors, did not elevate cyclic GMP levels in the rat 
gastrocnemus muscle, indicates that 'nicotinic' cholinergic 
effects may not be associated with cyclic GMP accumulation. 
Cholinergic, oxytocin, serotonin or prostaglandin ｆ Ｒ ｾ＠
activation of uterine smooth muscle contraction (Goldberg et 
al, 197 3b) and acetyl choline, ·serotonin or histamine 
· stimulation of intestinal contractility (Schultz, 197'2) 
is accompanied by rapid increases in tissue cyclic GMP levels, 
while cyclic AMP levels remain unchanged. These actions are 
in opposition to those produced by •fadrenergic' stimulation, 
which increases cellular cyclic AMP .levels (Robison et al, 
1971). Target organ receptor sites for adrenergic stimulation 
were first classified into two main types by Ahlquist (1948), 
depending on whether catecholamines and related compounds 
excited ( '()( adrenergic' receptors) or· inhibited ( 'p adrenergic' 
receptors) smooth muscle contractions. ﾷｾﾷ＠ and 'f' receptor 
effects may be studied independently by the use of adrenalin 
or noradrenalin stimulation together with the utilisation of 
specific ﾷｾﾷ＠ blockers (such as phentolamine) or 'fo' blockers 
(such as propranolol). The specific 'f' adrenergic agonist, 
isoprenaline (isopropylnoradrenalin), may also be used. 
There is evidence that ｾＭ｡､ｲ･ｮ･ｲｧｩ｣＠ stimulation is 
associated with increases in tissue cyclic GMP levelso 
Administration of catecholamines, with and without 'fX.' or •(J• 
blocking agents, to . human subjects has clearly demonstrated 
an elevation of plasma and urine cyclic GMP levels in response 
to ｾＭ｡､ｲ･ｮ･ｲｧｩ｣＠ stimuli. Plasma and urine cyclic AMP levels 
increase in response ｴｯｾﾷＭ｡ｾｲ･ｮ･ｲｧｩ｣＠ activation (Ballet al, 
1970 and 1972; ｋ｡ｭｩｮｳｫｩｾ＠ al, 1970; Williams et al, 1972). 
Prostaglandins F 2D<. and E1 , which have markedly different 
effects on smooth muscle, also produce quite different cyclic 
nucleotide responses. Prostaglandin ｆ Ｒ ｾＬ＠ which stimulates 
-
contraction of smooth muscle, increased canine and bovine vein 
segment cyclic GMP levels with 15 to 30 seconds of its 
｡ｰｰｬｩｾ｡ｴｩｯｮ＠ while prostaglandin E1 , which is a smooth muscle 
relaxant, decreased ｦｲｾ｣ｹ｣ｬｩ｣＠ GMP/cyclic AMP ratio in the 
same .tissues (Dunham et g, ＱＹＷｾＩＮ＠
The reported effects of cholecystokinin (CCK) on 
several tissues provide an example of a hormone -which can 
initiate different cyclic nucleotide patterns of response in 
different target tissues. CCK stimulation of contraction in 
rabbit gallbladder and fundic mucosa strips . is associated with 
increased cyclic GMP and decreased ·cyclic AMP content (Amer 
and McKinney, 1973) while its relaxation effects on the rat 
-- ---- ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠
sphincter of Oddi . are associated with increased cyclic AMP 
levels in this tissue (Anderson, 1972). Cyclic GMP levels 
were not measured in this last study. Cyclic AMP changes 
following CCK stimulation of the pancreas appear to differ fbr 
islets and for the whole tissue. The action of CCK on guinea 
pig pancreas islets produces a rise in both cyclic GMP and 
cyclic AMP content (Howell and Montague, 1974) while its 
action on guinea pig pancreas slices has been reported to 
i?crease cyclic GMP only (Albano et al, 1976). 
Calcium and the calcium regulatory horJmones parathyroid 
hormone (PTH) and calcitonin have been reported to influence 
urinary cyclic GMP excretion in some cases. Kaminsky and 
colleagues (1970a) showed that the infusion of 'hypercalcaemic' 
doses of PTH (450 units over 75 minutes) resulted in a doubling 
of urinary cyclic GMP excretion in human subjects, although 
low PTH doses raised cyclic AMP excretion'only. Calcium . 
infusions in human subjects also produced this effect, but 
the possible involvement of calcitonin was disproved by the 
observation that infusion of ｣｡ｬ｣ｾｴｯｮｩｮ＠ into human subjects 
did not increase urinary cyclic GMP excretion (Kaminsky et al, 
1970a: ｋ｡ｭｩｮｳｫｹｾ＠ al, 1970b; Murad and Pak, 1972). Goldberg 
and coworkers {1973b)did, however, observe an immediate 2-3 
fold increase in urinary cyclic GMP excretion on giving an 
infusion of calcitonin to thyroparathyroidectomised rats. 
Tissue cyclic GMP increases in response to calcium_ have 
been established for in vitro preparations of mouse · splenic 
ｬｾｵｰｨｯ｣ｹｴ･ｳ＠ (Katigiru et al, 1976) mouse brain tissue (Olson 
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et al, 1976), rat ductus deferens segments (Schultz et al, 
1973a) and rat parotid gland slices (Butcher, 1975). 
Studies on brain cyclic nucleotide levels following 
the administration of central nervous system (CNS) stimulatory 
and depressant drugs have indicated that cyclic GMP levels are 
strongly influenced by these agents. Cerebellar levels of 
cyclic GMP are altered by drugs which influence cholinergic 
transm.issi.on (Ferrende1li et al, 1970: Dinnendahl and Stock, 
ＱｾＷＵＩ＠ and catecholaminergic transmission (Ferrendelli et al, 
197 2) . Cyclic GMP has an excitatory effect on the brain, 
mimicking the action of acetyl choline, and opposing the 
effects of cyclic·AMP. Evidence that atropine, a potent 
antagonist of the 'muscarinic' actions of acetyl choline, does 
not inhibit the brain excitatory response to cyclic GMP suggests 
that cyclic GMP has a post-synaptic function (Ferrendelli et al, 
1972). 
CNS stimulatory drugs such as picrotoxin, pentetrazol, 
oxotremorine, harmaline, arecoline and amphetamines increase 
brain cyclic GMP levels, while depressant drugs, such as 
diazepam and pentobarbital, produce a dose dependent decrease 
in cyclic GMP levels (Opmeer et al, 1976). 
Opmeer and coworkers (1976) have discussed the 
relationship between cyclic GMP and changes in the concentration 
of .ts'-amino butyric acid (GABA), a potent inhibitor of CNS 
activity. ｲｲｾｨ･＠ same stimulatory . drugs which increase brain 
cyclic GMP.content also diminish the action of ｇａｂａｾ＠ either 
by decreasing brain levels or by blocking GABA receptors 
(Curtis et al, ＱＹＶＹｾ＠ Mao et al, 1975). Although very large 
-- -- -- --
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doses of GABA increase cyclic GMP levels in mouse cerebellum 
slices (Ferrendelli, 1975) there is little evidence to support 
the theory that GABA may be direc-tly involved in the regulation 
of cyclic GMP pr0duction in the brain. 
Ferrendelli (1975) has also demonstrated that agents 
which are known to cause 'depolarisation' of brain cells, 
such as potassium, veratridine, ouabain and glutamate, increase 
both cyclic GMP ｾｮ､＠ cyclic AMP concentrations in mouse 
cerebullar slices in vitro. He has postulated that the cyclic 
GMP change following the depolarisation of excitable cells 
is not caused by release of neurotransmitters such as acetyl 
choline, norepinephrine, glycine or GABA, but is more directly 
involved in a mechanism related to the triggering of the 
release of these neurotransmitters. The recent studies of 
Dretchen et al (1976) on in vivo ｳｴｩｭｵｬｾｴｩｯｮ＠ of cat motor 
axons by butyrated cyclic nucleotides, supports this hypothesis., 
The oestrogens 17ft-oestradiol and diethylstilboestrol 
have been observed to increase cyclic GMP levels in the uteri 
of ovariectomised rats in vivo and in vitro over periods of 
three and twenty four hours respectively (Kuehl et Q!, 1974; 
Goldberg et al, 1975). Cyclic GMP increases could be 
prevented by the coadministration of progesterone (Kuehl. et 
al, 1974) and the major oestrogen-promoted cyclic GMP rise 
was found in the endometrial layer, where the oestrogen 
receptors are concentrated (Nicolet al, 1974). 
S·t.eroid hormones are thought to act on target cells 
by a •two-step• mechanism, originally proposed independently 
by Jensen et al {1967) and by Shyamala and Gorski (1967) 
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to explain the interaction of ＱＷｾＭｯ･ｳｴｲ｡､ｩｯｬ＠ with rat uterus. 
In this two-step model of steroid hormone action, hormones 
enter the cytoplasm of a cell by diffusion across the plasma 
membrane. Target tissue cells for a particular hormone possess 
specific cytoplasmic •receptor' proteins for this hormone, which 
are instrumental in transferring the steroid into the cell 
nucleus. The steroid-receptor complex binds to nuclear 
I aCCeptOr I SiteS Which appear tO be heterogeneOUS 1 haVing bot.h 
protein and DNA components (Malkinson, 1975). Cyclic AMP may 
be involved in the transport of oestrogens from the cell 
surface into the nucleus (Szego, 1972). 
It is evident that cyclic GMP and cyclic AMP are 
implicated in the action of steroid hormones, which penetrate 
the cell membrane, and do not act in accordance with the 
second messenger concept. Cyclic nucleotide responses to 
steroid hormones are slower than those commonly found for a 
second ｭｾｳｳ･ｮｧ･ｲ＠ system. Steroid hormones are known to 
stimulate protein synthesis, and their influence on both 
transcription and translation processes has been reported 
(Bitensky and Gorman, 1972). It has been established that 
glucocorticoids have an overall 'permissive• action on the 
production of cyclic AMP by the second messenger system in 
response to stimulation by several hormones (Thompson and 
Lippman, 1974). 
Hardman, Davis and Sutherland (1969) investigated the 
effects of endocrine gland ablation on rat urinary cyclic 
nucleotide levelso Hypophysectomy resulted in a 50% drop 
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in urinary cyclic GMP levels, while cyclic AMP remained 
unchanged. Cyclic GMP excretion was res·tored to normal by 
the administration of cortisol with 'pharmacological' but not 
'physiological' doses of thyroxine. A mixture containing 
'physiological' doses of each of the hormones, corticotrophin 
(ACTH), leutenising hormone (LH), follicle stimulating 
hormone (FSH), prolactin (PRL), growth hormone (GH}, thyro-
trophin (TSH) and cortisol was necessary to restore urinary 
cyclic GMP excretion to normal. More recently, thymus, 
lung, liver, spleen and testis of hypophysectomised rats 
have been reported to contain only 50% of tne control level 
of cyclic-GMP (Goldberg et !!.!, 197 3b). Adrenalec·tomy has 
been shown to reduce rat urinary cyclic GMP levels slightly; 
cortisol replacement therapy restored cyclic GMP excretion to 
normal (Hardman et al, 1969)e In contrast to this finding, 
Goldberg and coworkers (1973b) have describeq cyclic GMP· 
increases in the lungs (25% increase) and renal tissue (20% 
increase) following adrenalectomy in rats. Hardman and 
associates (1969) also not.ed that small doses of thyroxin 
restored cyclic GMP and cyclic AMP excretion to normal in 
thyroparathyroidectomised rats. 
Although there is still much to discover in the field 
of hormonal influence of cyclic nucleotide ｬ･ｶ･ｬｳｾ＠ it is 
possible to make some generalisations from the available 
evidence:-
(i) Most of the experiments which have revealed 
increases in cyclic GMP levels as a result 
of stimulation have employed in vivo 
treatment or have used in yitro incubations 
43 
of tissue strips, slices, or whole cells. 
There are very few cases in which cyclic 
GMP increases have been shown in broken 
cell and purified membrane preparations. 
(ii) In the majority of reports in which cyclic 
AMP changes have also been monitored, they 
decreased or remained unchanged at the time 
of ·cyclic GMP increase. 
＼ｾｾｊ Ｎ Ｉ＠ The best-established systems in which cyclic 
GMP mediation of a hormone stimulus occurs 
are 'muscarinic' cholinergic neurotrans-
mission, o<-adr.energic stimulation and the 
stimulation of smooth muscle contraction by 
various agents. 
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1.2.5 'Mono-• and 'Bidirectional' Control Systems and the 
ｾｩｮＭｙ｡ｮｧＧ＠ ｾｰｯｴｨ･ｳｩｳ＠
There are at least two basic types of control mechanisms 
which govern cell metabolism, and these have been termed 'mono-' 
and 'bidirectional' systems by Goldberg and colleagues 
(Goldberg et al, 1974). In a monodirectional system, cells 
only respond to one type of regulatory signal, a stimulatory 
one. Non-activated cells are quiescent, become 'switched on' 
by an appropriate stimulus, and passively revert to a non-
functional state when stimulation ceases. Bidirectional 
systems have a more dynamic control in that activation and 
inhibition are mediated by separate s·timuli. Cell activity 
may be determined by the balance between two opposing ｩｮｦｬｵ･ｮ｣･ｳｾ＠
Goldberg et al (1975) have attempted to describe the intra-
---
cellular basis of these control processes in terms of cyclic 
AMP and cyclic GMP changes. In monodirectional control both 
cyclic nucleotides often act in parallel to produce an 
｡､ｾｻｴｩｶ･＠ influence on cell metabolism. Bidirectional systems, 
on the other hand, are associated with cyclic nucleotide 
influences which are antagonistic: cyclic AMP pulls the 
metabolism in one direction while cyclic GMP opposes this. 
The 'Yin-Yang' (or 'dualism') hypothesis (Estensen et al, 
1973; Goldberg et al, 1975 and 1976) draws a comparison 
between the Eas·tern concept of two opposing natural forces 
('Yin' and 'Yang') and the opposing influences of cyclic AMP 
and cyclic GMP on the cell in bidirectional control systems. 
The Yin-Yang hypothesis also ｡ｬｬｯｷｾ＠ for the possibility that, 
under certain circumstances, the two forces may enter into a 
mu·tual interaction with a resulting synergistic effect. 
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. The evidence of reciporc'al cyclic nucleotide changes 
following hormone stimulation in many tissues (Table lo2) 
supports thi$ theory. In partictilar, Goldberg and colleagues 
(Goldberg et al, ·1975) have discussed the relevance of changes 
in cyclic nucleotide balance to the control of cardiac and 
smooth muscle contraction, platelet aggregation, baceerial 
metabolism, cell proliferation" .and the mediation of oestrogen 
action on the uterus. 
If cyclic AMP and cyclic GMP act in opposition to each 
other in certain systems, the relative proportion of one to 
the other may be more important as a determinant of cell 
function than the absolute level of either. Measurements of 
cyclic AMP alone are therefore of limited value, and the 
monitoring of both cyclic nucleotides may provide a much truer 
indication of intracellular responses to hormonal stimulationft 
The balance between intracellular cyclic nucleotides 
can be influenced in several ways. The nucleoside triphosphate 
GTP stimulates both adenylate and guanylate cyclases, while 
both ATP and cyclic AMP have inhibitory effec·ts on guanylate 
cyclase (Section 1.2elb). It is possible that a common 
nucleotide cyclase enzyme may be influenced to produce either 
cyclic AMP or cyclic GMP, and that the cyclic nucleotides 
themselves can be interconverted in some tissues (Section 1 .. 2.1c). 
The intracellular level of one cyclic nucleotide may 
influence the activity of the phosphodiesterase enzyme for 
the other (Section 1.2e3). 
A third factor which may participate in intracellular 
control processes is the level of ionised calcium. 
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1. 2. 6 · 'l'he Importance of Calcium as an Intracellular Messenger 
The Yin-Yang hypothesis presupposes that each cyclic 
nucleotide has a direct act:ion on effector systems within 
the cellco In the case of cyclic GMP, this direct action is 
not always evident. It could be argued, for example, that 
the ｰｲｩｭｾｲｹ＠ intracellular stimulus in the induction of smooth 
muscle contraction is an increase in cytosol calcium ion 
concentration, and that cyclic GMP changes are subsequent to 
this (Schultz et ｾＬ＠ 1973b). Cyclic GMP may act as a ··third 
messenger' in this situationco 
Cytoplasmic calcium ion levels have been reported to 
be in the region of 10-6 mol/1 (Rasmussen ･ｾ＠ al, 1975}, 
. -3 I cons1derably lower than the concentration of 10 mol 1 found 
in the extracellular fluid. Within the cell, calcium seems 
to be sequestered in mitochondria (Chance, 1965) and endo-
plasmic retention (Ebashi and Endo, 1968) by energy dependent 
mechanisms. Mitochondrial calcium levels have been estimated 
to be in the region of 10-4 mol/1, and the calcium, although 
readily exchangeable, is present largely as calcium phosphate 
(Rasmussen et al, 1975). Ionised calcium levels in the 
cytosol could be raised as a result of increased permeability 
of the cell plasma membrane to calcium, or by liberation of 
calcium from intracellular (mitochondrial) pools. Plasma 
membrane permeability to calcium can be altered, with little 
change in membrane potential, by ACTH (adrenal cortex; Rubin 
et al, 1972), serotonin (insect salivary gland; Prince and 
Berridge, 1973) and acetyl choline and CCK (exocrine pancreas; 
Heisler et al, 1972). Calcium influx into the cell can also 
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be triggered by membrane depolarising agents. Rasmussen et 
al (1975} have proposed that mitochondrial release of calcium 
is a major factor in mediation of hormonal effects, and have 
suggested that mobilisation of as little as 0.5% of mito-
chondrial calcium ion would be sufficient ·to activate the cell. 
Berridge (1976}, in a-detailed survey of the 
significance of calcium in intracellular metabolism, has put 
forward a convincing case for the inclusion of calcium in 
the list of intracellular messengers, and has interpreted 
mono- and bidirectional control mechanisms in terms of the 
interaction of cyclic AMP with calcium ion, rather than with 
cyclic GMP. In general, mohodirectional systems could be 
explained in terms of cyclic AMP enhancement of a calcium-
activated signal, whereas in bidirectional systems cyclic AMP 
would act in opposition to the influence of calcium. 
Calcium ion is an important activator of guanyl cyclase 
in intact cells, and in all cases which have been studied, 
increases in intracellular calcium levels are associated with 
a corresponding increase in cyclic GMP (Berridge, 1976}. 
Rasmussen et al (1975} have proposed that a possible explanation 
of cyclic GMP and calcium mediation of the cholinergic 
activation of smooth muscle is that acetylcholine causes an 
influx of calcium into the cell, which acts as a trigger 
mechanism for the production of cyclic GMP. Increased cyclic 
GMP levels would then release more calcium ion from intra-
cellular pools which would bring about the main physiological 
response of the cell. 
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Cytoplasmic calcium ioh can inhibit adenylate cyclase, 
and is an important modulator of protein kinase and cyclic 
nucleotide phosphodiesterase activity. Although the available 
evidence is incomplete, it seems that one of the means by 
which the cyclic nucleotides cyclic AMP and cyclic GMP exert 
control within the cell is by interaction with, and regulation 
of cellular calcium metabolism. There is at present little 
data to prove whether cyclic GMP or calcium is tl1e 'prime 
mover' in cell activation in cases where levels of both 
messengers are increased. Figure 1.2B illustrates possible 
interactions of calcium and cyclic GMP in intracellular control 
processes .. 
The intracellular mechanisms of hormone action are still 
a subject for conjecture. At present, the complexity of 
control mechanisms is increasing, but it is hoped that a clear 
pattern will soon appear. 
so 
FIG.l .2B. Some interrelationships between cyclic AMP, 
cyclic GMP and ca2+ in cellular control processes. 
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. Hormone 2 may stimulate guanylate cyclase by producing a calcium ion 
influx into the cell (1). Cyclic GMP in turn could promote the release 
of calcium from intracellular pools (2) which may result in physiological 
responses in addition to those produced by protein kinase activation. 
ca 2+ has an inhibitory influence on adenylate cyclase (3) and stimulates 
cyclic AMP POE (4), which tends to decrease cyclic AMP levels.In turn, 
2+ 2+ cyclic ａｾＱｐ＠ can reduce cytosol Ca levels by stimulation of Ca extrusion 
from the cell (5) or sequestration in intracellular pools (6). 
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1. 3 Tissue and Ex-tracellular Fluid Cyclic' GMP Levels 
lo3.1 Tissue Cyclic GMP Levels 
Cyclic GMP was first reported to be a natural constituent 
of mammalian tissues (rat kidney,_ liver and brain) by Goldberg 
ｾ＠ al (1969) , and by Ishikawa and colleagues (1969) who also 
demonstrated the presence of cyclic GMP in the frog, minnow, 
cricket and earthworme All phyla of the animal kingdom whose 
tissues have been examined to date contain cyclic GMP. 
A large majority of the animal tissues which have been 
investigated possess less than 100 picomolas of cyclic GMP per 
gram wet weight of tissue, with cyclic GMP levels one 
tenth to one hundredth of those for cyclic ａｍｐｾ＠ Some tissues, 
either in the resting state, or as a result of ｳｴｩｭｵｬ｡ｴｩｯｮｾ＠ may 
however contain comparable cyclic GMP and cyclic AMP levels. 
This situation occurs in tissues from rat and mouse cerebellum, 
rat thymus and lung, sperm from several sources, bovine retinae, 
human lymphocytes, guinea pig macrophages and some insects 
(Table le3A).. Increased cyclic GMP levels have also been 
discovered in members of the plant kingdom. The fast-growing 
meristematic region of pea and bean seedlings possesses increased 
cyclic GMP levels (Haddox et al, 1974) and the bacteria ｾＮ｣ｯｬｩ＠
and B.licheniformis contain high cyclic GMP levels when grown 
on glucose, but not when grown on succinate (Goldberg et al, 1973). 
The report by Ishikawa et al (1969) that •crickets• (the 
species was not mentioned) contained 2,500-3,800 picomoles 
of cyclic GMP per gram wet weight of tissue, with cyclic GMP/ 
TABLE ·1, 3A 
Tissues with a high cyclic GMP content 
TISSUE 
Cerebellum 
ｉｮｴ･ｳｴｩｮｾ＠
(Proximal ｾ＠
of the small 
intestine) 
ｲｾｵｮｧ＠
Lymphocytes 
Macrophages 
Retinae 
Retinae 
(Dark adapted 
rod outer 
segments) 
Sperm 
Thymus 
Whole insect 
Male accessory 
sex. glands 
SPECIES 
Mouse 
Rat 
Rabbit 
Ra·t 
Rat 
Rat 
Rat 
Human 
Human 
Guinea pig. 
Mutant mouse 
Bovine 
Human 
Bovine 
'!'rout 
Sea Urchin 
Rat 
Cricket 
(Acheta 
domesticus) 
Cricket 
(Acheta 
ｾＭｾｆｩ｣ｵｳＩ＠
LEVEL* 
630 
860 
130-300 
100-150 
1160 
480-620 
150 
1000-1500 
ＹＰＰＭｾＲＵＰＰ＠
500-1000 
REFERENCE 
Steiner et al (1972) 
) Kuo et al 0.972) 
) 
Ishikawa et al (1969) 
Kuo et al (1972) 
MuraOland Gilman (1971) 
Kobayashi and Fang (1975) 
Steiner et al {1972) 
Hadden et al (1972) 
Goldberg et al (1973b) 
900 pmol/ Farber and Lolley (1974) 
mg protein 
200-600 Krishna et al (1975) 
pmol/mg · 
protein 
620 
120 
230-300 
100-900 
560 
2500-3800 
225-472 
pmol/mg 
protein 
Gray (1970) 
Garbers et al (1971) 
Gray (1970)-
Gray (1970) 
Goldberg _et al (1973b) 
Ishikawa et al (1969) 
Fallon and Wyatt (1975) 
1-.·pmol/g wet weight tissue unless otherwise stated 
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cyclic AMP ra·tios of between ·2 and 3, is :r;:a rticularly 
interesting. These cyclic GMP levels are 100 to 1000 times 
greater than those in typical vertebrate tissues. Fallon 
and Wyatt (1974 and 1975) have studied the cyclic nucleotide 
levels in Acheta domesticus, the crickets which they believe 
Ishikawa used, and other related species. They have confirmed 
the presence of cyclic GMP at high concentrations in the adult 
Aclieta domesticus. The male accessory sexual gland of this 
insect, with levels of 2000 picomoles of cyclic GMP per gland 
and cyc1i.c GMP/cyclic AMP ratios of over 100, was identified 
as the major source of this cyclic nucleotide. Of the other 
orthoptera which Fallon and Wyatt investigated, only the members 
of the subfamily Gryllinae · showed increased cyclic GMP content 
in the male accessory sexual glands, although levels were lower 
than those found in Acheta domesticus. 
----
In spite of this many 
of the insect abdominal cyclic GMP levels were still comparable 
with the highest cyclic GMP levels reported in vertebrate tissues. 
Rod outer segments from the dark-adapted bovine retina 
l1ave been reported to contain 550 picomoles of cyclic GMP/mg 
protein, with cyclic GMP/cyclic AMP ratios of. 100 (Krishna 
et al, 1975). This is the only example of a tissue which is 
known to possess comparable cyclic · GMP levels to those of 
Acheta domes ·ticus. 
Tissue cyclic GMP content can be increased by many 
hormones and other agents, and these were discussed in section 
1.2. 
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1.3.2 ·The Identification of cyclic UMP and Cyclic CMP in Tissues 
Attempts by several groups of workers to identify other 
cyclic nucle6tides in urine or animal tissues were unsuccessful 
(Price et al, 1967 ｾｴＮＮＮ＠ Hardman et a!, 1966; Steiner et al, 1970}'. 
Recently two more cyclic nucleotides have been detected by 
chrorna·tographic analysis of tissue and urine samples . Cyclic 
UMP has been isolated from rat liver extracts (Bloch,l975a), 
and cyclic CMP has been found in relatively high concentration 
in an acid soluble fraction of cultured leukaemic Ll210 cells, 
in the urine of patients with acute myelocytic leukaemia, and 
in regenerating rat liver (Bloch, 1975b). Exogenous cyclic 
CMP was shown to exert a strong positive influence on cell 
proliferation in the cultured leukaemic Ll210 cell system, 
and rapidly reversed the inhibitory effect on growth which was 
seen with cyclic ｾｬｐＬ＠ cyclic GMP and cyqlic UMP (Bloch, 1975b). 
1.3.3 Cyclic GMP in Extracellular Fluids 
The processes by which cyclic nucleotides reach the 
extracellular fluid from tissue cells have yet to be 
elucidated. Cyclic nucleotide loss from cells may be the 
result of simple diffusion or it may involve an active transport 
process. Active extrusion of cyclic nucleotides from cells 
could provide another means of regulating intracellular levels 
in addition to control of production and degradation within 
the cell. Pigeon erythrocytes have the capacity to 'pump' 
cyclic AMP out against a concentration gradient (Davoren and 
Sutherland, 1963) and the extrusion of cyclic AMP by several 
strains of E.coli can also be explained in terms of an energy 
requ:iring process (Makman and Sutherland, 1965; Pastan and 
Perlman, 1970) • 
Little is kno\1'/!1 of ·the physiological effec·ts of 
extracellular cyclic nucleotideso Cyclic AMP can act 
･ｾｴｲ｡｣･ｬｬｵｬ｡ｲｬｹ＠ to promote slime mould aggregation and 
differentiaton (Bonner et ｡ｬｾＢ＠ 1972; Ashworth, 1974). Contact 
inhibition of cultured human fibroblast growth can be increased 
6 2' by exposure to exogenous N -0 -dibutyryl cyclic AMP, which 
crosses lipid membranes more readily than cyclic AMP (Pastan 
1972)". Cyclic AMP also suppresses the tumorigenicity of 
skin cells which have been transformed by virus treatment 
(Reddi and Constantinides, 1972), Blood glucose levels of 
crayfish and fiddler crabs can be increased by injection of 
large doses of cyclic AMP, cyclic GMP, 5'-AMP or adenosine 
into the pericardia! cavity· {Spindler et al, 1976) .. 
Mobilisation of glucose from glycog:en-con·taining tissue probably 
occurs through the action of 'hyperglycaemic neurohormone' which 
is released from the eyestalks of these crustacea, rather than 
by. di·rec·t stimulation of phosphorylase by the cyclic nucleotides. 
Antibody production in antigen-sensitive cells is 
stimulated by an optimum cyclic AMP/cyclic GMP ratio, while 
cyclic AMP alone suppresses this process {Watson et al, 1973). 
The intravenous administration of pharmacological doses 
of cyclic AMP into human subjects has been shoM1 to produce 
hyperglycaemia, steroidogenesis, fatty acid changes, a marked 
antidiuresis, cardiac acceleration and increased cardiac 
outpu·t (Lev·ine, 1968a,b; Levin.e et al, 1968). In view of the 
fact that cyclic AMP levels of up to 10,000· times the 
physiological concentration were required to produce 
physio16gical responses in human tissues, a role of cyclic AMP 
as an extracellular messenger in man seems unlikely. 
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Broadus and colleagues (1970a) made a detailed study 
of kinetic parameters and renai clearance of plasma cyclic 
nucleotides in man following the intravenous administration 
of tritiated cyclic AMP and cyclic GMP. They concluded that 
in the basal state there is a dynamic equilibrium between 
intracellular and extracellular compaJ:-tments for both cyclic 
nucleotides .. Distribution volumes for cyclic AMP and cyclic 
GMP were larger than the extracellular fluid volume by factors 
of 1.5 and 2.3 respectively, and evaluation of the kinetic 
data provided evidence for a two-way traffic of nucleotides 
from, and into tissue cells. Plasma 'production' rates 
were estimated to be 9-17 nmol/min for cyclic AMP and 7-13 
. · nmol/min for cyclic GMP. Both tritiated cyclic nucleotides 
had a half life of approximately 30 minutes in plasma, 
although Barling and colleagues (1974) have reported a plasma 
half life of 14-16 minutes for a pulse of endogenous cyclic 
AMP · produced by PTH infusion. Even though cyclic nucleotides 
are rapidly removed from plasma in man, the kidneys dispose 
of only 15% of the plasma cyclic nucleotide -content; the 
remaining 85% is taken up by extra-renal tissues (Broadus 
et ｾＡ｟Ｌ＠ 1970a). 
Perfused rat liver rapidly takes up both cyclic 
nucleotides from the perfusion medium (Exton et al, 1971). 
Heikkinen (1977) has studied the tissue distrubi.t;.ion .of 
tritium in the cat 105 minutes after a single intravenous 
injection of [8- 3I:fl cyclic AMP. Increased . radioactivity 
relative to the plasma level was found in' the liver (163-fold 
concentiation), kidney (55-fold concentration) and lung 
(8-fold concentration). Several organs (for example, liver, 
lung, kidney) may be involved in simultaneous removal and 
addition of cyclic nucleotides, and although there may be 
no net change in cyclic nucleotide levels between the arterial 
and venous blood which perfuses a tissue it may still be highly 
active in terms of cyclic nucleotide turnover. 
Cyclic nucleotides do not bind to ｰｬ｡ｾｭ｡＠ proteimto 
｡ｮｾ＠ extent (Broadus et al, 1970b). There is little evidence 
for a contribution by the formed elements of blood to plasma 
cyclic nucleotide levels although cyclic AMP concentrations 
are relatively high in leukocytes (Strossel et al, 1970) and 
platelets (Cole et al, 1971). There is no significant 
degradation of cyclic nucle9tides by blood cells (Broadus 
et .al, 1970a). Cyclic nucleotide phosphodiesterase activity 
has been demonstrated in serum a·nd plasma from the human, dog, 
rabbit, and rat (Asano and Hidaka, 1975). Human plasma 
phosphodiesterase activity was 1.6 pmol/min/ml for cyclic AMP 
and 2.8 pmol/min/ml for cyclic GMP, while human serum 
activities were 1.8 pmol/min/ml (cyclic AMP) and 3.8 pmol/ 
min/ml (cyclic GMP). Plasma phosphodiesterase activity for 
each cyclic nucleotide was five times higher in the rat than 
in man. All species showed an increased phosphodiesterase 
activity in serum. This was particularly marked in the rat, 
and was probably due to enzyme release from pmtelets 
Ｈｐ｡ｴｴ･ｲｳｯｮｾ＠ al, 1975). 
lt is . therefore necessary to inhibit cyclic nucleotide 
ｰｨｯｳｰｨｯ､ｩ･ｾｴ･ｲ｡ｳ･＠ activity when collecting blood samples for 
cyclic nucleotide measurements (Section 1.5.4b). 
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.Plasma cyclic GMP concentrations, which are in the 
region of 5 nmol/ 1, are approximately half those found for 
plasma cyclic AMP. The levels reported by several research 
groups show reasonable agreement (Table 1.3B). 
Circadian rhythms for plasma cyclic AMP have been 
described (Holmes et al, 1974). There would seem to be at 
least two populations in normal subjects, with cyclic AMP 
levels reaching a maximum either in the morning or in the 
afternoon. Little data is available on plasma cyclic GMP 
variations, although Murad and coworkers (1975) commen·t tha·t 
they have observed similar circadian patterns in both plasma 
cyclic AMP and cyclic GMP in studies on normal adults. 
Plasma cyclic AMP levels are increased by vigorous 
exercise (Karlberg et al, 1974; Holmes, 1975) and return to 
pre-exercise levels after approximate1y .one hour. 
A rise in plasma cyclic GMP levels may be promoted by o<-
｡､ｲｾｮ･ｲｧｩ｣＠ stimulation, angiotensin II infusion, and by large 
intravenous doses of parathyroid hormone {Table 1.2). Insulin, 
which decreases intracellular cyclic AMP levels {Robison ｾｴ＠
?1, 1971; Park et al, 1972) and increases tissue cyclic GMP 
content in some experiments {Illiano et al, 1973; Goldberg et 
al, 1974) has no ｳｩｧｮｩｦｩｾ｡ｮｴ＠ effect on plasma cyclic 
nucleotide levels within 15 minutes of its intravenous 
injection {Siddle et al, 1976)o 
Human semen contains very high concentrations of cyclic 
AMP and increased cyclic GMP concentrations (Gray, 1970). It 
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is probable that cyclic AMP is deriv·ed mainly from the genital 
tract, since there is little difference in the cyclic AMP 
content of seminal plasma and whole semen from normal or 
vasectomised men (Gray, 1970). Human milk., another exocrine 
secretion, again has a high cyclic AMP content (0.8-8 nmol/ml; 
Kobata ｾ＠ ｾｾ＠ 1961}. Cyclic AMP has also been detected in 
human saliva (Stefanovich and Wells., 1971), amniotic fluid 
(Broadus et al" 1971), rat bile (Levine et al, 1969) and 
canine gastric juice (Broadus et al, 197l)o 
Cyclic nucleotides are present in cerebrospinal fluid 
at approximately the same concentrations as in plasma (Table 
1.3B). Rudman et al (1976a) have concluded that the CSF 
cyclic nucleotide decreases which they observed in comatose 
patients were a result of alterations in central nervous system 
activity rather than of changes in transport of cyclic nucleo-
tides from plasma into .CSF. The view that CSF cyclic nucleo-
tide concentrations may be independent of plasma concentrations 
is supported by the observation of Brooks et al (1976), that 
CSF cyclic AMP concentrations did not alter in seven patients 
during a glucagon infusion regime which produced a 25- to 40-
fold elevation in plasma cyclic AMP levels. 
Urinary cyclic GMP excretion in normal subjects is of 
the order of 1 fmol/day or 0.5 rmol/g creatinine, and is about 
one fifth of the normal cyclic AMP output ('!'able· 1. 3B). 
Approximately one half of the basal urinary cyclic Al-iP excretion 
in normal subjects is derived from glomerular filtration of 
plasma (Broadus et al, 1970a). The remainder is contributed 
mainly by the proximal nephron under the influence of PTH 
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{Chase and Aurbach, 1967). In contras ·t: to this situation, 
urinary cyclic GMP is derived solely from glomerular 
filtration of. plasma under basal conditions (Broadus ｾ＠ ｾＱＬ＠
1970a). 
Daily excretion rates for cy·clic AMP have been found 
to vary by only 10-30% from day to day, while cyclic GMP 
excretion, although stable in some subjects, showed considerable 
day to day variations in others (Murad and Pak, 1972a, b). 
There is evidence that the excretion of both cyclic nucleotides 
is independen·t of urine volume, and that this holds true over 
wide variations of fluid intake, urine volume and osmolarity 
(Murad, 1973; Hardman et al, 1969; Owen and Moffat, 1973). 
Urinary excretion of each cyclic nucleotide is subject 
to circadian variation. Cyclic AMP excretion patterns,. 
whether expressed in terms of absolu·te excretion rates or as 
cyclic AMP/creatinine ratios, are reproducible for individual 
subjects. Different individuals do, however, show large 
differences in excretion patterns. Peak cyclic AMP excretion 
occurs in the morning for some people, and in the afternoon 
for others (Murad and Pak, 1972; Holmes et al, 1974}. Murad 
and Pak (1972) observed a similar circadian variation in 
cyclic GMP excretion, with peak rates in the afternoon in a 
small nu.mber of subjects, although they noted that in many 
patients the cyclic GMP excretion was 'relatively stable' over 
a 24-hour period. Subjects who were 'phase-shifted' so that 
they were awake during the night and slept during the day 
.showed a similar phase shift in cyclic nucleotide excretion 
patterns (Muradf 1.973). 
------------------------- - - - ｾＭＭｾｾＭＭ Ｍｾ Ｍ Ｍ
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·Exercise does not alter the urinary levels of either 
cyclic nucleotide (Murad and Pak, 1972). Coffee intake does 
appear to influence cyclic GMP excretion. Cyclic GMP output 
. 
was increased by 44 and 22% in two subjects who drank six cups 
of coffee (equivalent to 600-900 mg caffeine) while cyclic AMP 
output remained unchanged (Murad and Pak, 1972). 
Murad {1973) noted a higher urinary cyclic AMP excretion 
.in five non-hospitalised normal subjects compared with twelve 
hospitalised normal volunteers. Cyclic GMP output did not 
differ significantly for these two groups. 
The excretion of cyclic nucleotides in 98 normal children · 
aged 2-18 years has been studied by Murad and colleagues (1975). 
Mean cyclic AMP ievels increased from 1 to 6 /J..mol/day over the 
age range, while mean cyclic GMP output increased from 0 .. 3 to 
0. 8 fmol/day. Plots of cyclic nucleotide excretion against age 
did not show a steady rise, but were 'biphasic' in appearance, 
with peak nucleotide excretions at ages 4-6 years and 16-18 
years .. Daily excretions for both cyclic nucleotides decreased 
with age when expressed as a ratio of creatinine output or body 
weight., Cyclic nucleotide measurements on six-hourly urine 
collections from three normal children revealed a similar 
circadian variation to that found in adults, with peak nucleotide 
excretion 'between 7 a.m. and 11 p .. m.' (Murad ｾ＠ al, 1975). 
Hamadah and colleagues (1973) monitored the 24-hour 
urinary cyclic AMP excretion in twelve women at weekly intervals 
over two menstrual cycles. A consistent mid-cycle peak in 
cyclic AMP excretion was observed. Women suffering from pre-
menstrual tension showed a cyclic AMP excretion rhythm of 
increased amplitude. 
Daily urinary cyclic AMP and cyclic GMP excretions 
during the menstrual cycles of tv1elve normal women aged 18-25 
have been studied (Lebeu et al, 1975). Only six women showed 
an increase in cyclic AMP, of variable amplitude, at about the 
time of ovulation. In five of these six women, cyclic GMP 
levels increased in parallel with cyclic AMP at this time. 
Ten of the twelve subjects had· increased cyclic GMP output in 
the luteal phase of the cyclic compared with their individual 
levels during the follicular-phase .. 
Tucci and Kopp (1976) noticed a sex difference in cyclic 
AMP excretion in studies on 25 normal men and 32 normal womeno 
Women showed significantly lower cyclic AMP excretion when 
expressed asfmol/day, but a significantly higher cyclic AMP 
excretion than men when expressed asfmol/g creatinine. 
Cyclic GMP output ｾｭｯｬＯ､｡ｹＩ＠ was significantly greater in the 
men, but _there was no difference between the sexes when results 
were expressed ｡ｳｾｭｯｬ＠ cyclic GMP/g creatinine. 
Parathyroid hormone has a pronounced effect on urinary 
cyclic AMP. When - PTH is administered intravenously, cyclic 
AMP output may be increased 200-fold (Murad, 1973). Cyclic 
AMP excretion can also be influenced by glucagon (Williams et 
ｾＡＬ＠ 1972) and catecholamine ｾＭ｡､ｲ･ｮ･ｲｧｩ｣Ｉ＠ stimulation 
(Kaminsky et al, 1970) .. 
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Less is known about the factors which influence urinary 
cyclic GMP excretion. Urinary levels may be raised following 
the administration of large intravenous doses of PTH 
Ｈｾ｡ｭｩｮｳｫｹ＠ et al, 1970), by calcium infusion (Kaminsky et al, 
1970) and by catecholamine (K-adrenergic) stimulation (Ball 
et al, 1972). 
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1.4 Cyclic Nucleotides in Disease States 
The only established clinical applications for cyclic AMP 
analyses are in the investigation of disorders of calcium 
homeostasis. Measurement of ｢ｯｴｾ＠ cyclic AMP and cyclic GMP 
may also be of value in several other disease processes which 
show associated changes in tissue or extracellular fluid cyclic 
nucleotide levels. 
1.4el Disorders of Calcium Homeostasis 
Chase and coworkers (1969} were the first to report an 
alteration in cyclic nucleotide metabolism in human disease. 
These investigators( found that patients with psudohypopara-
thyroidism showed less than a four-fold increase, in their 
urinary cyclic AMP excretion after the intravenous adntinistration 
of parathyroid hormone ('PTH'). Normal subjects and patients 
ｷｩｾｨ＠ hyperparathyroidism and 'ideopathic', or 'surgical• 
hyJ?oparathyroidism all. gave responses which were greater than 
the pseudohypoparathyroid group. 
The diagnosis of pseudohypopara thyroid ism on the basis of 
phosphaturic or hypercalcaemic responses to ｾｔｈ＠ has been 
complicated by the small and variable responses found in normal 
subjects. Because of the relatively large increases in cyclic 
AMP excretion which are normally observed compared with the 
small effect seen in psudohypoparathyroid patients, the 
measurement of urinary cyclic AMP before and after PTH 
administration is a much better diagnostic tes·t for this 
disorder. · The determination of plasma cyclic AMP levels, 
which normally show a four- to six-fold rise over basal levels 
in response to prrH (Barling et al, 1973: 'romlinson et a!, 1976) 
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also provides a convenient diagnostic test for pseudohypopara-
thyroidism. Diminished urinary and plasma cyclic GMP responses 
to P'J.1H have been reported in pseudohypoparathyroid patients 
(Murad, 1973). 
Calcium and cyclic AMP measurements in urine samples 
before and after a 1 g oral calcium load are o:E value in the 
di:fferential diagnosis of hypercalciuria (Pak et al, 1974; Pak 
et al, 1975). With this test it was possible to dist:inguish 
between patients with hyperparathyroidism and those with 
'absorptive' or 'renal' hypercalciuria (Table 1.4). Hyper-
parathyroid patients in the fasting state may have hypercalciuria, 
and in some cases, ｩｮ｣ｲ･｡ｳｾ､＠ urinary cyclic AMP excretion. 
After the calcium load these patients showed an exaggerated 
increase in urinary calcium, and their cyclic ａﾥｾ＠ output, 
which was not reduced, differentiated them from normal subjects 
and patients in the •renal' hypercalciuric group. Urinary 
cyclic AMP measurements give some indication of the circulating 
PTH levels; normally PTH secretion is suppressed following . 
the calcium load, and the ､･｣ｲ･｡ｳｾ＠ in urinary cyclic AMP output 
reflects the fall in circulating PTH concentration. 
Recently, Shaw and colleagues (1977) have reported that 
cyclic AMP/creatinine ratios in the urine of patients with 
primary hyperpa:t;athyroidism or ectopic PTH production are 
inappropriately high when interpreted in terms of their serum 
calcium concentration. Patients with hypercalciuria could 
be clearly.separated into those with, or without, excessive 
PTH production .. 
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TABLE 1.4 
Differential diagnosis of· hyPercalciuria 
Urinary calcium and cyclic AMP responses ·to a 1 g oral calcium 
load (from Pak et al, 1975) 
ｐａＧｊｾｉｅｎｔ＠ GROUP URINE ca
2+/ URINE CYCLIC AMP/ 
CREATININE RATIO CREATININE RATIO 
2 hr 4 hr. 2+ 2 hr 4 hr 2+ fasting post Ca fasting post Ca 
Normal subjects Normal Increased Normal Reduced 
iiyperpara thyroid Often Exaggerated Often Not 
high increase high reduced 
'Absorptive' Normal Exaggerated Normal Reduced 
} increase 
'Renal' High Exaggerated High Reduced 
increase to normal 
Normocalciuric Normal Normal Normal Reduced 
nephrolithiasis increase 
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·High urinary cyclic AMP excretion has also been 
reported in one case of rickets and one of vitamin D resistant 
rickets in children (Sovik et al, 1976}. The raised cyclic 
AMP outpu·t was consistent with the secondary hyperparathyroidism 
which was observed, and decreased in parallel with clinical 
improvement on vitamin D therapy. 
Of the patients with various calcium disorders which 
he has examined,·Murad {1973} found increased cyclic GMP 
excretion only in those with hypercalcaemic hyperparathyroidism .. 
Removal of hyperplastic or adenomatous parathyroid glands 
resulted in a drop in cyclic AMP and cyclic GMP excretion to 
within the normal range 'wi.th few exceptions ' • 
1.4.2 Affective Disorders and Disease of the Central Nervous ｓｹｳｴ･ｴｾ＠
Urinary cyclic AMP excretion has been reported to be 
increased in mania and decreased in depressive illness {Abdulla 
an¢1 Hamadah, 1970: ｐ｡ｵｬｾ＠ al, 1971}. Tricyclic antidepressants, 
L-DOPA, or lithium carbonate therapy produced improvements in 
pa·tients which were associated with a return to normal cyclic 
AMP excretiono The tissue source of altered cyclic AMP output 
has not been identified, however, and it is possible that 
urinary cyclic AMP excretion does not reflect changes in the CNS 
but rai.:her that it results from tissue responses to altered 
levels of catecholamines and other hormones. 
Robison ｾｴ＠ al (1970) found no change in CSF cyclic AMP 
levels in depression; and more recently Smith et al (1976) 
found li·ttle evidence for alterations in lumbar CSF cyclic AMP 
and cyclic GMP levels in depressed, manic, or schizophrenic 
patients. In this last study there was a tendency towards 
decreased cyclic GMP levels in the three affective disorder 
groups relative to control subjects, but results did not 
achieve statistical significance. These findings indicate 
that CSF cyclic nucleotide measurements may not help in the 
differentiation of psychiatric disorders. 
Electroconvulsive shock treatment for depressive illness 
is associated with increased urinary excretion of cyclic AMP 
(Hamadah et al, 1972). The tissue source of these cyclic AMP 
increases has not been established. Electroconvulsive 
shock treatment increases mouse cerebellum and cerebral cortex 
cyclic nucleotide content. Maximum levels were obtained 30 
seconds (cyclic AMP) and 1 minute (cyclic GMP) after shock 
treatment (Lust et al, 1976). 
Increased CSF cyclic AMP concentrations have been 
ｲｾｰ＿ｲ ｟ ｴ･､＠ in children with cerebellar glioma, hypothalamic 
ｰｲｾ｣ｯ｣ｩｯｵｳ＠ puberty, meningitis, and Cushing•s syndrome (Myllyla 
et al, 1975). Urinary cyclic AMP output was normal in these 
children. Rudman et al (1976a) have reported that nine 
children with retarded psychomotor development caused by 
diffuse brain disease of various kinds, but who had normal 
ventricular pressure, had low CSF cyclic AMP levels. CSF 
cyclic GMP concentrations in these ·children were normal. These 
researchers did, however, notice striking increases in 
ventricular fluid CSF cyclic GMP levels with increases in 
ventricular pressure. This was observed regardless of the 
type of hydrocephalus, age of the patient, or na-ture of the 
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underlying disease. The findings of normal CSF cyclic GMP 
concentrations in the presence of low cyclic AMP levels (diffuse 
brain disease in children) and normal cyclic AMP in the presence 
of increased cyclic GMP content (increased ventricular pressure) 
indicated that levels of the two cyclic nucleotides could alter 
independently. The data were taken as evidence but the 
observed CSF cyclic nucleotide changes were reflections of CNS 
cyclic nucleotide metabolism rather than of changes in cyclic 
nucleotide movement across the blood-brain barrier. 
CSF and plasma cyclic nucleotide levels were studied in 
six patients who had been comatose for 20 days or more following 
head trauma or spontaneous in-tracranial haemorrhage (Rudman .§.:!; 
· al, 1976b). CSF cyclic AMP concentrations showed decreases 
which corresponded with the degree of unconsciousness; the 
lowest cyclic AMP levels corresponded with the deepest comas. 
CSF cyclic GMP levels also showed some decrease in comatose 
. . . 
patients, but these changes were much less distinct. Plasma 
cyclic nucleotide levels in these patients were not significantly 
different from normal. Myllyla (1976) also found slightly 
reduced CSF cyclic AMP levels in patients with 'old' cerebral 
lesions relative to control subjects. In the first few days 
following brain concussion or contusion, however, CSF cyclic 
AMP concentrations were markedly ･ｬｾｶ｡ｴ･､Ｎ＠
Tominaga and coworkers (1976) investigated plasma cyclic 
AMP alterations in patients with acute cerebrovascular disease. 
The seve1.'ity of the lesions was assessed clinically, and by 
brain scintigraphy. 'Mild' cerebral infarction was associated 
with normal plasma cyclic AMP concentrations, while 'moderate' 
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damage was associated with a aecrease in plasma cyclic AMP 
content after two to four days. Patients with severe infarction 
and cerebral oedema did not show this drop in cyclic AMP levels. 
Sub-arachnoid haemorrhage was associated with high plasma 
cyclic AMP concentrations in the early stages. 
The intravenous administration of a bacterial pyrogen 
to unanaesthetised cats increases CSF cyclic AMP levels in 
association with the ·rise in body temperature (Dascombe and 
Milton, 1975). Cyclic AMP increments were related to the 
dose of pyrogen, and were not diminished when the febrile 
respopse to pyrogen was reduced with the antipyretic drug, 
4-acetamidophenol. 
In a recent publication, Trabucchi et al (1977) reported 
that CSF cyclic GMP concentrations in 18 patients with cerebral 
tumours were significantly higher than those found in 16 normal 
subjects. These authors have also demonstrated increased 
guanylate cyclase activity in cerebral tumour tissue relative 
to uninvolved cerebral cortex. 
1.4.3 ｾ･ｲｴ･ｮｳｩｯｮ＠
Although much of the data concerning cyclic nucleotide 
changes in hypertension has been obtained from animal studies, 
. there is evidence that alterations in the vascular tissue 
cyclic nucleotide balance are closely connected with this 
disease process. Amer (1975a) has demonstrated that, relative 
to controls, there are increases in rat aorta cyclic GMP/cyclic 
AMP ratios .in spontaneous, stress, deoxycorticosterone acetate, 
and ｮ･ｵｲｯｧ･ｮｩ｣｡ｬｬｹｾｩｮ､ｵ｣･､＠ hypertension. The immediate cause 
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of the altered cyclic GMP/cyclic AMP ratio varied in different 
groups and was either increased cyclic AMP phosphodies·terase 
activity, decreased sensitivity of adenylate cyclase, or 
increased guanylate cyclase activity. Increased cyclic GMP/ 
cyclic AMP ratios were not observed in those· animals which 
did not develop high blood pressure. A variety of anti-
hypertensive drugs, which act by different mechanisms, all 
decreased vascular smooth muscle cyclic GMP/cyclic AMP ratios 
in a dose-dependent manner, with close correlation between 
this effect and the decrease in blood pressure (Amer 1975b). 
Amer (1975b) has discussed the possible reasons for 
this change in cyclic nucleotide ratio. He has put forward 
the hypothesis that, in the early stages of hypertension, 
sustained increases in sympathetic nervous activity or in 
stimulation by the renin-antiotensin system might lead to a 
loss of vascular tissue adenylate cyclase responsiveness and 
ｴｾＮ＠ an. ｩｮｾｲ･｡ｳ･＠ in cyclic AMP phosphodiesterase ac·tivi ty. 
Raised cyclic GMP/cyclic AMP ratios would then cause the 
increased vascular smooth muscle tone and thickness which are 
characteristic of the increased peripheral resistance observed 
in hypertension. 
Messerli et al (1976) have monitored plasma cyclic AMP 
changes in response to isoprenaline · and glucagon administration 
0 0 
in patients w.ith borderline ('labile') hypertension and in 
control subjects. Plasma cyclic AMP responses to isoprenaline 
ｾＭ｡､ｲ･ｮ･ｲｧｩ｣＠ stimulation were increased in the hypertensive 
patients relative to the normal subjects. Glucagon challenge, 
howeverq resulted in similar plasma cyclic AMP increments in the 
·two groups. Although cyclic GMP levels.were not measured, 
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these findings suggest a hyperreactivef-adrenergic response 
in labile hypertension. 
1.4.4 Malignancy 
In vitro studies on cultured cells have demonstrated 
changes in cellular cyclic nucleotide levels at different 
stages of the cell growth cycle. Cultured human and animal 
ｦｩｾｲｯ｢ｬ｡ｳｴｳ＠ stop growing when the cells reach confluency, and 
intracellular cyclic AMP levels rise. 'Transformed' cells 
fail to stop dividing at this stage, and cyclic AMP 
concentrations in overgrown, transformed cells are greatly 
reduced when compared with those in contact inhibited cells 
(Olten ｾｴ＠ al, 1971,1972; Heidrich and Ryan, 1971; Sheppard, 
197 2) . The addition of cyclic AMP, · or agents which either 
increase cyclic AMP or reduce cyclic GMP content, to tumour 
and transformed cell lines alters their morphology and markedly 
reduces their growth {Criss, 1974). Cyclic AM.P inhibits the 
initiation of cell proliferation, while a lowering of cyclic 
AMP levels allows the process to begin. 
There is considerable evidence in support of the 
theory that cyclic GMP participates in the promotion of cell 
division . Stimulation of cell division in human lymphocytes 
. by phytohaemagglutininor concanavalin A, or of mouse fibroblast 
cultures by insulin or phorbol myristate acetate results in 
greater than ten-fold increases in cell cyclic GMP within 5-10 
minutesv with little change in cyclic AMP concentration 
(Goldberg ｾ＠ al, 1975 ｾ＠ Goldberg and colleagues {1975 ) have 
examined cyclic nuoleotide content and binding capacity in 
several strains of Morris hepatoma. Cyclic AMP levels were 
normal ·in some tumours, but in . these cases there was either 
a reduced cyclic AMP binding capacity, high cyclic GMP levels, 
or high cyclic GMP binding capacity. These authors have 
suggested that malignancy is associated with a low 'effective• 
cyclic AMP activity which is not simply a function of the 
tissue cyclic AMP content, but depends also on the amounts of 
proteins which react with cyclic AMP, and the 'effective' levels 
of antagonists, such as cyclic GMP. Kimura and Murad (1975b) 
have noted increased particulate and decreased soluble 
guanylate cyclase activity in regenerating, foetal and neonatal 
rat liver and in rat hepatoma tissue. These changes were 
particularly striking in hepatoma, which showed a nine-fold 
increase in particulate, and a two-fold decrease in soluble 
enzyme activity relative to normal liver. The findings 
indicate that guanylate cyclase activity and its subcellular 
distribution are in some way related to liver growth. 
Increased urinary excretion of cyclic GMP has recently 
been reported in rats bearing transplantable liver and kidney 
tumours (Criss and Murad, 1976). Of the six hepatoma and 
two renal tumour lines examined, two hepatoma and one renal 
tumour were associated with up to twenty-fold increases in 
· urinary cyclic GMP, with no changes in cyclic AMP excretion. 
Urinary cyclic GMP levels in rats bearing Morris hepatoma 
3724A correlated well with tumour size, and the effects of 
irradiation, chemotherapy, and surgical removal . (Murad et al, 
197 5) .. 
- -- ------- -- ---
77 
Neethling and Shanley (1976) examined cyclic GMP 
excretion in 3 patients with primary hepatoma, and in 24 
normal subjects. A significant increase in 24 hour urinary 
cyclic GMP levels was observed in the primary hepatoma patients. 
It remains to be seen whether increased urinary cyclic GMP 
output is associated only with primary hepatoma, or whether 
other tumours in man will also give rise to alterations in 
urinary cyclic nucleotide excretion. 
Regenerating rat liver, cultured leukaemia cells, and 
the urine of leukaemic patients contain high levels of cyclic 
CMP (Bloch, 1975b). These findings, and the observation that 
cyclic CMP will override the inhibitory influence of other 
cyclic nucleotides on leukaemia cell proliferation, suggest 
that cyclic CMP may also be involved in proliferative processes 
in general. 
1.4.5 Psoriasis 
Psoriasis, a proliferative skin disease characterised by 
epidermal hyperplasia, incomplete epidermal maturation and 
glycogen accumulation, is associated with altered cyclic nucleo-
tide levels. A study of involved and uninvolved tissue in 
fifty patients suffering from the disease has demonstrated 
significant decreases in cyclic AMP, and increases in cyclic 
GMP in the involved tissue (Voorhees et al, 1975; Voorhees and 
Duell, 1975). The cyclic AMP decrease was shown to be largely 
a result of increased cyclic AMP phosphodiesterase activity. 
Increased cyclic GMP levels may be directly responsible for 
activation of the cyclic AMP phosphodiesterase. Cyclic 
ｾｾＭＭＢﾷﾷ ｾﾷﾷ ﾷＧＭＢＢＧＢＭＢＧ Ｇ＠ .. = .. ·=·---='""-'-'-' ｾＭＭｾＭＭＭＭＭＭＭＭＭ ＭＭ Ｍ ＭＭ ---------
78 
nucleotide changes in psoriasis are, therefore, consistent 
with those which have been observed during cell proliferation 
in vitro. 
1.4.6 Asthma 
Bronchial asthma may be provoked by allergens or by a 
I 
variety of other factors such as cold air, deep breathing or 
laughing. Bronchial muscle in asthma sufferers seems to be 
hyperreactive. One possible explanation is that resting 
bronchial muscle tone is higher than normal, and that this 
could be caused by an imbalance of intracellular cyclic 
nucleotides (Schultz et al, 1973). A relative increase in 
cyclic GMP levels would increase smooth muscle tone and result 
in release of inflammatory mediators from mast cells. 
p-adrenergic responses to catecholainines, which s·timulate 
intracellular cyclic AMP production and, therefore, promote 
muscle relaxation, are diminished in asthmatic patients 
(Szentivanyi, 1968). Asthma patients show reduced urinary 
cyclic AMP increases after adrenalin challenge relative to normal 
subjects, but their response to glucagon is normal (Bernstein 
et al, 1972). Bronchial asthma has also been associated with 
an attenuated plasma cyclic AMP response to isoprenaline 
(Trembath and Shaw, 1976) and diminished urine and plasma 
cyclic AMP responses to ｡ｮｯｴｨ･ｲｾＭ｡､ｲ･ｮ･ｲｧｩ｣＠ agonist, 
salbutamol (Raij et al, 1976). Adenylate cyclase activation 
by isoprenaline is also diminished in peripheral lymphocytes 
of asthma sufferers (Parker and Smith, 1973). Increased 
()(-adrenergic or cholinergic stimula·tion, which antagonise 
p-adrenergic activation, could be responsible for this reduction 
I 
in adenylate cyclase activity. However, c(-adrenergic or cholin-
ergic stimulation of guanylate cyclase in lymphocytes of patients 
with acute asthma is reduced (Haddock et al, 1975). The 
underlying cause of the imbalance in control of bronchial 
smooth muscle contractility in asthma has yet to be discovered. 
1.4.7 Diabetes Insipidus 
'rhe administration of 'physiological' doses of anti-
diuretic hormone ('ADH') to normal subjects has little effect 
on urinary cyclic AMP excretion (I<aminsky ｾｴ｡ｬＬ＠ 1970) 9 although 
the hormone is known to increase cyclic AMP levels by action on 
adenylate cyclases in the renal medulla. These adenylate 
cyclases are anatomically ､ｾｳｴｩｮ｣ｴ＠ from those stimulated by PTH, 
which are localised in the renal cortex {Chase and Aurbach, 
1968). The difficulty in ·demonstrating a response in normal 
subjects has hampered attempts to differentiate between 
'nephrogenic' and 'pituitary' diabetes insipidus on the basis 
of urinary cyclic AMP measurements following the administration 
of ADH. 
Fichman and Brooker (1972) ·infused ADH into normal 
subjects and patients with pi ·tui tary or nephrogenic diabetes 
insipidus. The use of a very precise high pressure anion 
exchange chromatographic cyclic AMP assay enabled them to 
demonstrate a significant increase in urinary cyclic AMP/ 
creatinine ratios in the first two groups, but not in patients 
with nephrogenic diabetes insipidus. Nephrogenic diabetes 
insipidus patients also failed to increase urine osmolarity 
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or cyclic AMP output after tolbutamide/glucose administration, 
and showed a reduced urinary cyclic AMP response to PTH or 
glucagon. 
Ball ｾ＠ a! (1971) have reported that these patients, 
unlike normal subjects or patients with pituitary ADH 
insufficiency, are unable to increase urine osmolarity following 
cyclic AMP infusion. 
In contrast to these findings, Mann et al (1976) were 
unable to confirm a lack of cyclic AMP response to ADH or PTH 
in six children with nephrogenic diabetes insipidus who had 
otherwise normal renal function. They did, however, observe 
a reduced basal urinary cyclic AMP level and a diminished 
response ·to ADH or PTH in children with structural renal 
disorders and defective renal concentrating ability. 
Nephrogenic diabetes insipidus may be a heterogeneous 
ｧｲｾｵｰ＠ of disorders. Patients may show a relative inability 
to . generate or excrete cyclic AMP in response to ADH, glucagon 
or PTH. The diminished urine concentration effects following 
cyclic AMP infusion indicate that renal tissue could be 
1 resistant' to intracellular cyclic AMP in some cases. 
1.4.8 Other Disease Processes 
Urinary cyclic GMP output is increased in children 
suffering from cystic fibrosis. Cyclic AMP/cyclic GMP ratios 
in these children were approximately 4 compared with ratios of 
9 in normal children Ｈｍｵｲ｡､ｾ＠ al, 1975). 
Plasma cyclic AMP levels show marked changes in hypo-
and hyperthyroidism (Karlberg et al, 1974). Mean levels for 
8 
plasma ·cyclic AMP were 10.7 nmol/1 :fox· normal subjects I 
23.6 nmol/1 for hyperthyroid and 5.1 nmol/1 for hypothyroid 
patients. 
;(? 
Adipose tissue and muscle cyclic AMP were also 
raised in hyperthyroidism. Urinary cyclic AMP/creatinine 
and cyclic GMP/creatinine ratios are increased in male and 
female hyperthyroid patients relative to euthyroid control 
subjects (Tucci and Kopp, 1976). although a decrease in 
creatinine excretion was partly responsible for this. Cyclic 
AMP excretion was reduced in hypothyroid patients, whereas 
cyclic AMP/creatinine ratios and cyclic GMP output did not 
change significantly. Cyc lie GMP / crea.tinine ratios were 
slightly raised in female hypothyroid patients. 
Experimental myocardial ischaemia, produced in dogs by 
arterial occlusion, increases myocardial tissue cyclic AMP 
levels (Rabinowitz et al, 1975). Plasn:ta cyclic AMP levels 
in these animals were not a reliable indicator of small 
coronary occlusions. Studies in 44 patients with acute 
myocardial infarction have established that in surviving 
patients there is a slight increase in plasma cyclic AMP 
concentrations within the first 24 hours. Very high plasma 
cyclic AMP levels were associated with a fatal myocardial 
infarction (Rabinowitz et al, 1974). 
Plasma cyclic AMP responses to glucagon injection or 
infusion may be useful in the investigation of cholestatic 
liver disease. Davies and colleagues (1976) found 
exaggerated plasma cyclic AMP increments after the intravenous 
injection of glucagon (1 mg) into six patients with extrahepatic 
---------------------------------··---· .. 
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obstructive jaundice. Six patients with intrahepatic 
cholestasis and ten patients with cirrhosis had plasma 
cyclic AMP responses to glucagon injection which were not 
significantly different from those observed in control 
subjects. Francavilla and coworkers (1977) have reported 
similar findings with a regime in which glucagon was infused 
at a dose of 200 ng/kg/min for a period of one hour. When 
compared with ｰｲｾＭｩｮｦｵｳｩｯｮ＠ levels, the ten minute post-
infusion plasma cyclic AMP concentration gave the best 
diagnostic index for cholestatic jaundice. The authors 
concluded that a ten minute post-infusion plasma cyclic AMP 
level which was more than ten times the basal level was 
indicative of extrahepatic obstructive jaundice. 
Rapid increases in plasma cyclic AMP have been 
observed during the course of surgery, levels falling back 
almost to normal within six hours. Plasma cortisol rose 
more slowly to peak levels approximately six hours after 
operation, and fell back to normal within 24 hours (Gill et al, 
197 5} . The onset of complications after surgery in one 
patient was associated with a continued elevation of both 
plasma cyclic AMP and plasma cortisol. 
Vitek et al {1976} have monitored urinary cyclic AMP 
excretion in 150 patients at various times after severe 
accidental trauma. In general, patients showed two periods 
of increased cyclic AMP output, during the first 24 hours, 
and approximately 5 days after trauma. 
. -· ｾＺＮＮＮＮｴ＠ .......... ···'· ...... Ｍ ｾＮＮ＠ -. .., . .. ... · 
Maternal urine, plasma, and amniotic fluid cyclic 
AMP concentrations have been deterrnined during normal and 
abnormal pregnancies {Yuen et al, 1976. Uncomplicated 
pregnancies showed increases in urine and amniotic fluid 
cyclic AMP levels during the period of gestation. There 
was a tendency for urinary excretion to fall slightly from 
35 weeks to term. Plasma cyclic AMP concentrations did not 
change significantly during pregnancy, and were comparable 
to non-pregnancy values. The limited data on three abnormal 
ｰｲ･ｧｮｾｮ｣ｩ･ｳ＠ indicated that cyclic AMP excretion was strongly 
influenced by drug therapy and in one patient, by uncont-
rolled hyperthyroidism. Urine or amniotic fluid levels 
·did not necessarily correlate with the degree of risk to the 
foetus. 
Children with Down's syndrome have significantly 
raised salivary cyclic AMP levels (in the region of 30 nmol/ 
1) compared with concentrations in normal children (10 nmo1/ 
1) (Sproles, 197 3). 
1.5 Methods for Cyclic GMP Analysis 
1.5.1 Physical Separation Methods 
An early method for the measurement of cyclic GMP in 
urine relied on chromatographic separation techniques (Price 
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et al, ·1967). Urine samples were purified by a lengthy 
procedure involving ether washing of the acidified specimen, 
charcoal ads0rption of nucleotides and subsequent elution, 
and then 'Dowex l' ion exchange chromatography. Individual 
·nucleotides were finally isolated after successive one and 
two dimensional chromatographic separations on Whatman 3MM 
paper with three different solvent systems. 
With the advent of more convenient methods for cyclic 
GMP determination, physical separation techniques such as ion 
exchange chromatography (Schultz et al, 1974), thin layer 
chromatography on polyethyleneimine cellulose (Bohme and 
Schultz, 1974) or alumina column chromatography {White, 1974) 
are now mainly used in preliminary purification steps. 
High pressure anion exchange chromatography of cyclic 
AMP and cyclic GMP will give results within five minutes of 
sample injection {Brooker, 1974). Cyclic GMP separation 
was achieved by hydrochloric acid/sodium chloride elution 
on a column containing small glass beads to which the ion 
exchange resin was polymerised. Extensive purification 
involving ion exchange column and thin layer chromatography 
was, however, necessary before tissue homogenates could be 
analysed on the high ｰｲ･ｾｳｵｲ･＠ liquid chromatograph. 
1.5.2 Enzymatic Procedures 
The majority of enzymatic methods for cyclic GMP 
analysis have been based on the conversion of the cyclic 
nucleotide to GTP, which can then be measured by an enzymatic 
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recycling system. The sequence of reactions can be summarised 
as follows:-
(a) Conversion of cyclic GMP to 5'GMP with beef 
heart cyclic nucleotide phosphodiesterase. 
Beef heart 
CPDE 
Cyclic GMP -----+ 5 'GMP 
(b) Conversion of 5'GMP to GDP by the combined actions 
of ATP-GMP phosphotransferase and a creatine kinase/ 
creatine phosphate· ATP regeneration system. 
5'GMP 
+ 
GMP kinase 
GDP 
+ 
ａｔｐｾａｄｐ＠
creatine phosphocreatine 
(c) Generation of GTP from GDP by pyruvate kinase and 
phosphoenolpyruvate, and the determination of GTP 
in a cycling system using the nucleoside tri-
phosphatase, myosin (Hardman ･ｴ｡ｾＬ＠ 1969), or 
succinic thiokinase, succinate, and coenzyme A 
(Goldberg et al, 1972):-
--
Phosphoenol pyruvate · ｾｹｲｵｶ｡ｴ･＠
ｾｹｲｵｶ｡ｴ･｟ｫｩｮ｡ｳ･＠
GDP Ｎｾｾ＠ GTP 
'i'-. / 
............._.succinic thiokinase 
. 1 . ＭＭＭＭＭＭＭＭｾ＠ . 
. ｳｵ｣｣ｾｮｹ＠ --etA succ1nate 
+ + 
P. CoA 
ｾ＠
(d) Finally, lactate dehydrogenase is used to convert 
pyruvate to lactate with the formation of a 
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stoichiometric amount of NAD+ from NADH:-
+ + pyruvate + NADH + H ｾ＠ lactate + NAD 
Unreacted NADH can be destroyed by acid treatment, 
+ and NAD can then be measured fluorimetrically in 
strong alkali. 
The cycling system of Goldberg et al (1972) is 10-100 
times more sensitive than the myosin system, and will detect 
between 0.01 and 0.1 pmol of cyclic GMP. The presence of up 
to a 10,000 fold excess of othe·r guanine nucleotides in tissue 
samples would give rise to very large assay blanks, and 
therefore the preliminary fractionation of nucleotides is 
essential with this type o:f procedure. 
GDP, synthesised from cyclic GMP by the successive 
actions of phosphodiesterase and ａｔｐＺｇﾥｾ＠ phosphotransferase, 
has also been measured by the use of 'Elongation factor Tu' 
(EF-Tu) a soluble factor from Escherichia coli which enhances 
the.binding of amino-acyl-transfer RNA to ribosomes during the 
process of peptide chain elongation (Miller and Weissbach, 
1970). EF-Tu has a high affinity for GDP(dissociation 
-9 
constant KD = 10 mol/1) and this property has been utilised 
in two different assay systems. In the method of O'Dea and 
colleagues (1974) GDP competes with ｲｾＭ ＳＲ ｾ＠ GDP for binding 
to EF-Tu in a 'saturation analysis' system. The use of 
(o<- 32P] GDP with a specific activity of greater than 100 Ci/ 
mmol reduced the assay detection limit to 0.02 pmol cyclic GMP. 
Shibuya et al (1975) preparedG&·- 32PJ GDP from cyclic 
GMP by the use of ｛ｾＭ ＳＲ ｐｊ＠ ATP at the ATP:GMP phosphotransferase 
87" 
stage in the conversion of cyclic GMP to GDP. 
was then isolated by incubation with an excess of EF-Tu-GDP, 
and the bound radioactivity was separated by nitrocellulose 
membrane filtration. This method could detect 0.05 pmol of 
cyclic GMP. 
Schultz et al (1973) also utilised phosphodiesterase and 
ATP:GMP phosphotransferase with [o-32PJATP to generate 
UB- 32 P] GDP from cyclic GMP. Unreacted ｾＭ ＳＲ ｐ｝＠ ATP was 
degraded \r\Ti th myosin, and the [32P] inorganic phosphate which 
was formed was precipitated and counted. 
'Enzymatic isotope displacement assays' for cyclic AMP 
and cyclic GMP have been deyeloped by Brooker (1972). 
are based on the principle of competition between non-
These 
radioactive and radioactive substrates for enzymatic conversion. 
A rat brain cyclic nucleotide phosphodiesterase was used in an 
amount which would convert 40% ｯｾ＠ [3H)cyclic nucleotide in the 
absence of unlabelled substrate. The yield of rHJ-5' nucleo-
side monophosphate diminished as the amount of non-radioactive 
substrate in the assay system was increased. Snake venom 
enzyme was utilised to convert rHJ-5'GMP to rHJguanosine. 
Unreacted rH] cyclic GMP was adsorbed to anion exchange resin, 
while guanosine remained in solution. The addition of 
scintillation fluid to the reaction vial permitted the 
quantitation of rH] guanosine, while (3H] cyclic GMP, which 
was trapped within the resin, was not counted. 
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ｐｨｯｳｰｨｯ､ｩ･ｳｴ･ｲ｡ｳｾ＠
[_3H] cyclic GMP + cyclic GMP . - I> (3H J 5 'GMP + 5' GMP 
(fixed quantity) (variable I 
quantity) Snake venom 
(40% conversion in 
the absence of un-
labelled cyclic 
GMP) [3H) 
5' nucleotidase 
1 
guanosine + guanosine 
The ability of low levels of cyclic GMP to activate cyclic 
GMP. dependent protein kinase has also been used as the basis of 
a cyclic GMP assay (Kuo and Greengard, 1974). rrhe activated 
protein kinase phosphorylates a histone substrate using 
｛ＨＭ ＳＲ ｾ｝＠ ATP:-
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cyclic GMP dependent 
protein kinase Histone- 32 P + ADP 
cyclic GMP, ｍｧＲｾ＠ ｾ＠
Cyclic GMP activated protein kinases were purified from 
homogenates of lobster tail muscle or fat body tissue of 
· cecropia silkmoth pupae by acid precipitation, ammonium ·sulphate 
fractionation and (for the lobster preparation) DEAE-cellulose 
chromatography. 
Assay conditions were chosen so that the extent of 
histone phosphorylation was directly proportional to the cyclic 
GMP level in the incubation mixture. Protein bound radio-
activity was precipitated with trichloroacetic acid/sodium 
tungstate/sulphuric acid reagent, redissolved in sodium 
hydroxide solution, and counted. Detection limits for this 
system were between 0.3 and 0.5 pmol cyclic GMP per tube. 
Extensive sample purification was again necessary for this 
enzymatic assay. 
----------------------------- -- - -------
Although several enzymatic techniques have detection 
ljmits which compare very favourably with other cyclic GMP 
methods, thei-r specificity is only partly derived from the 
enzyme catalysedreactions employed. They rely largely on 
the effectiveness of the preliminary nucleotide fractionation 
procedures which are used to 'clean up• test samples. 
1.5.3 Saturation Analyses for Cyclic GMP 
'Saturation analysis', a term coined in 1963 by Ekins, 
is the most general one that can be applied to assays which 
involve competition between a fixed amoun·t of labelled 
substance and a variable amount of non-labelled substance for 
a limited number of binding.sites on a specific binding 
reagent. The principle of saturation analysis was formulated 
independently by Ekins (1960), as a result of studies on 
thyroxine binding to the endogenous plasma transport protein, 
thyroxine. binding globulin, and by Berson and Yalow (1960) 
foll.owing an investigation of insulin binding by antibodies. 
Specific binding proteins which can be used include 
antibodies {'radioimmunoassay•), plasma transport proteins, 
cell plasma membrane receptor site preparations, or intracellular 
binding proteins ('competitive protein binding', •radioligand 
displacement', or 'radioreceptor' assays). 
The general principle ofsaturation analysis can be 
explained in terms of the association of the substance to be 
measured {P) with a specific binding reagent (Q) of limited 
capacity. P saturates Q and is thus partitioned into free and 
bound fractions. . The ratio of free P to bound P will vary 
90 
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with the total amount of P present. 
p + Q ;=!. PQ 
An unknown quantity of P could be measured by comparing 
its free to bound distribution with the distributions found 
for a set of standards containing known amounts of P. Clearly, 
it is neqessary to use some marker to determine the distribution 
of P between the free and bound compartments. 
The majority of saturation analyses which have been 
developed have used a radioactive label for this purpose, 
although enzymes, fluorescent probes, or nuclear magnetic 
resonance labels may also be suitable. 
In practice, a small: fixed amount of labelled substance 
P* is added to the system, and competes with P for binding to Q:-
P* 
+ 
p + Q ｾｐｑ＠
Jt 
P*Q 
Since Q and P* are fixed quantities the amount of label 
P* in the bound fraction (PQ + P*Q) will decrease as P increases, 
since P* will face increasing competition for binding to the 
limited number of binding sites. Separation of the bound and 
free fractions and measurement of the bound and/or free radio-
activity will therefore enable the amount of unlabelled P in 
the system to be monitored. Standardisation tubes containing 
known amounts of P are included in the analysis, and the free 
or bound radioactivity counts from these tubes are used to 
construct 'standard', 'calibration' or 'dose-response' curves 
which can be plotted in several ways (Fig.l.5A). The radio-
activity counts for unknown samples can then be used to 
determine their P content from the dose-response curve. 
Ekins (1974) has developed a mathematical model for 
the optimisation of assay precision from a knowledge of the 
equilibrium constant K of the binding reaction, and the 
experimental and counting errors associated with the method. 
The 'detection limit' or 'sensitivity' of an assay 
may be defined as the least amount of test substance which 
can be reliably differentiated from zero, and may be calculated 
by the method of Ekins (1974) using the equation:-
Detection limit = Precision (2SD) _ _ a t zero dose level Initial slope of the dose response curve 
The detection ｬｾｭｩｴ＠ of a saturation analysis may be 
improved by delaying the addition of label. In conventional 
'equilibrium' assays, test substance, label and binding protein 
are all added at the start of the incubation and the components 
of· the system are allowed to equilibrate. In 'disequilibrium' 
or 'sequential saturation' methods, reagents are preincubated 
in the absence of label. The label is then added, and the 
second incubation is stopped before a state of equilibrium is 
attained. By this means the non-radioactive ligand is given 
a better opportunity to bind to the binding protein, and this 
effectively allows it to displace the label to a greater extent 
than would be possible in the equilibrium system. Zettner 
(1973) and Zettner and Duly (1974) have reviewed the principles 
of equilibrium and disequilibrium assays, and Rodbard et al (1971) 
9 
FIG. 1.5A. Typical methods of plotting saturation analysis 
dose-response curves. 
i 
% B 
t 
ｾｯﾷ＠
B 
1. 0 . 
p 
p 
t 
% B 
log P 
t 
logit Z 
log P Ｍｾ＠
% B = % Total radioactivity bound,corrected for non-specific binding ('NSB') 
B Zero standard bound count 
8° = Test bound count 
logit Z = log _z_ where Z = JlLL 
1-Z B
0
/F
0 
( F=free .radi oacti vi ty 
F =zero std. free radioactivity) 
0 
93 
have investigated the t?eoretical basis for the improved 
sensitivity which is obtained by delaying the addition of 
labelled ligand. 
Saturation analyses for cyclic GMP fall into two main 
categories, competitive protein binding assays which make use 
of specific fntracellular binding proteins, and radioimmuno-
assays, based on specific anti-cyclic GMP antisera. 
1.5.3a Competitive Protein Binding Assays for Qyclic GMP 
Protein binding assays for cyclic AMP have been based 
on binding proteins from skeletal muscle (Gilman, 1970) or 
adrenal cortex (Walton and Gqrren, 1970; Brown et al, 1971), 
which was associated with cyclic AMP stimulated protein kinase 
· activity. Murad et al (1971), working along these lines, used 
the lobster muscle cyclic GMP-dependent protein kinase described 
by Kuo and Greengard (1970) to set up a competitive protein 
binding assay for cyclic GMP. The method would only detect 
ＰＮＵｾＱ＠ pmol cyclic GMP, however, and cyclic AMP cross-reactivity 
was in the region of one twentieth of that for cyclic GMP. 
More recently, Fallon and Wyatt {1975) have made use of the 
silkmoth cyclic GMP-dependent protein kinase preparation 
characterised by Kuo et al (1971) to establish a competitive 
protein binding method with improved specificity for cyclic GMP 
The binding protein was purified frs>m an homogenate of the fat 
body tissue of silkmoth pupae (Hyalophora cecropia or Antheraea 
pernyi) by acid precipitation and ammonium sulphate fractionation. 
Kobayashi and Fang {1975) developed a protein binding 
assay based on a specific cyclic GMP binding protein from rat 
94 ; 
. . 
lung, following a report by Kuo (1974) of increased cyclic GMP 
protein kinase activity in guinea pig lung. Although as 
little as 0.2 pmol cyclic GMP could be detected, cyclic AMP 
interference was considerable. 
Table 1.5 lists some of the characteristics of the 
cyclic GMP protein binding assays which have been published. 
In every method, an ammonium sulphate fractionation step was 
necessary to reduce contamination with cyclic AMP binding 
proteins, and only in the case of the silkmoth assay of Fallon 
and Wyatt did .preliminary purification of the binding protein 
reduce cyclic AMP cross-reactivity to a low level. 
Sold and Hoffman (1974), investigated the cyclic GMP 
binding properties of supernatant fractions from homogenates 
of rat cerebrum, cerebellum, heart, skeletal muscle, adrenal 
glands, and thymus. Specific cyclic GMP binding was observed 
in preparations from all these tissues. The receptor protein 
from rat cerebellum, which had the highest ratio of cyclic GMP 
to cyclic AMP binding capacity, had a dissociation constant for 
-8 I . cyclic GMP binding of 1.2 x 10 mol 1, and was part1ally 
purified by ammonium sulphate precipitation. A specific cyclic 
GMP receptor protein has also been isolated from bovine adrenal 
(Gill and Kanstein, 1975). This protein was purified by 
ammonium sulphate fractionation and . affinity chromatography on 
a column of 8-(6-aminohexyl) amino-cyclic AMP-sepharose, ｷｨｾ｣ｨ＠
retarded cyclic AMP binding proteins. A dissociation constant 
of 1.4 x lo-8 mol/1 was determined by Scatchard analysis of the 
cyclic GMP binding data for the purified preparation. 
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1.5.3b Cyclic GMP Radioimmunoassay 
Cyclic nucleotide radioimmunoassays have been established 
largely as a result of the researches of Steiner and colleagues 
(Steiner et al, 1970: Steiner et al, 1972a,b: Steiner, 1974a,b) . 
....__ ....-
Cyclic nucleotides are small molecules which are 
endogenous to animals which may be used for antibody production. 
They would have negligible immunogenicity if administered 
without modification. Steiner overcame this problem by making 
use of the principle of 'haptenisation', which involves the 
conjugation of the small cyclic nucleotide (the 'hapten') to a 
large protein molecule. When such a conjugate is administered 
to an animal there is an inqreased chance of producing antibodies 
to _the hapten molecules, which are seen by lymphocytes as 
projections from the polypeptide chain of the carrier protein. 
The preparation of suitable cyclic nucleotide conjugates 
was achieved by (i) succinylation of cyclic nucleotides at the 
2' hydroxyl group on the ribose ring, and (ii) conjugation of 
the 2 '-0-·succinyl cyclic nucleotides to human serum albumin, 
keyhole limpet haemocyanin, or ｰｯｬｹｾｌＭｬｹｳｩｮ･＠ with the aid of the 
water soluble carbodiimide 'EDC' (1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide-HCl). These reactions are illustrated in 
.Fig.l.SB. 
Rabbits were immunised with the cyclic GMP-protein 
conjugates, and antisera of suitable specificity were used to 
set up a cyclic GMP radioimmunoassay. Antisera were also 
raised against cyclic AMP, cyclic IMP and cyclic UMP using 
similar techniques. 
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FIG. 1.58. Synthesis of ScGMP-Protein conjugate. 
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1. ·Succinylation 
cyclic GMP (trioctylammonium salt) 
+ succinic anhydride. ' 
(anhydrous pyridine: 18 hr./RT.) 
2. Conjugation to protein 
Carbodiimide (!EDC') 
+ protein (eg. kehole limpet 
haemocyanin) 
{16 hr./RT- in the dark) 
2 • -0-Succi nyl cyclic GMP-·protei n conjugate. 
Several anti-cyclic GMP antisera required more than 
a 10,000-fold greater concentration of cyclic AMP ·to produce 
a displacement of label equal to that of cyclic GMP. 
The detection limit for cyclic GMP radioimmunoassays-
using an [s- 3a] cyclic GMP label is in the region of 0.1 pmol/ 
tube {Zeilig, 1976). Synthesis of 2'-0-succinyl cyclic GMP-
tyrosine methyl ester, and the iodination of this derivative to 
provide an [125r] label of high specific activity {Fig.l.SC) has 
enabled Steiner to develop a radioimmunoassay which is 'sensitive 
to' 0. 03 pmol/tube cyclic GMP ·(steiner, 1974a). Radioimmuno-
assays,therefore,have advantages of sensitivity and specificity 
over established competitive·protein binding methods. 
The observation that anti-cyclic nucleotide antisera, 
raised against 2'-0-succinyl cyclic nucleotide-protein conjugates 
often have greater affinity for 2'-0-succinyl cyclic nucleotides 
than for the non-acetylated nucleotides (Steiner et al, 1972b) 
. . . 
has. led to the development of cyclic GMP radioimmunoassays with 
-t5 detection limits in the femtomole (1.0 mol) range. The assay 
described by Cailla et al (1976) utilises a rapid aqueous phase 
reaction to succinylate cyclic GMP in test samples. Although a 
100-fold improvement in sensitivity was achieved, free succinate 
remaining after the succinylation step interfered with antibody 
binding. Test samples had to be diluted to ｲ･､ｵ｣ｾ＠ this 
interference, and consequently the advantage of improved 
sensitivity was ｬｩｭｩｴ･､ｾ＠ The formation of 2'-0-acetyl cyclic 
nucleotide derivatives also provides highly·sensitive radioimmuno-
assays and it appears that simple substitution at the 2'-0-
position is the main requirement for enhancement of antibody 
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FIG 1.5C. Preparation of ｓ｣ｇｾｐＭｔｍｅＭ ＱＲＵ ｲ＠ derivative. 
l 
,ScGMP- ｔｾＱｅＭｴ＠ 25 r] 
ScGMP. 
1 . Synthesis of ｓ｣ｇｾＱｐＭ TlvJE 
+ TME 
+trioctylamine 
+ethyl chloroformate 
( in DMF ; 18 hr./RT) 
ScGMP- TME 
- ·---
2. Iodination ..,_.__ _____ , 
( ｣ｨｬｯｲ｡ｭｩｮ･ﾷｾ＠ T) 
loa! 
. . .. ... . -·-·------------ --------
binding (Zeilig, 1976). Frandsen and Krishna (1976) have 
reported a direct aqueous phase acetylation procedure for test 
samples. Their 2'-0-acetyl cyclic GMP radioimmunoassay system 
will detect 3-10 femtomoles of cyclic GMP. Acetylation reagents 
have little effect on antibody binding and, since dilution of 
the acetylation mixture is unnecessary, a maximum improvement 
in sensitivity can be attained. 
Zeilig (1976) has stressed the importance of checking 
the cross-reactivity of antisera with acylated cyclic nucleotides. 
Some anti-cyclic GMP antisera may show very high cross-reactivity 
with 2'-0-acylated cyclic AMP, and in this situation the use of 
a succinylation or acetylation step would invalidate the assays. 
Ammonium sulphate has been widely used to separate bound 
and free radioactivity in cyclic GMP radioimmunoassays (Steiner, 
1974a). Second antibody methods (Steiner et al, 1967), poly-
ethylene glycol precipitation (Desbuquois and Aurbach, 1971) or 
fiitration on 'Millipore' filters (Weinryb, 1972) have also been 
applied successfully to cyclic nucleotide radioimmunoassays. 
1.5.4 Sample Preparation for Cyclic Nucleotide Analysis 
1.5.4a Tissue Specimens 
Tissue cyclic nucleotide levels can change through enzyme 
activity during isolation. These artefactual changes may occur 
within seconds, and it is essential to inhibit tissue enzymes as 
quickly as possible. Techniques for the rapid fixation of 
tissue specimens include freeze clamping ｢･ｴｾ･･ｮ＠ metal plates 
which have been cooled in liquid ｮｩｾｲｯｧ･ｮＬｲ｡ｰｩ､＠ freezing of 
biopsy specimens in 'Freon 12' (dichlorodifluorornethane) or 
lOl ! 
· --- ·· - -·------------------: 
0 iso-pentane at -190 c, and microwave fixation of brain tissue 
specimens (Mayer et al, 1974). 
--
When tissue enzymes have been inactivated, the specimen 
can be homogenised in ｴｲｩ｣ｨｬｯｲｯ｡｣ｾｴｩ｣＠ acid (50 or 60 g/1) which 
is removed by subsequent ether extraction (Brown et al, 19717 
Steiner et al, 1970). The validity of this procedure has been 
questioned by Wright (1975) who observed that traces of 
trichloroacetic acid which remained after ether extrac·tion of 
tissue homogenates caused the overestimation of cyclic AMP in a 
pld:ein binding assay. Tissue samples can be homogenised in 
perchloric acid (0.4 mol/1) and the supernatant neutralised with 
potassium hydroxide (Schultz e·t al, 1973), or Tris base (Kuo and 
Greengard, 1972). CPDE has been inhibitied by boiling tissue 
specimens in theophylline(6 mmol/1). The homogenised sample 
was then extracted into acid- alcohol (Albano et ?1, 1976). 
Homogenisation in buffer containing EDTA (4 mmol/1) may also be 
satisfactory. 
Cyclic GMP radioimmunoassay is possible without further 
purification of tissue extracts (Steiner, 1974a)v Cyclic 
nucleotide fractionation, where it is necessary, can be 
achieved by alumina and ion-exchange column chromatography. 
Mao and Guidotti (1974) have developed a simple procedure for 
the separation of cyclic AMP and cyclic GMP in tissue samples 
of 0.5 to 500 mg. Extracts of tissue in 0.4 mol/1 perchloric 
acid were neutralised with Tris base and applied to small 
alumina columns. Cyclic AMP and cyclic GMP were separated from 
nucleotides containing multi-charged phosphate residues by 
102' 
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elution with 4.0 ml of Tris buffer,_ and a small . 'Dowex-IX2' 
column was then used to separate the two cyclic nucleotides. 
1.5.4b Blood ·samples 
Cyclic nucleo·tide phosphodiesterase activity in blood 
samples is high (Section 1.3.3) and must be inhibited if loss 
of cyclic nucleotides is to be prevented. 
Blood samples may be collected into 1% of their volume 
of EDTA (0. 5 mol/1; pH 7. 5) which acts both as· an anticoagulant 
and as a cyclic nucleotide phosphodiesterase inhibitor (Tovey 
et al, 1974). Latner and Prudhoe (1973) ｩｮｨｩ｢ｾｴ･､＠ phospho-
diesterase activity by collecting blood samples into heparinised 
tubes containing 10% of the"blood volume of Tris buffer (50 mmol/ 
11 pH 7.4) in which was dissolved theophylline (32 mmol/1) and 
2-mercaptoethanol (6 mmol/1). Once cyclic nucleotide phospho-
diesterase activity has been halted, plasma can be separated by 
｣･ｾｴｲｩｦｵｧ｡ｴｩｯｮ＠ at 4°c, and stored at -20°C. Although these 
methods were developed for use with cyclic AMP assay procedures, 
they are also effective in preventing cyclic GMP degradation 
in plasma specimens. Steiner (1974) treated blood samples with 
an equal volume of TCA (100 g/1) and, after centrifugation, 
I 
measured cyclic GMP levels directly in the ether-extracted 
supernatants. Plasma samples for cyclic AMP analysis lave been 
deproteinised by ethanol extraction (Brown et al, 1971) or by 
ethanolic 'Somogyi' precipitation (Rabinowitz and Katz, 1973). 
1.5 . 4c Urine Specimens 
Mura d (1973) reported that urinary cyclic AMP and 
cyclic GMP levels remained stable for one to two years when 
----------------------------------------- . .. ... . 
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spec1mens were stored at -20 C. Storage at room temperature 
0 for more than 'two or three' days or at -4 c for more than 
'several weeks' resulted in losses which were attributed to 
bacterial growth 'and hydrolysis. Bacterial growth in urine 
has been inhibited by collection into hydrochloric acid 
(Hardman et ｾｊＬ＠ 1966), acetic acid and thymol (Broadus et al, 
1971), sodium metabisulphite (Paul ｾ＠ al, 1971), chloroform 
(Abdulla and ｈ｡ｭｾ､｡ｨＬ＠ 1970), or phenyl mercuric nitrate (Owen, 
1976) • 
lo4 
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1.6 .Aims of the Research 
Of the methods which are available for cyclic GMP 
analysis, radioimmunoassay, with advantages of increased 
specificity and sensitivity, is the method of choice. Although 
it is possible to purchase suitable anti-cyclic GMP ｡ｮｴｩｳ･ｲ｡ｾ＠
their cost is prohibitively high, and this is a major drawbad{ 
to the development of a radioimmunoassay systemo For this 
reason it was decided to attempt to produce a suitable antiserum 
of our own. 
The introduction of the bovine adrenal protein binding 
assay of Brown ｾ＠ al (1971) has been a major advance in the 
field of cyclic AMP measurement, and a protein binding assay 
for cyclic GMP of similar simplicity and lov1 cost would be an 
advantage. Published protein binding assays for cyclic GMP 
require purification of the binding protein and, with the 
possible exception of the silkmoth preparation of Fallon and 
Wyatt (1975), lack specificity. A preliminary nucleotide 
fractionation step is, therefore, essential for the analysis 
of tissue samples, and is also recommended for the analysis of 
urine by these methods. 
It was anticipated that the production of suitable antir-
cyclic GMP antibodies would take several months, with no 
guarantee of success. In the meantime, it was decided to try 
to develop a competitive protein binding assay for cyclic GMP 
with improved specificity over existing me·thods. Silkmoth 
pupae were not readily available, and alternative sources of 
specific cyclic GMP binding proteins were inves ·tiga ted .. 
105· 
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Mammalian brain and cricket tissues had been reported to 
contain high cyclic GMP/cyclic AMP ratios (Ishikawa et al, 
1969), and it seemed possible tha·t these could also possess 
an increased ratio of cyclic GMP to cyclic AMP binding 
P=:oteins. 
The successful development of competitive protein 
binding or radioimmunoassay methods would enable possible 
clinical applications of cyclic GMP measurements in urine 
and plasma to be evaluated. 
' 
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Desert locust (Schistocerca gregaria) at the fifth instar stage. 
2.1 Materials and Methods 
ｾＭ Ｓ ｈ｝＠ cyclic GMP (15, 19 or 21 Ci/mmol Code TRK 392) 
and ｾＭ Ｓ ｈ｝＠ cyclic AMP (27.5 Ci/mmol Code TRK 498) were purchased 
from the Radiochemical Centre, Amersham. Nucleotides and ox-
heart phosphodiesterase were obtained from Boehringer Ltd. 
Cyclic ｾｍｐ＠ standards were made up from the free acid; cyclic GMP 
standard solutions were made up from the monosodium salt, using 
the manufacturer's figures for cyclic GMP content based on 
analysis for phosphorus. 
Hopkin and Williams Ltd. 
Norit 'GSX' charcoal was supplied by 
Bovine serum albumin for use in 
buffers was purchased as a sterile solution (300 g/1) from 
Armour Pharmaceuticals Ltd. Crystalline .bovine serum albumin 
(Cohn fraction V, Sigma Chemical Co.) was used in standards for 
protein analysis.p 'TES' (N-tris(hydroxymethyl)methyl-2-
aminoethane sulphonic acid), 'HEPES' (N.-2-hydroxymethylpiper-
azine-N'-2-ethane sulphonic acid), 'IBMX' (isobutyl methyl 
xanthine) and 'EGTA' (ethylene glycol bis (amino ethyl ether}-
tetra-acetic acid) were also supplied by the Sigma Chemical 
co. 
Scintillation chemicals were obtained from Packard 
109 
Ltd., and the 'Synperonic-NXP' detergent used in the scintillation 
'cocktail' was purchased. from Womersley Boorne Chemicals Ltd. 
All other reagents were 'Analar' grade (BDH Ltd.) unless a 
particular grade is stipulatedo 
Assays were set up in polystyrene test tubes (Luckham 
Ltd., Type 'LP3') with the aid of 'Oxford' samplers (Oxford 
- - - --- ----- -------.,..-----------------
Labs Ltdft) and a 'Compupet' Ｈｗｾｒｯ＠ Warner & Co. Ltd.}. Duplicate 
incubation tubes were placed in metal racks (Luckham Ltdo) and 
the temperature of reagents and incubation mixtures were 
maintained at 4°C by the use of a cooler tray (M.Ko Refrigeration 
Ltd: Type MK6 bottle cooler). Tubes were mixed on a vortex 
mixer (Gallenkamp Ltd., 'Whirlimixer'). A Mistral 4L centrifuge 
(MSE Ltd.) fitted with a 'Universal' head and 8 x 24 place multi-
tube · carriers was used to centrifuge batches of tubes at 4°C. 
2.2 General Methods 
2.2.1 Protein Estimations 
110 
The method of Goodwin and Choi (1970) was used to determine 
the protein content of binding protein preparations. This method 
has been used extensively in the department and has proved to be 
reliable for the analysis of mammalian tissue fractions. At a 
late stage in the research it was discovered that protein levels 
ｾｮ＠ ｬｾ｣ｵｳｾ＠ tissue preparations were considerably lower when 
me?sured by the method of Lowry et al (1951). 
2.2.la Method of Goodwin and Choi J1970) 
Protein estimations were carried out on 1 in 100 and 1 in 
200 dilutions of the binding reagents in sodium tetraborate 
solution (0.1 mol/1). Duplicate 10 ml capacity polystyrene 
test tubes (G.D. Searle and Co. Ltd.) contained 0 .. 5 ml of sodium 
tetraborate solution (0.1 mol/1) and 0.5 ml of diluted binding 
reagent or standard (o. 100, 200 and 500 pg/ml BSA in 0.1 mol/1 
sodium tetraborate). To these, 3o0 ml of a freshly prepared 
combined reagent consisting of equc:-1 parts by volume of solutions 
of sodium tetraborate (Ool mol/1), sodium sulphite (Oo05 mol/1 
in distilled water) and trinitrobenzene sulphonic acid 
('TNBS': 0.5 g/1 in distilled water) was added. Tubes were 
mixed, incubated for 15 minutes at 70°C, and allowed to cool 
to room temperature. The absorbancies of tests and standards 
were measured at 420 nm against the reagent blank, on an 'SP 
1800' spectrophotometer (Pye Unicam Ltd.). Tests, from which 
the TNBS reagent had been omitted, showed no increase in 
absorbance over the reagent blankc Results for 1 in 100 and 
1 in 200 dilutions were in clo·se agreement, and standard curves 
were linear over the whole of ·the standard range (0-250 ;Ug BSA/ 
tube). 
2. 2 • lb ｉｾ･＠ thod of Lowry ｾｊ［＠ ｾｬ＠ ( 19 51) 
Binding prepar.ations were diluted 1 in 100 with NaOH 
solution (0 .. 5 rn.ol/1) and left at room temperature to clear. 
Duplicate aliquots (0.5 ml) of test dilutions or standards 
<.o, ｾＰＬ＠ ｾＭＰＰＬ＠ 200, 300, 400, 500 ;«g/ml BSA in 0.5 mol/1 NaOH) 
were mixed with 6.0 ml of freshly prepared copper reagent 
(100 ml of Na 2co3 solution {20 g/1), mixed with 2.0 ml of a 
solution of cuso4 .sH2o (5 g/1) and sodium potassium tartrate 
(10 g/1) in distilled water). Tubes were left to stand at 
room tempera ·ture for 10 minutes. Folin and Ciocalteau 
reagent (BDH Ltd.) was diluted with an equal volume of distilled 
water, 0 .. 5 ml of this diluted reagent was added, with mixing, 
to each tube, and the incubation was continued for at least 
30 minutes at room temperature. Absorbancies of tests and 
standards were measured at 700 nm on an • sp· 1800 • spectra-
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photometer against the reagent blank. Plots of absorbance 
versus standard protein concentration were linear up .to 
approximately 150 ｾｧ＠ protein per tube. 
2.2.lc Comparison of the Methods of Goodwin and Choi (1971) and 
Lowry ｾｾ＠ (1951) for the Determination of Locust 
Tissue Protein Levels 
A preliminary experiment revealed that the protein 
contenrnof two locust tissue preparations were 37 and 35 g/1 
when measured by the method of Goodwin and Choi, and only 13 
and 11 g/1 when determined by the method of Lowry ｾ＠ ｾﾷ＠ A 
check of the protein levels with the 'biuret' reaction ('Auto-
analyser' method) gave ｲ･ｳｾｬｴｳ＠ in the region of 13 g/1. 
In contrast to these observations, protein concentrations 
in two quality control sera ('Wellcomtrol unassayed') were very 
similar when measured by the methods of Goodwin and Choi or 
Lowry ｾ＠ al {Table 2. 2A). 
The differences between the two protein methods for the 
analysis of locust tissue preparations were investigated by 
comparing direct protein assays with results obtained after 
precipitation of protein in test samples with TCA (100 g/l)o 
The results (Table 2.2A) confirmed the three-fold difference 
between results obtained using the two direct methods. The 
recoveries of BSA (100 rg/tube) added to the two samples were 
also high for both direct protein assays. TCA precipitation 
of protein in test samples resulted in a much closer agreement 
between the methods, and gave improved recovery results. It 
was concluded from· this that the TNBS method of Goodwin and 
Choi was more susceptible to interference than the method of 
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TABLE 2. 2A Comparison of results for protein analysis by the 
methods of Goodwin and Choi (1970) and Lowry ｾ＠
al (1951). 
Sample Dilution Results 
Direct ｡ｳｳ｡ｾＺＭ Goodwin & Choi Lowry et al 
--
Serum 
Q.C. serum 1 1 in 200 74 g/1 79 g/1 
Q.C. serum 2 1 in 200 67 g/1 71 g/1 
Locust :ere:es: --
4th Instar 1 in 100 37.4 g/1 12.6 g/1 
(X Ta_b1e 2.2C) 
Recovery* 1 in 100 120% 142% 
5th Instar 1 in ·100 34.7 g/1 11.2 g/1 
(XI Table 2.2C) 
Recovery 1 in 100 130% 130% 
TCA PreciEitation:-
4th Ins tar 1 in 100 6.8 g/1 7.2 g/1 
(X Table 2.2C) 
Re.covery 1 in 100 102% 96% 
5th Instar 1 in 100 6.8 g/1 7.0 g/1 
(XI Table 2. 2C) 
Recovery 1 in 100 109% 101% 
*Recovery tubes containing 100 f9 BSA in addition to the diluted 
test sample. 
. ' -- .,.._ -- . -- ---- ＭＭＭＭ ＭＭ ＭＭＭＭＭＭＭＭＭｾ＠
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Lowry et al for the measurement of locust tissue protein 
levels. 
2.2.2 Liquid Scintillation ｃｯｵｮｾｩｮｧ＠ Procedure 
A toluene-Synperonic NXP scintillation medium was 
used to count tritium activity in aqueous samples (Wood gt a!, 
19.7 5) • 
Composition of 1 litre of toluene-Synperonic NXP scintillation 
fluid:- · 
Toluene 667 ml 
'Synperonic NXP' non-ionic detergent 333 ml 
PPO ＨＲ Ｘ ＵＬ､ｩｰｨ･ｮｹｬｯｸｾｺｯｬ･Ｉ＠ 4.0 g 
Dimethyl POPOP (1 ,4-bis- [2- (4 methyl- 0.1 g 
5 phenyl oxazole)] benzene) 
The scintillants PPO and dimethyl POPOP were dissolved 
in toluene before the addition of the detergent. 
Aliquots (500 ｾＱＡ＠ of aqueous samples for counting were 
dispensed into numbered polypropylene 'minitubes' (G.D. Searle 
and CoG) and 4.0 ml of toluene-Synperonic NXP scintillant were 
added to each tube. Samples with volumes of less than 500 fl 
were made · to 500 /\1 with distilled water before addition of 
the scintillanto The minitubes were then capped, and the 
contents mixed for five seconds on a vortex mixer. The tubes 
were then inserted into low potassium glass vials (Packard Ltd.) 
and were equilibrated for at least 30 minutes at the counter 
i 
temperature before counting. Samples were counted for five 
minutes or for a maximum count of 10,000 per vial on a Packard 
2425 or a Wallac 1210 liquid scintillation counter. Tritium 
counting efficiency, determined by internal standardisation 
using a eHJ H20 I spike I of known activity was 33% for the 
Packard 2425 counter and 35% for the Wallac Ultrobeta 1210 
instrument. The external standard channels ratio method and, 
in the first instance, internal standardisation was used to 
monitor the efficiency of [HJ counting in standard and test 
sample mixtures. No differences in counting efficiency 
between tests and standards were observed, and ·for this reason 
radioactivity counts were not corrected to dpm. 
2. 2. 3 Homogenisa tion of Insect r.rissue Samples 
Table 2.2B summarises the method used for the preparation 
of fifth instar desert locust binding protein. The same 
protocol was used for all cricket and locust tissues which were 
･ｾ｡ｊｕｩｮ･､ｯ＠ Wings were removed from frozen adult locusts before 
they were powdered, and abdomens, used for some preparations, 
were also isolated at this stage. 
Crickets (Acheta domesticus were caught locally. Desert 
locusts (Schistocerca gregaria) and migratory locusts Ｈｌｯ｣ｵｳｴｾ＠
migratoria ｭｩｧｲ｡ｴｯｲｩｯｩ､･ｾＩ＠ were kindly provided by Shell 
Research Ltd., Sittingbourne, Kent. 
The fifth instar desert locust binding protein was 
prepared by freezing 25 live insects, each weighing between ＱｾＵ＠
and 2.0 g, in liquid nitrogen. Frozen locusts were then 
ground to a powder under liquid nitrogen in a large mortar and 
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TABLE 2. 2B Flow diagram for the preparation of 5th Instar 
Schistocerca gregaria binding protein. 
Live 5th Instar Schistocerca gregaria (1.5-2 g each) 
1 
Freeze and powder under liquid N2 
(mortar and pestle) 
1 
Homogenise in ice-cold Littlefields medium 
{6.0 ml/g powder: 2 x 30 seconds, 'Polytron Blender) 
1 
Centrifuge (10,000 g/15 minutes} 
l 
Decant supernatant through nylon cloth 
1 
Recentrifuge supernatant (10,000 g/15 minutes) 
l 
Decant through nylon cloth 
l 
Freeze 5.0 ml aliquots of the clear supernatant 
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pestleo The cold powder was rapidly weighed and extracted 
with 6.0 ml of ice-cold Littlefields medium (Tris, 50 mmol/1, 
pH 7.4 containing sucrose, 0.25 mol/1: KCl 25 ｭｭｯｬＯＱｾ＠ and 
MgC12 5 mmol/1) per gram, using two thirty second periods at 
maximum speed on a • Polytron' blender . (Northern Media Supply 
Ltd.}. The homogenisation vessel was cooled in ice. The 
homogenate was centrifuged at 10,000 ｾ＠ for 15 minutes . (MSE 
'HS18' ｣･ｮｴｲｩｦｵｧ･ｾ＠ 8 x 50 ml rotor}, the supernatant decanted 
ｾｨｲｯｵｧｨ＠ nylon cloth (125 )A pore size} to remove low density 
particles, and respun for a further 15 minutes at 10,000 ｾＭ
The resulting clear, pale yellow supernatant was again decanted 
through nylon cloth and 5.0 ml aliquots were stored frozen at 
Aliquots were thawed immediately before use and were 
not allowed to warm to a temperature greater than 4°C. 
Aliquots (5.0 ml) from some preparations were lyophilised on 
an Edwards model EF4-10 freeze drier with shelf stopperi·ng 
attachment. A batch of 25 fifth instar locusts yielded 
approximately 150 ml of binding reagent, sufficient for 1,500 
·cyclic GMP assay tubes. 
During the course of this study, several different 
insect binding protein reagents were prepared and ･ｶ｡ｬｵ｡ｴ･､ｾ＠
These are listed in Table 2.2C. 
2.3 An Investigation of Possible Sources of Cyclic GMP 
Binding Protein 
2.3.1 Bovine brain and adrenal tissue 
Bovine ｡､ｲ･ｾ｡ｬｳＬ＠ used in this study for the preparation 
TABLE 2. 2C Locust binding protein preparations used in ｴｨｾ＠
Preparation 
Reference No. 
I 
II 
III 
IV 
.v 
VI 
VII 
VIII 
IX 
X 
XI 
course of the study. 
Tissue Source 
Whole crickets 
{Acheta domesticus) 
5th Instar Schistocerca 
gregaria (whole) 
5th Instar Schistocerca 
gregaria (abdomens) 
5th Instar Schistocerca 
gregaria {whole) 
5th Instar Locusta migr-
atoria migratorioides 
{whole) 
Adult Schistocerca greg-
aria (whole male insECts) 
5th Instar Schistocerca 
gregaria (whole) 
Adult Schistocerca 
gregaria (male insect 
abdome11:s) 
5th Instar Schistocerca 
gregaria (whole·) 
·4th Instar Schistocerca 
gregaria (whole) 
5th Instar Schistocerca 
gregaria {whole) 
*F = Stored froze at -20°C 
L = Lyophilised and stored at -20°C 
Storage 
Method* 
F 
F 
F 
F & L 
F & L 
F 
F 
F 
F 
F 
F 
Protein 
Content+ 
{g/1) 
14.6 
38.6 
34.8 
30.9 
33.7 
26.5 
38.6 
14.6 
39.4 
37.4 
34.7 
+Protein levels measured directly by the method of Goodwin and 
Choi (1970). Please note that this method gives higher results 
tharr that of Lowry et al (1951) (see Section 2.2.1). 
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of cyclic AMP binding protein, and bovine brain tissues were 
processed by a method based.on that of Brown et al (i971). 
Bovine adrenals were collected from carcasses within 15 minutes 
of slaughtering and transported to the laboratory on ice. The 
adrenals were sliced in half, and the pale medulla was scraped 
from the cortex using a scalpel blade. Cortices were weighed, 
minced with scissors and macerated for 1 minute in ice cold 
Littlefields medium (3 ml/g wet weight tissue) in a 'Waring' 
blender. The mixture was then homogenised with a 'Polytron' 
blender for 15 seconds at maximum speed, with cooling.. The 
homogenate was centrifuged at 10,000 g for 10 minutes (MSE 
"""' 
'HS18' 8 x 50 ml rotor)c Supernatants were decanted and 
respun at 10,000 g for 30 minuteso Clear supernatant solutions 
were stored in 1.0 rnl aliquots at -20°C. Bovine brain tissues 
(cerebral cortex, cerebellum and corpora quadrigernina) were 
processed by the same procedure, with the ex9eptions that 
(i) tissues were hornogenised directly in the 'Polytron' and 
(ii) homogenates were centrifuged once at 10,000 ｾ＠ for 30 
minuteso 
l_B- 3H] cyclic Gf.1P and {?-3IiJ cyclic AMP binding for 
doubling dilutions of the bovine tissue preparations were 
assessed in incubation mixtures comprising of 150 fl assay 
buffer (Tris 50 mmol/1, pH 7.4, containing theophylline, 
8 mmol/1 and 2-mercaptoethanol, 6 ｾｭｯｬＯＱＩＬ＠ lOO)Al of tissue 
preparation diluted in assay buffer, and 50 rl (approximately 
1 pmol) of [8- 3H] cyclic AMP or [8- 3H] cyclic GMP. Tubes 
were incubated at 4°C for 90 minutes and then 100 fl of an 
ice-cold, continuously stirred suspension of charcoal (Norit 
119 
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GSX; 1 g) in 10 ml of a solution of BSA (20 g/1) in assay 
buffer was added. After vortex mixing, tubes were quickly 
transferred to the 'Mistral 4L' centrifuge and spun (at4°C) 
for 15 minutes at 1,800 ｾﾷ＠ 100 fl aliquots of the supernatant 
solutions were taken for liquid scintillation counting. 
Figure 2. 3A i llus tra tes the '\13- 3a] cyclic AMP and 
ｾｾ Ｓ ｈ｝＠ cyclic GMP binding observed for the bovine tissue 
preparations. The bovine adrenal reagent showed a high 
eapacity to bind rHJcyclic AMP, with a 1 in 16 dilution 
corresponding to 50% of maximum binding, or to a binding of 
approximately 30% of ·the total radioactivity added. [?- 3H] 
cyclic GMP was also bound by the adrenal preparation. All 
three brain tissue preparations were capable of binding @- 3H] 
cyclic AMP but showed a minimal cyclic GMP binding. 
2.3.2 Cricket and Locust Tissue 
The report of high cyclic GMP levels in crickets, 
(Ishikawa et al, 1969) prompted the initial study of . the (?- 3H] 
cyclic GMP binding properties of a supernatant fraction obtained 
from a homogenate of these insects. Crickets were difficult to 
catch, and a supplier could not be found. Large numbers of 
crickets were required to provide an adequate volume of binding 
protein .. 
ｲＮＮＮｾｯ｣ｵｳｴｳ＠ at the fifth 'instar' (the final 'hopper' stage 
before the moult to the adult insect) were readily available, 
more convenient to handle than the winged adult ｬｯ｣ｾｳｴｳ＠ and 
were cons iderabl.y .larger than crickets. Fifteen whole crickets 
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{Acheta domesticus) and 25 whole fifth instar locusts 
(Schis ·tocerca gregaria) were powdered and homogenised as 
described in· Section 2.2.3. In view of the fact that the 
fat body of the silkmoth had been used to provide a cyclic 
GMP binding protein (Fallon and Wyatt, 1975), abdomens were 
separated from a further 25 fifth instar desert locusts and 
these were carried through the same homogenisation procedure. 
eHJcyclic GMP bi_nding by dilutions of these three insect 
tissue preparations (numbers I, II and III, Table 2.2C) was 
assessed using the method detailed in section 2e3.1. All 
these preparations showed high binding of the label by 
100 fl of neat reagent Ｈｆｩｾｵｲ･＠ 2.3B). The highest binding 
(25% of total radioactivity added) was found with the neat, 
whole fifth instar desert locust preparation. 
2.3 .. 3 ｾｹ｣ｬｩ｣＠ GMP dose-response curves for bovine adrenal, 
cricket and locust binding Eroteins 
The displacement of fH]cyclic GMP by •cold 1 cyclic 
GMP in the range 0-100 pmol/tube was determined for the 
· bovine adrenal and insect preparations. Incubation tubes 
contained 100 ｾＱ＠ of assay buffer (Tris 50 mmo1/1, pH 7.4: 
theophylline 8 mmol/1: 2 mercaptoethanol 6 mmol/1), 50/tAl of 
cyclic GMP standard (0-100 pmol/50 1ul in assay buffer), 50 ｾＱ＠
(approx.. 1 pmol) of [8- 3H] cyclic GMP diluted in any buffer, 
and 100 fl of binding protein preparation. Cricket and 
locust binding reagents were used neat: the adrenal tissue 
preparation was added at a working dilution of 1 in 4 in assay 
l22 ! 
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buffer, which corresponded to a binding of 16% of total 
radioactivity in the absence of cold cyclic GMP (Figure 2.3A). 
Charcoal/BSA reagent was employed to separate bound and free 
radioactivity (Section 2.3.1). 
The dose-response curve for the adrenal binding protein 
was very shallow (Fig.2.3C). The three insect tissue 
reagents exhibited better displacement of the label with 
cyclic GMP standards. Although the abdomen preparation gave 
a slightly higher zero standard binding than the whole locust 
reagent in this experiment, the latter preparation ·showed a 
greater drop in bound radioactivity with increases in the 
level of cyclic GMP ｳｴ｡ｮ､｡ｲ､ｾ＠
Aliquots (5.0 ml) of the cricket, whole locust and 
locust abdomen preparations were thawed and subjected to the 
lobster binding protein purification procedure described by 
Kuo and Greengard (1972), up to and including the ammonium 
sulphate fractionation step. The tissue preparations were 
adjusted to pH 5.0 by the addition of acetic acid (1 mol/1) 
at 4°C. Precipitates were spun down at 27,000 g for 30 
minutes (MSE SS 50 centrifuge 10 x 10 ml rotor) the supernatants 
separated, and their pH adjusted to 6.5 with potassium phosplate 
buffer (1 mo1/l, pH 7.2). Ammonium sulphate (3.25 g/10 ml 
supernatant) was then added to each preparation and these were 
left to stir for one hour at 4°C. Precipitated protein was 
spun down at 27,000 ｾｦｯｲ＠ 20 minutes. Supernatant solutions 
were discarded and the pale precipitates were redissolved in 
5.0 ml of potassium phosphate buffer (5 mmol/1 pH 7.0, containing 
1241 
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disodium EDTA 2 mmol/l)o Solutions were dialysed against 
the same potassium phosphate buffer (1 ... 1) for 24 hours at 
4°C, with a change of the dialysis buffer after 3 hours. 
ｾｈ｝｣ｹ｣ｬｩ｣＠ GMP . binding of all three ammonium sulphate 
fractionated preparations was extremely low. Less than 3% 
of the total radioactivity was bound for incubations 
｣ｯｮｴｾｩｮｩｮｧ＠ 100 fl of undiluted reagent. 
Because of the lack of success of ammonium sulphate 
fractionation it was decided to adopt the crude preparation 
from whole fifth instar Schistocerca gregaria as the basis 
for a cyclic GMP assay. 
The optimum incuba t1on timet pH influence on tHJ cyclic 
GMP binding, and cross-reactivity ｾｦ＠ other cyclic nucleotides 
was assessed using the original preparation of fifth instar 
Schistocerca 9Eegaria binding protein and charcoal/BSA separation 
o{ bound and free radioactivity. New binding protein 
preparations,however, failed to show displacement of label by 
cyclic GMP standardso Attempts to improve the dose-response 
curve were unsuccessful, and it was finally established that 
the charcoal/BSA separation method was the cause of the problem. 
2.4 Results for an assay: using charcoal adsorEt:ion of free 
_EH] s_ycli.£_ GMP 
The pH dependence of [8-3Hj cyclic GMP binding was 
determined over the pH range 3-9 using acetate, phosphate, 
and Tris buffers. Duplicate tubes contain1ng 150 )"1 of the 
appropria ·te buffer (100 mmol/1), 50 fl (1 pmol) of [?- 3H] 
cyclic GMP in distilled water, and 100/1 of neat binding 
126 1 
reagent {preparation II Table 2.2C) were incubated for 2 hours 
Free and bound radioactivity was separated by addition 
of 100 ｾＱ＠ of charcoal/BSA reagent as described in section 2.3.1. 
ｾＭ Ｓ ｈ｝＠ cyclic GMP binding was approximately constant over the 
pH range 5.5-7.5 with rises from pH 4 to pH 5.5, and from 
pH 7.5 to pH 9 {Fig.2.4A). 
The effect of incubation periods ranging from 15 minutes 
to 4 hours was studied for zero and 10 pmol/tube cyclic GMP 
standards.with the method described in section 2.3.3. Bound 
radioactivity showed a steady increase with incubation time 
up to 3 hours {Fig.2.4B). The difference between zero and 
10 pmol/tube standard ｢ｩｮ､ｾｮｧ＠ was also greatest for a 3 hour 
incubation .. 
Cross-reactivities of six other cyclic nucleotides at 
levels of 1 to 10,000 pmol/tube, were examined using the same 
assay system with a three hour incubation period. 'lbe results 
(Fig.2o4C) indicated that the specificity of the binding protein 
for cyclic GMP was high. Greatest interference was observed 
with cyclic IMP, which had approximately one hundredth the 
potency of cyclic GMP for displacement of the label. Cyclic 
AMP cross-reactivity was less than 1 in 1000. Cyclic CMP 
appeared to enhance [3H] cyclic GMP binding at levels of 1 and 
10 pmol/tube .. 
At this stage in the development of the assay, supplies 
of the ·original fifth instar desert locust binding reagent 
were running low, and two new reagents from whole fifth instar 
desert and migrational locusts were prepared {preparations IV 
oo , , • ｾﾷﾷＧ＠ ｽＬ Ｎ ﾷ ｯﾷＭＮＮＭＭﾷ ﾷ ﾷ•ｾ＠ ... o.J> .... ｾｾＮＺＮＮＭ . .. ......... ｾ＠ .......... i, ... i,.' , 'i••• ....-'-o,.<0 .l_ • ＮＺＮＷＬ［ｾ｟ＬＧｗ｟Ｎ•＠ .• -... ....... - .... ..... -· - · • •• ｾ＠ ... . : 0 ,.· ＭＭ ｾ＠ • • -i.'o• •［ＮＬ ﾷ ｾ Ｚ＠ ﾷｾ＠ .-.. -•• , , 0 ｾＭ［ｾ｟Ｍ ... ［ｴＮＭ Ｎ ｾ ｴ＠ • .., -., ···.;.:·•, ' •' ＬＮｾＭＡ＠ Ｍｾ Ｍ ＮＭ -.-• .. T ·, •ＬＬＮＺ•ＺＺＮＺ［ＮｩｩＬ｟Ｇｾ｜ｾ Ｚ＠ ｾ Ｎ ﾷ ＭＺ［ＭＺ［ＺｾｾﾷＮ［ＺＬ ＮＮ｟ ｟ ［ＺﾷＮＮＭ［ ＭＮ＠ ........ ,. •:: ·•· Ｎ［［ＮｾＢＢ［ＰＬ ＮＷＢＢＺ＠ • . ,-, .,....,, ＭＭＺＭＺ［［ＭＬｾＭＭＮＮＮＮＬＭＭＮ＠ -=<1-.. ｾ ｴ＠
128 1 
I 
I 
•r-
> 
•r-
-1-> 
u 
n:s 
0 
.,... 
-o 
n:s 
s... 
r--
n:s 
-1-> 
0 
1-
-o 
s::: 
:::J 
0 
.c 
ｾ＠
.,... 
>. 
•r-
-1-> 
u 
tO 
0 
•r-
-o 
tO 
s... 
r--
tO 
.f.J 
0 
1- -
ｾ＠
20 
10 -
0 
20 
10 
rn.., 
L 
3 4 5 6 
pH 
0 
. A 
J J 
7 8 . 9 
e-rn ___ E'J __ ｛ｩｾ＠ 13---
+10 pmo1/tube cyclic GMP 
0 ｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭｾＭＭＭＭＭＭｾ＠
1 2 3 4 -
Incubation time (hr.) 
FIG.2.4A 
3 ' pH dependence of [8- H] eye 1 i c GMP 
bindinq. 
(inc. time- 2hr ;charcoal/BSA. separation 
binding protein prep.II) 
acetate buffer (50 mmo1/l) 
phosphate buffer II 
Tris buffer II 
ElG .2 .4B 
Effect of increasing incubation 
times on [8-3H]cyclic GMP biJJding 
(charcoal/BSA separation; 
binding protein prep.II) 
--------------------------------------------------- ·----------...L.--· 
129 
FIG.2.4C. Cyclic nucleotide cross-reactivities. 
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and V, Table 2.2C). Although zero standard binding of r:H] 
cyclic GMP was 25% (preparation IIc) and 20% (preparation y), 
dose response curves over the range 0-100 pmol cyclic GMP/ 
tube were very 'flat• for both binding proteins. '11he label 
appeared to be much less easily displaced by cyclic GMP. 
Aliquots of the two new binding reagents which had been freeze 
dried on the day of preparation also showed very poor dose-
response curves. Zero standard binding was 3-4% lower for· 
the freeze dried preparations. 
These observations led 'to a search for a way to improve 
the dose-response curve for the method. 
2.5 Variation of incubation times and ｴ･ｭｰ･ｲ｡ｴｵｲｾｳ＠
Four batches of standards (0, 1, 10 and 100 pmol/tube 
cyclic GMP per batch) were preincubated with 100 fl of undiluted 
binding protein (preparation IV, Table 2.2C) for 18 hours at 
4C?c. · Following the addition of [8- 3H] cyclic GMP, incubations 
were continued for ｾＬ＠ 1, 2 or 3 hours and free and bound radio-
activity was separated using charcoal/BSA reagent. Very lit.tle 
displacement of the label by the standards resulted from this 
disequilibrium procedure. There was considerable variation 
between counts for duplicate tubes. 
Incubation of cyclic GMP ｳｴｾｮ､｡ｲ､ｳ＠ (0-100 pmol/tube}, 
binding reagent (preparation IV, Table ＲｾＲｃＩ＠ and label for 
0 0 0 three hours at 4 C, 21 C, or 37 C did not result in displacement 
of label by the standards at any ｴ･ｭｰ･ｲ｡ｴｵｾ･ｯ＠ Zero standard 
binding was approximately 25%, 12%. and 5% at the ·three 
incubat'ion temperatures. 
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2.6 Binding ｰｾｯｴ･ｩｮ＠ purification procedures 
Freeze dried aliquots of 5th instar Schistocerca 
gregaria binding protein (preparation IV, Table 2.2C) were 
reconstituted and treated with, charcoal, ammonium sulphate, 
or by Sephadex G200 gel filtration. 
procedures were carried out at 4°C. 
All purification 
2.6.1 Charcoal extraction procedure 
Two 5.0 ml aliquots of binding protein were 
reconstituted with 2 x 5.0 ml . ice cold distilled water. The 
two aliquots were combined, and charcoal (Norit 'GSX'; 1 g) 
was added. The suspension.was stirred for 15 minutes at 
4°C, and charcoal was then"removed by centrifugation for 
30 min at 2000 g (MSE 1 Mistral 6L 1 . centrifuge). 
0 
supernatant was stored at -20 c. 
2 .. 6. 2 Ammonium sulphate ｰｲ･｣ｩＺｰｩｴ｡ｴｾｯｮ＠
The pale 
This method was based on that described by Sold and 
Hoffman (1974) for the purification of rat cerebellum binding 
protein. Two 5.0 ml aliquots of binding reagent was 
reconstituted with 2 x 2e5 ml ice cold distilled water. The 
aliquots were pooled and 5.8 ml of saturated (NH2 ) 2so4 solution 
(at 4°C) were then added to give a 55% saturated solution. 
The mixture was left at 4°C for 30. minutes, and precipitated 
ｰｾｯｴ･ｩｮ＠ was separated by centrifugation at 30,000 ｾ＠ for 30 
minutes (MSE 8850; 10 x 10 ml rotor). The supernatant was 
decanted, the pellet redissolved in 10 ml of Tris/theophylline/ 
2-mercaptoethanol assay buffer, and this solution was dialysed 
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against 21 of the same buffer for 36 hours. Following a 
change of dialysis buffer and a further dialysis period of 
48 hours the preparation was centrifuged at 30,000 ｾ＠ for 30 
minutes and the supernatant stored in aliquots at -20°Co 
Sold and Hoffman (1974) reported that streptomycin 
su_lphate treatment removed 80% of a contaminating protein 
from their protein kinase preparation, and in view of this, 
samples of the ｾｭｯｮｩｵｭ＠ sulphate fractionated and crude binding 
proteins were treated with this antibiotic (0.5 mg/ml reagent)o · 
The cloudy suspensions were cleared by centrifugation at 
30,000 g for 30 minutes, and supernatants were stored at -20°Co 
2.6.3 Sephadex G-200 gel filtration 
Two 5.0 ml aliquots of freeze-dried binding protein 
were reconstituted with phosphate buffer (50 mmol/1 pH 7,0; 
0.5 ml per aliquot) and applied to a 250 mm x 11 mm internal 
diameter column. The column was eluted with the same phosphate 
buffer, and 1.0 ml fractions were collected. Protein 
concentration and EHJ cyclic GMP binding properties of the 
fractions were assessed. Separation was hindered by the 
fact that the binding protein formed a viscous brown polymer 
on the column. Both protein and [?- 3H] byclic GMP binding 
capacity elution patterns showed a single broad peak, although 
there was some dissociation of protein content and binding 
capacity. 
------------------------------------· .... - . 
2.6.4 Assessment of the 'purified' binding proteins 
@- 3H] cyclic GMP binding for zero and 100 pmol/tube 
cyclic GMP standards was assessed using the incubation· 
procedure described in section 2 •. 3. 3 and a 3 hour in
1
cilba tion 
period. No preparation showed more than a 1-2% displacement 
of label with the 100 pmol cyclic GMP standard (Table 2.6). 
Ammonium sulphate fractionation resulted in a loss of protein 
content which corresponded wi ·th a drop in zero standard binding o 
Streptomycin sulphate treatment caused a small decrease in 
protein content and binding capacity. Charcoal extraction 
diminished the binding properties of the preparation without 
reducing the total protein level; this observation brought 
into question the validity of charcoal separation of free and 
bound radioactivity in the assay system. 
The report of high cyclic GMP content in the male · 
accessory sex glands of Acheta domesticus(Fallon and Wyatt, 
1975) suggested that it may be of interest to prepare a 
binding protein from adult male Schistocerca gregaria. This 
binding reagent (VI Table ＲｾＲｃＩ＠ again showed little displacement 
of label by cyclic GMP standards. The use of a new batch of 
ｾＭ Ｓ ｈ｝＠ cyclic GMP and a new cyclic GMP standard preparation 
did not improve the assayo 
The original cricket and locust binding preparations, 
when re-examined, also failed to give a standard curve, although 
dose-response curves had been obtained with both these reagents 
previously (Figure 2.3C). Alterations in the binding 
properties of the ·insect binding proteins with age could be 
TABLE 2.6 ｾＭ Ｓ ｾ＠ cyclic GMP binding by 'purified' binding 
proteins. 
Binding Protein 
Prep.IV {Table 2.2C) 
Stored frozen 
- Lyophilised and 
reconstituted 
Charcoal treatment 
Streptomycin sulphate 
treatment 
(NH4 ) 2so4 fractionation 
(NH4 ) 2so4 /streptomycin treatment 
Sephadex G-200 gel filt-
ration-frac3ion showing 
maximum [8- F!J cyclic GMP 
binding . 
Protein 
content* 
(g/1) 
30.9 
30.9 
29.9 
32.6 
9.8 
9.3 
23.7 
% Total Radioactivity Bound 
(corrected for an 'NSB' of 
9%) for cyclic GMP standards 
0 pmol/tube 
31.7 
27.5 
2.6 
20.7 
0.8 
0.1 
11 
100 pmol/tube 
28.6 
28.5 
2.7 
22.6 
0.5 
o. 3 
10.9 
*Measured directly by the method of Goodwin and Choi (1970). 
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responsible for this. Three new preparations, however, 
had failed to give better standard curves. 
It seemed possible that the assay procedure itself 
could be at fault. 
2 .. 7 _Separation of free and bound radioa.cti vi ty 
The efficacy of ammonium sulphate, silica, charcoal/ 
BSA or charcoal/Dextran T70 reagents for the separation of 
bound and free counts was assessed for cyclic GMP standards 
(0, 10, and 100 pmol/tube). ·Whole male adult Schistocerca 
gregaria binding protein (preparation VI Table 2.2C) was 
used in ·the incubation system described in section 2. 3. 3. 
·· Following a 3 hour incubation at 4°C, bound and free radio-
activity was separated by the addition of one of the above 
reagents • Table 2.,7 lists the concentrations and volumes 
. of reagents which were used together with the results for 
bound radioactivity, expressed as a percentage of total radio-
actl..vi ty. 
Silica did not adsorb free [?-3H] cyclic GMP. 
Charcoal/BSA again produced very little change in bound 
radioactivity with increases in the cyclic GMP standard. 
Charcoal/Dextran T70 separation resulted in a slight improve-
ment in the displacement of label ｾｹ＠ standards. The ammonium 
sulphate separation procedure, as described by Fallon and 
Wyatt (1975) in their silkmoth protein binding assay for 
cyclic GMP, gave a much better dose-response curve• 
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TABLE 2. 7 Assessment of reagents for the separation of free 
and bound [8- 3H] cyclic GMP. 
Apparant % total radioactivity bound 
Reagent and Method Cyclic GMP stds 
'NSB' 
0 10 100 
1. ｾｬＲｓＰＴ＠ 27.9 14.7 6.1 2.8 
l·ml saturated . (at 
4°C) solution was 
added to each tube. 
After centrifugation 
the precipitate was 
redissolved in 1.0 
ml water and a 500 
rl aliquot was 
counted. 
2. Silica (20 g/1 in 84.6 86.2 85.3 98 
assay buffer} 
500 1 (10 mg) per 
tube. Supernatant 
(500 1) counted 
after centrifugation 
3. CharcoalLBSA reagent 8.3 7.8 7.1 4.3 
· ·Method as described 
. in Section 2.3.1 
4. Charcoal (100 1) 8.8 7.0 6.7 4.0 
Dextran T-70 (10 
Method as for (3) 
I 
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In a second experiment, using the same incubation 
system, the optimum concentration and volume of ammonium 
sulphate for precipitation of bound counts was determined 
for zero standard tubes. At the end of the 3 hour incubation 
period 0.5 ml or 1.0 m1 of ice cold ammonium sulphate solutions 
at different concentrations were added, with or without 10 fl 
of a solution of bovine ｾｧｬｯ｢ｵｬｩｮ＠ 'carrier' protein (Sigma 
Cohn fraction ｉｉｾ＠ 10 mg/ml). Tubes were mixed, left to 
stand at 4°C for 10 minutes, and centrifuged for 30 minutes 
at 1800 ｾ＠ (MSE Mistral 4L centrifuge). Supernatant solutions 
were aspirated with a Pasteur pipette attached via a trap to 
a water pump .. ｐｲ･｣ｩｰｩｴ｡ｴｾｳ＠ were redissolved in distilled 
water (1.0 ml) and a 500 fl aliquot was removed for liquid 
scintillation counting .. The results, illustrated in 
Figure 2.7A, indicated that tre highest bound radioactivity 
count was obtained with the use of 1.0 ml of ice cold ammonium 
sulphate solution at a concentration of 500 g/1 (3.8 mol/1). 
Scintillation mixtures from pellets obtained by precipitation 
.with saturated ammonium sulphate solution were cloudy in 
appearance, and this may have been the cause of the apparent 
decrease in bound radioactivity which was observed. A 
combination of'the addition of 1.0 ml of ammonium sulphate 
(500 g/1), resuspension of the precipitate in 1.0 ml of 
distilled water, and removal of a 500 ｾＱ＠ aliquot for 
scintillation counting gave the highest results for bound 
ｾＭ Ｓ ｈ｝＠ cyclic GMP and avoided the formation of milky 
precipitates in the counting medium. This system was used 
for the' separation of bound radioactivity in subsequent 
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experiments. Bovine ｾｧｬｯ｢ｵｬｩｮ＠ improved the bound count 
for sub-optimal ｾｯｮ｣･ｮｴｲ｡ｴｩｯｮｳ＠ of ammonium sulphate but had 
little effect on the separation procedure which was adoptedo 
For this reason the ｾｧｬｯ｢ｵｬｩｮ＠ carrier protein was not 
included in the assay system. 
The lack of displacement of label by cyclic GMP 
standards which was found for the second and subsequent locust 
protein binding preparations resulted from the use of charcoal/ 
BSA to adsorb 'free• cyclic GMPo Figure 2.7B illustrates the 
marked difference between standard curves obtained \'.ri th 
charcoal/BSA and ammonium sulphate separation procedures for 
the same binding protein preparation. The charcoal/BSA 
reagent gave similar results to ammonium sulphate for zero 
standard binding tubes but did not show decreased bound radio-
activity .. when cold cyclic GMP was included in the assay. 
Displacement of label by the standards was clearly demonstrable 
ｵｳｾｾｧ＠ the ammonium sulphate separation· procedure. 
2.8 Optimisation of incubation times 
A reassessment of changes in zero standard binding of 
ｾＭ Ｓ ｈ｝＠ cyclic GMP with length of incubation, using ammonium 
sulphate separation of bound counts (section 2.7) confirmed 
that the binding was greatest for a three hour incubation 
period. 
The effect of a 30 minute 'preincubation• of standards 
and binding protein, with a further 2, Ｒｾ＠ or 3 hour incubation 
period after addition of the ｬ｡｢･ｬｾ＠ was also examined. A 
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'disequilibrium' incubation system employing a 30 minute 
preincubation and a Ｒｾ＠ hour main incubation gave an 
improvement in the dose response curve compared with a 3 hour 
'equilibrium' assay (Figure 2.8 ). 
The assay protocol which was adopted for further 
development work is summarised as follows:-
Assay buffer 
{Tris 50 mmol/1, pH 7.4 containing 
theophylline, 8 mmol/1, and 2-
mercaptoethanol 6 mmol/1) 
Cyclic GMP standard (in assay buffer) 
Binding protein preparation 
Mix, incubate for 30 min at 4°C 
Then add:-
[8-3n] cyclic GMP 
(1 pmol/50 /'1 in assay buffer) 
. 1 0 Mix, incubate for Ｒｾ＠ hours at 4 C 
Then add:-
Ice-cold (NH4 ) 2so4 solution 
(500 g/1; 3.8 mol/1) 
Mix, leave 10 min at 4°C 
Centrifuge for 30 min. at 1800 ｾ＠
50 fl. 
100 rl 
1.0 ml 
Aspirate supernatants, redissolve precipitates in 1.0 ml 
distilled H2o. 
Take 0.5 ml aliquot for liquid scintillation counting. 
rc-,_3H] 1 2o9 · Enhancement of ｾ＠ cyclic GMP binding with a Tris 
EDTA/BSA assay buffer 
Tovey et al (1974) found that the use of a Tris buffer 
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(50 mmol/1 pH 7.4) containing disodium EDTA (4 mmol/1) and 
BSA (0.5 g/1) increased the binding of 3 . [?- H] cyclic AMP by 
a bovine muscle preparationo In view of this report, the 
influence of EDTA and albumin on the locust assay were 
investigated. 
The effect of four different buffer systems (listed 
in Table 2. 9A) on zero and 100 pmol/tube cyclic GM.P standard 
bound radioactivity were assessed using the incubation system 
described in section 2.8. Adult male Schistocerca gregaria 
\ 
binding protein (preparation VI: Table 2.2C) was used ·as the 
binding reagent. Zero standard binding was increased from 
24 to 38.1% with ·the ｔｲｩｳＯｾｄｔａＯｂｓａ＠ buffer (Table 2.9A). The 
method was not improved by increasing the BSA concentration 
to 20 g/1. 
Further characteristics of the locust protein binding 
assay were examined using a Tris buffer (50 mmol/1 pH 7.4) 
containing disodium EDTA (4 mmol/1) and BSA (5 g/1). 
The binding protein dilution curve for locust 
preparation VI indicated that it could be used at a working 
dilution of 1 in 2.5 in the new assay buffer without a 
reduction in zero standard binding. The dose response curve 
was steeper ｦｯｾ＠ the diluted binding reagent. 
Cross-reactivities for sixteen nucleotides were 
determined in the Tris/EDTA/BSA assay buffer, with binding 
protein preparation VI at a working dilution of 1 in 2.5. 
The assay protocol described in section 2.8 was followed. 
Cyclic AMP and cyclic IMP cross-reacted extensively in the 
144 
TABLE 2.9A Influence of a Tris/EDTA/BSA assay buffer on tpe 
method*. 
Buffer System 
Tris (50 mmol/1) pH 7.4 
+ theophylline (8 mmol/1) 
+ 2 mercaptoethano1 (6 mmo1/1) 
Tris (50 mmol/1) pH 7.4 
+ disodium EDTA (4 mmol/1) 
Tris (50 mrno1/l) pH 7.4 
+ disodium EDTA (4 mmol/1) 
+ BSA . (5 g/1) 
Tris (50 mmo1/1) pH 7.4 
+ disodium EDTA {4 mmol/1) 
+ BSA (20 g/1) 
%Total Radioactivity Bound 
(Not corrected for NSB) 
Cyclic GMP stds 'NSB' 
0 pmol/tube 100 pmol/tube 
24.0 6.2 1.1 
27.6 6.2 2.9 
38.1 7.1 2.8 
35.2 6.1 5.0 
Incubation system as described in Section 2.8: binding protein 
preparatipn VI (Table 2.2C). 
system .. Cyclic AMP was equipotent with cyclic GMP in 
displacing the label. 
In an attempt to establish the cause for increased 
interference by cyclic AMP, the cross-reactivities of cyclic 
AMP and cyclic GMP were compared for five different binding 
protein preparations (IV, V, VI, VII and VIII, Table 2.2C) 
in Tris/theophylline/2-mercaptoethanol or Tris/EDTA/BSA buffers. 
Cyclic GMP was added at concentrations of O.l-100 pmol/tube 
and cyclic AMP at concentrations of 1-10 0 000 pmol/tube. 
Cross-reactivity results, expressed as pmol/tube cyclic 
nucleotide to cause a SO% drop in ID- 3H] cyclic GMP binding, 
are shown in Table 2o9B. 
Two conclucions were drawn from this comparison .. 
Firstly, assays in the Tris/theophylline/2-mercaptoethanol 
incubation buffer were much more specific for all binding 
ｰｾｯｴ･ｩｮ＠ preparations 6 even though dose-response curves were 
less steep. Secondly, the increase in cyclic AMP inter-
ference with the Tris/EDTA/BSA buffer was exaggerated for 
the adult locust binding proteins .. This effect was most 
noticeable for the adult male locust abdomen preparation 
(preparation VIII Table 2.2C) which had a specificity comparable 
to the fifth ins tar preparations ｾｶｩ＠ th the original buffer 
system. The change to the Tris/EDTA/BSA buffer, however, 
resulted in a 1000-foJ..d increase in cyclic AMP cross-reactivity. 
The marked alterations in binding properties and 
ｳｰ･｣ｩｦｾ｣ｩｴｹ＠ of binding reagents in the presence of EDTA and 
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______________________ _;_ _______________ ----- ·. . . . . -· ...... ·-
TABLE 2.9B 
- - - --------- --- ------------"""""! 
A comparison of assay ｳｰｾ｣ｩｦｩ｣ｩｴｹ＠ with Tris/ 
ｾｏｐｄｙｬｬｩｮ･ＯＲＭｭ･ｲ｣｡ｰｴｯ･ｴｨ｡ｮｯｬ＠ and Tris/EDTA/ 
BSA buffers for five b.inding protein preparations. 
Relative Potencies of Cyclic GMP and 
Cyclic AMP 
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Binding Proteins 
Expressed as pmol/tube cyclic nucleotide to 
produce 50% displacement of bound [8- 3Iij 
cyclic GMP 
5th Instar desert locusts 
(IV Table 2.2C) 
5th Instar migratory 
locusts 
(V Table 2.2C) 
Adult male desert locusts 
(VI. Table 2. 2C) 
5th Instar desert locusts 
(VII Table 2.2C) 
Adult male desert locust 
abdomens 
(VIII Table 2.2C) 
ｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｴﾷＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭ Ｍ
Tris/theophylline/ 
2-mercaptoethanol 
buffer: 
Cyclic GMP Cyclic AMP 
14.0 7,400 
18 .. 0 6,200 
25.0 500 
15 > 10,000 
30 >10,000 
Tris/EDTA/BSA 
buffer* 
Cyclic GivlP Cyclic AMP 
-
5.0 1,130 
ＱＳｾＰ＠ 1,120 
7.5 8.0 
11.3 1,420 
22 28 
*Binding proteins were used at a working dilution of 1 in 2.5 for 
assays in this buffer system. 
., 
BSA prompted an investigation into the effects of different 
assay buffer constituents on the method. The aim was to 
improve the dose-response curve without reducing specificity. 
2.10 The effects of buffer con$tituents on the method 
The influence of buffers (.'Tris', 'TES' and 'HEPES'), 
phosphodiesterase inhibitors and chelating agents (theophylline, 
IBMX, EDTA and EGTA} and proteins (BSA and gelatin) were 
evaluated in a series of three experiments. The assay 
ｰＺｾ［ｯｴｯ｣ｯｬ＠ described in section 2 .. 8 was used, with the exception 
that 100 fl of different buffer systems were added at three 
times their usual concentrationQ and label and standards were 
diluted in distilled ｷ｡ｴ･ｲｾ＠ This procedure avoided the 
necessity to make up separate label and standard reagents for 
each buffer systemo Standard tubes contained cyclic GMP at 
levels of 0, 1, 10 and 100 pmol/tubef or cyclic AMP at levels 
of 1, 10, 100, and 1000 pmol/tube .. 
The buffers 'TES' and 'HEPES', with pKa's (the pH 
corresponding to the midpoint of the buffering range) of 
7.5 and 7o55 ｲ･ｳｰ･｣ｴｩｶ･ｬｹｾ＠ may be ｾｯｲ･＠ appropriate for a 
pH 7.4 buffer system than is Tris (pKa = 8.3) (Good et al, 
1966). 'TES' and 'HEPES' also show smaller pH variations 
with temperature change than Tris, and have very low 
affinities fardivalent cations. Gelatin has been reported 
to enhance the binding of radioactive ligand in several 
competitive protein binding assays (Murphy and Marvin, 1974). 
147 
148 
The first experiment compared the effects of the buffers 
Tris and TES with different combinations of the reagents 
theophylline, EGTA, and BSA. Table 2.10 summarises the assay 
systems used and the results for each system, expressed as 
zero standard binding and cyclic AMP cross-reactivity. 
\1 
The substitution of EGTA for theophylline resulted in a 
reduction in ｾＭ Ｓ ｈ｝＠ cyclic GMP binding for incubations with or 
without BSA. Previous experiments had shown that EDTA enhanced · 
the binding of the label (Section 2.9). The two chelating 
agents therefore exhibited markedly different effects on the 
binding reagent. TES buffer systems gave a small improvement 
in binding relative to the corresponding Tris buffers. 
In a second experiment, the three buffers Tris, TES, 
and HEPES containing 2-mercaptoethanol, theophylline, EDTA, 
BSA or BSA and EDTA were tested. The results (Table 2.10) 
revealed several interesting effects which are summarised as 
follows:-
(i) Buffers containing 2-mercaptoethanol alone 
gave low binding of ·[s-3H] cyclic GMP (5-6% 
of total radioactivity). 
(ii) Zero standard binding increased to 14-16% for 
the theophylline buffers, and specificity was 
high., Results for the HEPES buffer showed a 
small improvement in binding. 
· {iii) The presence of EDTA (4 mmol/1) in the 
incubation medium increased zero standard 
binding to 21%, but cyclic AMP cross-reactivity 
was much greater. 
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TABLE 2.10 Effects of buffer constituents on the assay 
Buffer system* Zero Std Binding 
(corrected for 
NSB and expressed 
as % of total 
radioactivity 
added) 
Cyclic AMP 
cross-reactivity 
(pmol cyclic AMP 
equivalent to 1 proal 
cyclic GMP for 
､ｩｾｰｬ｡｣･ｭ･ｮｴ＠ of 
(8- H) cyclic GMP) 
Experiment l:-
Tris/theophyl1ine/2-
me-rcaptoethanol 
Tris/theophyl1ine/BSA 
TES/theophy11ine 
TES/theophy1line/BSA 
TES/EGTA 
TES/EG1J:IA/BSA 
Experiment 2:-
Tris/2-mercaptoethanol 
TES/2-mercaptoethanol 
HEPES/2-mercaptoethano1 
Tris/theophy1line 
TES/theophyl1ine 
HEPES/theophy1line 
Tris/EDTA 
TES/EDTA 
HEPES/EDTA 
T:(is/BSA 
TES/BSA 
HEPES/BSA· 
Tris/EDTA/BSA 
TES/EDTA/BSA 
HEPES/EDTA/BSA 
Experiment 3:-
HEPES/theophylline 
HEPES/IBMX 
ｾｦｦｩｐｅｓＯｴｨ･ｯｰｨｹｬｬｩｮ･Ｏｂｓａ＠
HEPES/IBMX/BSA 
HEPES/theophylline/gelatin 
HEPES/IBMX/gelatin 
13.0 
21.3 
14.3 
26.3 
10.0 
12.1 
5.6 
6.4 
6.3 
14-.3 
12.8 
15.5 
21.5 
21.0 
21.4 
8.5 
13.0 
13.3 
36.8 
37.4 
43.0 
17.0 
19.0 
22.0 
25".0 
11.8 
16.0 
>1000 
>1000 
>1000 
>1000 
. >1000 
>1000 
>1000 
>1000 
>1000 
>1000 
>1000 
>1000 
50 
20 
20 
>1000 
>1000 
>1000 
30 
37 
30 
>1000 
460 
>1000 
1000 
>1000 
>1000 
*Final concentrations of reagents used in the assay were: 
Buffers Tris,TES, and HEPES- 50 mmol/1 pH · 7.4 
2-mercaptoethanol .... 6 mmol/1 theophylline - 8 mmol/1 
EGTA - 4 mmol/1 · EDTA - 4 mmol/1 
IBMX - 8 mmo1/l BSA _ S g/l 
ｧ･ｬ｡ｾｩｮ＠ - 5 g/1 
... -· ·- ＭＭＭＭＭＭ ＭＭ ＭＭＭＭＭＭＭＭＭＭＭＭ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠
(iv) BSA enhanced binding (to 8-14%) and did not 
affect the specificity. 
(v) The combination of BSA (5 g/1) and EDTA 
(4 mmol/1) resulted in an increase in zero 
standard binding (to 37-43%) which was 
considerably larger than the sum of the 
individual BSA and EDTA effects. Cyclic 
AMP cross-reactivity was increased to 
approximately the same extent with the EDTA 
and BSA/EDTA buffers. Higher binding was 
again found with the HEPES buffer. 
The results indicated that EDTA, rather than BSA, was 
the main cause of the loss of specificity which had been 
observed in earlier experiments (Section 2.9). 
HEPES buffer (50 mmol/1 final concentration, pH 7.4) 
was adopted for the third experiment in which buffer systems 
｣ｯｾｾ｡ｩｮｩｮｧ＠ different combinations of BSA, gelatin, theophylline 
or the potent phosphodiesterase inhibitor isobutyl methyl 
xanthine (IBMX) were compared. 
Gelatin at a final concentration of 5 g/1, resulted in 
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a diminished binding of @- 3H} cyclic GMP when compared with 
buffers contai.ning phosphodiesterase inhibitors only (Tabte 2 .10). 
IBMX did not enhance binding to the same extent as EDTA, nor 
did. it reduce specificity to the same extent. Cyclic AMP 
cross-reactivity was increased with IBMX for buffers which 
did not contain BSA, while IBMX and theophylline buffers 
showed closer cyclic AMP cross-reactivities in the presence of 
BSA. 
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Tl1e buffer system HEPES (50 mmol/1 pH 7.4) containing 
2-mercaptoethanol (4 mmol/1), theophylline (8 mmol/1) and BSA 
(5 g/1), which gave the best results in terms of enhancement 
of binding without alteration of cyclic AMP cross-reactivity, 
was chosen for the locust assay system. 
Cross-reactivities of fifteen nucleotides were determined 
for a fifth instar Schistocerca gregaria preparation (VII 
Table 2.2C) using the HEPES buffer system, and tl1e assay 
protocol described in section 2e8. The cross-reactivities 
(Fig.2.10) were similar to those found in the earlier study 
using charcoal separation of free and bound label (FigG2o4C)ft 
Greatest interference was again seen for cyclic IMP. Cyclic 
GMP and cyclic AMP potencies for displacement of label were of 
the order of one thousandth of that shown by cyclic GMP. 
2.11 Validation of the locust protein binding assay for the 
measurement of urinary cyclic GMP levels 
2.11.1 Recovery of cyclic GMP in urine specimens 
Morning specimens of urine were obtained from ten healthy 
subjects (5 men, 5 women) aged between 19 and 35, and these were 
stored at -20°C prior to analysis. Urine samples were diluted 
1 in 20 in assay buffer and analysed in duplicateo Recoyery 
tubes contained cyclic GMP (10 pmo1/tube) in addition to the 
aliquot of diluted urine. 
Incubation mixtures for recovery experiments consisted of 
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100 ｾ＠ of assay buffer (HEPES 50 mmol/1, pH 7.4: 2-mercaptoethanol, 
6 mmol/1; theophylline 8 mmol/1; BSA 5 g/1), 100 fl of cyclic GMP 
standard (0-50 pmol/tube in assay buffer) or test urine diluted 
1 in 20 in assay buffer, and 100 ｾＱ＠ of neat ｬｯｾｵｳｴ＠ binding 
protein reagent (preparation IX Table 2.2C). After a 30 minute 
preincubation at 4°C, 50/1 of ｡ｾｳ｡ｹ＠ buffer containing (?- 3H] 
cyclic GMP ( 1 pmol/50 ftl) was added, and the incubation was 
continued for Ｒｾ＠ hours at 4°C. Ammonium sulphate was used to 
separate bound radioactivity, following the protocol described 
in Section 2.8. · 
Results from this experiment revealed high and variable 
recovery of cyclic GMP in urine specimens when compared with 
standards made up in assay buffer. Recoveries ranged from 
182 to 356% (mean recovery_250o/o) for the ten urine samples. 
iwo additional recovery experiments with the same urine samples 
gave recoveries ranging from 178 to 275% (mean 205%) and 150 to 
ＳＲｾｾ＠ (mean 232%) which confirmed the original findings. In a 
similar recovery experiment, cyclic GMP levels were measured by 
radioimmunoassay with antiserum T5 according to the assay 
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protocol desctibed in section 3.4. The RIA gave a mean recovery 
of 95% (range 83-104%) for cyclic GMP (10 pmol/tube) added to the 
ten urine specimens. Furthermore, cyclic GMP levels in the 
unspiked test urines were, on average, three times higher when 
measured by the locust assay than they were when measured by RIA. 
It was concluded from this that some constituent of urine 
was causing an overestimation of cyclic GMP in both test and 
recovery samples, and that the extent of this overestimation 
varied from one urine specimen to another. 
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In an attempt to identify the urine constituent responsible 
for these effects, the influence of the cations sodium, potassium, 
calcium, magnesium, manganese, and of urea, uric acid and 
creatinine was determined. These substances were added in 
100 rl of assay buffer to standard tubes containing 0 and 10 
pmol cyclic GMP. The concentration of each substance tested 
(listed in Table 2 .. 11A) was higher than that which would be 
present in 100 ｾＱ＠ of a 1 in 20 dilution of normal urine. The 
ｾｳｳ｡ｹ＠ procedure described above for urine analysis was followedG 
Table 2.11A shows the results for 0 and 10 pmol/tube 
cyclic GMP standard binding, expressed as a percentage of total 
radioactivity added, for ･ｾ｣ｨ＠ constituent. Of the substances 
tested, none showed an alteration in the standard binding results 
which would be compatible with increased displacement of label by 
cyclic GMP. 
The report of Kobayashi and Fang (1975) that zn2+ caused 
a marked enhancement of [3H] cyclic GMP binding to their rat 
lung binding protein preparation, led to the assessment of the 
effects of this cation on the locust assay. The influence of 
high levels of ca 2+ and Mg 2+, alone or in combination with zn2+, 
was also evaluated. The metal ions, at concentrations of 
50 mmol/1 (Ca 2+ and Mg 2+) or 5 mmol/1 {Zn 2+) were added in 100 /' 1 
of assay buffer to standard tubes (0, 1, 10, 100 pmol/tube cyclic 
GMP)o The method described in this section for urine assay was 
followed. 
1 . . 2+ d 2+ 1 d On y tl1:e comb1nat1on of Zn an Mg resu te in a 
'downward' displac"ement of the standard curve (Figure 2.11A). 
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TABLE ·2 .llA Effects of urine constituents on the dose-
response curve. 
% Total Radioactivity aound 
{corrected for NSB) 
Constituent and concentration Cyclic GMP standards 
0 pmol/tube 10 pmol/tube 
No addition 25.4 13 .. 1 
Na+ (as NaCl) 25 rg/tube 27.8 12.5 
K+ (as KCl) 25 fg/tube 27.4 13 01 
2+ (as CaC12 ) 2. 5 /"g/tube 28.3 12.3 Ca 
Mg2+ (as MgC1 2 ) 1 fg/tube 26.7 12.1 
Mn2+ (as MnC1 2 ) 10 pg/tube 25.4 12.5 
Urea 150 /.Ag/tube 27.1 12.5 
Uric acid 5 f'g/tube 25.4 13.9 
Creatinine 12.5 fg/tube 27.4 13.9 
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The levels of Mg 2+ and zn2+ which produced this effect were 
approximately 200 and 20,000 times greater than those which 
would be present in a 1 in. 20 dilution of normal urine. This 
fact militates against an explanation of enhanced displacement 
of label by cyclic GMP as a result of the combined influence 
of zinc and magnesium in urine specimens. 
Since it was possible that another urine constituent 
could be influencing the method, the effect of making up 
standards in urine treated with cyclic nucleotide phospho-
doesterase ('cPDE') was investigatedo Freshly voided urine 
from a normalsubject (1.0 ml} was diluted with 1.0 ml of 
phosphate buffer (0.5. mol/1 pH 7 .. 4) and incubated with 20 f'l 
(0.03 units) of ox-heart phosphodiesterase (Boehringer Ltd .. ) 
for 1 hour at 37°C. The mixture was then placed in a boiling 
water bath for 10 minutes to inactivate the enzyme. After 
ｾｯｯｬｾｮｧ＠ ' · the urine sample was diluted with 8. 0 ml of HEPES assay 
｢ｵｾｾ･ｲ＠ to give a 1 in 10 dilution of the original ｵｲｩｾ･＠ aliquot. 
The recoveries of cyclic GMP (10 pmol/tube) in two 
normal urines were examined using the protocol described in this 
section, but substituting the 1 in 10 dilution of cPDE-treated 
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urine for the 100 ;u of assay buffer. The two urine samples 
gave recovery results of 226% and ＲＴｾｦｯ＠ in this incubation system. 
cPDE-treated urine at twice the normal concentration did not, 
therefore, improve the recovery results. This suggested that 
the cause of enhanced displacement of label might be another 
cyclic nucleotide. 
The influence of cyclic ａｍｐｾ＠ cyclic CMP and cyclic IMP 
on the standard curve was tested. Each cyclic nucleotide was 
added to standard tubes at levels which did not by themselves 
produce displaceinen t of [?- 3H] cyclic GMP. These levels, 
determined from an earlier cross-reactivity study (Figure 2.10) 
were 100 pmol/tube {cyclic AMP), 10 pmol/tube (cyclic CMP) and 
1 pmol/tube {cyclic IMP). Each cyclic nucleotide was added in 
100/1 of assay_buffer to duplicate standard tubes (0-100 pmol/ 
tube cyclic GMP). 
All three cyclic nucleotides produced changes in the 
standard curve {Figure 2.11B). Cyclic CMP and cyclic IMP 
enhanced @- 3H] cyclic GMP binding at 0, 1 and 10 pmol/tube 
·standard levels. This effect would, however, produce 
underestimation rather than overestimation of cyclic GMP test 
results. Cyclic AMP at a level of 100 pmol/tube caused a 
marked decrease in bound radioactivity for standard tubes other 
than the zero standards. The cyclic AMP content of 100 "1 of 
a 1 in 20 dilution of urine is normally within the range 0-50 
pmol (0-10 ｾｭｯｬＯＱ＠ in undiluted urine). The changes observed 
in the standard curve could, therefore, occur with the amounts 
of cyclic AMP present in test urines. 
A more detailed ｾｴｵ､ｹ＠ of the influence of increasing 
amounts of cyclic AMP on the cyclic GMP standard curve revealed 
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that as little as 5 pmol/tube cyclic AMP would cause a marked 
effect, and that increases in the cyclic AMP level above 100 pmol/ 
tube did not produce any further downward displacement in the 
standard curve (Figure 2.11C). The drop in zero standard 
binding with low levels .of cyclic AMP, shown in Figure 2.11c, 
was not obse.rved in two experiments which had been carried out 
approximately one month earlier (Cross-reactivity studies, 
Figure 2.10 and cyclic nucleotide effects Figure 2.11B}. The 
reason for this change in the influence of cyclic AMP on zero 
standard binding was not clear, al·though it may have been the 
result of ageing of the binding protein preparation. 
Four urine specimens were analysed in assay systems in 
which both cyclic GMP standard and test tubes contained O, 100, 
200, or 500 pmol/tube cyclic AMP, added in 100 ｾＱ＠ of assay 
I 
buffer. Inclusion of cyclic AMP in the assay reduced the 
measured cyclic GMP content of the four urines to values which 
agreed with those obtained by RIA (Table 2.11B). In the light 
of ·these results it was decided to add 200 pmol cyclic AMP to 
both standard and test tubes to 'swamp out' the influence of 
variable amounts of cyclic AMP in test urine. 
A check on the effects of cyclic CMP (10 pmol/tube) and 
cyclic IMP (1 pmol/tube) in the presence of cyclic AMP (200 
pmol/tube) revealed that neither cyclic CMP nor cyclic IMP had 
any influence on the standard curve, although both cyclic 
nucleotides enhanced the binding of label in the absence of 
cyclic AMP (Figure 2.11B). 
The modified assay protocol used for the analysis of 
urine samples is set out in Table 2.11C. 
159 
A repeat of the recovery experiment on ten urine specimens 
using this assay protocol now gave an average recovery of 98% 
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FIG. 2.11C. Influence increasing amounts of cyclic AMP 
on the cyclic GMP dose-response curve. 
{binding protein prep. IX; ｾＯＲｾ＠ hr.incubation 
times) 
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TABLE 2.11B Urinary cyclic GMP levels measured in an assay 
system containing increasing amounts of cylic 
AMP. 
Assay System 
Locust assay 
{as described in section 
2.11.1) 
No cyclic AMP 
+ 100 pmol/tube cyclic AMP 
in tests and standards 
. + 200 pmol/tube cyclic AMP 
in tests and standards 
+ 500 pmol/tube cyclic AMP 
in tests and standards 
RIA (Antiserum T5) 
Cyclic GMP Levels* 
(pmol/tube) 
Patient 1 
9.5 
1.4 
1.9 
1.8 
1.8 
2 
6.3 
1.4 
1.3 
1. 3 · 
0.9 
3 
9.7 
2.3 
2.5 
2.6 
1.8 
4 
18.8 
4.0 
4.0 
4.0 
4.8 
*Urine samples were diluted 1 in 20 in HEPES assay buffer 
and 100 ｾ＠ aliquots were taken for analysis. 
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TABLE 2.11C Locust protein binding assay; protocol for the 
measurement of urine cyclic GMP levels. 
Additions (microlitres) Tests Standards 'NSB' 
Assay buffer 
(HEPES 50 mmol/1, pH 7.4, 2-
mercaptoethanol, 6 mmol/1, theo-
phylline 8 mmol/1, BSA 5 g/1) 
Assay buffer + cyclic AMP 
(200 prnol/100 1) 
·standard 
(0-25 pmol/tube cyclic GMP in 
assay buffer) 
Test urine 
(Diluted 1 in 20 in assay buffer) 
. Binding reagent 
(neat) 
100 100 
100 
100 
100 100 
Mix, and incubate at 4°C for 30 minutes, then add:-
[s- 3H] cyclic GMP 50 50 
(1 pmol/50 rl assay buffer) 
Mix, and incubate at 4°C for Ｒｾ＠ hours, then add:-
Ice-cold (NH4 ) 2so4 solution (3. 8 mol/1) 
1.0 ml 1.0 ml 
300 
50 
1.0 ml 
Mix, leave at 4°C for 10 minutes. Centrifuge, aspirate super-
natants, and resuspend pelletsm 1.0 ml distilled water. Take 
500 tl aliquots for liquid scintillation counting. 
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(range ＸｬＭＱＳｾｦｯＩ＠ for cyclic GMP (10 pmol/tube) added to test 
urines (Table 2.11D). 
2.11.2 Comparison of urinary cyclic GMP levels determined by 
the locust protein binding ｡ｳｾ｡ｹ＠ and by radioimmunoassay 
Figures 2.11D and 2ollE show the correlations which were 
obtained for results of urine analyses by the locust assay, as 
detailed in Table 2ollC, and by RIA with antiserum TS (28 
urine specimens) or T2 (20 urine specimens). The locust 
protein binding assay gave ｲ･ｾｵｬ＠ ts which agreed closel'y wi t.h 
both radioimmunoassays. Table 2.11E lists the equationsof the 
regression lines and correlation coefficients for the two 
comparisons. 
TABirE 2 o llE 
Regression equation y = mx + c Number of Correlation 
data points coefficient 
. :x;* . Y* m c (N) (r) 
CPB RIA (A/s TS) 1.085 -0.218 28 0.969 
CPB RIA (A/s T2) 0.999 +0.163 20 0.964 
*pmol/tube cyclic GMP 
2.llo3 Parallelism of test results with the standard curve 
The locust assay was used to analyse doubling dilutions 
of a morning specimen of urine from a normal subject. Cyclic 
GMP results were independent of urine dilution for dilutions of 
1 in 2 to 1 in 32 (Table 2.11F} which.gave measured cyclic GMP 
levels within the standard range (0-25 pmol/tube cyclic GMP). 
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TABLE 2ollF 
RESULTS FOR THE ANALYSIS OF DOUBLING DILUTIONS OF A URINE 
SAMPLE 
CYCLlC GMP CONTENT 
URINE DILUTION 
pmol/tube tmol/1 urine 
• 
1 in 2 17.5 0.35 
1 in 4 8.7 Oo35 
1 in 8 4 .. 7 0.38 
1 in 16 2.0 0.32 
1 in 32 lol 0.35 
2.11.4 Detection limit of the method 
The detection limit for the locust protein binding assay 
was calculated from the precision of measurements on zero 
standard replicates, and the initial slope of the dose response 
166 
curve, using the formula described by Ekins .(1974) {Section 1. 5. 3}. 
Table 2ol1G lists the data used to calculate detection 
limits for assays using two different fifth instar Schistocerca 
gregaria preparations. 
BINDING 
PROTEIN 
PREPARATION 
IX TABLE 2.2C 
XI TABLE 2 • 2 C 
TABLE 2 .. 11G 
ｃａｌｃｕｊｾｔｉｏｎ＠ OF DETECTION LIMITS 
(a) 
PRECISION FOR ANALYSIS 
OF 10 ZERO STD 
REPLICATES 
{2SD: o/o BOUND) 
1.90% 
(b) 
INITIAL SLOPE OF 
THE DOSE-
RESPONSE CURVE 
o/o BOUND/pmol 
CYCLIC GMP 
6.97%/pmol 
8.53%/pmol 
a/b 
DETECTION 
LIMIT 
pmol 
cyclic 
GMP/tube 
0. 27 
0.18 
- -- -··-· · .. _. .. --- ·--- ·-------- ---------------=-----------....., 
Ox-heart cPDE treatment of ｾ･ｮ＠ urine specimens from 
normal subjects, by the method detailed in section 2.11.1, 
reduced the-measured cyclic GMP content to below 0.3 pmol/ 
tube in every ｣ｾｳ･ｷ＠
2.11.5 Precision of the method 
Three urine specimens containing approximately 0.2, 0.6 
and 1 /mol/1 GMP were stored at -2o0 c in 100 1"1 aliquots.. One 
aliquot of each · was thawed and assayed with every batch of 
cyclic GMP analyses, as a guide to the reproducibility of the 
method. 
'Within batch' precisions, obtained from the analysis . 
o_f ten replicates of each control urine, and 'between batch • 
precisions, calculated from the con·trol results from twelve 
batches of tests, are listed in Table 2.11H. 
TABLE 2.11H 
PRECISIONS FOR THE LOCUST PROTEIN BINDING ASSAY 
'WITHIN-BATCH' 'BETWEEN-BATCH' 
NO. OF RESULTS (N) 10 10 10- 12 12 12 
MEAN CYCLIC GMP 1.22 3.36 5.,30 1.28 3.27 5.64 LEVEL (pmol/tube) 
167 
S.D. 0.124- 0.450 0 .. 567 0.153 0.557 0.895 
C.Vo% 10.2 13.4 10 .. 7 11.7 17 .o 15.9 
Coefficients of variation were rather high for both intra-
assay ｰｲ･｣ｩｳｾｯｮｳ＠ {range 10 .. 2-13.4%) and inter-assay precisions 
(range 11 . 7-17.0%). 
_______ ......;.. ______________________________ - - -
2.12 Scatchard analysis of the locust protein binding data 
The binding data from the incubation of increasing levels 
of [?-3H] cyclic GMP with two fif·th ins tar Schis tocerca gregaria 
preparations (IX and XI Table 2.2C) was used to determine 
dissociation constants for the cyclic GMP-binding protein 
interaction. 
The assay protocol described in Table· 2 .llC was followed, 
with the excep·tions that 100/1 of assay buffer was substituted 
for the cyclic GMP standards or tests, and the preincubation was 
omitted. @- 3H] cyclic GMP was added at concentrations ranging 
from 10 to 0. 25 pmol/tube in 50! 1 of assay buffer, and tubes 
were incubated for Ｒｾ＠ hours at 4°C. 
In two similar experiments, the effects of omission of 
cyclic AMP from the assay system were assessed for the same two 
binding reagents. 
Bound counts for these experiments were expressed as a 
percentage of the total activity added for each ｾＭ Ｓ ｈ｝＠ cyclic 
GMP dose level, without correction for non-specific bindingo 
The amount of_ cyclic GMP bound, in pmol/tube, was calculated 
from the percentage binding and the total amount ｾｮ＠ pmol) of 
cyclic GMP added at each dose level. Plots of the ratio of 
bound/free radioactivity versus pmol/tube cyclic GMP bound were 
thenconstructed for the two binding proteins, each in the 
presence or absence of cyclic AMP (200 pmol/tube) (Figures 2.12A 
and 2.12B). 
Scatchard (1949) first proposed this form of plot, 
based o"n the relationship:-
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where B = Number of moles of ligand bound per mole 
of binding protein. 
F = Molar concentrat1on of unbound ligand. 
n = Number of binding sites per molecule of 
binding protein. 
KA =:.:Apparent association constant 
= ｾ＠ the apparent dissociation constant. 
In this study, since the concentration of the binding 
prote.in was unknown, 'B' was expressed as pmol cyclic GMP 
bound per assay tube. The affinity of binding was expressed 
in terms of the dissociation constant KD, in accordance with 
the majority of the published data on cyclic nucleotide binding 
proteins. 
The curved Scatchard plots which were·obtained from the 
data were interpolated in terms of the presence of at least 
two populations of binding sites on the cyclic ｇｾｾ＠ binding 
protein. Dissociation constants _and bindingcapacities for 
the low affinity sites were determined from the slopes and X-
intercepts of tangents drawn to the curve in the high bound 
ligand region. Data points in the high affinity site region 
were corrected for the contribution of low affinity sites to 
avoid overestimation of high affinity binding capacity. For 
each data point in the low bound ligand region, the low affinity 
site contribution was extrapolated from the low ｡ｦｦｾｮｾｴｹ＠ site 
tangent. These extrapolated values were then subtracted from 
the corresponding total B ·levels, and the corrected high affinity 
F 
171 
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B 
site F levels were replotted. The dissociation constants 
and binding capacities of high affinity sites were determined 
from the slope and X-intercept of the tangent to the replotted 
curve (Figure 2.12C). Dissociation constants were calculated 
using the formula:-
Dissociation constant KO (mol/1) 
1 
= Slope of tangent [(mol/tube}1] x incubation volume (1) 
1 ］ｾｬｯｰ･＠ of target x 0.35 x 10 3 
Table 2.12 lists the dissociation constants and binding 
capacities derived from the data shown in Figures 2.12A and 
2.12B. 
Dissociation constants for ｾｩｧｨ＠ affinity sites of the 
two locust preparations were decreased slightly in the presence 
of cyclic AMP (200 pmol/tube), indicating increased binding 
affinity for cyclic GMP in the presence of cyclic AMP. In 
contrast to this effect, the low affinity site dissociation 
constants increased slightly when cyclic AMP was included in 
the assay. Cyclic AMP also reduced the low affinity site 
binding capacity by approximately 50%, while the high affinity 
site binding capacity was influenced to a much smaller extent. 
2.13 Cross-reactivity studies on . different binding protein 
J2reparations 
The cross-reactivities of fifteen nucleotides with two 
fifth instar Schistocerca gregaria preparations (IX and XI 
Table 2.2C) and one fourth instar Schistocerca gregaria reagent 
(X, Table 2.2C) were determined in addition to the earlier 
------------------------------------ -- - -- ---
.. $, 
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FIG.2.12C. Calculation of binding data from a non-linear 
Scatchard plot: 
c · _slope ｾＱ＠ /K02 
- sl opeo(l /K01 
ｾＭＭＭＭＮＬＬＮＮＭＮＮＮＮＮＮＺＭＭＱ＠
binding capacity 1 
I 
binding capacity 2 
Bound cyclic GMP (pmol/tube) 
Points A,B,C etc. were corrected by subtraction of the B/F 
contributions A• ,s•,c• etc.,extrapolated from the tangent 
to the low affinity region of the curve.The corrected values 
a,b,c etc. were replotted and the tangent to this curve was 
used to calculate the dissociation constant and binding capacity 
of high affinity sites. 
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TABLE 2.12 Apparent dissociation constants and binding 
capacities for two locust binding protein 
preparations; effects of cyclic AMP. 
Binding protein * Dissociation constants Binding capacities** 
(Table 2.2C) 
Preparation IX 
+ cyclic AMP 2.82 
-
cyclic AMP 3.82 
Preparation XI 
+ cyclic AMP 2.29 
- cyclic A1"1P 2.72 
ｾＱ＠
X 10-9 2.4 
X lo- 9 2.2 
X lo- 9 4.1 
X lo- 9 3.6 
X lo-8 
X lo-8 
X 10-8 
X 10-8 
CAP 1 
0.10 
0.12 
0.08 
0.11 
-A·I<ol = High affinity site dissociation constant 
ｾＲ＠ = Low affinity site dissociation constant 
o. 54 
1.00 
0.67 
1.12 
**cAP 
1 
· CAP 2 
= 
= 
High affinity site binding capacity) pmol cyclic GMP/ 
Low affinity site binding capacity ｾ＠ mg protein 
114 
study on 5th instar Schistocerca gregaria preparation VII 
(Figure 2.10). The assay protocol described in Table 2.11C 
was followed. Figures 2.13A, B and C illustrate the cross-
reactivity results which were obtained for preparations IX, X 
and XI. Table 2.13A summarises the cyclic nucleotide cross-
reactivities which were observed with the four binding agents. 
The three fifth instar reagents gave very.similar cross-
reactivity patterns. There was a general decr·ease in binding 
for reagent XI, which was prepared after storage of the whole 
fifth instar hoppers for one month at -40°C. Cyclic IMP, 
with cross-reactivities ranging from 1 in 20 to 1 in 40 
compared with cyclic GMP, ｾｮｴ･ｲｦ･ｲ･､＠ to the greatest extent. 
Cyclic AMP showed approximately one thousandth the potency of 
175 
cyclic GMP for displacement of label. Of the other non-synthetic 
cyclic nucleotides, only cyclic CMP had measurable cross-
reactivities, which varied from 1 in 130 to 1 in 1,800 relative 
to cyclic GMP. 
The fourth instar binding reagent (preparation X) 
exhibited a very similar cross-reactivity pattern, although 
cyclic AMP interference was increased to 1 in 200. 
A few remaining aliquots of adult desert locust (whole 
male and male abdomen preparations), fifth instar migratorial 
.locust and cricket binding protein preparations were screened 
for cyclic AMP cross-reactivity using the assay system described 
in Table 2.11C. All preparations now showed low cyclic AMP 
interference (Table 2.13B) although the adult Schistocerca 
gregaria preparations gave much lower binding in the assay 
system. 
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Reagents prepared from Acheta domesticusand fifth 
instar migratory locusts both exhibited similar cyclic GMP 
and cyclic AMP dose-responses to those observed with fifth 
instar desert locust binding ｰｲｯｴ･ｩｮｳｾ＠
____________________ __;_......:...,_ ________________ .. 
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3.1 
3.2 
3.3 
3.4 
3.5 
CHAPTER 3 
THE DEVELOPMENT OF RADIOIMMUNOASSAYS FOR THE 
DIRECT MEASUREMENT OF CYCLIC GMP IN URINE 
AND BLOOD PLASMA. 
Preparation of 2'-0-succinyl cyclic GMP-
protein conjugates. 
The production of anti-cyclic GMP antisera. 
Characterisation of antisera T2 and TS. 
A radioimmunoassay for urinary cyclic GMP 
levels. 
A direct radioimmunoassay for plasma cyclic GMP 
------------------------------------····---
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3.1 Preparation of 2'-0-succinyl cyclic GMP-protein conjugates 
2'-0-succinyl cyclic GMP ＨＧｓ｣ｇｍｐＧｾ＠ a gift from the 
Boehringer Corporation) was conjugated to ovalbumin (Sigma 
Cohn fraction V), keyhole limpet haemocyanin (Cal-Biochem), 
human or bovine albumin (Sigma Cohn fraction V) and poly-L-
lysine (Sigma) in the presence of the carbodiimide •·EDC •, 
according to the method of Steiner et al {1972a). 
ScGMP (10 mg) , EDC (10 mg) and protein {20 mg) were 
dissolved in 2.0 ml distilled water. The pH was adjusted 
to 5.5 with dilute hydrochloric acid (0.1 mo1/l), and the 
mixture was then stirred slowly in the dark, at room 
temperature, for 16 hours. Each conjugate was dialysed 
against 1 litre of sodium phosphate buffer (0.01 mo1/1, 
pH 7.4), containing sodium chloride (0.15 mol/1) for six hoQrs, 
and for a further 24 hours with fresh ､ｩ｡Ｑｹｳｾｳ＠ buffer. -Aliquots 
of conjugates, containing 1 mg protein, were freeze-dried and 
stored at -2o0 c. 
The approximate number of hapten molecules linked to 
each molecule of protein was determined from· the absorbance 
spectra of dilutions of protein conjugates using a ｾ｡ｬ｣ｵｬ｡ｴｩｯｮ＠
method based on that described by Tigelaar ｾ＠ al (1973). 
Where 
[AJ280 [A]. 255 [ 1255 [ J 280 A ScGMP A ScGMP Prot Prot 
= n 
-780· A 255 A 255. A 280 A . ConJ Conj ConJ Conj 
(A]A = Molar absorpt.i vi ty at wavelength A for solutions 
of ｵｾ｣ｯｮｪｵｧ｡ｴ･､＠ protein or ScGMP 
.... _,s: ,!.i 
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· { ｛ａ｝ｾｾｾｍｐ＠ = 1. 24 X 104 1 . ｛ａ｝ｾ Ｎ ｾｾｍｐ＠ = 0. 7 X 104 ) 
A A . = Absorbance at wavelength A 1 of a solution of ConJ 
the conjugate 
n = Number of hapten molecules per molecule of protein. 
The wavelengths 255 and 280 nm were chosen because 
they cor+esponded to the absorbance maxima of unconjugated 
ScGMP and protein respectively. 
Absorbance spectra were measured over the wavelength 
range 210-310 nm using an SP-1800 spectrophotometer (Pye-
Unicam Ltd.). Figure 3.1 .. illustrates the spec:tra obt.ained 
for solutions of ScGMP 1 keyhole limpet haemocyanin (KLH) and 
the ScGMP-KLH conjugate. The degrees of haptenisation 1 
calculated for conjugates from the spectrophotomebdc data, 
are shown in Table 3.1. Animals which were immunised with 
each conjugate are also listed. 
. 
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FIG.3.1. Absorption spectra of 2'-0-succinyl-cyclic GMP, 
keyhole limpet haemocyanin,and the ScGMP-KLH conjugate. 
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TABLE 3.1 
ScGMP-protein conjugates 
ａｰｰｲｯｸｩｭ｡ｴｾ＠ ScGMP 
Conjugate mol. wt. of residues/ protein molecule Animals irnmunised . 
(Daltons) 
ScGMP/ovalbumin 45,000 
(Batch 1) 
ScGMP/ovalbumin 45,000 
(Batch 2) 
ScGMP/KLH 3 X 106 
(Batch 1) (Av. mo 1. wt . ) 
ScGMP/KLH 3 X 106 
(Batch 2) (Av. mol. wt. ) 
ScGMP/hSA 69,000 
ScGMP/BSA 69,000 
ScGMP/poly-L-lysine 70,000 
of protein 
2.1 
5.9 
162 
500 
3.0 
6.8 
8.3 
Rabbits Tl-T5 
Rabbits Tl-T5 
Sheep 134 
Rabbits Tl-TS 
Sheep G228,0257 
Sheep 274 
Sheep Rl33 
Sheep G270 
3.2 The production of anti-cyclic GMP antisera 
3;2.1 Rabbit antisera 
Five white half-lop rabbits (Ranch Rabbits Ltd.) were 
each given a primary immunisation, into six intramuscular 
sites in the fore and hind legs, of a total of 1 mg ScGMP-
ovalbumin conjugate (Batch 1, Table 3.1) per rabbit. The 
conjugate was dissolved in sterile water and emulsified in 
two volumes of 'Marcel 52' adjuvant (Marks et al, 
1974) containing Bacillus Calmette Guerin ('BCG'; 3 mg/mg 
conjugate). Emulsification was achieved by repeatedly forcing 
the oil and water phases from one syringe to another, through 
a narrow-bore syringe connector. The consistency of the 
..... -··--------------------------, 
emulsion was checked by dropping a small amount onto water: 
if the drop did not 'spread' on the surface of the water the 
emulsion was ready for use. The rabbits were given seven 
boosts at monthly intervals, using the same ｲｾｧｩｭ･Ｌ＠ but with 
the omission of BCG from the adjuvant. ScGMP-ovalbumin 
conjugate batch 2 was used for the third and subsequent boosts. 
Blood samples (10 ml) were taken from an ear vein ten 
days after each boost. The clotted specimens were centrifuged, 
serum was separated and sodium azide (1 g/1) was addeq as a 
preservative. 
. The binding of [?-3I!J cyclic GMP by dilutions of rabbit 
serum was assessed using an incubation system which comprised 
200 fl of assay buffer (Tris 50 mmol/1, pH 7.5 containing 
theophylline, 8 mmol/1 and 2--mercaptoethanol, 6 mmol/1) , 50 f 1 
of [s- 3H] cyclic GMP (approximately 1 pmol/50 fl. assay buffer) 
and 100 fl of the ｲ｡｢｢ｾｴ＠ serum diluted in assay buffer. · Tubes 
were incubated for two hours at 4°C, and free and bound radio-
activity was separated with charcoal/BSA reagent, using the 
186 
method described in Section 2.3.1. for the locust protein binding 
assay. 
Serum antibody titres, determined from the antiserum 
dilution curves, were expressed in terms of the •working dilution' 
of antiserum. This was the dilution of the antiserum which, 
when added to the assay, would bind half the amount of label 
bound by 100 ｾ＠ of ｮ･ｾｴ＠ antiserum, in the absence of unlabelled 
cyclic GMP (Figure 3.2). Displacement of label was checked for 
those sera which showed high ｾＭ Ｓ ｈｊ＠ cyclic GMP binding, by the 
addition of unlabelled cyclic GMP (100 pmol/tube) to antiserum 
dilution tubes. 
' ........ .. _ .. __ ...,.: .... ｾ｟＠ .. .... ｾ＠ ｾ Ｎ Ｎ ＮＮ＠ ·:- ....... .............. ...... • ...... ｾ＠ .. ｾ＠ .... Ｚｾ＠ .. ｾ＠ .. : .. ... ｾ＠ .............. , - . . ｾ＠ .. : ... .. . ·. . ｾＭＺ＠ ...... ｾ｣ＮＺＺＮ＠ ＺＭＮｾ ｌ ＭＺＭＭＺｻﾷＮｯｾＺＭｾＭ ... ---,----,-,-.,....,.,,!  ... ＭＭＭＭＮｲＺｾ Ｎ＠ ___,..,.,.-,----...,...,. :-Ji"'"" ... l
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Serum antibody titres for rabbits Tl to T5 remained at 
a level of 1 in 5 or less on the ScGMP-ovalbumin immunisa ti.on 
course. The ScGMP-KLH conjugate (Batch 1, Table 3.1) 
emulsified in the same adjuvant system as before, was then 
used to boost the rabbitso Each rabbit received 0.25 mg 
conjugate, given as six intramuscular injections into the 
fore and hind legs. 
Following the second monthly boost with the ScGMP/KLH 
conjugate, antiserum titres for three rabbits (T2, T3 and TS) 
rose to between 1 in 10 and 1 in 20. When antiserum titres 
were checked using ammonium sulphate separation of bound 
counts, however, they were.in the range 1 ·in 20 to 1 in 80 
(Table 3. 2) • Figure 3.2 , which shows the dilution curves 
for antiserum T2, illustrates the effects of the two separation 
methods on antiserum titrese 
Binding of label by neat antiserum was difficult to 
assess when ammonium sulphate was used to precipitate bound 
counts. The large protein precipitates were difficult to spin 
down, .and ammonium sulphate, trapped in the bulky pellet, 
produced a dense white precipitate in the scintillation medium 
when an aliquot of the redissolved precipitate was added. 
Antiserum titres were based on the maximum binding of label 
which was ｯ｢ｳ･ｲｶ･､ｾ＠ this was normally seen for a 1 in 5 or 
1 in 10 dilution of antiserum (see Figure 3.2 ). 
·Preliminary studies revealed that antisera from two 
rabbits, T'2 and TS, had very low cyclic AMP cross-reactivity. 
188 
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TABLE 3.2 
Influence of charcoal/BSA and ammonium sulphate separation 
methods qn antiserum titres 
189 
Antiserum (NH4 ) 2so4 separation* Charcoal/BSA separation 
% Total % Total 
Titre radioactivity Titre radioactivity bound at bound at 
titre titre 
Rabbit T2 1 in 50 30% 1 in 10-· 30% 
(B.leed 27/7/75) ·1 in 20 
Rabbit T3 1 in 20 32% 1 in 10 20% 
(Bleed 27/7/75 
Rabbit TS 1 in 80 30% 1 in 10 30% 
(Bleed 27/7/75) 
Sheep 134 1 in 20- 29% 1 in 5 29% 
(Bleed 14/8/75 1 in 40 
*To each tube was added 10 ｾＱ＠ of a solution of bovine gamma 
_globulin (10 g/1) followed by 1.0 ml of ice-cold ammonium sulphate 
solution (500 g/1). After vortex mixing, tubes were left to 
stand at 4°C for 10 minutes. Assay tubes were centrifuged for 
30 minutes at 1,800 g, the supernatant solutions aspirated, and 
the precipitates redissolved in 1.0 ml distilled water. 
(500 fl) were taken for liquid scintilla·tion counting. 
Aliquots 
Rabbit T5 developed a middle ear infection, and had to be 
sacrificed before a third boost with the ScGMP/KLH conjugate 
could be given. 
Serum was separated from qlood obtained by cardiac 
puncture, and, after screening for titre and cyclic AMP cross-
reactivity, this was pooled with the serum obtained 10 days 
｡ｾｴ･ｲ＠ the second ScGMP/KLH boost. Rabbit T2 was boosted 
with the ScGMP/KLH conjugate at monthly intervals for a further 
six months. Antisera from different bleeds were pooled after 
screening for titre and cyclic AMP cross-reactivity. Titres 
and cyclic AMP cross-reactivities for antiserum T2 did not 
alter during this six month periodo The two antiserum pools 
from rabbits T2 and T5 were diluted to 1 in 5 with Tris/ 
theophylline/2 mercaptoethanol buffer and aliquots (5.0 ml} 
of the diluted antisera were freeze-dried and stored at 4°C. 
Antisera showed less than a 2% fall in zero·standard binding 
of label as a result of lyophilisation and reconstitution. 
3.2.2 Sheep ｡ｮｾｩｳ･ｲ｡＠
Six sheep (mixed Suffolk crossbreeds) were immunised 
with ScGMP conjugated to ovalbumin, keyhole limpet haemocyanin, 
poly-L-lysine and human or bovine serum albumin, using the 
'Marcol 52' adjuvant system described for the immunisation of 
rabbits. Each animal received a primary immunisation with 
5 mg conjugate, given as six intramuscular injections into 
axillary and inguinal tissue. .Subsequent boosts were given 
in the same manner, using a total of 1 mg conjugate per 
animalo Sheep were bled from the jugular vein ten days after 
190 
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each boost. After the fourth monthly boost, all sheep had 
serum antibody titres in the range 1 in 10-1 in 50, using 
ammonium sulphate separation of bound counts. Charcoal/BSA 
separation gave much lower titres when tested with antiserum 
from sheep 134 (Table 3.2A}. Cyclic AMP cross-reactivity 
was high (one tenth or more relative to cyclic GMP) for all 
sheep antisera. Attempts to 'swamp out' cyclic AMP interference 
by the addition of cyclic AMP (100 or 1000 pmol/tube) to the 
assay resulted in large decreases in (8- 3H] cyclic GMP binding 
with little improvement in specificity. 
A blood sample (50 ml) was collected from a seventh 
sheep (number 188). ｓ･ｲｵｾ＠ was separated from the clotted 
specimen and this was used to prepare a conjugate of ScGMP 
with serum proteins. 1.0 ml of serum was incubated with 
ScGMP (1 mg) and 'EDC' (1 mg) using the method described in 
Section 3.1 for ScGMP-protein conjugation. The dialysed 
. . 
serum sample was diluted to 10.0 ml with untreated serum 
and 1.0 ml aliquots were stored at -2o0 c. One aliquot of 
the sheep serum protein conjugate was administered to sheep 
188 by intravenous injection for a primary immunisation and 
for each of two monthly boosts. Later monthly boosts with 
1.0 ml serum conjugate were by intramuscular injection into 
six sites. Anti-cyclic GMP antiserum titres of serum from 
sheep 188 remained less than 1 in 5 during this course of 
immunisation. 
Of the rabbit and sheep antisera which had been produced, 
only rabbit antisera T2 and TS were sufficiently specific to be 
used as the basis for cyclic GMP radioimmunoassays. 
3.3 Characterisation of antisera T2 and TS 
3.3.1 Influence of pH on ｾＭ Ｓ ｈ｝｣ｹ｣ｬｩ｣＠ GMP binding 
@- 3H] cyclic GMP binding was studied over the pH range 
3.5-9.0 using 50 mmol/1 acetate, phosphate, or Tris buffers 
containing theophylline {8 mmol/1) and 2-mercaptoethanol (6 
mmol/1). Assay tubes contained ＲＰｾ［ｫｬ＠ of the appropriate 
buf_fer, 50 /'1 of [s- 3H] cyclic GMP {1 pmol/50 f'l distilled water) 
and 100 rl of either antiserum T2 or TS at a working dilution of 
l·in 50 in distilled water. Bound radioactivity was separated 
by ammonium sulphate precipitation {described in Table 3.2} 
after .an incubation of 30 minutes at 4°C. 
The two antisera differed in their ability to bind the 
label at different pH•s. Antiserum T2 showed a steady level 
of binding over the pH range 4.5-9.0, ·while antiserum TS showed 
an increased binding at pH 4.5 {Figure 3.3A). ｎ･ｶ･ｲｴｨ･ｬｾ＠ ss, 
it was decided to adopt. a pH 7.5 buffer system to simplify 
comparisons between assays using each antiserum. 
3.3.2 Incubation times 
The length of incubation had little effect on @- 3H]-
cyclic GMP binding to either antiserum. Zero standard binding 
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remained ·constant for increases in incubation times from 5 to 240 
minutes (Figure 3.3B). Incubations of 5, 30, 60, 90 or 180 
minutes yielded similar standard curves; standard curves for 
5 minute and 3 hour incu·bations using antiserum T5 (Figure 3. 3C) 
were not significantly different (p> 0.05) when comp_ared by a 
paired Students •t• test on the standard points. Standard 
curves for the 5 minute incubation were not reproducible, however, 
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and test results for the 5 minute and 3 hour incubations did 
not agree. Cyclic GMP in test urines and recovery specimens 
was overestimated by up to 100% using the shorter assay 
protocol with poor agreement ｢･ｴｾ･･ｮ＠ duplicate tubes. An 
incubation period of 3 hours was chosen for routine analysis, 
as this allowed sufficient time to complete cyclic AMP 
estimations on the same test ｳｰ･｣ｩｭ･ｮｳｾ＠
3.3.3 Cross-reactivity studies 
The cross-reactivities of seventeen nucleotides were 
assessed for RIA 1 s using antiserum T2 or T5. Assay tubes 
contained lOO)Al assay ｢ｵｦｦｾｲ＠ (Tris 50 mmol/1, pH 7.5, 
containing theophylline, a·mmol/1 and 2-mercaptoethanol 6 
mmol/1), 100 f 1 of nucleotide solution in assay buffer, 50/' 1 
(1 pmol} of [8- 3H] cyclic GMP and 100 fl of antiserum at a 
working dilution of 1 in 50 in assay buffer. Ammonium sulphate 
ｷｾｳ＠ used to separate bound radioactivity after an incubation 
period of 3 hours at 4°C. 
Both antisera exhibited similar cross-reactivity 
patterns {Figures 3.3D and E). Cyclic AMP ｾ｡ｳ＠ 10,000 times 
less potent in displacing the label from antiserum binding 
than was cyclic GMP. Cyclic IMP cross-reacted to the 
greatest extent with both antisera, and the synthetic butyrated 
cyclic nucleotides were also capable of displacing the label. 
2 1 -0-succinyl derivatives of cyclic GMP and cyclic AMP showed 
increased potency in displacing ·[e-3H] cyclic GMP relative to 
the non-succinylated nucleotides. Table 3 .. 3 summarises the 
cross-reactivities found for cyclic nucleotides with each 
antiserum. 
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FIG.3.3D. Nucleotide cross-reactivities: antiserum T5. 
I 
ｾＭｉｉ＠ 0.1 
-mean result (± SEM.) for nucleotides 
which are not plotted individually. 
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H- mono butyryl eye 1 i c ｕｾﾷＱｐＬ＠ I- eye 1 i c UMP, J ... eye 1 i c AMP, K- eye 1 i c Ct··1P, 
L- mean result for 5'AMP, 5'ATP, 5'GTP,2' ,3'-.cyclic GMP,2' ,3' ,-cyclic ａｾＱｐＬ＠
AMP-PNP, GMP-PNP. 
I -mean result (± SEM.) for nucl eotides which are 
not plotted individually, 
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TABLE 3. 3 
Summary of 3'5' cyclic nucleotide cross-reactivities 
with antisera T2 and T5 
Cross-reactivity* 
Cyclic nucleotide 
A/s r.e5 A/s T2 
Cyclic GMP 1 .. 6 1.6 
ScGMP 0.45 0.40 
ScAMP 150 560 
Cyclic IMP 150 4.5 
Cyclic AMP > 10,000 >10,000 
Cyclic dTMP >10,000 3,500 
Cyclic CMP .>10,000 >10,000 
Cyclic UMP > 10,000 7,000 
Dibutyryl cyclic GMP 180 35 
Dibutyryl cyclic AMP 110 ·250 
Monobutyryl cyclic UMP 60 3,500 
*Expressed as pmol/tube to reduce ｾＭ Ｓ ｈ｝＠
cyclic GMP binding by half. 
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3.3.4 Scatchard analysis of antiserum binding data 
Scatchard plots of the data from five standard curves 
using antiserum T5 were approximately linear, and showed close 
. 
agreement. A Scatchard plot of the combined data from these 
five dose response curves is shown in Figure 3.3F. An apparent 
dissociation constant ｾ＠ of 3.1 x 10-9 was calculated from the 
slope of a straight line drawn through the data points. 
Data from two standard curves using antiserum T2 gave 
similar Scatchard plots which showed a sharp change in gradiento 
Figure 3.3G illustrates the Scatchard plot for one of these 
standard curves. Both plots were interpreted in terms of two 
populations of binding ｳｩｴ･ｳｾ＠ Dissociation constants for 
antiserum T2 obtained from two Scatchard plots were ｉｾ Ｑ＠ (high 
affinity sites) = 0.93 x lo-9 and 1.01 x 10-9 mol/1 and KD 2 
-8 8 (lower affinity sites) = 1.75 x 10 and 1.75 x 10- mol/1. 
3.-4 A radioimmunoassay for urinary cyclic GMP levels 
3.4.1 Assay protocol for urine analysis 
The method which was adopted for the analysis of urine 
specimens is described in Table 3.4A. 
A Tris buffer (50 mmol/1, pH 7.5) containing disodium 
EDTA (6 mmol/1), a more potent cyclic nucleotide phosphodiesterase 
inhibitor than theophylline, was substituted for the Tris/ 
theophylline/2-mercaptoethanol assay buffer which had been 
used in the original assay ｳｹｳｴ･ｾＮ＠ Standard curves were not 
altered by the change of a·ssay buffer (Figure 3.4A). There 
was no difference between cyclic GMP content of four quality 
control urines when measured in assays employing the Tris/ 
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TABLE 3.4A 
cyclic GMP RIA protocol - urine specimens 
Incubations in duplicate polystyrene tubes 
(Luckham Ltd: Type LP3) 
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ADDITIONS (microlitres) Tests Stds 
Non-specific 
binding 
Assay buffer 
(Tris 50 mmol/1, pH 7.5, 
containing disodium EDTA, 
4 mmol/1) 
Test urine 
(Diluted 1 in 20 in assay buffer) 
Standards 
(0-10 pmol cGMP per 100 p.1 
assay buffer) I 
in 
[8- 3H] cGMP 
{Amersham TRK 392; 1 pmol/50/{1 
in assay buffer) 
Antiserum 
(T2 or T5; working dilution 1 
in 50 in assay buffer) 
Mix; incubate for 3 hours at 
4°C 
Then add:-
Bovine gamma globulin 
(Sigma fraction II; 10 mg/ml 
assay buffer) 
(NH4 ) 2so4 solution (ice-cold; 3.8 mol/1) 
( 'NSB I) 
100 100 300 
100 
100 
50 50 50 
100 100 
10 10 10 
1.0 ml 1.0 ml 1.0 ml 
Mix, leave at 4°C for 10 min., centrifuge for 30 min at 1,800 g 
(Mistral 4L Centrifuge). Aspirate supernatants and redissolve 
precipitates in 1.0 ml distilled water. Mix and take 0.5 ml 
aliquots for liquid scintillation counting. 
ｾ＠ . , , •• - • ... .-. J• '.' ｾﾷ Ｚ Ｎ＠
FIG.3.4A. Standard curves in two buffer systems. 
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buffer ] Antiserum 
T5 
buffer ] Antiserum 
T2 
ｾﾷ＠ ｾ ﾷ ﾷＭﾷＭＭ ｾ＠ ...... -_, .. ＮＮＮＬＬＭＭＭＬＭ ＮＬＭＭＬＭ ｾＮＮＬＮＮＮＮＬＮＮＮＮＬｾＭ ＭＺＭＮ＠ "r"', Ｎ ｾ＠ ... ｾ Ｎ ＧＺＧＺＢＺＧ ＬＮ Ｎ ＧＡＢＺＢＧＢ＠•• -:-: . • ::-:::-.• ｾ＠ ... -::-: .• ,'"::" .. ＢＢＢＧＢＺ Ｎ ｾ＠ ... ＺＮ Ｍ ｾ ｾ ＭＭ .. · - •• -.. Ｌ Ｍ｟ｾ＠ . . ｾ Ｎ＠ , .. ｾＮ＠ Ｌ ｾ＠ . ....... ｾ＠ •• ':""". ｾ Ｎ Ｌ Ｍ Ｎ ｾ ＮＮＱＡＡ＠
theophy1line/2-mercaptoethanol buffer (cyclic GMP levels 1.0, 
3.2, 4.7 and 8.1 pmol/tube) or the Tris/EDTA buffer (cyclic 
GMP levels 1.1, 3.0, 4.6 and 8.3 pmol/tube). 
The addition of 10 fl of a solution of bovine gamma 
globulin (Sigma fraction II, . lO g/1) to incubation tubes before 
the ammonium sulphate reagent was necessary to ensure maximum 
precipitation of bound radioactivity, and the protein pellet 
obtained after centrifugation vras more easily seen. The 
omission of gamma globulin from the assay resulted in large 
discrepancies between counts for duplicate tubes, with under-
estimation of bound radioactivity. 
3.4.2 Validation of the urine cyclic GMP radioimmunoassay 
The recovery of cyclic GMP (2fmol/l) added to morning 
urine specimens from 10 normal subjects averaged 94.1% (range 
86-107%} and 95.2% (range 83-104%) for antisera T2 and T5 
respectively (Table 3.4B). 
Analysis of a test urine at dilutions ranging from 1 
in 10 to 1 in 320 gave cyclic GMP results which were independent 
of urine dilution (Table 3.4C). 
Detection limits for the RIA's, calculated by the method 
of Ekins (1974) were 0.09 pmol/tube (antiserum T2} and 0.08 
pmol/tube (antiserum T5)e 
The effect of c-PDE treatment of urine on measured cyclic 
GMP content was investigated. Aliquots ＨＱＰＰｾＱＩ＠ from 11 morning 
specimens of urine from normal subjects were incubated with 
100 f1 phosphate buffer (0.5 mol/1, . pH . 7.5) and 20 fl(0.03 
'Units • )· of ox-heart phosphodiesterase (Boehringer Ltd.) for one 
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TABLE 3.4C 
Results for the analysis of dilutions of a test urine 
Cyclic GMP levels by RIA 
Urine Antiserum T2 Antiserum T5 
'dilution 
pmo1/tube );.mo1/1 pmol/tube rmol/1 
I 
1 in 10 9.20 0.92 8. 70 0.87 
1 in 20 4.65 0.93 4.30 0.86 
1 in 40 2.35 0.94 2.18 0.87 
1 in 80 1.10 0.88 1.05 0.84 
1 in 160 0.60 0.96 1.55 0.88 
1 in 320 0.30 0.96 0.25 0.80 
hour at 37°C. Reaction tubes were then placed in a boiling water 
bath for ten minutes. Incubation mixtures were made to 2.0 ml, 
and their cyclic GMP content was determined by RIA with antisera 
T2 and TS. Cyclic GMP levels in cPDE treated urines were reduced 
to the detection limit or below in every case (Figure 3.4B). 
A comparison of results of cyclic GMP analyses on 20 urine 
samples with antiserum T2 or TS demonstrated a close correlation 
between the two assays (Figure 3.4C}. The locust protein binding 
assay for urinary cyclic GMP also gave results in good agreement 
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with those determined by RIA (Figures 2. llD and E_, Section 2 .. 11. 2) • 
Four urine specimens containing approximately ＰｾＲＬ＠ 0.6, 1.0 
and 1.6 mol/1 cyclic GMP were stored at -20°C in 200 ｾＱ＠ aliquots. 
One aliquot of each urine was thawed and analysed with each batch 
of test urines as a guide to the reproducibility of the method. 
Intra- and inter-assay precisions from the results of analyses on 
these four quality control urines are illustrated in Table 3.4D. 
3.4.3 The stability of urine specimens 
A fresh morning specimen of urine from a normal subject was 
divided into two, and one half of the specimen was •spiked' with 
cyclic GMP (approximately 1 nmol/ml urine}. Two aliquots (10 ml) of 
each urine sample were left at 4°C or room temperature (approximately 
25°C) for up to five days. Samples (1.0 ml) were taken from the 
urine specimens at various times during the five-day period and were 
0 
stored at -20 c. All samples were analysed in the same batch. Cyclic 
GMP levels in the two urine specimens showed little change at either 
temperature (Figure 3.4D). 
Although there was no evidence for cyclic GMP degradation 
in the urine specimens studied, all urine samples for analysis 
were ｾｴｯｲ･､＠ at -20°C as an . added precaution • 
.... __ ...., ___ ....,;, ________________________ --'------- --- - - - - - -
Cyclic GMP 
{pmol/tube) 
Cyclic GMP 
(pmol/tube) 
FIG.3.4B. Effect of phosphodiesterase treatment on 
ｾｲｩｮ｡ｲｹ＠ cyclic GMP levels. 
11 urine specimens- normal subjects. 
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3.5 A direct radioimmunoassay for plasma cyclic GMP 
A radioimmunoassay for plasma cyclic GMP levels, which 
avoided sample extraction or purification, would be an improvement 
over existing methods and wouJd facilitate the analysis of batches 
of test samples. 
Ammonium sulphate precipitation of the bound counts, used 
successfully for the analysis of urine specimens, created problems 
when plasma or other types of sample with a high protein content were 
analysed. Considerable amounts of the reagent were trapped in the 
bulky protein pellet, and the addition of an aliquot of the resus-
pended· pellet to the scintillation medium produced a dense white 
precipitate. In order to ｯｶｾｲ｣ｯｭ･＠ this difficulty, a direct plasma 
RIA, based on second antibody separation of bound counts, was 
developed. 
3.5.1 The plasma cyclic GMP radioimmunoassay protocol 
Table 3.5A describes the assay method which was adopted for 
the analysis of plasma samples. Antiserum TS, which possessed a 
higher titre than antiserum T2, and which had slightly better spec-
ificity, was used for the development of the plasma assay. 
In order to establish ｾｨ･＠ concentration of second antibody to 
be used, dilutions of donkey anti-rabbit precipitating antiserum 
(Guildhay HPDS-llF) were added to zero standard tubes after an incub-
ation period of 3 hours at 4°C, and the incubation was continued 
overnight.. It was necessary to add second antibody at a working dil-
ution of 1 in 2 to ensure ｭ｡ｸｩｭｵｾ＠ ｾｲ･｣ｩｰｩｴ｡ｴｩｯｮ＠ of bound radioactivity. 
Plasma effects on the method were examined using charcoal 
'stripped' plasma, added to standardisation tubes. Plasma was 
. .. .. _ ..... · ...... ... )/ ...... ;.. ... .z ｾｾｾ＠ .  -.... ..... .... ｾｾﾷ ｾ ［＠ ﾷﾷｾﾷﾷＧﾷ＠ ﾷｾﾷｾﾷﾷ＠ ................ &! ... · •·' "" ' . 
Ｇ ｾＢＧ＠ ﾷﾷｾ ｾ＠ ｾｾｾＭＭﾷ ＢＢ＠ ... . : .r. 
TABLE 3. SA 
Plasma cyclic GMP RIA protocol 
Assay buffer 
(Tris 50 mmol/1 pH 7.4 
+ disod. EDTA 4 mmol/1) 
Assay buffer + standard 
( 0-10 pmo 1/ tube) 
'Stripped' plasma 
Test plasma 
ｾＭ Ｓ ｈ｝＠ cyclic GMP (Amersham TRK392) 
1 pmo1/50 f\ 1 
First antibody 
(Antiserum T5, working 
dilution 1 in 50) 
0 Incubate for 3 hours at 4 C, 
then add:-
Second antibody 
Test Std 
100 r 
200 r 
200 F-
50 r1 50 rl 
100 fl 100 '1 
1oo rl 100 fl 
'NSB' 
2oo ,..1 
200 f-1 
50 fl 
100 fl 
(Donkey anti-rabbit IgG 
Guildhay HPDS-llF) 
---------------
Incubate overnight at 4°c 
Centrifuge, aspirate supernatants, resuspend precipitates in 
0.6 ml saline (9 g/1), mix. Remove 0.5 ml aliquot for L.S.C. 
(As for the urine assay). 
separated from acid-citrate-dextrose blood which, due to age, 
was no longer suitable for transfusion, and stirred with Norit 
'A' charcoai (200 g/1 plasma) for 24 hours at 4°C. The 
. 
mixture was centrifuged and the supernatant plasma was filtered 
through a Seitz bacteriological filter. Disodium EDTA (0.5 
mol/1, pH 7.5) was added to give a final concentration of 
5 mmol/1 and the clear plasma was stored in small aliquots at 
-2o0 c .. 
Standard curves containing stripped plasma showed a 
small decrease in slope and a drop in zero standard binding 
when compared with standards in assay buffer only (Figure 3.5A) . 
and for this reason ｳｴｲｩｰｰｾ､＠ plasma was included in standard 
tubes. 
The pr.ecipi ta ted second antibody complex, obtained 
after centrifugation,was resuspended by vortex mixing for five 
seconds with saline (9 g/1; ＶＰＰｾＱＩ＠ to give a uniform, finely 
divided suspension. An aliquot (500 fl) was then removed 
for liquid scintillation counting. Scintillation mixtures 
containing these aliquots were clear and counting efficiency 
was not impaired. 
3.5.2 The collection of blood samples 
Blood samples for cyclic nucleotide analysis were taken 
from an antecubital vein and collected into lithium heparin 
tubes (10 IoU. heparin/ml blood) containing 1% of the blood 
volume of disodium EDTA (0.5 ml/1, pH 7.5) to prevent cyclic 
nucleotide degradation by endogenous cPDE enzyme. Specimens 
were mixed thoroughly, and after centrifugation at 4°C, plasma 
0 
was· quickly separated and stored at -20 c .. 
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extract of stripped plasma on the standard curve. 
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3.5.3 Validation of the plasma cyclic GMP radioimmunoassay 
The average recovery of cyclic GMP (6 pmol/tube) added 
+ + to 18 plasma samples was 98.1 - 2. O% (Mean - SEt-1) (Table 3. SB) • 
The detection limit for the plasma· assay, calculated by the 
method of Ekins (1974) was 0.05 pmol cyclic GMP per tube, or 
0.25 nmol/1 of plasma. 
Specificity was checked by measurement of the cyclic 
GMP content of plasma samples, collected without EDTA 
preservative, after they had been left overnight at room 
temperature. Blood samples were taken from 18 normal subjects 
(16 men, 2 women, aged 22-30 years) and each specimen was 
. 
divided into two. Half was added to a lithium heparin tube 
containing EDTA, the plasma separated and stored frozen. The 
other half was taken into heparin alone and plasma, after 
separation, was left overnight at room temperature. In every 
·ca·se· the endogenous cPDE enzyme present in the samples left 
overnight reduced the cyclic GMP levels to below the detection 
limit of the method (Figure .3.5B). 
Results for the direct plasma assay were compared with 
those obtained after ethanol extraction of plasma according to 
the method of Brown et a1 (1971). Aliquots (1.0 ml) from 
five plasma samples were extracted with absolute ethanol 
(2.0 ml) for 60 seconds on a vortex mixer. The mixtures were 
then left to stand at room temperature for five minutes. After 
centrifugation, supernatants were ｣ｯｬｬ･｣ｾ･､＠ and the pellets 
were re-extracted with 1.0 ml of a solution of ethanol/water 
(2:1, v:v). Supernatants were collected after centrifugation, 
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FIG.3.5B. Test and ·blank plasma cyclic GMP levels. 
10 
8 
Plasma 6 
cyclic GMP 
(pmol/tube) 4 
2 
0 
18 Blood samples- normal subjects. 
TESTS 
(plasma + EDTA 
stored at -20°C} 
0 
e 
0 
0 0 c c (I) e c 
0 e o Q;) 0 
0 
e 
0 
10 
8 
6 
4 
2 
0 
BLANKS 
(plasma - EDTA, left 
at RT. overnight) 
\ ....... : < 
combined with the first ethanol extracts, and evaporated to 
0 dryness at 55 C under a stream of dry nitrogen. Dried plasma 
ｾｸｴｲ｡｣ｴｳ＠ were taken up in 1.0 ml of assay buffer and analysed 
for cyclic GMP content. The recovery of @- 3H] cyclic GMP 
(1 pmol) added to five aliquots of a test plasma which were 
+ taken through the extraction procedure was 82.1 - 1.4% (Mean 
± 'SEM). Cyclic ｇｬｦｾ＠ results from the analysis of plasma 
extracts were corrected for losses in the extraction stage 
using this mean recovery figure. Stripped plasma, when 
extracted by the same procedure and added to standard tubes, 
caused a reduction in the percentage of total radioactivity 
bound compared with standards in buffer only (Figure 3.5A). 
Ethanol extracts of stripped plasma· were therefore included 
in standard tubes for the plasma extract radioimmunoassay. 
Direct and ethanol extraction methods showed good agreement 
for the five plasma specimens analysed (Table 3.5C). 
Analysis of two plasma specimens at dilutions of 1 in 
2 to 1 in 16 in stripped plasma gave results which agreed 
with those obtained by assay of the undiluted plasma samples 
('!•able 3. SD) • 
The reproducibility of the plasma cyclic GMP RIA was 
monitored by analysis of two quality control plasmas with 
each batch of tests. Blood samples (50 ml) were taken from 
two normal subjects and dispensed into lithium heparin tubes 
containing EDTA following the procedure described in Section 
3.5.2. Plasma, separated after centrifugation, was stored 
at -20°C in small aliquots. The intra- and inter-assay 
coefficients of variation calculated from the results of 
. ... ｾ＠ ..... ｾ＠ ! 
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analyses on these two quality controls varied between 8.4 
and 17.3% (Table 3.5E). 
TABLE 3.5C 
Comparison of ethanol extraction and direct 
plasma cyclic GMP RIA's 
Cyclic GMP (nmol/1 plasma) 
Plasma sample 
1 2 3 4 5 
Direct RIA 1.0 4.9 9.0 11.3 28.0 
Ethanol extraction* 1.3 5.0 9.3 10.3 26.0 
*Results corrected for a recovery of 82% in the 
extraction stage. 
TABLE 3. 5D 
Results for the analysis of two plasma specimens 
at doubling dilutions in stripped plasma 
Cyclic GMP levels 
Dilution · Plasma 1 Plasma 2 
pmol/tube nmol/1 pmol/tube nmo1/l 
Neat 3.3 16.5 1.06 5.3 
1 in 2 1.55 15 •. 5 0. 51 5.1 
1 in 4 0.79 15.8 0.28 5.6 
1 in 8 0.43 17.2 0.12 4.8 
1 in 16 o·. 22 17 . 6 o .. o75 6.0 
..._ ___________________________ :....___ ____ -
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CHAPTER 4 
POSSIBLE CLINICAL ａｐｐｌｉｃｾｔｉｏｎｓ＠ FOR URINE 
AND PLASMA CYCLIC NUCLEOTIDE MEASUREMENTS. 
Analytical methods. 
Normal urine and plasma ｣ｹ｣ｾｩ｣＠ nucleotide 
levels. 
Urinary cyclic nucleotide and phosphate 
excretion following the administration of PTH. 
Evaluation of an oral calcium load test in 
the investigation of hypercalcaemia and 
hyi?ercalciuria. 
Pre- and post-operative cyclic nucleotide 
excretion in patients with oesophageal or 
lung carcinoma. 
Plasma cyclic nucleot"ide levels in malignancy 
and cachexia. 
Cyclic nucleotide excretion in asthma patients, 
and the effects of 'salbutamol' on normal 
subjects. 
Hypertension. 
The influence of adrenal corticosteroid 
output on urinary cyclic nucleotide 
concentrations. 
4.10 Plasma cyclic nudleotide levels in 
hyperthyroidism. 
4.11 Increased plasma cyclic AMP levels in 
a patient with glucagonoma. 
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4.1 Analytical methods 
The locust protein binding assay was used to measure 
cyclic GMP in urine samples from twelve normal subjects and 
from three patients admitted to hospital with status 
asthmaticus (Section 4.7). All other urine and plasma 
specimens were analysed by radioimmunoassay with antiserum T5 
following the protocols set out in Table 3.4A ·and 3.5A. 
Urine cyclic AMP levels were measured by the method 
of Brown et al (1971). Two batches of. bovine adrenal binding 
proteins were prepared by the procedure described in Section 
2.3.1. Binding protein ｡ｬｾｱｵｯｴｳ＠ (1.0 ml) were stored at -2o0 c. 
Working dilutions of these"reagents, determined from binding 
protein dilution curves (Fig.2.3A) . were 1 in 16 and 1 in 8 
for the first and second batches of reagent. Between-batch 
coefficients of variation, calculated for three urine controls 
ｷｾｩ｣ｨ＠ were analysed in seven consecutive batches were 14.1% 
(mean 1.5 pmol/tube), 10.8% (mean 3.7 pmol/tube) and 8.2% 
(mean 5.0 pmol/tube). 
Plasma cyclic AMP concentrations were measured using 
the bovine muscle protein binding assay of Tovey et al (1974) 
{cyclic AMP assay kits, code TRK 432, The Radiochemical Centre, 
Amersham) and, later, by a modification of the method of Brown 
et al (1971) in which charcoal-stripped plasma was added to 
standard tubes to compensate for the effects of plasma proteins 
{Table 4.1). Between-batch coefficients of variation for the 
bovine adrenal plasma cyclic AMP ｡ｾｳ｡ｹ＠ were 9.8% (mean level 
223 
TABLE 4.1 
Plasma cyclic AMP ｡ｳｳ｡ｾｾｾｲｯｴｯ｣ｯｬ＠
ADDITIONS (microlitres) 
Buffer 
(Tris 50 mmol/1, pH 7.5, disodium EDTA 
5 mmol/1, BSA 5 g/1) 
Standard 
(0-5 pmol cyclic AMP/50 ｾＱ＠ assay buffer) 
Test plasma 
Charcoal stripped plasma 
[a- 3H] cyclic AMP 
Ｈ｡ｰｰｲｾｸ＠ 1 pmol/50 rl assay buffer) 
Bovine adrenal binding protein 
TEST 
50 
100 
50 
100 
STD 
50 
100 
50 
100 
Mix, incubate for 2 hours at 4°c, then add 
Norit GSX charcoal (100 g/1 assay buffer) 
containing BSA (20 g/1) 
100 100 
Mix, centrifuge immediately {10 min at 1,600 ｾＩｾ＠
.Remove 200 ｾＱ＠ aliquot for liquid scintillation 
counting. 
224 
'NSB' 
250 
50 
100 
-- -- - -- -- ---------------------., 
10.4 nmol/1) and 10.9% (mean 5.0 nmol/1) for quality control 
aliquots analysed in ten batches of tests. 
Urine creatinine concentration was determined on the 
'Auto-Analyser• using the ｡ｬｫ｡ｬｩｾ･＠ picrate reaction. 
4.2 Normal urine and plasma cyclic nucleotide levels 
4.2.1 Urine cyclic nucleotide excretion 
ｾｹ｣ｬｩ｣＠ AMP and cyclic GMP concentrations were determined 
in morning urine specimens from twelve healthy subjects (6 men, 
6 women) aged 25 to 37 years. The results, summarised in 
Table 4.2A, revealed a significantly higher excretion of cyclic 
GMP ｾｭｯｬＯＱＩ＠ in men (p < 0. ｾＰＱ［＠ Wilcoxon test) • This difference 
was abolished when cyclic GMP/creatinine ratios were compared 
for men and women (p > 0. 05) . Cyclic AMP excretion ｾｭｯｬＯＱＩ＠
\'Jas not significantly different for the two series (p > 0.05) 
although cyclic ａｍｐＯ｣ｲｾ｡ｴｩｮｩｮ･＠ ratios were higher in women 
Cyclic GMP/cyclic AMP ratios were not · 
significantly different in men and women. Measurement of 
cyclic GMP levels in these specimens by the locust assay or by 
radioimmunoassay with antiserum T2 gave very similar results to 
those obtained with antiserum T5, with exactly the same 
differences in cyclic GMP excretion between men and women. 
Variations in urinary cyclic AMP and cyclic GMP excretion 
were monitored in four men and two women over a 24 hour period, 
and in one man over a 48 hour period. All subjects were 
healthy and were aged between 20 and 30 years. The study 
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constituted part of a fourth year undergraduate project 
undertaken by Mr. c. Page, who also analysed the urine 
specimens for cyclic AMP. 
Subjects were asked to ｣ｯｬｾ･｣ｴ＠ a small aliquot of 
urine (approximately 10 ml) on each occasion that urine was 
passed during the 24 hour period. 
Figure 4.2A illustrates the patterns of cyclic nucleo-
tide excretion which were found. Cyclic AMP output peaked 
ih the morning, afternoon, or evening in different subjects. 
The cyclic GMP excretion pattern followed that of cyclic AMP 
in three subjects (numbers 1, 4 and 6) but differed markedly 
in the other four. Cyclic.nucleotide excretion patterns for 
subject number one, who collected urine specimens over a 48-hour 
period, showed repeating patterns of cyclic nucleotide peaks in 
the late afternoon although the variation in urinary cyclic 
GMP output was less consistent than that for cyclic AMP. There 
was no significant correlation between urinary cyclic AMP and 
cyclic GMP concentration in the specimens collected for this 
study. 
The two- to three-fold changes in cyclic nucleotide/ 
creatinine ratios which were seen in individual subjects were 
. completely masked when results for each nucleotide were averaged 
over four hour periods and combined to give mean excretion 
patterns for the seven subjects (Figure 4.2B) . 
.A:n indication of the changes in urinary cyclic AMP and 
cyclic GMP ·output' during pregnancy was obtained from the analysis 
of morning specimens of urine collected at weekly intervals from 
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FIG.4.2A . . Variation in urinary cyclic nucleotide 
excretion for seven subjects over a 
24 hour period. 
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FIG.4.2B. Urine ｣ｹ｣ｬｩ｣ ﾷ ｮｵ｣ｬ･ｾｴｩ､･＠ excretihn in 
seven normal subjects averaged over 
four hour periods. 
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the eighth week of a twin pregnancy. The results are 
illustrated in Figure 4.2C together with urinary oestrogen 
concentrations determined by the continuous flow method of 
Hainsworth and Hall (1971). 
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There was considerable fluctuation in cyclic nucleotide/ 
creatinine ratios, with particularly large cyclic GMP variations, 
during the first trimester of pregnancy. Cyclic AMP/creatinine 
ratios doubled during the eight to thirty week gestation period. 
Cyclic GMP/creatinine ratios showed the greatest rise in the 
first trimester of pregnancy, and then remained relatively 
steady. After thirty six weeks there was a downward trend in 
the excretion of each cyclic nucleotide. 
4.2.2 Plasma cyclic nucleotide levels 
Cyclic AMP and cyclic GMP concentrations were determined 
in plasma samples ｦｲｯｾ＠ 11 subjects (5 men, 6· women) aged 22 to 
33 years, and plasma cyclic GMP levels were measured in a 
further 19 subjects (16 men, 3 women) aged 19-35 years. Blood 
samples were collected between 9 a.m. and 12 noon, and plasma 
was separated according to the procedure detailed in Section 
3.5.2. 
Table 4.2B lists the means and ranges for the results 
which were obtained. Plasma cyclic GMP concentrations were 
approximately half the corresponding cyclic AMP levels. There 
was no .difference in plasma cyclic nucleotide concentrations 
in men and women (p > 0. OS; Wilcoxon test). No significant 
correlation was found between plasma cyclic AMP and cyclic 
GMP content in 11 normal subjects . 
.... --------------------------------"------·-- ····-
ﾷｾ＠ • r - ••••• 
.... . ···- -- ｾ Ｍ
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TABLE 4.2B 
Plasma cyclic ａｍｾﾣ＠ cyclic GMP levels in normal subjects 
Mean .SD Absolute range (nmo1/1) 
Cyclic GMP 5.1 2.1 1.5 -10.6 
(21 men, 9 women) 
Cyclic AMP 11.7 2.8 7.2 -18.0 
(5 men, 6 women) 
Cyclic GMP/cyclic 0.57 0.16 0.24-0.77 AMP 
(5 men, 6 women) 
....._ ______________________ _:_ __________ __ ___ - -- - -
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Changes in plasma cyclic GMP levels were monitored 
over a twelve hour period in three normal women and in 
identical twin female diabetics controlled by low carbohydrate 
diet. Plasma cyclic AMP concentrations were also measured 
for the diabetic twins; specimen volumes from the three 
normal women were too small to permit cyclic AMP analysis. 
Subjects were studied as part of an investigation into 
metabolic rhythms by Dr. M. Nattrass, Southampton General 
Hospital. Blood samples were taken through an indwelling 
｣｡ｮｮｵｾ｡Ｌ＠ and aliquots for cyclic nucleotide and glucagon 
estimation were diluted with one tenth their volume of 'Trasylol'/ 
EDTA preservative ('Trasylol' 10,000 units/ml, containing 
disodium EDTA 100 mmol/1). · Plasma specimens were stored at 
-20°C until they were analysed. Charcoal-stripped plasma used 
in assay standardisation tubes, contained the same concentration 
of Trasylol/EDTA preservative as test specimens. For each 
ｳｾ｢ｪ･｣ｴＬ＠ blood samples were drawn at 8.20 and 8.30 a.m. and 
thereafter at half hourly intervals for twelve hours. Three 
standard meals, each containing 30 ｾ｣｡ｲ｢ｯｨｹ､ｲ｡ｴ･Ｌ＠ were eaten 
at 8.30 a.m., noon and 6 p.m. Subjects also drank one cup of 
coffee at 10-10.30 a.m. and one cup of tea at 3-3.30 p.m. 
All three normal women showed a morning peak in plasma 
cyclic GMP levels with a constant level during the rest of 
the twelve hour period (Figure 4.2D). 
Plasma cyclic nucleotide patterns for the diabetic twins 
showed a striking similarity although levels for twin 1 were 
generally higher than those for twin 2. Plasma cyclic GMP 
levels did not show the morning peak which was observed with 
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FIG.4.2D. Twelve hour variation in plasma cyclic GMP 
levels; three normal women. 
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three normal women, and were more variable (Figure 4.2E). Plasma 
cyclic AMP concentrations fluctuated considerably during the twelve 
hour period. Levels of both cyclic AMP and cyclic GMP 
occasionally dropped to abnormally low levels in comparison 
with results obtained from a single morning venepuncture in 
normal subjects (Table 4.2B). There was a significant 
correlation between the plasma cyclic AMP and cyclic GMP conc-
entrations in specimens taken from the diabetic twins (Figure 
4. 2F) • 
4.3 Urinary cyclic nucleotide and phosphate excretion 
following the adminis_tra tion of PTH 
Two patients under investigation for hypoparathyroidism, 
and two normal subjects were each given an intravenous injection 
of bovine PTH (200 MRC Units). Urine was collected for one 
hour periods before and following the PTH dose. Figure 4.3 
depicts the urinary phosphate/ creatinine, cyclic AMP/creatinine 
and .cyclic GMP/creatinine ratios. which were observed in urine 
specimens during the course of the test. 
Urine cyclic AMP/creatinine ratios increased approximately 
50- to 100-fold following PTH injection in all four subjects. 
Cyclic GMP/creatinine ratios doubled in one normal subject; 
peak cyclic GMP excretion showed a _lag relative to the 
cyclic AMP excretion peak. A small but consistent rise in 
cyclic GMP/creatinine ratios was also observed in one patient 
following PTH stimulation. ｔｨ･Ｇｰｨｯｳｰｨ｡ｴｵｾｩ｣＠ effect of PTH 
was evident in only one of the four experiments. 
. . 
.•.. .. • :ft . 
FIG.4.3. The effect of PTH administration on urinary cyclic nucleotide 
and phosphate excretion. 
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4.4 Evaluation of an oral calcium load' test in the 
investigation of hypercalcaemia and hypercalciuria 
The oral calcium load test described by Pak et al 
(1975) for the differential diagnosis of hypercalciuria was 
used to study 18 patients with hypercalcaemia (4 men, 14 women, 
aged 35 to 87 years), and 28 patients (24 men, 4 women, aged 
22 to 54) with hypercalciuria. or with a history of nephro-
lithiasis. The test was also carried out on 9 normal subjects 
(7 men, 2 women) aged 30 to 39 years. The investigation of 
! 
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patients was undertaken by Dr. W. Alston (Frimley), Dr. J. Wright 
(Guildford) or D. G. Batstone (Salisbury). 
The test protocol was the same as that employed by 
Pak et al, with the exception that. subjects were not placed 
on a low calcium diet before the test. Patients and control 
subjects fasted from 9.00 p.m. on the evening preceding the 
ｴｾｳｴ ﾷ Ｎ＠ Each person was allowed to drink 300 ml distilled water 
at 9 p.m. and at midnight. A further 600 ml of distilled 
water was taken at 7.00 a.m. the next morning, and a urine 
specimen was collected from 7.00 a.m. until 9.00 a.m. ('fasting 
urine •). At 9.00 a.m. blood was sampled without venous stasis, 
for the estimation of serum calcium and, for some patients, 
serum immunoreactive parathyroid hormone ('PTH') concentration. 
A light breakfast consisting of two pieces of toast, 1 small 
pat of butter, and marmalade was eaten together with a drink 
consisting of 1 g of calcium as calcium gluconogalactogluconate 
('Calcium Sandoz' tablets) · dissolved in 300 ml distilled water. 
Urine was collected from 9 am until 1 pm: subjects were 
ｾ＠ ｾ＠ ｾ＠ ••• . Ｚ ｾＬ ｾ ﾷ＠ .... - ... ｾ＠ ｾ＠ • • • • • • • ｾ＠ ........ ,. .. ｾ＠ ... • .. ｾ＠ ... ><\o>< l<• • .. .... • : . .... ' • •• • 
allowed to drink 300 ml of distilled water during this time. 
A second blood sample was taken at 11.00 a.m. from patients 
investigated at Salisbury. 
Urine specimens were analysed for cyclic AMP, cyclic 
GMP, creatinine, and calcium. Serum and urine calcium 
concentrations were determined by atomic absorption spectro-
photometry. Serum PTH levels were determined by. Dr. D. 
O'Riordan (Middlesex Hospital) or, for the Salisbury patients, 
by Dr. J.S. Woodhead (Cardiff). 
Pak and coworkers (1975) were able to divide their 
patients into 'primary hyperparathyroid', 'absorptive' or 
'renal' hypercalciuria , and 'normocalciuric nephrolithiasis' 
groups (Table 1.4, Chapter 1). When the criteria of Pak et 
al were used to assess the results of the present study, 
patients could be assigned to a 'hyperabsorptive-1' group on 
the basis of a normal ·fasting calcium excretion and an 
excretion greater than 0.2 mg/mg creatinine after the calcium 
load. A group of patients with no abnormalities in calcium 
or cyclic AMP output before or after the load could be 
classified as 'normoca1ciuric nephrolithiasis' patients. 
ｾｨ･＠ identification of patients with a response typical of the 
'renal hypercalciuria' group of Pak et al presented problems, 
however. Although 11 patients had increased urinary calcium 
excretion in fasting urine specimens, they did not have the 
240 
high fasting cyclic AMP ･ｸ｣ｲ･ｴｩｯｾ＠ described by Pak and colleagues. 
Furthermore, serum PTH levels, measured in three patients in 
--------------------------------- .. - -·-··. ··-
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this group, were all normal, whereas Pak et al reported that 
•most• of their 'renal hypercalciuric' patients had secondary 
hyperparathyroidism with raised serum PTH levels. The 
existence of renal hypercalciuria. has recently been ｾ･ｳｴｩｯｮ･､＠
by Nordin (1977) who has stated that it is possible, after a 
fast of less than twelve hours, for some 'spill-over' from the 
previous day's calcium intake to be present in the urine of 
hyperabsorptive patients. In view of this it was decided to 
classify 11 patients with high fasting urinary calcium excretion 
and normal serum calcium, serum PTH and urinary cyclic AMP 
levels as a second hyperabsorptive group. 
Figure 4.4A illustrates the calcium and cyclic nucleotide 
levels before and after the oral calcium load test in normal 
subjects and in patients, classified into four groups. 
Table 4.4A summarises the mean values for calcium, cyclic AMP 
｡ｾ､＠ cyclic GMP excretion in each group, expressed in the units 
used by Pak et al (1975). 
--
The mean results published by Pak 
and colleagues are included for comparison. 
Calcium/creatinine ratios in pre- and post-calcium load 
urine samples from normal subjects were similar to those 
reported by Pak et al (1975). Cyclic AMP/creatinine ratios 
in ｴｾ･＠ fasting urines from control subjects were lower in this 
study. Cyclic AMP output decreased in six of the nine subjects 
after the load .. Cyclic GMP excretion was lower in the post 
calcium load specimens for seven· of the nine subjects. When 
pre- and ｾ･ｳｴＭｬｯ｡､＠ cyclic nucleotide/creatinine ratios were 
compared for the group of control subjects, the trend towards 
• Ｂｾ＠ • • .... ·' .. - " _. _.. ... • • · - - .• • · - • • • , . - 1 . ; : . ＺＮｾ ＭＺｾ＠
FIG.4.4A. Urine calcium and cyclic nucleotide excretion 
before and after an oral calcium load. 
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lower values after the calcium load did not achieve statistical 
significance for either cyclic nucleotide (p>O.OS; Wilcoxon 
signed rank test on paired data). 
The mean control data plus two standard deviations were 
taken as an approximation of the 95% confidence limits for 
calcium, cyclic AMP and cyclic GMP responses to the calcium 
load, . in normal subjects. 
Patients in the two hyperabsorptive groups had normal 
cyclic nucleotide excretion before and after calcium ingestion, 
with one exception. Serum PTH and calcium concentrations were 
determined ｾｮ＠ one patient in.hyperabsorptive group 1 who had a 
_ fasting urinary cyclic AMP excretion of 6 fmol/g creatinine and 
a post load cyclic GMP output of 1. 93 fmol/g creatinine, both of 
which could be suggestive of hyperparathyroidism. Results of 
0.5 ng/ml (PTH) and 2.50 mmol/1 (serum calcium) did not confirm 
this possibility. 
There was no correlation between cyclic AMP or cyclic GMP 
excretion and calcium output in the urine specimens from normal 
subjects or from any of the four groups of patients. 
The calcium load test results for hypercalcaemic patients, 
who had serum calcium concentrations greater than 2.55 mmol/1 
on two or more occasions, were examined in greater detail with 
a view to establishing the value of the test in the diagnosis 
of primary hyperparathyroidism. 
Hypercalcaemic patients were divided into three groups. 
Hyperparathyroid group 1 consisted of 7 patients in whom the 
presence of a parathyroid adenoma was subsequently confirmed 
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at surgery. Hyperparathyroid group 2 patients had 
inappropriately high serum PTH levels. Serum PTH concentrations 
greater than 0.5 ng/ml, in the presence of hypercalcaemia, were 
considered to be abnormal (Woodhead and Walker, 1976). Surgery 
performed on two patients in this group revealed the presence 
of non-parathyroid tumours. Two patients with hypercalcaemia 
and undetectable PTH levels were treated as a third group. 
Table 4.4B lists details and results for the hypercalcaemic 
patients who were studied. Data from one patient with 
osteomalacia and secondary hyperparathyroidism are also included. 
Five of the seven patients with a parathyroid adenoma had 
high cyclic AMP excretion in thefasting specimen compared with 
the upper limit for control subjects ＨＵｾｭｯｬＯｧ＠ creatinine). 
After the calcium load, urine specimens from five patients in 
the group showed suppression of cyclic AMP o.utput; in two of 
these patients the post load cyclic AMP/creatinine ratio was 
suppressed to normal. Similarly, cyclic AMP excretion was high 
in the fasting urines from six of nine patients in hyperpara-
thyroid group 2 and decreased after the load in six patients. 
Serum PTH levels were determined before and after the calcium 
load for eight patients from hyperparathyroid groups 1 and 2; 
in six of these patients the serum PTH concentration decreased 
in the post load specimen. 
It is interesting that 9 of the 16 patients in the two 
hyperparathyroid groups responded to the calcium load w.ith a 
rise in urine cyclic GMP/creatinine ratios. Only one normal 
subject showed a similar rise. This increase in cyclic GMP 
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excretion was not seen in one patiept who was retested after 
the surgical removal of her adenoma (Table 4.4C). 
Patients in the hyperparathyroid groups were 'scored' 
on the basis of the finding of raised ·cyclic AMP or cyclic 
GMP excretion after the oral calcium load test,compared with 
normal subjects. The upper limit of the post calcium lpad 
cyclic nucleotide excretion in normal subjects may be a guide 
to the maximum output appropriate for suppressed PTH secretion. 
In the presence of hypercalcaemia, PTH excretion should be 
suppressed. Assuming this to be the case, a second scoring 
system was employed in which the fasting urinary cyclic nucleo-
tide excretion ｾｮ＠ the hyperparathyroid patients were assessed 
in terms of the post load excretion range in normal subjects. 
Table 4.4D sets out the findings for these two methods of 
evaluation. 
For cyclic AMP excretion, the second method of assessing 
the data gave the best indication of inappropriat·e PTH excretion, 
because post load cyclic AMP output was decreased in the majority 
of hyperparathyroid patients. Fasting urinary cyclic AMP/ 
creatinine ratios were in excess of 4.7 fmol/g creatinine(mean 
normal post load level + 2 SD) in six of the seven patients with 
parathyroid adenomata. ｾｨ･＠ seventh patient had poor renal 
function. This method of interpretation also gave a 'correct' 
finding in six of the nine patients in hyperparathyroid group 2. 
Similar scoring systems based on cyclic GMP/creatinine 
ratios revealed that post load cyclic GMP levels were raised 
just as often as cyclic AMP levels in cases of ｩｮ｡ｰｾｲｯｰｲｩ｡ｴ･＠ PTH 
secretion. Cyclic GMP/creatinine ratios were not as helpful 
when used with the second assessment method. 
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TABLE 4.4D 
Assessment of hypercalcaemic patients in terms of pre-
and post-load cyclic nucleotide levels 
Number of patients with high levels 
Group Cyclic AMP Cyclic GMP 
Assessment method* 
1 2 1 2 
Normal subjects 0; 0; 1; 1; (9) 9 9 9 9 
Primary hyperparathyroid 4; 6; 4; 2; group 1 
(7) 7 7 7 7 
Primary hyperparathyroid 4; 6; 3/ 4; group 2 
(9) 9 9 9 9 
Non-PTH mediated 
0/2 0/2 1 2;2 hypercalcaemia . /2 (2) 
*Assessment method 1 Post load cyclic nucleotide/creatinine 
ratios in patient groups compared with 
normal post load response. 
method 2 Fasting urine cyclic nucleotide excretion 
in patients, compared with post . load levels 
in normal subjects. 
--
Two patients with non-PTH mediated ' hypercalcaemia both 
had high fasting urine cyclic GMP/creatinine ratios relative 
to the post load levels in normal subjects. Cyclic AMP 
excretion was normal in both patients. One of these two 
patients, Mrs. Tucker, had cyclic GMP/creatinine ratios in pre-
and post-calcium load urine specimens which were approximately 
ｾ･ｶ･ｮ＠ times the mean normal levels. These values were much 
higher than any others which were measured,and this observation 
is particularly interesting in view of the fact that three 
other members of the patient's family have a history of hyper-
calcaemia with little evidence of endocrine abnormality. 
The relationships between serum calcium, serum PTH and 
urine cyclic -nucleotide/creatinine ratios were also examined. 
There was a significant positive correlation between serum 
calcium and PTH levels in pre- and post-load specimens from 
b9th hyperparathyroid . groups (Figure 4.4B). A positive 
correlation was also found between serum PTH levels in fasting 
blood samples and fasting urinary cyclic AMP/creatinine ratios 
for specimens with PTH levels less than 4 ng/ml (Figure 4.4C). 
Urine cyclic AMP/creatinine ratios for the three parathyroid 
adenoma patients with serum PTH concentrations in excess of 
4 ng/ml were considerably lower than the levels which were 
predicted from the regression line. 
There was no correlation between serum PTH concentration 
and fa.sting urine cyclic GMP/crea tinine ratios for normal PTH 
levels (Figure 4.4D). There was, however, a distinct negative 
correlation between serum PTH and urinary cyclic GMP 
ＭＭＭＭＭＭＭＭＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＮＮＺｾＭ Ｍ ＭＭ ﾷﾷ Ｍ --- -
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-- •• ,. .j • \ . 
FIG.4.4B. Correlation between serum ca 2+ and PTH 
concentrations: hyperparathyroid ｰ｡ｴｩ･ｮｴｾ＠
groups 1 & 2. 
Regression equation : Y = 0.135 X+ 2.718 
Correlation coefficient (r) = 0.694 (p< 0.001) 
N = 23 
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concentration for the four adenoma patients with PTH levels 
in excess of 2 ng/ml. 
When serum calcium concentration was compared with 
fasting urine cyclic AMP/creatinine ratios, there was a 
significant positive correlation between the two for serum 
calcium levels less than 3.5 mmol/1 (Figure 4.4E). There 
was a trend towards a negative correlation between serum 
calcium content and fasting urinary cyclic GMP/creatinine 
ratios for serum calcium levels in excess of 2.55 nmol/1 
(Fig?re 4.4F)r although this correlation did not achieve 
statistical significance. 
The one patient with secondary hyperparathyroidism who 
was studied had urinary cyclic AMP/creatinine ratios which 
were much higher than those observed for primary hyperpara-
thyroid patients. Cyclic GMP levels, although high, were 
not raised to such a large extent relative to primary hyper-
parathyroid patients (Table 4.4B). 
4.5 Pre- and post-operative cyclic nucleotide excretion 
in patients with oesophageal or lung ·carcinoma 
The aim of this study was to determine whether the 
presence ·of oesophageal or lung tumours was associated 
with altered cyclic nucleotide excretion, and to monitor the 
effects of surgical removal of the tumours. Specimens were 
colleqted as part of a larger study of endocrine changes in 
ｭ｡ｬｩｧｮ｡ｮｾ＠ disease, and were kindly made available by 
Professor J. Dickerson and Mr. A. Boroumand-Naini (Department 
of Biochemistry, University of Surrey). 
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Ten patients wi.th oesophageal carcinoma, seven with 
cancer of the lung and one patient with carcinoma of the 
bronchus were studied. Eleven patients undergoing similar 
surgical procedures for treatment of non-malignant illnesses, 
mainly hiatus hernia, served as a control group. Details of 
the patients who were studied are set out in Table 4.5A. 
Twenty four hour urine specimens were collected on the 
day before operation and on the second, seventh and fourteenth 
days after surgery. 
Figure 4.5 illustrates the mean cyclic nucleotide/ 
creatinine ratios which were observed in the three groups 
of patients. 
For each collection period, cyclic nucleotide levels 
for the two groups of ｣｡ｾ｣･ｲ＠ patients were compared with 
control patients by means of the Wilcoxon r ·anking test: There 
was no significant difference between cyclic nucleotide creatinine 
ratios in specimens from the three groups before operation 
(p > 0. 05) . After surgery, there was a tendency for cyclic GMP/ 
creatinine ratios to be higher in the two cancer groups than in 
the corresponding control group, although this trend only 
achieved statistical significance for oesophageal cancer 
patients fourteen days after the operation (p < 0.001). Post-
operative cyclic AMP/creatinine ratios in cancer patients were 
not significantly different from control data (p > 0.05) although 
again there was a trend towards higher levels in the oesophageal 
cancer group two and fourteen days after surgery. 
Wh.en pre- and post-operation cyclic nucleotide excretions 
were ｣ｯｭｾ｡ｲ･､＠ by students 't' test for paired data, statistically 
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significant increases in cyclic GMP/creatinine ratios were 
found for cancer patients on the second and seventh day after 
surgery. Increases in the mean cyclic GMP excretion for 
control patients on days two and seven relative to pre-operation 
levels were not significant. Cyclic AMP/creatinine ratios after 
surgery were not significantly greater than pre-operation levels 
in the three groups of patients. Plasma cortisol levels 
measured by the method of Mattingly (1962) were significantly 
increased immediately after operation, but were not 
significantly elevated on the second and subsequent days following 
the operation (Table 4.5B). 
4.6 Plasma cyclic nucleotide levels in malignancy and cachexia 
Plasma cyclic AMP and ｣ｹ｣ｬｩｾ＠ GMP concentrations were 
determined in thirteen patients with malignant disease, many of 
whom had either carcinoma of the intestine or lung. In addition, 
p'lasrria cyclic nucleotide levels were also measured in several 
cachectic or well nourished patients with a variety of illnesses. 
Patients were kindly made available by Dr. P. Beaconsfield 
(Bedford College, London). 
Table 4.6A lists the cancer patients who were investigated 
together with the plasma cyclic nucleotide results which were 
obtained. 
Five patients with carcinoma of the lung or bronchus 
did not show a significant alteration in plasma cyclic nucleo-. 
tide concentration relative to young normal subjects (P > 0.05; 
Wilcoxon test). One patient with·metastasising cancer of the 
bladder, and two of seven patients with cancer of the intestine 
P
a
ti
en
ts
 
CA
 L
un
g 
o
r
 
B
ro
nc
hu
s 
P
a
ti
en
t 
1 2 3 4 5 
CA
 B
la
dd
er
 
P
a
ti
en
t 
6 
CA
 
In
te
st
in
e
 
P
a
ti
e
n
t 
7 8 9 10
 
11
 
12
 
13
 
A
ge
 
60
 
60
 
64
 
62
 
59
 
75
 
66
 
63
 
68
 
72
 
63
 
67
 
71
 
TA
BL
E 
4 
.
.
 
6A
 
P
la
sm
a 
c
y
c
li
c 
n
u
c
le
o
ti
d
e 
le
v
el
s 
in
 m
a
li
g
n
an
t 
d
is
ea
se
 
S
ex
 
M
 
M
 
M
 
M
 
M
 
M
 
M
 
M
 
M
 
F M
 
F M
 
C
y
cl
ic
 A
M
P 
C
y
cl
ic
 G
M
P 
(n
m
ol
/1
 p
la
sm
a)
 
8
.5
 
9
.6
 
22
.3
 
1
3
.4
 
1
1
.3
 
1
5.
8 
1
5.
4 
1
2
.1
 
15
.7
 
22
.4
 
1
3.
8 
1
1
.3
 
9.
2 
2
.8
 
5
.0
 
7
.3
 
4
.8
 
8
.3
 
1
9.
9 
9.
7 
7 
.
.
 
5 
7
.5
 
2
.3
 
1
1
.1
 
1
5
.0
 
6
.3
 
D
ia
gn
os
is
/c
om
m
en
ts
 
CA
 
lu
ng
 
•
·
w
e
ll
-n
ou
ri
sh
ed
 • 
CA
 b
ro
nc
hu
s 1
ja
un
di
ce
d 
CA
 
lu
ng
 w
it
h
 m
e
ta
st
a
si
s 
CA
 b
ro
nc
hu
s 
CA
 b
ro
nc
hu
s 
CA
 b
la
d
d
er
 w
it
h
 ｭ･ｴ｡ｳｴ｡ｳｩｾ＠
'
c
a
c
h
ec
ti
c'
 
CA
 c
o
lo
n 
'
w
e
ll
 n
o
u
r
is
h
ed
' 
C
A
 
s
m
a
ll
 i
n
te
st
in
e
 w
it
h
 m
e
ta
st
a
si
s 
C
A
 
s
m
a
ll
 i
n
te
st
in
e
 
CA
 
c
o
lo
n
 
CA
 c
o
lo
n
 
CA
 s
m
a
ll
 i
n
te
st
in
e
 
CA
 p
an
cr
ea
s 
a
n
d 
s
m
a
ll
 i
n
te
st
in
e
 
(\
) 
<1'
1 
ｾ＠
ｾ＠ｾ＠ f:. }:! i ｾ＠ ｾＮ＠ ;-' L! ··j i! ｾ＠ ::. ｾ＠
.. .. . .. ＭＭＭＭＬＭＭｾＭｾＭＭＭＺＭＭＭＭＭＬＮＮｾＭＭＭＺＭＭＮＭＭＭＭ
_. ... .. •• - • .'; ... , ·- • . lJ,,. , • I .•• «' ,#_, ,:; ... :' •·• ＮＬＮ［ｉｾ＠ of 
·. 
had elevated plasma cyclic GMP levels. As a group, the 
bladder and intestinal cancer patients had significantly 
higher plasma cyclic GMP concentrations than young normal 
subjects (p = ＰＮＰＱｾ＠ Wilcoxon test). Plasma cyclic AMP levels 
were also higher, on average, than those for normal subjects 
but the difference was not statistically significant (p > 0.05; 
Wilcoxon test). 
When data for patients with clinical features of 
cachexia, with or without malignant disease, were grouped 
together and compared with a group of patients with similar 
illnesses who were described as 'well nourished'y there was 
a striking increase in ｰｬ｡ｳｾ｡＠ cyclic GMP concentration in five 
of the six cachectic patients (Table 4.6B). As a group the 
cachectic patients had significantly increased plasma cyclic 
GMP levels relative to the well nourished patients (0. 05 > p > 
ＰＮＰＱｾ＠ Wilcoxon test) and also when compared with young normal 
subjects (p = ＰＮＰＱｾ＠ Wilcoxon test). Plasma cyclic AMP 
concentrations in the cachectic and well nourished groups were 
not significantly different (p > 0. 05; Wilcoxon test). 
Plasma cyclic nucleotide concentrations did not show any 
large variations from normal in four patients aged 30-41 with 
pneumonia and marked pyrexia, nor were there any consistent 
alterations in levels in four patients aged 65 to 71 years, 
approximately 14 to 24 hours after cerebrovascular accidents. 
------------------------------··- - · -- . . .. -
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TABLE 4.6B 
Plasma cyclic nucleotide concentrations in cachectic or well-
nourished Eatients 
Age Sex Cyclic AMP Cyclic GMP Comments 
(nmol/1 plasma) 
Cachectic patients 
1 75 M 15.8 19.9 CA Bladder 
(Patient 61 
Table 4.6A) 
2 75 F 14.0 10.6 Lipodystrophy 
3 62 M 27.6 17.7 Metastic cancer, 
primary site 
unknown 
4 72 M 10.1 13.4 'Senile dementia' 
5 67 F 6.5 . 3. 6 No known cause 
6 70 F 10.1 22.9 Hemip-legia 
Well-nourished Eatients 
1 80 M 18.0 4.4 Hypertension 
2 67 F 5.6 9.7 Hemiplegia 
3 69 F 6.7 5.9 Hemiplegia 
. 4 60 M 8.5 2.8 CA lung (Patient 1 
Table 4.6A) 
5 57 M 5.6 3.7 Sarcoma 
6 66 M 15.4 9.7 CA colon 
(Patient 7 1 
Table 4.6A) 
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4.7 Cyclic nucleotide excretion in asthma patients, and the 
effects of 'Salbutamol' on normal subjects 
4.7.1 Cyclic nucleotide excretion during recovery from an attack 
of severe bronchospasm 
Urine cyclic nucleotide/creatinine ratios were determined 
in specimens collected from three patients admitted with severe 
bronchospasm to Frimley Park Hospital, Surrey. Cyclic nucleotide 
excretion patterns in consecutive 24 hour urine collections from 
two of these patients were quite different. In one patient, 
'RM', clinical improvement was associated with an increase in 
urinary cyclic AMP output, while cyclic GMP excretion remained 
constant (Figure 4.7A). Urinary cyclic GMP excretion decreased 
in patient 'CW', while cyclic AMP levels remained relatively 
steady. The urinary cyclic GMP/creatinine ratios observed for 
patient 'CW' were considerably higher than those measured in 
morning urine specimens from normal subjects (Table 4.2A). 
Urine specimens were collected at frequent intervals from 
the third patient, 'MR'. Cyclic GMP/creatinine ratios were 
increased in this patient on admission, and showed a tendency 
to fall during the recovery period. A second attack of severe 
bronchospasm was followed by a rise in urinary cyclic GMP/ 
creatinine ratios. 
4.7.2 Effects of 'Salbutamol' on plasma cy_clic nucleotide levels 
in normal subjects 
Plasma cyclic nucleotides were measured as part of a 
study by Dr. S. Holgate (University of Southampton) on the 
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FIG.4.7A. Urinary cyclic nucleotide excretion during 
recovery from acute asthma attacks. 
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short and long term effects of administration of the f Ｍ｡､ｲｾｮ･ｲｧｩ｣＠
bronchodilator 'Salbutamol' to normal subjects. 
Six healthy male subjects, aged 21 to 30 years, were used 
to follow the bronchodilatory and metabolic effects of intra-
venous bali of Salbutamol {25 fg) up to a total dose of 300 fg. 
Venous blood was withdrawn from an indwelling cannula after each 
ｓ｡ｬ｢ｵｾ｡ｭｯｬ＠ dose for measurement of intermediary metabolites and 
cyclic nucleotides. Following this experiment the subjects book 
inhaled Salbutamol (400 fg q.i.d) for two weeks. Twelve hours 
after the last dose, the bronchodilatory effects and metabolite 
dose-response curves to intravenous Salbutamol were re-examined. 
After regular SalbutiSmol dosage over the two week period 
the bronchodilatory effect, and the increases in blood glucose, 
pyruvate, lactate, glycerol, ketone and insulin levels in 
response to intravenous Salbutamol challenges were all attenuated. 
· Mean plasma cyclic AMP levels also showed a smaller rise 
after regular .salbutamol dosage (Figure 4.7B). When · plasma 
cyclic AMP levels at each intravenous Salbutamol dose level 
were compared before and after regular Salbutamol dosage, four 
of the six subjects had significantly reduced cyclic AMP 
responses after Salbutamol inhalation treatment {p < 0.01; 
Wilcoxon signed rank test on paired data). Two of the six 
subjects showed a significant ｩｮ｣ｲ･｡ｳｾ＠ in ｰｬ｡ｳｭｾ＠ cyclic GMP 
dose responses after regular Salbutamol inhalation (p<O.OS), 
although this was not apparent from the mean results for the 
group (Figure 4.7B). Cyclic GMP dose-responses before and 
after ｲｾｧｵｬ｡ｲ＠ Salbutamol therapy were not significantly 
different in the other four subjects. 
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4.8 ｾｰ･ｲｴ･ｮｳｩｯｮ＠
The finding of increased cyclic GMP/cyclic AMP ratios 
in the vascular tissue of hypertensive animals (Amer, 1975a) 
prompted an investigation into urinary cyclic nucleotide 
excretion in hypertensive patients. 
Cyclic nucleotide/creatinine ratios were determined in 
urine specimens obtained from 23 hypertensive patients (17 men, 
6 women, aged 26-73 years) who were attending outpatient clinics 
at St. Luke's Hospital, Guildford. It was not possible to 
organLse 24 hour urine collections on these ｰ｡ｴｩ･ｮｴｳｾ＠ random 
urine specimens were obtained during the course of morning 
clinics. Patients with biochemical evidence of impaired renal 
function (reduced creatinine clearance or increased plasma 
creatinine or urea concentrations) were excluded from the study. 
All but four patients were receiving drug therapy in the. form 
of diuretics (3 patients}, diuretics plus methyl dopa (6 patients), 
diuretics plus/!!:; Ｍ｢ｬｯ｣ｫ･ｲｾ＠ {6 patients) or all three types of 
drug (4 patients). Blood pressures, either taken on the day 
of specimen collection or as close to that date as possible, 
ranged from 140/85 to 220/110 for the group. 
Figure 4.8 illustrates the cyclic nucleotide/creatinine 
ratios which were observed in these patients. Absolute ranges 
for data from young healthy adults (Table 4.2B) are also shown 
for comparison. There was no significant difference between 
urinary cyclic GMP/creatinine ratios in the hypertensive patients 
and younger subjects (p > 0. 05; Wilcoxon test). Cyclic AMP/ 
creatinine ratios for the hypertensive patients showed a 
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.J :; 
displacement towards higher levels compared with normal subjects. 
In view of the sex difference in urinary cyclic AMP/creatinine 
normal ranges (Section 4.2), data for male and female hyper-
tensive patients were compared with male and female normal 
ranges. Male hypertensive patients had significantly higher 
cyclic AMP/creatinine ratios than normal males (p < 0. 01; 
Wilcoxon test) , while there was no significant difference between 
cyclic AMP/creatinine ratios in hypertensive women and healthy 
female subjects (p > 0. 05; Wilcoxon test). The urinary cyclic 
GMP/cyclic AMP ratios in the hypertensive patients were 
significantly lower than those determined for normal subjects 
(p < 0. 01; Wilcoxon test). 
One patient, a woman aged aged 27 years, who had developed 
hypertension while on the contraceptive pill, had a high urine 
cyclic GMP/creatinine ratio (2.2f"mol/g creatinine). A second 
patient, a 25 year old man with very mild hypertension who was 
on a reducing diet, had a urine cyclic AMP/creatinine ratio of 
12. 3 /"mol/g creatinine. There was no evidence of other 
clinical or biochemical abnormalities in these two patients, 
and the reasons far these high levels remain obscure. 
No significant correlation was found between cyclic GMP/ 
creatinine, cyclic AMP/creatinine or cyclic GMP/cyclic AMP 
ratios and diastolic or systolic blood pressures, ages of the 
patients, or type of drug therapy. 
4.9 The influence of adrenal corticosteroid output on urinary 
cyclic nucleotide concentrations 
·Cyclic nucleotide/creatinine ratios were determined in 
24 hour urine specimens from six hypopituitary patients who had 
------------------------------ ----- ---
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low urinary corticosteroid exriretion. Cyclic nucleotide 
excretion was also monitored during ACTH stimulation {three 
patients) or. dexamethasone suppre-ssion (two patients). Urinary 
fluorogenic 11-hydroxy corticosteroid (11-0CHS) levels were 
determined by the method· of Mattingly et al (1964). 
Three patients who responded to an ACTH stimulation test 
(4 0 I .-u. p arcine ACTH b. d. for 3 days) with one hundred- fold 
increases in urinary 11-0CHS output showed relatively little 
change in urinary cyclic nucleotide excretion (Figure 4.9A). 
Cyclic GMP/creatinine ratios doubled during the course of the 
test in all three patients, while the cyclic AMP excretion 
changes were less consistent. A low dose dexamethasone 
suppression test (0.5 mg q.d.s. for 3 days) was also performed 
on one of these patients. In spite of a ten-fold decrease in 
urinary 11-0HCS levels, the cyclic nucleotide/creatinine ratios 
showed very similar changes to those seen with ACTH stimulation. 
A high dose dexamethasone suppression test (2 mg q.d.s. for 3 
day.s) was carried out on one patient with Cushing • s syndrome. 
Cyclic nucleotide changes during this test were similar in 
pattern to those seen in the low· dose test although variations 
were ｩｮ｣ｾ･｡ｳ･､＠ in amplitude. 
Urinary cyclic nucleotide concentrations were compared 
for two groups of samples ｾ･ｰｲ･ｳ･ｮｴｩｮｧ＠ extremes of urinary 11-
0HCS excretion. Data for the low corticosteroid group was 
obtained from hypopituitary patients and from urine samples 
during a normal response to dexamethasone suppression. High 
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FIG.4.9A. The influence of ACTH stimulation and 
dexamethasone suppression tests on 
urinary cyclic nucleotide excretion. 
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11-0HCS output, one of whom had Cushing's syndrome, and from 
three patients following ACTH stimulation. 
There was no significant difference in cyclic nucleotide/ 
creatinine ratios between the high and low corticosteroid 
excretion groups (p > 0.05; Wilcoxon test) although cyclic AMP/ 
creatinine output tended to be lower when corticosteroid 
･ｾ｣ｲ･ｴｩｯｮ＠ was high (Figure 4.9B). 
4.10 Plasma cyclic nucleotide levels in ｨｾｴｨｹｲｯｩ､ｩｳｭ＠
Plasma cyclic AMP and cyclic GMP concentrations were 
determined in five 'thyrotoxic' women attending the Department 
of Nuclear Medicine, Southampton General Hospital. Blood 
. 
samples from these patients were dispensed into two lithium 
heparin tubes, one of which contained disodium EDTA. Plasma 
which did not contain EDTA was left overnight at room temperature 
to provide a test 'blank' for cyclic nucleotide levels. · 
Patient details and plasma cyclic nucleotide concentrations 
are listed in Table 4.10. 
Plasma cyclic AMP content was high in thyrotoxic patients 
(p<O.Ol; Wilcoxon test) compared with levels in healthy adults, 
(Table 4.2B) although the two groups were not matched for age. 
Plasma cyclic GMP concentrations in the thyrotoxic patients were 
not significantly different from those of normal subjects (p> 0.05; 
Wilcoxon test). 'Blank' cyclic AMP and cyclic GMP levels were 
below the assay detection limits in every case. 
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4.11 Increased plasma cyclic AMP levels ip a patient with 
glucagonoma 
Plasma cyclic AMP and cyclic GMP concentrations were 
determined for a 52-year-old woman in whom there was strong 
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clinical and biochemical evidenc·e of a glucagonoma. · The 
patient, who was kindly made available by Dr. S. Bloom (Hammer-
smith Hospital) had a characteristic skin rash and a three year 
h·istory of diabetes which had required insulin therapy for three 
months prior to presentation. 
Blood samples were withdrawn from an indwelling cannula 
､ｵｲｾｮｧ＠ the ccurse of a metabolic rhythm study undertaken by 
Dr. D. Johnson, Southampton General Hospital. The patient ate 
a standard meal containing 30 g carbohydrate at 8.30 am, 12 
noon, and 6 pm. Plasma cyclic nucleotide and glucagon levels 
which were observed over a period of ten hours · are illustrated 
in Figure 4.11. 
Plasma glucagon concentrations varied between values 
approximately ten and twenty times the upper limit of normal 
during the study. Plasma cyclic AMP concentrations were also 
consistently high throughout the day, while . plasma cyclic GMP 
levels remained well within the normal range. 
ｾＱＸ＠
FIG.4.11 .. Plasma glucagon and cyclic nucleotide levels in a patient 
with glucagonoma. 
Mrs. E.J. Aged 52 years. 
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5.1 ·The locust competitive protein binding assay for cyclic GivlP 
The method of Goodwin and Choi (1970) was chosen for 
measurement- of protein levels because the standard curve is linear 
. 
over a large range of protein concentrations, and because results 
are less susceptible to variations in the amino acid content of 
proteins than those obtained by the method of Lowry et al (1951). 
The TNBS method, however, gave inappropriately high results 
for locust tissue protein levels, with increased recovery of added 
BSA (Table 2.2A). The direct method of Lowry et al also gave 
increased recovery of BSA in the presence of the locust tissue 
preparations, although the protein levels were closer to those 
found after TeA· precipitation. 
TNBS will react with free amine groups in peptides, amino 
acids, and other amines to form a trinitrophenyl derivative which 
is stabilised by the formation of a complex with sulphite at 
alkaline pH (Goldfarb, 1966). 
Although the tyrosine and tryptophan content of protein 
will contribute to some extent towards chromogen production in 
the Lowry reaction, the major part of the colour is derived from 
chromogenic amino acid sequences (Chou and Goldstein, 1960). 
Colour development is enhanced by the capacity of the peptide 
chain to form quadrirlentate chelates with copper. Electron 
transport from the copper-peptide complex is thus facilitated 
and the phenol reagent is rapidly reduced. 
The non-protein amino acid content of haemolymph can be 
as high as 20 g/1 in some insects (Gilmour, 1961), and this 
)., 
would make a greater contribution to the TNBS colour than to 
the Lowry result. Amino sugars, such as N-acetylglucosamine, 
the basic unit of chitin, could also contribute to TNBS colour 
formation. N-acetyl hexosamine levels of 1.2 g/1 have been 
reported in the ｨ｡･ｭｯｬｹｮｾｨ＠ of the cecropia silkmoth in the 
late phase of moulting (Passoneau and Williams, 1953). Other 
amines which could react are dihydroxyphenylalanine (DOPA) , 
derived from tyrosine, and kynurenine, which is synthesised from 
tryptophan. 'Ommochromes', a family of yellow, red and brown 
insect pigments which are formed by condensation of two molecules 
of 3-hydroxy kynurenine, also contain an amino group. 
It seems likely that the overestimation of protein levels 
.by the TNBS method resulted from a high free amino acid content 
of the locust tissue preparation. .This would also account for 
the overestimation found with the direct Lowry method, since free 
tyrosine and tryptophan would be measured. It is not clear why 
the pr·esence of the locust tissue preparation enhanced the 
recov·ery of BSA in both direct protein assays. 
The bovine brain tissues which were investigated in this 
study did not show promise as sources of cyclic GMP binding 
protein, although high cyclic GMP levels have been reported in 
".. ｾ＠
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mammalian cerebellum (Table 1.3A). The approach of investigating 
tissues with high cyclic GMP content . as possible sources of 
binding protein was justified in the case of the cricket, and its 
close relative, the locust. Rat lung, another tissue with a 
high cyclic GMP concentration has been successfully used as the 
basis for a cyclic GMP assay (Kobayashi and Fang, 1975). sold 
and Hofman (1974) have commented that the ratio of intracellular 
.. ... . , · ..• Ｚ＾Ｍｾ Ｍ ｾ Ｍ -- ··'· Ｍﾷ｜ｾﾷｾＬ Ｍ ＭＭ .•.••. ·_.., , __ ;_,., •.•. .- ; -·-· ' -10 --- -· ..... • • . . ... ! 
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concentrations of cyclic GMP and cyclic AMP in a rat cerebellum 
preparation was very similar to the observed ratio for bound cyclic 
GMP to bound cyclic AMP, and that their results suggested the 
possibility that the binding ratio for the two cyclic nucleotides 
reflects the intracellular concentration of their respective rec-
eptor proteins. These findings support the view that tissues with 
high _cyclic GMP content and cyclic GMP/cyclic AMP ratios may also 
be good sources of specific cyclic GMP binding proteins. 
Fifth instar desert locusts, which were easy to obtain and 
convenient to handle, provided a binding reagent for [B- 3H] cyclic 
GMP which had potentiai for use in an assay system. However, it 
was necessary to solve several problems before a reliable cyclic 
GMP assay could be achieved. 
The reason for the failure to obtain a usable standard curve 
after several successful experiments was not apparent for some 
time; The separation procedure was not suspected at first, since, 
for -fresh binding protein preparations, zero standard binding was 
similar to that found in earlier assays. The use of a 'dis-
equilibrium' incubation system did not improve the dose-response 
curve, and elevated temperatures caused a decrease in ｾＭ Ｓ ｈ｝＠ cyclic 
GMP binding, presumably due to inactivation of the binding protein. 
Attempts to purify the receptor protein by ammonium sulphate 
precipitation using the methods of Kuo and Greengard (1972) or 
Sold and Hofman (1974) resulted in a loss of binding activity. 
Ammonium sulphate fractionisation has been used successfully for 
purification of cyclic GMP binding proteins fr9m lobster tail 
(Gilman, 1972), silkmoth pupae (Fallon and Wyatt, 1975), rat 
lung (Kobayashi and Fang, 1975) and rat brain (Sold and Hofman, 
_____________________ ___:___ ______ -- ----
I 
..... __.!( ·- · .. , ' •. ｾ＠ : ﾷﾷﾷＭｾＭ . .. ｾ＠ • • . ｾ＠ ............. : .• ,:_ , .. ................ _ ............. ｾＺＺ Ｍ ｾ［ ｟ Ｌ＠ Ｍ ﾷﾷ Ｍ ｾ＠ i' . -"·-·-.C • .. . . ···-··· .:::: .. 
1974). Failure to isolate the active binding protein could 
have resulted from inactivation during the precipitation process 
or from the use of ammonium sulphate at a concentration too low 
to precipitate the locust protein. The binding protein may also 
have precipitated during dialysis. Fallon and Wyatt (1975) have 
reported that slow removal of ammonium sulphate gave the best 
recovery of ｳｾｬｫｭｯｴｨ＠ binding reagent, and that dialysis against 
more than twenty volumes of buffer resulted in precipitation of 
the binding protein. 
Gel-filtration of the binding protein on 'Sephadex G-200' 
was hampered by the tendency.of the reagent to form a brown 
viscous polymer on the column. This reaction may be due to 
polyphenol oxidase activity in the ｾｲ･ｰ｡ｲ｡ｴｩｯｮＬ＠ and can be 
inhibited by the use of anaerobic conditions (Chan, 1977). The 
fraction with the highest ｾＭ Ｓ ｈ｝＠ cyclic GMP binding capacity 
s .till. showed a marked drop in activity relative to the crude 
preparation when differences in protein content were taken into 
account ·(Table 2.6). 
Kobayashi and Fang (1975) increased the yield of rat 
lung binding protein by the addition of 2-mercaptoethanol (6 
mmol/1) to their homogenisation and dialysis media, and the 
use of 2-mercaptoethanol may have improved the recovery of locust 
283 : 
binding protein in the purification procedures which were employed. 
A recent attempt to purify the locust binding protein by 
ammonium sulphate precipitation and by chromatography on a DEAE-
cellulose column (1.7 x 15 em) in the presence of 2-mercapto-
ethanol (18 mmol/1) has also resulted in loss of binding activity 
• ·- ¥ • ) • • : ... • 
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(Chan, 1977). Several authors have reported that attempts . to 
purify cyclic GMP binding reagents beyond an ammonium sulphate 
precipation stage have resulted in a reduction in binding 
capacity. Murad et al (1971) tried unsuccessfully to purify 
a dialysed ammonium sulphate fraction from lobster tail muscle 
by DEAE cellulose, carboxymethyl cellulose, phosphocellulose or 
Sephadex G-100 chromatography. Gilman (1972) reported similar 
difficulties with attempts to purify the lobster tail binding 
reagent. Sold and Hofman (1974) noted an 'almost complete loss' 
of rat cerebellum cyclic GMP binding protein as a result of 
column chromatography on DEAE cellulose, protamine-4B-sepharose, 
or calcium phosphate gel. Loss of binding activity is, therefore, 
·a common finding when cyclic GMP receptor proteins are subjected 
to purification procedures other than ammonium sulphate fraction-
ation. It may be worthwhile to try to purify the locust binding 
reagent by affinity chromatography using a method similar to that 
described by Gill and Kanstein (1975) in which a cyclic GMP 
derivative could be covalently linked to 'Sepharose'. Kobayashi 
and Fang (1976) have used blue dextran-sepharose chromatography 
to purify a calf lung cyclic GMP-dependent protein kinase 
preparation. This system may also be suitable for isolation of 
the locust cyclic GMP binding protein. 
The results of charcoal treatment of the locust binding 
reagent provided the first indication that the method used for 
the separation of bound and free radioactivity was unsuitable. 
When different separation methods were compared, it became clear 
that the failure to obtain a standard curve was d.l e to the 
ｾ＠
I ••• f, ﾷ ｾ＠ .J • " ｾ＠ • . .. .. : ....... 'L."' . 
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charcoal/BSA separation procedure rather than to the incubation 
conditions or assay reagents. 
The reason for the apparent lack of displacement of ｾＭ Ｓ ｈ｝＠
cyclic GMP by cyclic GMP standards when charcoal/BSA separation 
was employed remains obscure. For a fresh binding protein 
preparation, the zero standard binding of label was similar to 
that found with ammonium sulphate separation (Fig.2.7B). If 
charcoal/BSA reagent were 'stripping' the label from the binding 
protein the zero standard binding would be low. One possible, 
if unlikely, explanation is that charcoal/BSA had a greater 
affinity for cold cyclic GMP than for ｾＭ Ｓ ｈｽ＠ cyclic GMP. It 
.seems improbable, however, that are-equilibration in favour of 
the binding of label by the locust reagent could take place 
during the few minutes taken to separate bound and free cyclic 
GMP. An alternative possibility is that the binding protein 
was.adsorbed onto the charcoal reagent, and that the radioactivity 
in -the supernatant solution represented non-specific binding of 
the label. The observation that charcoal treatment of the 
locust binding reagent resulted in the loss of 90% of the binding 
capacity with a minimal reduction in protein content (Table 2.6), 
supports this theory. On the other hand, ｾＭ Ｓ ｈ｝＠ cyclic GMP zero 
standard binding levels were often similar for charcoal/BSA and 
ammonium sulphate separation methods (Figure 2.7B), and agreed 
with earlier experiments in which a dose response curve was 
obtained with the charcoal/BSA reagent (Figure 2.4C). This 
agreement in zero standard binding levels argues against an 
explanation in terms of precipitation of the binding protein. 
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Binding capacity and specificity of the locust binding 
reagents were influenced by exogenous factors in the assay such 
as chelating agents, other .cPDE inhibitors, and BSA 
concentration (Section 2.10). 
Enhancement of ｾＭ Ｓ ｈ｝＠ cyclic GMP binding in the presence 
of EDTA could be interpreted in terms of its greater potency as 
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a cPDE inhibitor. If the concentration of theophylline (8 mmol/1) 
in the assay buffer was insufficient to prevent cPDE activity, some 
label would be broken down during the incubation, with a 
. . 
consequent reduction in the percentage of bound radioactivity. 
In addition, if cyclic AMP was degraded to a greater extent than 
cyclic GMP, its ｣ｲｯｳｳＭｲ･｡｣ｴｩｾｩｴｹ＠ in the assay would be reduced. 
·EDTA, by preventing cyclic nucleotide degradation, could increase 
both ｾＭ Ｓ ｈ｝＠ cyclic GMP binding and cyclic AMP interference. 
The findings on the influence of IBMX on the assay do not 
support an explanation of the effects of EDTA in terms of increased 
cPDE inhibition. IBMX is also a powerful cPDE inhibitor. Zenser 
et al (1977 ') have studied cPDE activity in rat renal cortex slices 
and tissue fractions. Cyclic AMP PDE activity (116 pmol/mg 
protein/min) and cyclic GMP PDE activity (163 pmol/mg protein/min) 
·in a 100,000 ｾｳｵｰ･ｲｮ｡ｴ｡ｮｴ＠ fraction were completely inhibited by 
IBMX at concentrations greater than 0.1 mmol/1. An IBMX cone-
entration of 2 mmol/1 was 'completely · effective' as an inhibitor 
of cPDE enzyme in renal cortex slices, although theophylline (10 
mmol/1) did not completely halt cyclic AMP hydrolysis. 
IBMX at a concentration of 4 mmol/1 in the locust assay 
buffer should be sufficient to inhibit cPDE activity completely. 
---------------------------'--·------ - - -
e ｾ ﾷ •ﾷ ﾷ ＬＮ＠
The influence of IBMX on the binding of ｾＭ Ｓ ｈ｝＠ cyclic GMP and 
on cyclic AMP cross-reactivity was, however, much smaller than 
that observed with EDTA. Thus the influence of EDTA cannot 
be due to a more effective inhibition of cPDE enzyme. 
EGTA, a chelating agent which binds magnesium ion less 
strongly than EDTA, reduced @- 3H] cyclic GMP binding in the 
assay·. without influencing specificity. The reduction in binding 
of label may have been due to increased cPDE activity in the 
binding protein preparation as a result of the increased avail-
ability of magnesium. Cyclic nucleotide phosphodiesterase 
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enzymes requiring magnesium ion for maximal activity have recently 
been described in Acheta domes ticus (Fallon and Wyatt, 197 7 )· and 
Hyalophora cecropia (Filburn et al, 1977). 
Increased ｾＭ Ｓ ｾ＠ cyclic GMP binding by the locust preparation 
in the presence of BSA is in accordance with the observed effects 
ｯｾ＠ ｂｓｾ＠ on bovine muscle cyclic AMP binding protein. Gilman (197 2) 
reported that the addition of a 'protein kinase inhibitor fraction' 
isolated from bovine muscle, increased the affinity and number of 
receptors on a bovine muscle cyclic AMP binding protein, but that 
similar increases in total binding capacity could also be achieved 
in the presence of albumin. This influence of BSA on the bovine 
muscle cyclic AMP binding preparation has been confirmed by Tovey 
et al (1974). If the action of BSA was mainly due to a 
'protective' influence on the binding protein, a similar effect 
might be expected with gelatin. ｾｵｲｰｨｹ＠ and Marvin (1974) found 
that gelatin (0.5 g/1) enhanced the binding of labelled ligand by 
several antibodies, transport proteins and by bovine adrenal 
.2; 
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protein kinase. Although gelatin reduced the binding of label 
in the locust assay, the concentration used (5 g/1) may have been 
too high. 
Studies of the effects of urine constituents on the locust 
protein binding assay have established that the overestimation of 
cyclic GMP in urine test and recovery specimens was almost 
certainly due to the presence of variable amounts of cyclic AMP 
in test specimens. Cyclic AMP at levels as low as 5 pmol/tube 
increased the slope of the dose response curve (Figure 2.11C). 
Zero standard binding for fresh binding protein preparations was 
not reduced in the presence of cyclic AMP. The addition of 
cyclic AMP (200 pmol/tube) to the assay to 'swamp out' the 
influence of variable amounts of cyclic AMP in test specimens 
gave acceptable recovery results (Table 2.11D) and test values 
agreed well with those obtained by RIA (Table 2.11B). This 
interesting action of cyclic AMP could be due to protection of 
cyclic GMP from hydrolysis, or to a direct influence on the 
binding protein. 
If cPDE enzyme were not completely inhibited in the assay 
system, cyclic AMP could appear to enhance the potency of cyclic 
GMP by competing for cPDE enzyme. Cyclic GMP would be hydrolysed 
less in the presence of high concentrations of cyclic AMP if the 
cPDE enzyme was active for both cyclic nucleotides. Increases 
in levels of intact cyclic GMP would then produce greater 
displacement of ｾＭ Ｓ ｈ｝＠ cyclic GMP .in the assay. If this were 
the case, however, zero standard binding of the label should also 
be increased since less ｾＭ Ｓ ｈ｝ Ｎ＠ cyclic GMP would be hydrolysed 
during the incubation. In fact the binding of label was the 
same, or, in the case of an older binding protein preparation, 
reduced in the presence of cyclic AMP. 
An alternative explanation would be that cyclic AMP was 
interacting directly with the binding protein or proteins. 
Scatchard analysis of the binding data for two locust binding 
ｰｲｯｴ･ｾｮ＠ preparations indicates that the addition of cyclic AMP 
(200 pmol/tube) caused a 50% reduction in the number of 'low 
affinity' binding sites and a 20% reduction in the number of 'high 
affinity' sites (Table 2.12). The influence of cyclic AMP on 
dissociation constants was much less pronounced, although there 
was a tendency for [s- 3H] ｣ｹｾｬｩ｣＠ GMP to be bound more strongly 
by high affinity sites (KD1 reduced) and less strongly by the low 
affinity sites ·(KD2 increased) in the presence of cyclic AMP. 
Although the interpretation of Scatchard plots in terms of 
two Ｎ ｯｾ､･ｲｳ＠ of binding sites may be useful for the comparison of 
experimental data, this model may bear little resemblance to the 
true situation. Scatchard (1949) made several assumptions when 
deriving his expression for the interaction between small molecules 
or ions and proteins. These were that binding sites have identical 
affinities for ligand molecules, that each binding site will bind 
only one ligand molecule, and that binding of ligand at one site 
does not influence the binding of li"gand at other sites. Non-
linear Scatchard plots could result from a single population of 
binding sites which did not obey t?ese criteria, or from two or 
more populations of binding sites. 
------------------------------- ---- - - - -
Scatchard plots of similar shape to those obtained in 
this study could resul·t from lack of correction for non--specific 
binding (CUatrecasas and Hollenberg, 1976). 
However, Scatchard plots constructed from binding data 
corrected for non-specific binding at each level of ｾＭ Ｓ ｈ｝＠ cyclic 
GMP used in the assay were also non-linear, although data points 
showed a greater scatter. Since the binding data were obtained 
from incubations with label only, problems arising from different 
binding protein affinities for labelled and unlabelled ligands 
(Taylor, 1975) were avoided. 
Scatchard plots with 'concave upwards' shape can also 
arise from heterogeneity of.the labelled ligand, interactions 
between binding sites of the •negative-cooperative' type, ligand-
ligand interactions, inactivation or transformation of the ligand 
or binding site during the binding reaction, or as a result 
of an interaction which is not of the form A + B ｾ＠ AB 
(Cuatrecasas and Hollenberg, 1976). 
The.influence of cyclic AMP could be due to occupancy of· 
low affinity binding sites which could bind either cyclic AMP or 
cyclic GMP. Alternatively, cyclic AMP could exert an allosteric 
control over cyclic GMP binding sites by interaction with the 
binding protein at a separate location. At present, the data 
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does not permit a distinction to be made between these possibilities. 
Although cyclic GMP binding proteins from lobster tail and 
cecropia silkmoth have been identi£ied as protein kinases (Kuo 
and Greengard, 1971), the nature of the cyclic GMP binding protein 
obtained from locusts has not been established. The locust 
binding protein preparation did not exhibit maximal binding of 
3 . ｾＭ H] cyclic · GMP at pH 4.0, a feature common to both lobster 
and silkmoth reagents (Gilman, 1972; Fallon and Wyatt, 1975). 
However, Tovey et ｾｾ＠ (1974) have reported a pH optimum of 7.5 
for binding of ｾＭ Ｓ ｈ｝＠ cyclic AMP by a bovine muscle protein 
kinase preparation. 
The possibility that the locust binding protein is a 
phosphodiesterase needs to be considered. Cyclic GMP binding 
by a cPDE would be possible if enzyme activity could be inhibited 
with retention of cyclic GMP binding sites. Four distinct 
mechanisms of action of cPDE inhibitors have been established 
{Weiss and Hait, 1977). Inhibition can involve reversible or 
irreversible binding to the enzyme substrate site, inactivation 
of cPDE activator proteins or cofactors, or allostearic influence 
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on the substrate binding site. Methyl xanthines and theophylline 
compete with cyclic nucleotide substrate for binding to the active 
site of the. enzyme in cardiac tissue preparations (Butcher and 
Sutherland, 1962) and in purified isoenzyme fractions from rat 
cerebellum (Weiss et al, 1974). Irreversible binding to the 
substrate site has been observed with high levels of papaverine, 
although at lower levels papaverine inhibits cPDE enzyme 
competitively (Weiss et al, ｾＹＷＴＩＮ＠ Trifluoperazine or chlor-
promazine can inhlbit some cPDE enzymes by binding reversibly to 
endogenous cPDE activator protein (Weiss and Hait, 1977). Cyclic 
GMP can exert an allosteric controi over cyclic AMP hydrolysis by 
cPDE {Appleman and Terasaki, 1975). 
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It is difficult to see how cyclic GMP could bind to a 
cPDE enzyme in the presence of high concentrations of theophylline 
or IBMX, which would saturate binding sites, and for this reason 
it seems unlikely that the locust ｾｩｮ､ｩｮｧ＠ protein is a phospho-
diesterase. Cyclic nucleotide binding by a cPDE may be possible 
when inhibition of enzyme activity does not involve the substrate 
site. This concept may explain the influence of EDTA on the 
binding reagent. It is most probable that EDTA inhibits cPDE 
･ｮｾｹｭ･＠ by sequestration of calcium and magnesium,necessary for 
enzyme activation. Increased @- 3H] cyclic GMP binding by the 
locust -preparation in the presence of EDTA could result from 
occupation of cyclic GMP binding sites on an inactive phospho-
diesterase enzyme. If the enzyme was capable of binding either 
cyclic GMP or cyclic AMP this increased binding capacity would 
be associated with an increase in cyclic AMP cross-reactivity. 
Binding capacity and ｣ｲｾｳｳＭｲ･｡｣ｴｩｶｩｴｹ＠ studies in the presence 
of both EDTA and a methyl xanthine would be helpful in testing 
this ｨｹｰｯｴｨｾｳｩｳＺ＠ the addition of a cPDE inhibitor which competes 
for the cPDE substrate site should reduce binding to its original 
level and restore specificity. 
High cyclic AMP cross-reactivity in adult locust preparations 
in the presence of EDTA (Table 2.9B) could be explained in ｴ･ｲｭｾ＠
of the presence of increased amounts of cyclic AMP-specific or 
non-specific cPDE enzymes in addition to the normal binding protein. 
Bielinska and Piechowska (1975) have studied cyclic nucleotide 
phosphodiesterase activity in the tissues of Schistocerca gregaria 
adults and larvae. . Tissue cyclic GMP PDE activity was in the 
region of 200 pmol/mg protein/min in the adult insects, while 
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cyclic AMP PDE activity was 10-15 times higher in muscle, and 
five times higher in the fat body. Homogenates and 12,000 g 
supernatants from whole larvae also showed greater PDE activity 
for cyclic AMP, although in 12,000. g sediments there was an 
excess of cyclic GMP PDE over cyclic AMP PDE activity, 'especially 
in the last larval instars'. 
Although the cyqlic GMP binding protein has not been 
characterised, the fifth instar desert locust ｰｲｾｰ｡ｲ｡ｴｩｯｮ＠ has 
been used successfully to develop a cyclic GMP competitive protefn 
binding assay. Locusts are inexpensive and readily obtainable. 
The preparation of the binding protein is straightforward: batches 
of 25 locusts can be ｰｲｯ｣･ｳｳｾ､＠ '"'i thin three hours, and yield 
sufficient binding protein for 1,500 assay tubes. 
Crickets (Acheta domesticus) and fifth instar I..ocusta 
migratoria also provided a source of binding protein which was 
acceptable for use in the assay system in terms of ｾＭ Ｓ ｈ｝＠ cyclic 
GMP binding and cyclic AMP cross-reactivity (Table 2.13B). 
Binding reagents prepared from crickets and fifth instar 
desert or migratory locusts remained usable for several months 
0 
when stored at -20 C. Results for cricket and migratory locust 
preparations, shown in Table 2.13B, were obtained after the 
0 
reagents had been stored at -20 C for over one year. The 
binding capacity of the fifth instar desert locust reagent 
remained constant for approximately two months when it was stored 
After this time binding capacity decreased slowly. 
Cyclic AMP cross-reactivity in the locust protein binding 
assay for cyclic GMP, which is in the region of 1 in 1000 (Table 
2.13Al is comparable to that of the silkmoth pupae binding assay, 
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and much lower than the cyclic AMP cross-reactivity with the 
lobster tail assay (1 in 20) or the rat lung protein binding 
method (1 in 15) (Table 1. 5) . Purification of the binding 
protein is necessary for all these published cyclic GMP protein 
binding methods in order to reduce cyclic AMP cross-reactivity. 
r 
ｔｾｲ･･＠ different preparations of fifth instar ､ｾｳ･ｲｴ＠ locust 
binding proteins showed very similar patterns of cross-reactivity 
with the fifteen ·nucleotides which were tested. Of these nucleo-
tides, only 3'5' cyclic nucleotides were capable of competing 
with ｾＭ Ｓ ｈ｝＠ cyclic GMP for binding to the receptor protein. The 
t . 't f 1' MP h' h ' d f . l l f cross-reac lVl y o eye lC I , w lc varle rom 30 to 70 o 
that shown by cyclic GMP, ｩｾ＠ probably of little practical 
importance. Steiner et al (1970) were unable to detect cyclic 
IMP by a specific RIA in the tissue samples which they examined. 
Since 5'-IMP is a common precursor in the synthetic pathway for 
5'-AMP and 5'-GMP, the cross-reactivity of cyclic IMP in the assay 
is not unexpected. The fact that cyclic IMP cross-reacts to a 
much greater extent than cyclic AMP in the method would suggest 
that the binding site 'recognises' the oxo group at c6 on the 
purine ring, which is common to cyclic IMP and cyclic GMP, in 
addition to the 3'5' monophosphate grouping on ribose. 
The assay detection limit of 0.2-0.3 pmol cyclic GMP per 
assay tube, calculated by the method of Ekins (1974), is equal to 
that reported by Kobayashi and Fang (1975) for their rat lung 
protein binding assay, and is lower-than that reported for lobster 
tail and silkmoth pupae methods (Table 1.5). Direct comparisons 
of these detection limits may be invalid, however, since the 
calculation methods were not described. 
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The locust protein binding assay for cyclic GMP, therefore, 
possesses a specificity and detection limit equal to or better 
than existing protein binding methods, without the need to purify 
the binding reagent. 
Dissociation constants for 'high affinity' binding sites 
(Table 2.12) are of the same magnitude as those reported for 
other cyclic GMP receptor assays (Table 1.5), while the low 
affin.ity sites of rat lung binding protein bind cyclic GMP less 
strongly than those of the locust reagent. 
The assay method in its final form (Table 2.11C) has 
been validated for the measurement of urinary cyclic GMP levels. 
Recovery of cyclic GMP (10 pmol/tube) added to urine specimens 
·averaged 98% (Table 2.11D) and results were independent of urine 
dilution over the dilution range 1 in 2 to 1 in 32 for the 
urine specimen which was tested (Table 2.11F). cPDE treatment 
reduced the cyclic GMP content of ten urine specimens to below 
the ·detection limit of the method. Urinary cyclic GMP levels, 
measured by the locust assay and by RIA using two different 
antisera showed close agreement (Table 2.11E). 
The cost of reagents and consumable apparatus used in 
the method,excluding the cost of locusts, which were obtained 
free of charge in this study, is approximately 6.5p per assay 
tube. This compares with a cost of approximately 28p per tube 
for the 'Amersham' cyclic GMP RIA kit. 
The method has been applied. to the measurement of cyclic 
GMP levels in human blood plasma and saliva (Chan, 1977). Fresh 
plasma and saliva specimens were deproteinised by the addition 
of an equal volume of ice-cpld perchloric acid (100 g/1). Super-
natant solutions obtained after centrifugation were neutralised 
with potassium hydroxide (10 mol/1) and left to stand at 0°C 
for at least 30 minutes. Potassium perchlorate precipitates 
were removed by centrifugation and the clear supernatants were 
analysed for cyclic GMP. 
One disadvantage of the locust assay for cyclic GMP is 
the relatively large intra- and inter-assay variation. The 
separation procedure may well be a contributory factor to this. 
Addition of ammonium sulphate to the assay tubes results in the 
formation of a bulky precipitate. Centrifugation at 1,800 ｾ＠
for at least 30 minutes is required to produce a compact pellet 
which is necessary to minimise the loss of precipitate when the 
.supernatant solution is aspirated. The use of a 'Microfuge' 
(Beckman Instruments) which has a maximum speed of 11,000 rpm, 
has produced a compact pellet within five minutes, and has 
increased the precision of the assay (Greenbaum, 1977). 
The detection limit for the method, although comparable 
with other protein binding methods, is higher than those which 
are attainable with RIA. Nevertheless, if an economical cyclic 
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GMP RIA is not available, the locust protein binding method offers 
ｾｮ＠ accurate, inexpensive and convenient means of determining 
cyclic GMP concentrations in urine and other body fluids. 
5.2 Direct radioimmunoassays for urine and plasma cyclic GMP levels 
The factors which contribute to the production of specific, 
high titre antisera are still poorly understood. There is 
evidence from the present study that the change to a keyhole limpet 
----------------------- · --· - - . 
haemocyanin (I<LH) carrier protein, ｾｨｩ｣ｨ＠ is itself highly 
immunogenic, elicited a better immune response in the rabbit 
to the hapteQ cyclic GMP than did the ovalbumin conjugate. 
It may be inferred from the reports of Steiner and colleagues 
(1970, 1972a) that they also found improved antibody production 
with KLH conjugates. Although human serum albumin, KLH, or 
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poly-L-lysine carriers were used to prepare cyclic AMP conjugates, 
antibodies to cyclic GMP, cyclic UMP and cyclic IMP were obtained 
by the administration of the cyclic nucleotide-KLH conjugates 
only. It is known that the variable immune response of animals 
is due in part to their genetic constitution (Green et al, 1969). 
Individual animals, or several animals of an inbred strain, may 
have a genetic inability to"recognise regions of the carrier 
protein of a hapten conjugate. A change of carrier protein 
may overcome this problem (Benacerraf and McDevitt, 1972). 
Conversely, it may be advantageous to breed from animals which 
produce specific, high titre antibodies. 
The intramuscular method of immunisation which was used 
during this research was successful in producing antibodies to 
cyclic GMP, although these were of rather low titre. The 
preparation of a cyclic GMP-protein conjugate from the plasma 
protein. of a sheep, and the intravenous injection of the conjugate 
into the same animal did not result in the production of anti-
cyclic GMP antibodies. 
The dose and form of an immunogen influence the production 
of antibodies; administration in too large a dose, or too soluble 
a form, can give rise to 'tolerance' in an animal (Playfair et al, 
1974). Subcutaneous or intramuscular injections have often been 
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us·ed for immunisation, while injection into individual lymph 
nodes (Boyd and Peart, 1968) or by multiple intradermal injections 
(Vaitukaitis et al, 1971) have also been advocated. Intra nodal 
injection has few advantages over intramuscular immunisation, and 
is technicaUydemanding (Hurn and Landon, 1971). The multiple 
intradermal procedure described by Vaitukaitis and coworkers 
(1971) permits · the production of antibodies with small amounts 
of immunogen, and gives a maximal antibody response eight to ten 
weeks after one set of injections (Playfair et al,. 1974). This 
--
response time is quite distinct from the ten to fourteen day 
maximum response period for intramuscular or subcutaneous boosts. 
The multiple intradermal method may have advantages for the 
.production of anti-cyclic nucleotide antisera. At Southampton 
cyclic AMP antibodies have been obtained recently in three 
rabbits, each of which received one multiple intradermal 
immunisation with 1 mg ScAMP-KLH conjugate, and one intramuscular 
boos-t ·with 0. 25 mg of the same conjugate after a period of three 
months. 
The molar ratios of bound cyclic GMP and protein in the 
conjugates which were prepared (Table 3.1) are similar to the 
figures of '5 to 6' and '4 to 5' molecules of cyclic AMP per 
molecule of hSA reported by Steiner {1974a) and Weinryb (1972} 
respectively. Steiner has not ｧｩｶｾｮ＠ details of the degrees of 
haptenisation of the other cyclic AMP, cyclic GMP, cyclic UMP and 
cyclic IMP conjugates which he obtained. The ScGMP-hSA 
conjugate prepared by Cailla et al· {1976) contained an average 
of 7.4 residues of cyclic GMP for ea.ch molecule of hSA. 
... ﾷＭＭＭ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾｾｾｾｾＭＭｾ＠
The production of antisera in sheep has the advantage 
that large volumes of reagent are available if antibody titres 
are low. None of the ScGMP-protein conjugates produced a 
specific anti-cyclic GMP antiserum in sheep, although titres 
were comparable with those of the rabbit antisera. It is not 
clear whether this finding is related to the breed of sheep which 
were used. To date, the production of specific, high titre 
antisera to cyclic GMP in the ·sheep has not been reported, 
although goats have been successfully immunised using a rlgime 
of direct injections into lymph nodes followed by six-weekly 
subcutaneous boosts {Weinryb, 1972). 
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Titres for both rabbit and sheep antisera were.considerably 
lower when charcoal/BSA reagent was used rather than ammonium 
sulphate for the separation of bound and free ｾＭ Ｓ ｈ｝＠ cyclic GMP 
(Table 3.2). This discrepancy between the results using the 
two separation methods was most probably due to the 'stripping' 
of bound ｀Ｍ Ｓ ｾ＠ cyclic GMP from the antibody by the charcoal 
reagent. Charcoal/BSA separation ·of bound and free radioactivity 
has proved to be unsuitable for both the locust pr9tein binding 
and RIA methods which have been developed in this study. 
Rabbit antisera T2 and TS are both highly specific for 
cyclic GMP. Of the range of nucleotides tested, only the 3'5' 
cyclic nucleotides cross-reacted at a level greater than 1 in 
10,000. Cyclic AMP cross-reactivity was in the region of 1 in 
10,000 for each antiserum. Steiner (1974a) has stated that a 
cyclic AMP interference of 1 in 10,000 or less is desirable for 
a •specific' anti-cyclic GMP antiserum. Of the other cyclic 
nucleotides, cyclic IMP cross-reacted to the greatest ·extent with 
both antiserum T2 and TS (Table 3.3). This observation agrees 
with the report of Steiner (1974a} that cyclic IMP interfered 
to the greatest extent in his cyclic GMP RIA, showing one 
hundredth the potency of cyclic GMP for displacement of label. 
High cyclic IMP cross-reactivity is, therefore, a common finding 
with both the locust protein binding and radioimmunoassays, and 
implies that the C-6 oxo group common to both cyclic IMP and 
cyclic GMP is an important determinant of both biological and 
immunological reactivity in addition to the 3'5' cyclic phosphate 
structure. Since the presence of cyclic IMP in mammalian tissue 
has not been established (Steiner, 1972a) this interference is 
unlikely to be a practical problem. 
Synthetic butyrated cyclic nucleotides cross-reacted to 
a considerable degree in the cyclic GMP assay (Table 3.3}. This 
finding can be explained by the fact that one of the sites of 
·substitution of the ｢ｵｾｹｲｹｬ＠ group is the 2'-o=position on the 
ｾＰＰ＠
ribose ring, which is the point on the cyclic GMP molecule through 
which it was linked, via a succinyl group,to carrier protein prior 
to immunisation. Antisera raised _against 2'-0-succinyl cyclic 
nucleotide-protein conjugates often cross-react extensively with 
2'-0 substituted cyclic nucleotides (Steiner et al, 1972b: Cailla 
et al, 1976; Frandsen and Krishna, 1976). 2'-0-succinyl and 2'-0-
acetyl cyclic nucleotides possess increased potency over the non-
substituted cyclic nucleotides for displacement of label. Antisera 
vary in their preference for the two derivatives. Although 2 • -0-
succinyl and 2'-0-acetyl cyclic GMP exhibited similar cross-
reactivities with one anti-cyclic GMP antiserum (Zeilig, 1976), 
Frandsen and Krishna (1976) found that 2'-0-acetyl cyclic GMP 
had half the potency of 2'-0-succinyl cyclic GMP in their assay 
system. Cyclic GMP and ScAMP were 50 and 1000 times less potent 
than ScGMP in displacing [r125J ｓｾｇｍｐＭｔｍｅ＠ label with the assay 
system described by Cailla et al (1976). 
ScGMP and ScAMP cross-reactivity studies with antiserum 
T2 or TS, using ｾＭ Ｓ ｈ｝＠ cyclic GMP label, have demonstrated that, 
while ScGMP has a fourfold greater potency in the assay relative 
to cyclic _GMP, the cross-reactivity of ScAMP is increased 67-fold 
(antiserum TS) and 18--fold (antiserum T2) relative to cyclic AMP. 
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In thi·s case, the in traduction of a preliminary succinyla tion step 
for test samples could result in a marked reduction in assay 
specificity with only a small improvement in detection limits. 
The lower interference shown by ScAMP and 2'-0-monobutyryl 
cyclic UMP with antiserum T2 (Table 3.3) indicates that 2'-0-
substituted cyclic nucleotides are bound less avidly by antiserum 
T2 than by antiserum T3. 
Few researchers have published details of titre or binding 
avidity for the anti-cyclic GMP antisera which they have produced. 
Cailla and colleagues (1976) obtained antisera from three rabbits 
which could be used at a dilution of greater than 1 in 10,000 in 
their assay system and a dissociation constant of 1.2 x 1010 mol/1 
was reported for one of these antisera. Although this figure is 
one order of magnitude lower than those determined for antiserum 
T2 and TS, it referred to an assay.system.which utilised [j125] 
ScGMP-TME label and succinylated tests and standards. ｾ ＱＲＵ ｝ｳ｣ｇｍｐﾭ
TME has been reported to bind to antisera 200 times more avidly 
ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭ Ｍ ﾷＭ ﾷ Ｍ ﾷ ﾷ ﾷ＠ . -- . . 
._ 
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than ｾＭ Ｓ ｾﾷ＠ cyclic GMP (Steiner, 1972a). One possible advantage 
of the use of an iodinated cyclic GMP derivative would be the 
saving in antiserum which would result if it could be used at a 
higher dilution in the assay. However, the detection limit of 
0.03 pmol cyclic GMP per tube which has been reported for an assay 
using iodinated label (Steiner, 1974a) represents only a small 
improvement over those of approximately 0.08 and 0.05 pmol/tube 
which have been found with the present urine and plasma cyclic GMP 
radioimmunoassays. 
Although the titres of anti-cyclic GMP antisera which have 
been achieved in this study are rather low, the high specificity 
and avidity of these antisera have permitted the development of 
reliable assays for cyclic GMP in ur.ine and blood plasma. 
Recoveries· of cyclic GMP added to test specimens averaged 
94.1% (antiserum T2) and 95.2% (antiserum TS) for the urine 
cyclic GMP assay system and 98.1% for the plasma cyclic GMP assay. 
Plasma and urine results were independent of the dilution of test 
samples over a range of concentrations which spanned the dose 
response curves (Tables 3.4C, 3.5D). This finding serves as a 
useful indication that the assays are specific, but does not 
provide complete proof of assay specificity (Ekins, 1974). 
The treatment of urine samples with cPDE enzyme, or the 
hydrolysis of cyclic GMP by endogenous cPDE in plasma samples 
collected in the absence of EDTA resulted in complete disappearance 
of measurable cyclic GMP content '(Figures 3.4B, 3.5B). Steiner 
(1972a) has reported the same findings. These results indicate 
that there is little need to analyse individual 'blank' plasma 
specimens, collected in the absence of a cPDE inhibitor, for 
normal sphiects. 
- - · · - · _________ ..,......,,.....,... .. .,.., ___,....,._ .  """' . .. . ＬＮＮＮＮＮ Ｎ ＭｾＭＭｾｾ＠
303 
Further evidence for the validity of the urine cyclic 
GMP RIA is provided by the finding of a close agreement in results 
obtained by locust protein binding assay and by RIA with antiserum 
TS or T2 (Figures 2.11D, 2.11E, 3.4C}. 
The measurement of urine cyclic GMP levels by RIA offers 
the advantages of a lower detection limit (approximately 0.08 
ｰｭｾｬＯｴｵ｢･ｽ＠ and an improved inter- and intra-assay precision 
relative to the locust protein binding assay. Inter-assay 
precisions of between 4.2 and 8.7% found in this study are slightly 
lower than those of 6.4 to 13.6% reported for a similar RIA system 
('Cyclic GMP RIA' Radiochemical Centre, Amersham;booklet}. 
Cyclic GMP levels in·a urine specimen from a normal subject 
0 . 0 
were unaffected by storage at 4 C or 25 C for at least two days 
(Figure 3.4D}. This indicates tbat postal delivery of urine 
specimens for cyclic nucleotide analysis should be ｡､･ｱｵｾｴ･Ｎ＠
The use of a double antibody separation procedure, together 
with an antiserum of high specificity for cyclic GMP has permitted 
the direct analysis of plasma samples. This development 
represents an improvement over all previous ｭｾｴｨｯ､ｳ＠ for plasma 
cyclic GMP analysis, which require preliminary extraction of test 
specimens. The assay will detect as little as 0.05 pmol cyclic 
·GMP per assay tube, and results for the direct and ethanol 
extraction methods showed good agreement over a wide range of 
plasma cyclic GMP levels (Table 3.5C}. 
The cost of reagents and consumable apparatus, excluding 
the cost of antisera, is in the region of 6p per tube for both 
the urine and plasma radioimmunoassays, and represents a 
considerable saving over the cost of commercially available 
reagents for cyclic GMP RIA. 
In view of the high specificity of antisera T2 and TS for 
cyclic GMP, the analysis of tissue extracts should be possible 
without the use of nucleotide fractionation procedures. 
Preliminary results from measurements on rat brain and pancreas 
specimens after homogensation in perchloric acid (100 g/1) and 
neutralisation of extracts ｷｩｴｾ＠ potassium hydroxide (10 mol/1) 
have been encouraging. Antiserum TS has also been employed 
successfully for the measurement of cyclic GMP concentrations 
. in rat kidney tissue after extraction by the perchloric acid/ 
potassium ·hydroxide procedure .(Greenbaum, 1977). 
5.3 Clinical applications for urine and plasma cyclic 
nucleotide measurements 
Urinary cyclic GMP concentrations, determined in morning 
urine specimens from twelve normal subjects (Table 4.2A) agreed 
well with published data (Table 1.3B). The mean cyclic AMP 
excretion in six healthy men was rather low in comparison to 
published results, although cyclic AMP excretion in six normal 
women was in better agreement with the literature. The finding 
of increased cyclic GMP excretion ｾｭｯｬＯＱＩ＠ in men ｲ･ｾ｡ｴｩｶ･＠ to 
women, and of higher cyclic AMP output (fmol/g creatinine) in 
women relative to men, paralleled those reported by Tucci and 
Kopp (1970) for 24 hour urine spscimens. ｾｴ＠ present the limited 
information which is available suggests that sex related 
differences need to be taken into account when cyclic nucleotide 
excretion data are interpreted. 
A study of the variation in urinary cyclic nucleotide/ 
9reatinine ratios over a 24 hour period has established that 
there is considerable variation in the excretion of cyclic AMP 
and cyclic GMP, and that ·the excretion patternsfor each cyclic 
nucleotide are often quite different (Figure 4.2A). Although 
some researchers have been unable to detect a circadian rhythm in 
ur-inary cyclic AMP excretion (Chase et al, 1969; Broadus et al, 
1971; Shaw et al, 1974; Coffey and Middleton, 1974) the presence 
of such a rhythm has been reported in several other publications 
(Murad and Pak, 1972; Sagel ｾ＠ al, 1973; Stone et al, 1974; 
Holmes, 1975). In this investigation there was a marked 
periodicity in cyclic nucleotide excretion in one subject who was 
studied over a 48 hour period, while the results for all subjects 
suggested that the timing of peak cyclic nucleotide excretion 
varied from person to person. Kopp and colleagues (1977a) have 
recently studied cyclic AMP and cyclic GMP excretion in three 
normal subjects (2 men, 1 woman) in four-hourly urine collections 
over periods from 14 to 33 days. Although the output of each 
cyclic nucleotide showed a circadian variation, patterns for 
cyclic GMP and cyclic AMP excretion were quite distinct. These 
findings support the view that the urinary excretion of each 
cyclic nucleotide may vary independently. 
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A .more exhaustive study of urinary cyclic nucleotide 
variations ｾｯｵｬ､＠ require collection of specimens at strict time 
intervals and should be continued for several days. One possible 
drawback to the collection of urine specimens during the night is 
-that interruption of the normal sleep pattern could influence 
the observed cyclic nucleotide excretion rhythm (Kopp et al, 
1977a). 
Individual variations in cyclic nucleotide excretion, 
although large, tended to cancel out when they were averaged 
30() 
for all subjects over four-hourly periods (Figure 4.2B). This 
ｦｩｮｾｩｮｧ＠ underlines the fact that erronious conclusions can be drawn 
from grouped cyclic nucleotide excretion data. The independent 
changes in cyclic AMP and cyclic GMP excretion in different 
individuals make the interpretation of results of analyses on 
morning or rand?m urine specimens extremely difficult. The 
collection of 24 hour urine qpecimens avoids this problem. 
Although a twin pregnancy cannot be assumed to be 'typical', 
the cyclic nucleotide excretion levels which were observed during 
the pregnancy (Figure 4. 2C) were in general agreement with. those 
reported by Kopp et al (l977b) in 24 hour urine specimens from 89 
normal pregnancies. Kopp and colleagues also found a rapid rise 
in cyclic GMP output in the first trimester of pregnancy, while 
cyclic AMP excretion increased steadily during the gestation 
period. The factors responsible for the increased cyclic nucleo-
tide excretion in pregnancy have not been established. Cyclic 
AMP is readily transferred across the placenta of the rhesus monkey 
(Ling, 1977), and the rapid fall in human maternal cyclic AMP 
output following parturition, noted by Taylor et al (1970) suggests 
that the £oeto-placental unit may be a major source of cyclic AMP. 
The last ｴｲｩｾ･ｳｴ･ｲ＠ of pregnancy is associated with a physiological 
hyperparathyroid status in the mother (Cushard et al, 1972) and 
this could increase the renal contribution to urinary cyclic AMP 
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levels. This seems unlikely in view of the fact that cyclic 
AMP excretion also rose during the pregnancy of one patient 
with ideopathic hypoparathyroidism (Taylor et al, 1970). Increases 
in metabolic rate during pregnancy could also potentiate the 
actions of PTH on the kidney (Ashby et al, 1977) or of glucagon 
and adrenalin on liver and adipose tissue (Gumaa et al, 1977) 
and may. contribute to increases in urinary cyclic nucleotide 
excretion (Tucci and Kopp, 1976). 
Plasma cyclic nucleotide concentrations determined in 
normal subjects (Table 4.2B) were very similar to those reported 
by other researchers (Table 1.3B). 
Cyclic GMP concentrations, measured in half-hourly plasma 
specimens from three healthy women, peaked in the morning in all 
three subjects (Figure 4.2D). The reason for this two-fold rise 
in plasma cyclic GMP concentration in the morning is not known. 
It is unlikely that coffee intake could have a delayed effect of 
this .magnitude. If this pattern is confirmed in a larger number 
of studies with the avoidance of coffee and tea, it would suggest 
that plasma cyclic GMP levels measured in the morning may over-
estimate the circulating levels during the rest of the day. 
The diabetic twins did not exhibit a morning peak in plasma 
cyclic GMP levels. There · was an increased variation in plasma 
cyclic GMP concentration during the day, with several very low 
levels. In view of the lack of effect of insulin on plasma 
cyclic GMP content (Siddle et al, 1974) these variations are 
unlikely to be due to abnormalities of insulin secretion. Plasma 
cyclic AMP also fluctuated markedly, and showed a pattern more 
consistent with a pulsatile release of cyclic AMP into the 
__ Ｎ［ＮＮＮ｟ＬＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾＭＭＭ ＭＭ ＭＭＭＭＭ ＭＭ Ｍ Ｍ
circulation. These changes could be related to the relative 
hyperglucagonaemia, resulting from abnormal pancreatic alpha 
cell function, which has been associated with diabetes (Unger 
et al, 1972). A similar study of plasma cyclic AMP variations 
·in normal subjects will be of value in determining whether 
short term plasma cyclic AMP fluctuations are common. The 
striking ' similarity between the cyclic nucleotide patterns in 
each identical twin could reflect their similar genetic 
constitution. Since the two metabolic studies were carried 
out at the same time, however, the possibility that the 
parallelism is due to errors in specimen handling cannot be 
ruled out, although this seems unlikely. 
ｾＰＸ＠
In their original diagnostic test for pseuodohypopara-
thyroidism Ellsworth and Howard (1934) monitored the phosphaturic 
effect of PTH as a guide to the integrity of the renal response 
to this hormone. The administration of bovine PTH (200 MRC 
units) to two normal subjects and to two hypoparathyroid patients 
has 'demonstrated that urinary phosphate excretion is an 
unreliable indicator of PTH action (Figure 4.3). Cyclic AMP 
excretion rose promptly in all four subjects, confirming that 
the measurement of urinary cyclic AMP, as prepared by Chase et 
al (1969) gives a better index of the effect . of PTH stimulation 
on the renal tubule . Cyclic GMP excretion increased in one 
. normal subject and in one hypoparathyroid patient following PTH 
injection. Although PTH is capable of increasing urinary GMP 
· output (Murad, 1973) the results of this small study show that 
PTH stimulated urinary cyclic GMP increments are less consistent 
than rises in urinary cyclic AMP. 
The findings from·the investigation into urinary calcium 
and cyclic nucleotide responses to an oral calcium load test were 
difficult to interpret. Of the 28 patients with normocalcaemia 
and hypercalciuria or nephrolithiasis who were studied, none 
could be assigned to the 'renal hypercalciuria' group of Pak et 
al (1975) using their guidelines. Although there was a group 
of ｰ｡ｾｩ･ｮｴｳ＠ with fasting hypercalciuria, these did not have 
elevated fasting urinary cyclic AMP excretion, nor was there any 
evidence of increased circulating PTH levels. Nordin (1977) has 
recently put forward strong arguments against the existence of 
renal hypercalciuria and, in view of his comments on the 
inadequacy of a 12-hour fast. in reducing renal calcium excretion 
to normal in some hyperabsorptive patients, it was decided to 
classify patients under the heading 'hyperabsorptive group 2'. 
Since no patients with renal hypercalciuria, as defined by Pak 
et al, could be identified, the test has been of no value in 
predicting which patients would ·benefit from therapy with 
thiazide diuretics. Normocalciuric nephrolithiasis and 
absorptive hypercalciuria patients could be distinguished solely 
by differences in urinary calcium excretion. These findings are 
· similar to those of Rush et al (1977) who have commented that the 
oral calcium load test was not helpful in differentiating 
hypercalciuric states except in those patients with hyperpara-
thyroidism. In spite of the lack of evidence for a primary 
defect in renal calcium handling in hypercalciuria, the kidney 
has been implicated as the possible cause of ·absorptive hyper-
calciuria. Haussler and colleagues {1976) have proposed that 
the hypophosphataemia resulting from increased renal loss of 
ｾＰＹ＠
phosphate may induce an increase in , the production of 1,25 
dihydroxy vitamin o3 (1,25 diOH o3), which in turn would 
augment intestinal calcium absorption. Measurements of 1,25 
diOH o3 in patients with ideopathic hypercalciuria could confirm 
this hypothesis. 
The calcium load test has revealed interesting differences 
between urinary cyclic nucleotide responses in control subjects 
and hypercalcaemic patients. Urinary calcium and cyclic AMP 
excretion in normal subjects before and after the oral calcium 
load test showed close agreement with values reported by Pak et 
al (1975), with the exception of fasting cyclic AMP output, 
which was lower in this study (Table 4.4A). The lower fasting 
cyclic AMP excretion is most probably due to the fact that 
patients in this investigation were not put on a low calcium 
diet before the test. Fasting serum PTH ｬ･ｶｾｬｳ＠ (and cyclic 
AMP output) may have been higher in the patients of Pak et al 
due to the effects of a low calcium diet. 
The decrease in urinary cyclic AMP excretion after the 
load test in six of nine normal subjects is consistent with 
the concept that PTH secretion is diminished as a result of 
calcium intake. Cycli.c GMP output also fell in the majority 
of normal subjects after calcium loading. 
When patients in hyperparathyroid groups 1 and 2 were 
studied, it became clear that serum PTH and urinary cyclic AMP/ 
creatinine ratios decreased in many of the patients following 
calcium ｡､ｭｩｮｩｳｴｲ｡ｴｾｯｮ＠ (Table 4.4B). In contrast to the 
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observations of Pak et al (1975), the oral calcium load test 
tended to reduce the distinction between hyperparathyroid and 
normal states. This finding provides further evidence that 
many parathyroid tumours are not autonomous, but rather that 
negative feedback regulation of PTH secretion by calcium is 
still possible, albeit at an abnormally high calcium level 
(Monchik et al, 1977; Shaw et al, 1977). 
Shaw and coworkers (1977) infused calcium into normal 
supjects in order to determine an upper limit of cyclic AMP 
excretion (4 fmol/g crea tinin.e) which was consistent with 
suppressed parathyroid function. This information was valuable 
in the assessment of inappropriate cyclic AMP excretion in the 
presence of hypercalcaemia. A similar approach was used in 
the present study. The cyclic AMP/creatinine ratios in post 
calcium load urine samples from control subjects were assumed 
·to be representative of .a state of suppressed parathyroid 
activity. The upper limit of normal after calcium intake 
(4.7 ｾｯｬ＠ cyclic AMP/g creatinine) was then used to interpret 
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the fasting urinary cyclic AMP excretion in hypercalcaemic subjects. 
This method of assessing inappropriate PTH secretion was more 
successful in identifying parathyroid adenoma patients than the 
comparison of post-load cyclic AMP excretions (Table 4.4D). One 
patient with a confirmed parathyroid adenoma had normal fasting 
cyclic AMP excretion. This finding can be explained by the fact 
that the patient had poor renal function, which is known to result 
in diminished urinary cyclic AMP responses to PTH stimulation 
(Taylor et al, 1970). Renal function, as judged by creatinine 
clearance, was normal in the three patients in hyperparathyroid 
group 2 who had normal fasting urina·ry cyclic AMP levels. 
However, two of these patients had borderline serum PTH levels 
(0. 6 ng/ml) . Results indicate that a two-hour fasting urine 
cyclic AMP/creatinine ratio of more than 4.7 ｾｭｯｬＯｧ＠ in a hyper-
calcaemic patient is strongly suggestive of inappropriate PTH 
ｳ･｣ｲ･ｴｩｯｾＮ＠ However, although cyclic AMP measurements are more 
convenient than PTH analyses, there is no evidence that cyclic 
AMP output is any better a predictor of primary ｨｾｰ｡ｲ｡ｴｨｹｲｯｩ､ｩｳｭ＠
than serum calcium and PTH estimations. The true test of the 
value of cyclic AMP analyses would be if they could confirm the 
presence of a tumour in a situation where serum ·calcium and PTH 
results were equivocal. One patient in the present study had 
a cyclic AMP excretion which was compatible with primary hyper-
parathyroidism, with normal serum calcium and PTH levels. 
However, the significance of increased cyclic AMP output in this 
situation would only be determined by exploratory surgery. 
Urinary cyclic GMP levels were not as useful in the 
identification of hyperparathyroid patients. Two patients 
with non-PTH mediated hypercalcaemia had elevated cyclic GMP 
excretion with normal cyclic AMP output. This suggests that 
cyclic GMP excretion is closely associated with hypercalcaemia 
whether or not this is due to inappropriate PTH secretion. The 
association between urinary cyclic GMP and hypercalcaemia has 
been reported by Kaminsky et al (1970a) and by Murad (1973) 
although the reasons for this are not clear. Calcitonin 
infusion does not elevate urinary cyclic GMP levels in normal 
subjects, although it does increase plasma and urine cyclicAMP 
concentrations · (Kaminsky et al, 1970a). Since calcium ion has 
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a regulatory influence on cyclic GMP production in some tissues 
(Schultz et al, 1973; Butcher, 1975) it is possible that 
--
increased extracellular fluid calcium concentrations could 
s·timula te increased production of cyclic GMP in the kidney or 
other tissues. Alternatively, other agents such as osteoclastic 
factor (Mundy et al, 1974) or prostaglandin E (Robertson and 
Baylink1 1975) which have been associated with hypercalcaemia in 
malignant disease could possibly alter cyclic GMP metabolism 
without influencing cyclic AMP. One hypercalcaemic patient, 
Mrs. Tucker, had very high urinary cyclic GMP excretion with no 
other abnormal biochemical findings. Three other members of 
this patient's family, the father and two of three brothers, have 
a history of hypercalcaemia with very few clinical symptoms. One 
brother has had an unsuccessful parathyroid exploration. There 
.is a report in the literature of 'familial benign hypercalcaemia' 
(Foley .et al, 1972). This disorder was inherited as an autosomal 
dominant trait and was associated with normal or decreased plasma 
phosphate levels and normal serum PTH concentrations. 
The renal tissue contribution to urinary cyclic GMP 
excretion was calculated for Mrs. Tucker by subtracting the 
fraction contributed by glomerular filtration of plasma from the 
total excretion. Cyclic GMP output derived from plasma was 
estimated from creatinine clearances and plasma cyclic GMP 
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concentrations. 94% of urinary cyclic GMP in the fasting specimen, 
and 98% in the post calcium load specimen were contributed directly 
from the kidney. Corresponding values for cyclic AMP were 26% 
(fasting urine) and 13% (post load specimen). It is clear that 
hypercalcaemia in this patient is associated with marked 
elevation in renal cyclic GMP production. Although this could 
be secondary to the hypercalcaemia, it is possible that there 
may be an inherited abnormality associated with increased calcium 
resorption (and increased cyclic GMP production) without 
corresponding increases in cyclic AMP production. Studies on 
[ 45 ] Ca efflux from isolated rat renal tubules in response to PTH 
stimulation have shown that, although cyclic AMP levels increase 
more rapidly than cyclic GMP levels, . the delayed rise in cyclic 
GMP correlated very closely with the actual transfer of calcium 
from the tubule cells (Biddulph and Wrenn, 1977). Investigations 
on the other members of Mrs.· Tucker's family will be of interest. 
Normally, high serum calcium levels inhibit PTH secretion, 
and this interaction results in a negative correlation between 
serum calcium and PTH concentrations (Berson apd Yalow, 1966: 
Arnaud et al, 1971; Shaw et al, 1977). The positive correlation 
between serum calcium and PTH levels in hyperparathyroid patients 
(Figure 4.4B) has also been noted by Pak et al (1974). and by 
Shaw et al (1977) and presumably reflects ･ｸ｣･ｾｳ＠ PTH drive in 
the absence of normal calcium negative feedback regulation. The 
existence of a significant correlation between serum PTH up to a 
level of 4 ng/ml and fasting cyclic AMP excretion (Figure 4.4C) 
is consistent with increased stimulation of the renal tubule by 
PTH. Three patients with serum PTH content in excess of 4 ng/ml 
had relatively low cyclic AMP excretion. This could be due to 
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the presence of an increased proportion of non-biologically active 
PTH (Arnaud et al, 1974: Segre et al, 1972) to the development of 
renal 'resistance' to high circulating PTH levels (Tomlinson et al, 
1976) or to hypercalcaemic nephropathy. One patient had 
impaired renal function; serum creatinine levels were not 
measured on the other two, although their urinary creatinine 
ｾｵｴｰｵｴ＠ was normal. Positive correlation between serum PTH and 
urinary cyclic AMP excretion has also been reported by Pak et al 
(1974) for hyperparathyroid patients. 
The marked negative correlation between serum PTH 
concentration and urinary cyclic GMP levels in patients with 
confirmed parathyroid adenomata (Figure 4.4D) implies that serum 
PTH concentrations greater than 2 ng/ml were inversely related to 
cyclic GMP excretion. A similar negative relationship was 
observed between serum calcium levels greater than 2.55 mmol/1 
and cyclic GMP excretion, although this was not statistically 
significant (Figure 4.4F). 
The negative correlation between serum PTH and urinary 
cyclic . GMP in parathyroid adenoma patients, although difficult 
to interpret, does afford a possible explanation for the fact 
that cyclic GMP excretion was often increased in hyperparathyroid 
patients after calcium ingestion. According to this inverse 
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relationship, an increase in urinary cyclic GMP output would be 
predicted when PTH secretion was reduced from a high level. The 
observation that urinary cyclic GMP did not increase after the 
calcium load in eight of nine control subjects and in two patients 
with non-PTH mediated hypercalcaemia argues against an explanation 
of increased cyclic GMP output as a direct result of increased 
serum calcium levels. 
- Ｍ Ｍ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠
Very high urinary cyclic AMP excretion (24 )Amol/g 
creatinine), was found in a patient with secondary hyperpara-
thyroid ism. Sovik et al (1976) have reported cyclic AMP/ 
ｾｲ･｡ｴｩｮｩｮ･＠ ratios of 30 ｾｭｯｬＯｧ＠ in a child with rickets. Cyclic 
AMP excretion in secondary hyperparathyroidism appears to be 
considerably higher than it is in primary hyperparathyroidism, 
although serum PTH levels are of similar magnitude in these two 
disease states (Woodhead and Walker, 1976). These findings 
could result from a greater proportion of biologically active 
PTH in the circulation or from greater renal responsiveness to 
PTH in secondary hyperparathyroidism. 
The present study has. shown that fasting urinary cyclic 
AMP levels, when interpreted relative to control data for 
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suppressed PTH secretion, ·are a reliable indicator of inappropriate 
PTH levels. This is true whether increased PTH levels are the 
result of ectopic production or of a parathyroid adenoma, provided 
that the patient has adequate renal function. Cyclic AMP 
excretion was not elevated in two cases of non-PTH mediated 
hypercalcaemia, although cyclic GMP output tended to be high in 
the presence of hypercalcaemia irrespective of the cause. This 
.investigation would. have benefitted from the measurement of serum 
phosphate and creatinine levels on all patients. Correction of 
urinary cyclic AMP output for glomerular filtration rate (Schmidt-
Gayk et al, 1977) or the calculation of •renal' cyclic AMP 
production {Babka et al, 1976: Drezner et al, 1976) have been 
claimed to give better separation between normal subjects and 
primary hyperparathyroid patients • -This approach may have been 
. useful in' the present study. However, the correction of total 
cyclic AMP excretion for cyclic AMP derived from plasma must 
·underestimate the renal component of cyclic AMP excretion, 
since a considerable fraction of plasma cyclic AMP also 
·arises from PTH action on the kidney (Broadus et al, 1970a). 
An assessment of the thyroid status of the patients in this 
study would have been desirable in view of the dependence of 
the renal cyclic AMP response to PTH on circulating thyroid 
hormone levels (Ashby et al, 1977). 
--
Urinary levels of cyclic GMP or cyclic AMP in patients 
with ｾｯｮＭｭ･ｴ｡ｳｴ｡ｳｩｳｩｮｧ＠ tumours of the lung, bronchus or 
oesophagus were no different from those found in a control 
group of patients before ｯｰｾｲ｡ｴｩｯｮ＠ (Figure 4.5). Bershtein 
and colleagues (1976) have reported no significant differences 
in cyclic AMP excretion in pqtients with breast or lung cancer 
and control subjects in a study of over 150 people. There are 
no .· reports in the literature of cyclic GMP excretion in patients 
with lung or oesophageal tumours. In contrast to the report 
of increased urinary cyclic GMP excretion in primary hepatoma 
patients (Neethling and Shanley, 1976) the re$ults of this 
investigation suggest that the presence of oesophageal or lung 
317 
cancer is not associated with altered cyclic nucleotide excretion.· 
·It seems probable , that increased urinary cyclic GMP output may 
only be associated with certain tumour types, and not with 
malignanqy in general. The large. variations in the relative 
concentrations of cyclic AMP and cyclic GMP in different tumours 
(Goldberg et al, 1975 ) also argue against the possibility of a 
common finding of increased extracellular fluid cyclic GMP 
concentrations for all tumour types. 
Cyclic GMP excretion increased after surgery, and was 
ｾｩｧｨ･ｲ＠ in patients with malignancy than in patients with non-
malignant disease. Higher cyclic GMP· output after the removal 
ｾＱＸ＠
of a tumour may reflect a· greater incidence of post-surgical 
complications with an associated stress to the patients. However, 
plasma cortisol levels were· not significantly increased in any 
group on the second and subsequent days after surgery (Table 4.5B). 
There was therefore no evidence of increased stress in the cancer 
patients after operation. Prolonged elevation of plasma cyclic 
AMP levels were associated with a continued elevation of plasma 
·cortisol in one patient studied by Gill et al (1975) who developed 
postoperative complications. 
The choice of urine collection days was not ideally suited 
to the observation of urinary cyclic AMP rises, which occur on 
the first and fifth days after surgery (Vitek et al, 1976). In 
view of this the absence of a significant increase in cyclic AMP 
output on days 2, 7 and 14 after surgery is not altogether 
surprising. The fact that cyclic GMP excretion was elevated on 
·these days indicates that postoperative excretion of this cyclic 
nucleotide may be more prolonged, or may occur later, than rises 
in cyclic AMP excretion. 
The observation that cancer of the lung or bronchus was 
not associated with altered cyclic nucleotide excretion is re-
inforced by the fact that five patients with similar tumours had 
normal ｰｬｾｳｭ｡＠ cyclic nucleotide levels (Table 4.6A). 
... - .. .. Ｍ ＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭｾ＠
High plasma cyclic GMP levels were found in association 
with cancer of the intestine (Table 4.6A) or with cachexia 
(Table 4.6B). To date, only angiotensin II (Rosman et al, 1976), 
calcium infusion (Kaminsky et al, 1970a) and adrenalin or nor-
adrenalin in the presence of propranolol (Ball et al, 1972) have 
been reported to increase human plasma cyclic GMP content. At 
present the evidence.suggests that high plasma cyclic GMP levels 
may be more closely associated with cachexia, whether or not 
this is due to malignant ､ｩｳ･｡ｳｾＬ＠ than with the presence of 
malignant tumours. However, two patients with carcinoma of the 
intestine who were reasonably well nourished also had elevated 
plasma cyclic GMP ｣ｯｮ｣･ｮｴｲ｡ｴｾｯｮｳＮ＠ The intestine has been 
identified as an important contributor to plasma cyclic GMP 
concentrations in the dog (Wehman et al, 1974) and high cyclic 
GMP levels have been reported in rat intestine (Ishikawa et al, 
19?9). _ Guanylate cyclase activity is concentrated in the tips 
of ｾｨ･＠ microvilli in the intestinal brush border of the rat 
(Quill and Weiser, 1975). This information, together with the 
observation that tumour tissue cyclic GMP/cyclic AMP ratios are 
increased in carcinoma of the colon (De-Rubertis et al, 1976), 
ﾷ｡､ｾ＠ weight to the hypothesis that the presence of malignancy in 
the intestine could result in an increased output of cyclic GMP 
into the circulation. 
At present there are few indications as to the source of 
the increased plasma cyclic GMP concentrations found in five of 
six patients with cachexia. Two possible factors which may be 
involved .are decreased activity of the intestinal mucosa or the 
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marked ｣ｨ｡ｾｧ･ｳ＠ in body metabolism which accompany a state of 
malnutrition with increased protein catabolism (Cahill, 1976). 
The liver could exert an influence either by increased output 
or decreased uptake of cyclic GMP, although the latter mechanism 
. 
would also tend to increase plasma cyclic AMP levels. The 
increased emphasis on ｬｩｾｯｬｹｳｩｳ＠ to provide fatty acid fuels for 
the liver during starvation may also be relevant in view of the 
rec.ent observation that arachidonic acid and related fatty acids 
can stimulate guanylate cyclase ·activity in several tissues 
(Goldberg and Haddox, 1977). 
· These preliminary findings suggest that the measurement 
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of urine and plasma cyclic nucleotide levels in patients suffering 
from malnutrition or malabsorption may be worthwhile. The 
determination of tissue cyclic nucleotide concentrations in 
starved animals would also be of value in the identification of 
·possible tissue sources. of plasma cyclic GMP. · A more detailed 
investigation of patients with tumours of the gastrointestinal 
tract and of patients with cachexia, whether associated with 
malignancy or not, is also indicated. 
Results from a study of urinary cyclic nucleotide levels 
in three patients recovering from asthma attacks revealed a 
tendency for urinary cyclic GMP/cyclic AMP ratios to fall during 
the recovery period. The decrease in cyclic GMP/cyclic AMP 
ratios was due to a rise in cyclic AMP output in· one patient, 
and to a fall in an initially high cyclic GMP excretion in the 
other two (Figure 4.7A). A second acute asthma attack in one 
patient was followed by a second rise in cyclic GMP excretion. 
There is no ' proof that urinary cyclic nucleotide changes in 
these patients were a reflection of lung cyclic nucleotide · 
metabolism, although the lung has been associated with net 
·addition of cyclic nucleotides to the circulation in dogs 
(Wehman et al, 1974). The cyclic nucleotide changes which 
were observed could alsci be directly related to different drug 
therapies rather than to inherent differences in cyclic nucleo-
tide metabolism; This tentative evidence that recovery from 
bronchospasm is associated with decreases in urinary cyclic GMP/ 
cyclic AMP ratios is compatible with the suggestion by Schultz 
and colleagues (1973) that bronchospasm is associated with an 
alteration of ·lung intrace:).lular cyclic nucleotide balance in 
favour of cyclic GMP. 
Normal subjects who regularly inhaled thej3-adrenergic 
agent salbutamol exhibited a marked attenuation of the broncho-
dilatory response and of the increases in plasma levels of 
intermediary metabolites following intravenous salbutamol 
challenge. In four of the six subjects ·this • resistance • to 
salbutamol challenge after regular salbutamol dosage was 
associated with significant decreases in plasma cyclic AMP 
responses while two subjects also had increased plasma cyclic 
GMP increments in association with the resistant state. The 
contribution made by the 1·ung to circulating cyclic nucleotide 
levels is not known: it is probable that the observed changes 
in plasma cyclic nucleotide levels were a result off-adrenergic 
stimulation of the liver and other tissues in general. 
321 
. . . ···---:-. ＭＭＭＭＭＭＭＭＭＭＭｾ｟ＮＭｯＡＧＢＡＢＢＢＢＡＧｾＭｾｾＧｐＡＡＢＢｾｾＭＭｾ＠
It is not clear why there were much smaller differences 
in plasma cyclic AMP increments in response to intravenous 
salbutamol between control and resistant states relative to 
.the bronchodilatory and metabolite changes. If the development 
of salbutamol resistance were confined to lung tissue it might 
be anticipated that plasma cyclic AMP levels would not reflect 
｣ｹ｣ｬｾ｣＠ nucleotide changes in this tissue to any great extent. 
Nevertheless the large differences in plasma metabolite and 
insulin responses suggest that 'resistance' to salbutamol is 
also present in the liver and possibly in the pancreas. It 
is possible that attenuation of the physiological and metabolic 
responses to salbutamol can. be achieved with a relatively small 
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change in intracellular cyclic AMP concentration. Alternatively, 
'resistance' could involve not only a 'down-regulation• of cell 
surface receptors, with a reduction in adenylate cyclase 
activity, but also the attenuation of the second messenger system 
at some stage following cyclic AMP generation. 
The results of a similar study on asthma sufferers, who 
show little tendency to develop resistance to the broncho-
dilatory effect of salbutamol, even on long term therapy (Holgate 
et al, 1977), will provide an interesting comparison to the 
findings in normal subjects . 
. . Urinary cyclic GMP/creatinine ratios in 23 hypertensive 
patients were no different from those in twelve normal subjects. 
Those results do not reflect the finding of Amer (1975) that 
increases in vascular smooth muscle tone found in hypertensive 
animals ｾ･ｲ･＠ associated with increases in vascular tissue cyclic 
__________________ __,;.. ____________ .... . .. . . - .. . -..... -- . 
GMP/cyclic AMP ratios, although it is quite possible that 
any such changes may not be paralleled by altered cyclic 
nucleotide excretion. Significant increases in urinary cyclic 
. 
. AMP/creatinine ratios in male hypertensive patients relative to 
healthy male subjects are compatible with the evidence of 
Messerli.et al (1976) that mild hyper-tension is associated with 
increased plasma cyclic AMP responses ｴｯｾＭ｡､ｲ･ｮ･ｲｧｩ｣＠ stimulation. 
The finding of significantly elevated cyclic AMP excretion in 
male hypertensive patients must be interpreted with some caution, 
however, in view of the rather low cyclic AMP excretions 
measured in six healthy male subjects relative to published data . 
(Table 1.3B) and relative to control data in the calcium load 
test and cancer studies (Sections 4.4 and 4.5). This study was 
unsatisfactory for several reasons. Control subjects and 
hypertensive patients were not age matched, and individual 
variations in cyclic AMP and cyclic GMP excretion throughout the 
day make the interpretation of data from morning urine specimens 
rather difficult. Only four patients were not receiving drug 
therapy, and the variety of treatment regimes used for the 
remaining patients introduce an added complexity into the inter-
pretation of results. Improvements in the study protocol would 
include the collection of 24 hr urine specimens, the investigation 
of a large number of ｰ｡ｴｩ･ｮｾｳ＠ before the commencement of treatment, 
and comparison of the results with data from age matched control 
subjects. 
Comparison of urinary cyclic nucleotide levels in patients 
with very ｨｾｧｨ＠ or very low urinary corticosteroid excretion has 
not revealed any significant differences in urinary cyclic AMP 
ＭＭＭＭｬｬｬｬｬｬｩＡＮＭＭｾＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭＭ Ｍ ﾷﾷＭﾷ ﾷＭ . -·· 
or cyclic GMP excretion, although there was some indication 
that cyclic AMP/creatinine ratios were lower when corticosteroid 
output was high (Figure 4.9B). These observations are in 
·accord with the . report of Williams et al (1972) that neither 
ACTH nor cortisol exerted a definite influence on urinary cyclic 
AMP excretion. The lack of a consistent pattern in urinary 
cyGlic AMP response to ACTH (Figure 4.9A) is again in agreement 
with Williams et al {1972) but contrasts with the recent paper 
of Raij (1977) which described increases in urinary cyclic AMP 
,following ACTH stimulation. The results of Raij may not be 
directly comparable, since ｳｹｮｴｨ･ｴｩ｣ｾＨｬＭＲＴＩ＠ ACTH was infused 
over a period of eight hours, and cyclic AMP was determined by 
an enzymatic technique. 
There is little information in the literature concerning 
cyclic GMP changes following ACTH stimulation.. In the present 
study, three patients who responded normally to ACTH with a 
prompt rise in corticosteroid excretion all produced a rise 
in urinary cyclic GMP/creatinine ratios. The reason for this 
is not clear. Possible influencing factors are the action of 
ACTH on the adrenal and other target tissues such as adipocytes, 
smooth muscle or kidney, or the interaction of corticosteroids 
·with their many target organs. The finding of a very similar 
cyclic GMP excretion response in one patient during a dexa-
methasone suppression test could imply that it is corticosteroids 
which are responsible for increased cyclic GMP output. 
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Both. hypophysectomy and adrenalectomy have been associated 
with a reduced cyclic GMP excretion in rats {Hardman et al, 1969). 
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The effects of adrenalectomy were corrected by cortisol therapy, 
suggesting that it may be glucocorticoids rather than ACTH 
which are capable of increasing urinary cyclic GMP excretion. 
Apart from the rises in urinary cyclic GMP/creatinine 
ratios during ACTH treatment, there is little evidence in the 
present study for any strong influence of adrenocortical status 
on urinary cyclic nucleotide excretion. 
The observations of Tucci and Kopp (1976) that urinary 
cyclic nucleotide/creatinine ｲｾｴｩｯｳ＠ were increased in patients 
with hyperthyroidism prompted an investigation into the influence 
of hypffiXhyroidism on plasma cyclic nucleotide levels. The 
· ·finding of significant increases in plasma cyclic AMP concentration 
in five hyperthyroid patients (mean ·level 19.7 nmol/1) relative 
to eleven healthy subjects (mean cyclic AMP 11.7 nmol/1) is in-
close agreement with published data. Karlberg et al (1974) 
--
report-ed plasma cyclic AMP levels of 10.7 nmo1/1 and 23.6 nmo1/l 
for .euthyroid and hyperthyroid subjects respectively. Corresponding 
values published by Ashby et al (1977) were 10.5 and 16.3 nmol/1. 
Plasma cyclic GMP concentrations in the five hyperthyroid patients 
were not significantly different from normal. Plasma cyclic GMP 
levels in thyrotoxic patients have not been reported to date. 
This investigation indicates that, in contrast to the situation 
with cyclic AMP, increased urinary cyclic GMP/creatinine ratios 
in this disease (Tucci and Kopp, 1976) are not associated with a 
corresponding rise in plasma cyclic GMP concentrations. 
The cause of the increase in plasma cyclic AMP content in 
. hyperthyroidism has not been established. The evidence available 
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at present suggests that plasma cyclic AMP rises may be 
secondary to a generalised increase in the 'permissive' influence 
of thyroid hormones on second messenger systems in many tissues, 
rather than by a direct stimulation of cyclic AMP production in 
target cells. Thyroid hormones potentiate the actions of 
glucagon and adrenalin op liver and adipose tissue (Gumaa et al, 
1977) and exaggerated urinary cyclic AMP rises have been 
observed following adrenalin infusion into thyrotoxic patients 
(Guttler et al, 1975). The discovery of a direct correlation 
between free thyroxine index and plasma cyclic AMP response to 
PTH (Ashby et al, 1977) indicates that enhanced action of PTH 
on the kidney could also contribute to plasma cyclic AMP levels 
in thyrotoxicosis. 
The analysis of 'blank' plasma specimens from hyperthyroid 
patients has demonstrated that levels of both cyclic AMP and 
cyclic GMP were undetectable in all patients, a finding in common 
with results from the analysis of similar 'blank' specimens from 
normal subjects (Section 3.5.3). 
Plasma cyclic AMP increases following the administration 
of glucagon have been well documented (Kaminsky et al, ＱＹＷＰｾ＠
Broadus et al, 1970b; Davies et al, ＱＹＷＶｾ＠ Francavilla et al, 
1977; Brooks et al, 1977). These increases, although they 
parallel increases in cyclic AMP in · several tissues (Murad, 1973) 
are most probably due to the action of glucagon on the liver 
(Broadus et al, 1970b}. The observation that plasma cyclic AMP 
levels were increased in a patient with glucagonoma represents 
the first report of raised plasma cyclic AMP content'resulting 
--------------------------------'------ -- --- - - - -·· - -
from excessive endogenous production of glucagon. The fact 
that plasma cyclic AMP concentration was only doubled relative 
to normal levels in the presence of a ten-fold increase in plasma 
glucagon levels may indicate that either there is an increased 
proportion of biologically inactive glucagon in the plasma, or 
that there was some degree of hepatic resistance to glucagon 
in this patient. Constant hepatic stimulation by glucagon 
impairs the ｣ｹ｣ｬｾ｣＠ AMP response (Liljenquist et al, 1974; De-
Rubertis and Craven, 1976) and a marked and rapid attentuation 
of plasma cyclic AMP rises in response to an infusion .or to 
sequential injections of glucagon in normal ｳｵ｢ｪｾ｣ｴｳ＠ has been 
described (Hendy et al, 1977). The observation that plasma 
cyclic GMP levels were normal in the presence of a glucagonoma 
is in accordance with reports of the lack of influence of 
glucagon on cyclic GMP levels in hepatic and cardiac tissues 
(Goldberg et al, 1967; ｓｴ･ｾｮ･ｲ＠ et al, 1970; Kuo et al, 1972) 
or in plasma (Brooks et al, 1977). 
In conclusion, fasting urinary cyclic AMP measurements 
have been valuable in the identification of hyperparathyroioism 
in addition to the established value of urine or plasma cyclic 
AMP analyses in the diagnosis of pseudohypoparathyroidism. At 
present few disease states have been identified in which extra-
cellular fluid cyclic GMP ｭｾ｡ｳｵｲ･ｭ･ｮｴｳ＠ would be of diagnostic 
value. The most promising lines of investigation appear to be 
the study of plasma and urinary cyclic GMP levels . in gastro-
intestinal and certain other types of cancer, and in cachexia. 
In addition, parallel measurements of cyclic AMP and cyclic GMP 
levels in tissues and extracellular fluids will continue to be 
of value as a guide to the mechanism of hormone influence on cell 
metabolism. 
Although it is fifteen years since cyclic GMP was first 
identified, there is still no clearly defined scheme for its 
influence on cell function, and the role of cyclic GMP as an 
alternative second messenger to cyclic AMP is still the subject 
of some controversy. This lack of understanding of the complex 
cellular events and regulatory controls which are operating 
hinders the interpretation of clinical data. Much has still 
to be discovered about the factors which influence tissue and 
extracellular cyclic GMP levels in health and disease. 
For the future, the development of convenient assay 
methods for cyclic UMP and cyclic CMP may enable the inter-
relationships between cyclic nucleotides to be clarified, 
particularly in cell proliferative processes. Plasma cPDE 
activity, if it were variable, could be an important determinant 
of plasma cyclic nucleotide levels. To date, little attention 
has been paid to plasma cPDE activities in disease. A study of 
the enzyme and its possible isoenzymes in plasma would assist in 
·the interpretation of changes in plasma cyclic nucleotide levels, 
while an evaluation of cPDE enzyme activity as a diagnostic 
indicator of tissue damage may well be worthwhile. 
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Direct measurement of cGMP in blood plasma and 
urine by radioimmunoassay 
P. J. WOOD* AND V. MARKS 
From the Department of Biochemistry, University of Surrey, Gui/dford 
SUMMARY Antisera, raised against 2'-0-succinyl-cGMP conjugated to ovalbutnin or kehole ｬｩｴｮｾ･ｴ＠
haetnocyanin, have been used to develop radioimmunoassays for the direct ､･ｴ･ｲｭｾｮ｡ｴｩｯｮ＠ of ｵｲｵｾ･＠
and plasma cGMP levels. Details of these assays are presented, together with evtdence for thetr 
validity. 
cG MP·r has becon1e the subject of considerable 
interest during the last five years as an alterpative 
'second messenger' to cAMPt for the actions of some 
hormones. There is now evidence that cholinergic 
and cx.-adrenergic stin1ulation and the actions of 
certain peptide hormones-such as cholecysto-
kinin, histamine, and possibly insulin-are mediated 
by an increase in the intracellular level of cGMP 
rather than of cAMP (Nature, 1973). In smne 
tissues, changes in the cAMP/cGMP ratio tnay 
detern1ine the nature of the response to hormone 
stimulation (Goldberg et a/., 1975), and it should, 
therefore, be of interest to be able to n1onitor both 
cyclic nucleotides in tissues and extracellular fluids. 
In mamn1alian tissues cGMP is present at ap-
proximately one-tenth to one-hundredth the con-
centration of cAMP. Human plasn1a and urine 
cGMP/cAMP ratios are approxitnately 1:2 and 
1:10 respectively. Consequently, an assay systen1 
of high sensitivity as well as of high specificity is 
required to measure cG MP in the presence of cAMP 
and other nucleotides, 
Protein-binding assays for cGMP, which utilise 
tracellular receptor proteins frotn lobster tail 
scle (Murad et al., 1971}, silktnoth pupae 
and Wyatt, 1975}, or rat lung (Kobayashi 
and Fang, 1975) lack sensitivity and are not specific 
enough to be used for the analysis of tissue extracts 
without preliminary nucleotide fractionation. 
The measurement of cG MP by radioimmunoassay 
(Steiner eta/., 1972b) has the advantages of greater 
sensitivity and specificity over protein-binding 
*Present address: Department of Chemical Pathology 
Southampton General Hospital, Southampton 
tcGMP is used as the abbreviation for guanosine-3'5'-cyclic 
phosphate, cAMP as the abbreviation for adenosine-3'5'-
cyclic phosphate 
tnethods and for this reason it was decided to develop 
such an assay system. 
Materials and methods 
ANTISERUM PRODUCTION 
2'-0-Succinyl cGMP (a gift fron1 the Boehringer 
Corporation) was conjugated to ovalbun1in (Sigtna 
Fraction V) or to kehole limpet haemocyanin (Cal-
Biochenl) using the carbodiimide 'EDC' (1-ethyl-3 
(3-ditnethyl-amino-propyl)-carbodiinlide HCl) in 
accordance with the tnethod of Steiner et al. (1972b). 
The conjugates were esthnated by n1aking spectro-
scopic tneasurements of solutions of the conjugates, 
unconjugated 2 '-0-succinyl cG MP, and proteins, to 
contain six tnolecules of cGMP per molecule of 
ovalbumin or 160 molecules of cG MP per n1olecule 
of kehole litnpet haemocyanin (average tnol. wt. 3 
25 
x 100 Daltons). The conjugates were stored ｦｾ･･ｺ･ﾭ
dried in aliquots containing 1 mg protein. 
Five white half-lop rabbits (Ranch Rabbits Ltd) 
were each given a primary imn1unisation in six 
intran1usctllar sites with a total of 1 mg of the 
2 '-0-succinyl cG MP-0valbumin conjugate per rabbit. 
The conjugate was dissolved in sterile water and 
etnulsified in two volumes of 'Marco! 52' adjuvant 
(Marks et al., 1974) containing Bacillus Calmette 
Guerin (BCG; 3 mg/Ing conjugate). The rabbits were 
given seven boosts at 1nonthly intervals using the 
same regimen, but with the on1ission of BCG fron1 
the adjuvant. Blood samples were taken from an ･ｾｲ＠
vein 10 days after each boost. Because serun1 anti-
body titres retnained very low on this regimen, the 
2 '-0-succinyl cGMP-kehole lin1pet haetnocyanin 
conjugate, suspended in the satne ｡､ｪｵｾ｡ｮｴ＠ systen1 
as before, was then used to boost the rabbits (0·25 mg 
protein per rabbit given as six intramuscular 
·' 
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injections). After the second n1onthly boost with 
this conjugate, antibody titres rose to between 1 in 
50 to 1 in 100 (working dilution). Antisera fron1 two 
of the rabbits, T2 and T5, proved highly specific for 
cGMP. These were diluted 1 in 5 with buffer (50 
mmol/1 Tris, pH 7·5, containing theophylline 
8 tnmol/1 and 2-mercaptoethanol 6 n1moljl) and 
stored freeze-dried in small aliquots. 
CHARACTERISATION OF ANTISERA T2 AND 
T5 
The influence of pH on the binding of BH cGMP 
was studied over the pH range 3·5 to 9·0 using 
50 n1mol/l acetate, phosphate, or Tris buffers 
containing theophylline (8 mn1ol/l) and 2-n1ercapto 
ethanol (6 tntnol/1). The two antisera differed in 
their ability to bind the label at different pHs. 
Antiserun1 T2 showed a steady level of binding over 
the pH range 4·5 to 9·0, while antiserum T5 showed 
increased binding at pH 4·5. Further studies on the 
properties of both antisera were carried out at pH 
7 · 5, using the assay protocol described below for the 
analysis of urine (Table 1). 
The length of incubation had little effect on the 
standard curve for either antiserum. Incubations of 
5, 30, 60, 90, or 180 minutes yielded very sin1ilar 
standard curves, and the S-n1inute and 3-hour 
incubation standard curves were not significantly 
different when compared by a paired Student's t test 
on the standard points. Test results for incubations 
of less than 30 minutes were unreliable, however. 
An incubation titne of three hours was routinely 
used for the analysis of test samples. 
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Table 1 cGMP radioimmunoassay protocol: 
specimens. Incubatiolls in duplicate polystyrene 
tubes (Luckham Ltd: type LP3) 
urine 
Additions (f.l.l) Tests Standards Non·specific 
binding 
(NSB) 
Assay buffer (Tris 50 mmol/1, 100 100 300 
pH 7·5, containing disodium 
EDTA, 4 mmol/1) 
Test urine (Diluted 1 in 20 100 
in assay buffer) 
Standards (0-10 pmol cGMP 100 
per 100 fJ.) in assay buffer) 
[8-3H] cGMP 
(Amersham TRK 392; 1 pmol/50 50 50 50 
fJ.} in assay buffer) 
Antiserum (T2 or T5; working 100 100 
dilution 1 in 50 in assay 
bufter) 
Mix, incubate for 3 hours 
at 4 °C, then add : 
Bovine 'Y globulin 10 10 10 
(Sigma fraction II; 10 mg/ml 
assay buffer) 
ＨｎｈｾｨｓＰＴ＠ Solution 1·0 ml 1·0 ml 1·0 ml 
(Ice-cold; 3·8 mol/1) 
Mix, leave at 4°C for 10 min, centrifuge for 30 min at 1800 g 
(Mistral4L Centrifuge). Aspirate supernatants and redissolve 
precipitates in 1·0 ml distilled water. Mix and take 0·5 ml 
aliquots for liquid scintillation counting. 
Scatchard plots of the data fron1 five standard 
curves using antiserum T5 were linear, and were 
interpreted in terms of a single antibody population 
with a mean dissociation constant Kn = 3·1 x 10-9 
n1ol/l. A similar treatment of the data fron1 two 
standard curves using antiserutn T2 yielded curved 
Scatchard plots which could be interpreted in terms 
K I 
10000 
Cross-reactivity of 17 .nucleotides 
with antiserum T5 determined 
using the incubation procedure 
described in Table 1. 
A: 2'-0-succinyl-3'5' cGMP 
B: 3'5' cGMP 
C: monobutyryl-3'5' cUMP 
D: dibutyryl-3'5'-cAMP 
E: dibutyryl-3'5'·cGMP 
F: 3'5'ciMP 
G: 3'5' cAMP 
H: 3'5' cTMP 
I: 3'5' cCMP 
J: 3'5' cUMP 
K: Mean result (± s.e.m.) for 
5'-AMP, 5'-ATP, 5'GTP, 
2'3' cAMP, 
2'3' cGMP, AMP-PNP, 
GMP-PNP. 
i: Mean result (± s.e.m.)-nucleo-
... tides which are not plotted 
individually. 
-----------------------------------------------------------------------.---.--------------------- - ---
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I 00 J.tl aliquots from 11 normal urine samples were incubated 
with 100 1-'1 phosphate buffer (0·5 moljl, pH 7·5) and 20 1-'1 
(0·03 U) ox-heart phosphodiesterase (Boehringer) for 1 hour 
at 37°C. Reaction tubes were then placed in a boiling water 
bath for 10 minutes. Incubation mixtures were made to 
2·0 ml and their cGMP content was determined using anti-
serum T2 . 
cGMP levels in plasma from 18 normal subjects, coiJected 
with or without disodium EDTA. EDTA-plasma was stored 
at - 20°C, while 'blank' samples were left at room temperature 
overnight (for details see the text) . 
Fig. 2 (top) 'Blank' urine levels,· (bottom) 'Blank' plasma levels. 
of two antibody populations with tnean dissociation 
constants Kn1 = 1·0 x 10-9 mol/1 and Kn2 = 1·8 
x 10-8 mol/1. Figure 1 illustrates the cross-
reactivities of 17 nucleotides in the assay system 
using antisermn T5. Shnilar results were obtained 
with T2 (not shown). In particular cAMP was 
10 000 times less potent in displacing the [3H] cGMP 
label from the antisermn than was cG MP. 
cGMP assay protocol-ul'ine analysis 
Details of the assay protocol for the analysis of 
urine and protein free tissue extracts are shown in 
Table 1. The addition of 10 ,ul of a solution of 
bovine y-globulin (Sigma Fraction II; 10 mg/nll) as a 
'carrier' protein, before the precipitation of bound 
radioactivity with amtnonium sulphate increased 
the precision of results for duplicate analyses. 
ｉ ｾＧ＠ Half-millilitre aliquots from the dissolved pre-
cipitates were transferred to 'tninivials' (G.D. Searle 
and Co.), mixed with 4·0 ml of toluene-'Synperonic-
NXP' scintillant (Wood et al., 1975), and the tritium 
t content tneasured on an LKB 'Ultrabeta 1210' liquid 
scintillation counter with an efficiency of 35 %. 
Initially a Tris-mercaptoethanol buffer con-
taining theophylline, a less potent inhibitor of 
cyclic nucleotide phosphodiesterase than EDT A, 
was used as the assay buffer. Standard curves for 
incubations with the two buffer systetns were ident-
ical, and no change in the cG MP levels measured in 
four urine quality control pools was observed as a 
result of the change to the Tris/EDT A buffer. 
There was no evidence of rapid degradation of 
cGMP, and samples showed no loss of cGMP 
content after being left at either room temperature 
or at 4 °C for periods of up to five days. Nevertheless, 
quality controls and urine specimens for clinical 
investigation were stored at - 20°C before analysis. 
VALIDATION OF THE URINE ASSAY 
Recovery of cG MP (2 ,umol/1) added to urine 
san1ples fron1 10 normal subjects was 95·2 ± 2·6% 
(mean ± s.e.tn.) and 94·1 ± 2·1% with antisera T5 
and T2 respectively. The analysis of a high test urine 
gave results which were independent of the urine 
dilution, provided the individual assay values fell 
within the range 0·1-10 pn1ol cGMP per tube. 
Detection lin1its calculated by the method of 
Ekins (1974) for assays using either antiserum T2 or 
T5, were both in the region of 0·08 pmol cGMP per 
tube. Treatment of urine samples from 11 normal 
subjects with ox-heart phosphodiesterase reduced 
the n1easured cGMP levels to below the detection 
limit in every case (Fig. 2, top). 
A cotnparison of the results of analyses for cG MP 
in urine obtained using two radioimtnunoassays 
employing antiserum T2 and antiserum T5, and a 
specific locust protein binding assay (Wood et al., 
1976) showed close agreement between all three 
tnethods (Table 2). 
Interassay coefficients of variation for radio-
ilnnlunoassay using either antiserum T2 or T5 
--------------------------------- ---- --- -
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varied between 4·2% and 8·7% for test levels in the 
range 0·9 to 8·7 pmol cGMP per tube. 
Table 2 Correlation between cGMP levels measured 
by three different assay systems. Test urines were 
diluted 1 in 20 for analysis 
X y M c No. of 
pmol/wbe For regression Corl'elation data 
equation coefficient points 
Y = MX + C R N 
Locust CPB v. t ·085- 0·218 0·969 28 
Radioimmunoassay T5 
Locust CPB v. 0·999+0·163 0·964 20 
Radioimmunoassay T2 
Radioimmunoassay T2 v. 0·996-0·213 0·963 20 
Radioimmunoassay T5 
A DIRECT RADIOIMMUNOASSAY FOR 
PLASMA CGMP 
Amn1onimn sulphate precipitation of the bound 
counts created probletns when plasma or other 
types of sample with a high protein content were 
analysed. Considerable atnounts of the reagent were 
trapped in the bulky protein pellet and the addition 
of an aliquot of the resuspended pellet to the 
scintillation mediun1 produced a dense white 
precipitate. To overcotne these difficulties a direct 
plasma radioiminunoassay, using second antibody 
separation of bound counts, was developed. The 
protocol for this tnethod is set out in Table 3. 
Table 3 Plasma cGMP radioimmunoassay protocol 
Additions (p,l) Test 
(p,l) 
Assay buffer 100 
(Tris 50 mmol/1 pH 7·5 
+ disodium EDTA 4 mmol/l) 
Assay buffer + standard 
(0-10 pmol/tube) 
'Stripped' plasma 
Test plasma 200 
[8-3HJ cGMP (Amersham 50 
TRK 392) 1 pmol/50 p,l 
First antibody (Antiserum T5, 100 
working dilution 1 in 50) 
Incubate for 3 hours at 4 °C, 
then add: 
Second antibody (Donkey anti- 100 
rabbit LgG Guildhay 
HPD5-11F) 
Incubate overnight at 4 oc. 
Standards Non-specific 
(p,l) binding (NSB) 
(p,l) 
200 
100 
200 200 
50 50 
100 
100 100 
Centrifuge, aspirate supernatants, resuspend precipitates in 
0·6 ml saline (9 g/1), mix. Remove 0·5 ml aliquot for liquid 
scintillation counting (as for the urine assay). 
cGMP-free plasma, used in standard tubes to 
compensate for protein effects on the assay, was 
prepared by charcoal 'stripping' plastna. 
Plasma was separated fron1 acid-citrate-dextrose 
P. J. Wood and V. Marks 
blood which, because of age, was no longer suitable 
for transfusion, and stirred with Norit A charcoal 
(20 g/100 ml plastna) for 24 hours at 4 °C. The 
mixture was centrifuged and the supernatant plastna 
vacuum filtered through a Seitz bacteriological 
filter. The clear plasma was tnixed with 0·5 mol/1 
EDTA (pH 7 · 5) to give a final EDTA concentration 
of 5 mmol/1 plastna, and stnall aliquots were stored 
at - 20°C until required. 
Blood satnples for cGMP analysis were coiiected 
into lithiun1 heparin tubes (10 iu lithium heparin/ml 
blood) containing 1 % of the blood volume of 0· 5 
tnoljl EDTA (pH 7·5) to prevent cyclic nucleotide 
degradation by endogenous cyclic nucleotide phos-
phodiesterase enzytne. Plasn1a was quickly separated 
and stored at - 20°C. 
VALIDATION OF THE PLASMA ASSAY 
To test the specificity of the assay, blood samples 
were taken from 18 nonnal subjects and each 
specitnen was divided into two. Half was added to a 
lithiun1 heparin tube containing EDTA, the plasma 
was separated and stored frozen; the other half was 
taken into heparin alone, and the plasma, after 
separation, was left overnight at roon1 temperature. 
In each case the endogenous phosphodiesterase 
present in the satnples left overnight at room 
tetnperature reduced cG MP levels to below the 
detection limit of the n1ethod, calculated to be 
0·05 ptnol per tube or 0·25 pmol per ml of plastna 
(Fig. 2, bottmn). 
Recovery of cGMP (6 ptnoljtube) added to 18 
plastna samples was 98·1 ± 2·0% (mean ± s.e.m.). 
The tnethod as described was also satisfactory with 
regard to parallelistn of the results with the standard 
curve when high test plasn1as were analysed at 
different dilutions in stripped plastna. 
Five plasn1a samples were extracted with ethanol, 
the extracts were dried, and the residues taken up 
in assay buffer according to the method of Brown 
eta!. (1971). These extracts were then analysed for 
cG MP by radioirmnunoassay, using standards 
n1ade up in a similar extract of stripped plasma. 
There was good agreement between results obtained 
after ethanol extraction and by direct plasma assay 
(Table 4). 
Table 4 Results for the analysis offive plasma 
samples by direct radioimmunoassay and by radio-
immunoassay of ethanol extracts ofplasma 
Plasma sample cGMP (pmol/ml plasnw) 
I 2 3 4 
Dit'ect radioimtnuno- 1·0 4·9 9·0 11·3 
assay 
Ethanol extraction 1·3 5·0 9·3 10·3 
5 
28·0 
26·0 
------------------------------ ------ - ----
\o 
... 
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CGMP LEVELS IN NOR MAL HUMAN URINE 
AND PLASMA 
Concentrations of cAMP and cGMP found in the 
same spechnens of urine and of plasn1a from nonnal 
subjects are shown in Table 5. Urinary cAMP 
concentrations were detennined by the tnethod of 
Brown et a/. (1971), plasma cAMP content was 
tneasured using the n1ethod of Tovey eta/. (1974) 
(Atnershanl kits; TRK 432), and cGMP by the 
methods described above. 
Table 5 Cyclic nucleotide levels in normal subjects, 
urinary cyclic nucleotides (morning urine specimens) 
12 Normal subjects (6 men, 6 women) 
Mean 
cGMP 0·41 
cAMP 1·69 
cGMP 
cAMP 0·27 
Plasma cyclic mtcleotides 
Range 
0·26-0·66 Mmol/g creatinine 
0·83-3·23 Mmol/g creatinine 
0·12-0·47 
No. of subjects !vfean Range 
cGMP 30 
cAMP ll 
cGMP 
cAMP 11 
Discussion 
5·1 
11·7 
0·57 
1·5-10·6 pmol/ml 
7·2-18·0 pmol/ml 
0·24-0·77 
The factors which influence the production of 
specific, high titre antisera are still poorly under-
stood. There is smne evidence fron1 this study that 
2'-0-succinyl cGMP conjugated to kehole lin1pet 
haetnocyanin, itself a highly imtnunogenic protein, 
may have elicited a better iffilnune response to the 
hapten cGMP than did the ovalbumin conjugate. 
Both the antisera, T2 and T5, chosen for investi-
gation for their potential use in radioimtnunoassay 
were found to be ren1arkably specific for cGMP. Of 
the four other cyclic nucleotides, ciMP cross-reacted 
to the greatest extent. This is probably of little 
practical hnportance. Steiner et a/. (1970) were 
unable, using a specific radiohnmunoassay, to 
detect ciMP in tissue san1ples. cUMP and cCMP 
have, however, recently been isolated fron1 rat liver 
and other tissues (Bloch, 1975a,b). Synthetic 
butyrated cyclic nucleotides cross-reacted to a 
measurable degree in the assay procedure. This was 
not altogether surprising, since one of the positions 
of substitution of the butyryl group is the 2' 
position on the ribose ring, which is the point on the 
cGMP n1olecule through which it was linked, via a 
succinyl group, to protein before imtnunisation. 
Succinyl-cyclic-GMP was 10 tin1es more potent in 
displacing labelled cGMP fron1 antibody binding 
than was cGMP itself. There is, therefore, the poten-
tial to develop assays of even greater sensitivity than 
those described here by the introduction of initial 
succinylation for test satnples. 
The values for norn1al urine and plastna cGMP 
levels obtained with the present n1ethod agree well 
with published data (Murad and Pak, 1972; Steiner 
et a/., 1972a; Lebeau et a/., 1975; Neethling and 
Shanley, 1976; Rosman eta!., 1976; Rudman eta/., 
1976; Siddle et a!., 1976). 
The high specificity of the antisera towards cG MP 
alone among naturally occurring con1pounds pern1its 
direct analysis of urine and plastna san1ples. This 
is in contrast to all previous n1ethods for n1easuring 
plastna cG MP, which have required preliminary 
extraction of test satnples. It tnay also prove possible 
to analyse tissue hon1ogenates for cGMP without 
preliminary nucleotide fractionation, but this has 
still not been tested. 
The results indicate that there is little need to 
analyse individual 'blank' plasn1a samples, collected 
in the absence of a phosphodiesterase inhibitor, at 
least fo1· nonnal subjects. It will be necessary in the 
future to establish whether there is a need to do so 
for pathological satnples. 
We thank Brian Morris and Janet Smith for advice 
with this study, and Boehringer Limited for a gift of 
2'-0-succinyl cGMP. 
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Book reviews 
Blood Glucose Monitoring: Hormone and 
Metabolic Reseat·cb Supplement Series 
No. 7. Guest editors: J. D. Kruse-Jarries 
and G. D. Molnar. (Pp. 157, 169 figures, 
28 tables; DM 49· 80). Georg Thieme, 
Stuttgart, 1977. 
with the methodology of continuous in 
vivo glucose measurement and a further 
nine are concerned with its clinical and 
research applications and pathobiology. 
Blood glucose is presumably the first of 
many substances to be capable of exam-
ination in this way. This volume well 
describes the progress that is being made 
in this direction and is certainly worthy 
of consultation by anyone interested in 
the future of clinical biochemistry as well 
as by all diabetologists. 
the subject of demarcation disputes 
between clinical biochemists, pharmacists, 
and clinical pharmacologists but it is, 
nevertheless, likely to become one of the 
most important and fruitful branches of 
clinical biochemistry. Drug interference 
with conventional laboratory tests, on the 
other hand, is unquestionably the responsi-
bility of clinical biochemists and theirs 
alone. If clinical biochemists do not know 
how particular drugs interfere with theh· 
analyses it is unlikely that anyone else will 
either. Most symposia make poor books, partly 
because the papers prepared for oral 
delivery are not for permanent written 
recm·d, and partly because of the in-
ordinate delay between their presentation 
and their appearance in print. Neither of 
these criticisms is valid in the present case 
which represents the well-edited proceed-
ings of a workshop sponsored by the 
German Society of Clinical Chemistry in 
March 1976. 
Great interest has been aroused by 
the invention of an 'artificial pancreas' 
which depends upon the ability to monitor 
continuously blood glucose concentration 
in vivo and adjust it by means of insulin 
or glucose infusions depending on whether 
it is too high or too low. Six of the con-
tributions in this volume are concerned 
VINCENT MARKS 
Drug Interfei'ence and Drug Measurement 
in Clinical Chemistl·y. Edited by G. Siest 
and D. S. Young. (Pp. 207; $37·75 
approximately). Karger: Basel, 1976. 
This volume, which is the proceedings of 
the Third International Colloquium on 
Prospective Biology held in Pont-a-
Mousson, France in October 1975, is con-
cerned, as its title suggests, with two of the 
most important growth areas in clinical 
biochemistry-namely, the measurement 
of drugs in biological fluids and the inter-
ference by drugs with conventional clinical 
biochemistry tests. The two subjects have 
little in common, however, except their 
concern with drugs. The measurement of 
drugs in blood runs the risk of b€coming 
The conference at which these subjects 
were discussed may have been as interest-
ing and important as its contents deserved. 
Unfortunately, the proceedings, like those 
of so many other successful meetings, fail 
to capture and impart the importance of 
the occasion. What may have made a first 
class lecture can too often become a third 
class paper which detracts from, rather 
than enhances, the value of the volume in 
which it appears. The topics dealt with 
are, in my opinion, too important for 
this generally unsatisfactory method of 
publication. 
VINCENT MARKS 
Book reviews continued on page 36 
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A SIMPLE AND SPECIFIC LOCUST PROTEIN BINDING ASSAY FOR CYCLIC 31 51 GMP 
Peter Wood, Gordon Hartman and Vincent Marks 
Department of Biochemistry, University of Surrey, Guildford, Surrey. 
Received June 22,1976 
The 10,000 g x 15 min supernatant from homogenised whole 
fifth instar Schistocerca gregaria hoppers provides a 
binding protein which may be used for the measurement of 
cyclic GMP without further purification. Specificity is 
greater than that reported in previously published protein 
binding procedures. Urine levels may be measured directly 
and agree well with results obtained by radioimmunoassay. 
The increasing interest in the role of cyclic GMP* as an 
alternative second messenger to cyclic AMP*l 2 has led to a search 
for suitable methods for its measurement. 
Radioimmunoassay is well established3 but the production or 
purchase of antisera is a drawback. The bovine-adrenal receptor 
assay 4 has had a major impact on the measurement of cyclic AMP and 
a protein binding assay for cyclic GMP of similar simplicity and low 
cost is desirable. Published receptor procedures for the measurement 
of cyclic GMPS 6 7 8 require purification of the binding protein and 
have not achieved a specificity comparable to that shown by cyclic AMP 
assays 4 9 
*Cyclic GMP is used as the abbreviation for guanosine-3'5'-cyclic phosphate, 
Cyclic AMP as the abbreviation for adenosine-3'5'-cyclic phosphate. 
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We have developed an assay of high specificity for cyclic GMP 
using, as a source of binding protein, a supernatant fraction from 
whole desert locusts (Schistocerca gregaria) at the fifth instar stage. 
Hembers of Sutherland 1 s group reportedlO in 1969 that 11Cricket 11 
tissue was markedly different from the wide range of mammalian tissues 
tested in that it contained more than two nanomoles cyclic GMP per gram, 
with a two- to three-fold excess of cyclic GMP over cyclic AMP. These 
findings, which have recently been confirmed8 ll led us first to 
investigate crickets and, later, locusts as a source of binding protein 
for eye 1 i c GMP. 
EXPERIMENTAL 
Preparation of the binding protein 
Fifth instar Schistocerca gregaria, each weighing 1.5-2 g, were 
rapidly frozen and ground to a powder in liquid nitrogen. The cold 
powder was extracted with 6.0 ml ice-cold homogenisation medium 
(250 mM-sucrose; 50 mH-Tris, pH 7.4; 25 mM-KCl; 15 mM-MgC1 2) per gram, 
using t\'IO thirty-second periods at maximum speed on a 1 Polytron 1 
blender (Northern Media Supply Limited) with cooling in an ice-bath. 
The homogenate was centrifuged at 10,000 ｾｦｯｲ＠ 15 minutes, the super-
natant decanted through nylon cloth (125 ｾ＠ pore size) and respun for a 
further 15 minutes at 10,000 ｾﾷ＠ The resulting supernatant was again 
decanted through nylon cloth and 5.0 ml aliquots were frozen and 
0 
stored at -20 C. Aliquots were thawed immediately before use, the 
frozen preparation maintaining its binding properties for at least 
three months. 
Assay procedure (at 4°C) 
The incubation mixture comprised 100 ｾｾ＠ assay buffer (50 mM-HEPES, 
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pH 7.4; 8 mM-theophylline; 6 mM-2-mercaptoethanol; 5 g/1 bovine serum 
albumin (Armour)) in which is dissolved 200 pmol cyclic AMP; 100 ｾＱ＠ of 
binding protein (3.5-4.0 mg protein); and 100 ｾＱ＠ of test or standard (in 
the range 0-50 pmol cyclic GMP) made up in the assay buffer. 
One picomole of [8-3H] cyclic GMP (Radiochemical Centre; 19 Ci/ 
mmol), in ＵＰｾｾ＠ of assay buffer, was added after a thirty minute pre-
incubation at 4°C and the incubation continued for a further two and a 
half hours. 
Bound cyclic GMP was separated by the addition of 1.0 ml of 
ice-cold 3.8 M-ammonium sulphate solution. The tubes were mixed in 
a 'Whirlimixer•, kept at 4°C for ten minutes, then centrifuged for 
thirty minutes at 1,800 ｾ＠ (MSE 'Mistral 4L 1 refrigerated centrifuge). 
The supernatant was aspirated; the precipitate taken up in 
1.0 ml distilled water and mixed. An a1 iquot (0.5 ml) from each tube 
was transferred to a 'Minivia1 1 (G.D. Searle and Company), four ml of 
toluene- 'Synperonic-NXP' scintillantl 2 added and the tritium content 
measured with a counting efficiency of 35%. 
RESULTS AND DISCUSSION 
Preliminary experiments, in which cyclic AMP was not included in 
the assay buffer, gave cyclic GMP concentrations in urine which were 
two to three times higher than those obtained by radioimmunoassay using 
antisera raised in this laboratory. The addition of a known amount of 
cyclic GMP to urine samples gave recovery values with the locust assay 
in the range 150-300% in comparison with standards in assay buffer. The 
setting-up of standards in phosphodiesterase pre-treated urine did not 
alter these recovery values. Addition of cyclic AMP to the cyclic GMP 
standards increased the sensitivity of the assay. The effect was 
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TABLE I 
Cyclic GMP levels in urine 
Nine random urine samples were diluted 1 in 20 and analysed in duplicate 
by the locust protein binding method and by radioimmunoassay with two 
different rabbit anti-cyclic GMP antisera of high specificity. The 
radioimmunoassay is based on the method of Steiner et a1 (1972). 
LOCUST ASSAY RADIOIMMUNOASSAY 
ANTISERUM 1 ANTISERUM 2 
SAMPLE 
Cyclic GMP Cyc 1 i c GMP 
pmol/ml lJffiOl/g pmol/ml vmol/g pmol/ml vmol/g 
creatinine creatinine creatinine 
1 2ltO 1. 18 200 0.99 240 1.18 
2 400 1.22 420 1. 28 420 1.28 
3 560 0.92 600 0.98 540 0.89 
4 320 1. 14 300 1. 07 340 1. 21 
5 90 0.50 90 0.50 100 0.56 
6 180 0.64 200 0.71 160 0.57 
7 680 1. 19 700 1. 23 640 1.12 
8 860 1. 26 860 1.26 1000 1.47 
9 400 0.80 360 0.72 380 0.76 
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detectable with the addition of as 1 ittle as 5 pmol cyclic AMP per tube, 
and was maximal at a level of 100-200 pmol/tube. Thus, cyclic At1P 
affects the binding of cyclic GMP and the addition of 200 pmol cyclic 
AMP per tube to both standards and tests gave results which agreed well ,in 
the urine samples investigated, with those determined by radioimmunoassay 
(Table 1). Moreover, recovery of cyclic GMP added to ten urine specimens 
now averaged 98%. Measurements of ｾｹ｣ｬｩ｣＠ GMP were independent of urine 
dilution in the range 1:2 to 1:32. 
The detection 1 imit of the locust assay was calculated13 to be 
0.2-0.3 pmol cyclic GMP per tube. Preincubation of urine samples with 
excess ox-heart phosphodiesterase at pH 7.4 reduced the cyclic GMP 
content to below the detection 1 imit. 
Cross reactivities of fifteen nucleotides in the assay are 
illustrated in Figure l, similar results being obtained with three 
different binding protein preparations. Cyclic IMP cross-reacted with 
less than one fi .ftieth the avidity of cyclic GMP and cyclic AMP with less 
than one-thousandth. Other cyclic nucleotides cross-reacted to the same 
extent or less than cyclic AMP. Specificity is, therefore, considerably 
higher than that of existing protein binding methods for cyclic GMP. 
Scatchard plots of the binding data revealed smooth curves which 
could be interpreted in terms of two populations of binding sites with 
dissociation constants of the order K01 = 1.5-2.5 x 10-
9M and 
K02 = 2.4-5.2 x 10-aM. 
The use of EDTA as an antic.oagulant. and phsphodiesterase inhibitor 
in plasmp cyclic AMP studies 14 led us to investigate the effect of 
replacing theophylline by this compound in the assay buffer. This 
resulted in a 20-30% increase in zero standard binding but also markedly 
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FIGURE 1 
Specificity of the Method 
The cross reactivities of fifteen nucleotides were determined using the 
incubation procedure described in the test. 
A:- 3'5 1 cyclic GMP; B:- 3'5 1 cyclic IHP; C:- 3'5' cyclic CMP; 
0:- dibutyryl 3'5 1 eye 1 i c GMP; E:- 3'5 1 cyclic AMP; F:- 3'5' cyclic UMP; 
G:- dibutyryl 3'5' cyclic AMP; H:- He an result (± SEM) for 31 5' cyclic-
dTMP, 51 AMP, 5' ATP, 5' GTP, 2131 cyclic AMP, 2131 cyclic GMP, AMP-PNP, 
GMP-PNP, and monobutyryl 3'5 1 cyclic UMP. 
(*) and (•) show the means (±SEM) of results for nucleotides which are 
not plotted individually. 
increased the cross-reactivity of cyclic AMP. In contrast to this, the 
use of isobutylmethyl xanthine (8mM) in the assay buffer gave binding 
and specificity results in good agreement with those found for theophylline. 
1144 
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Binding protein extracts from Schistocerca gregaria showed distinct 
differences in specificity between the adult and juvenile stages. 
ｔｩｳｳｾ･＠ preparations from adult males (either whole insects or isolated 
abdomens) showed much greater cyclic AMP cross-reactivity than fourth or 
fifth instar hoppers. Further investigation of this phenomenon 
may prove of interest in studies on insect endocrinology. 
Preliminary investigations with fifth instar Locusta migratoria 
migratorioides indicated that this species will also be suitable as a 
source of cyclic GMP binding protein. 
The locust method combines the advantages of a simple procedure 
for the preparation of binding protein with high specificity for cyclic 
GMP. Urine may be analysed without preliminary purification, and it 
may be possible to carry out measurements on plasma and tissue extracts 
without prior nucleotide fractionation. 
We thank Shell Research Limited (Sittingbourne, Kent, UK) for 
gifts of the locusts used in this study. 
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